<SEC-DOCUMENT>0001493152-22-012261.txt : 20220506
<SEC-HEADER>0001493152-22-012261.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505163155
ACCESSION NUMBER:		0001493152-22-012261
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HARROW HEALTH, INC.
		CENTRAL INDEX KEY:			0001360214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450567010
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35814
		FILM NUMBER:		22896908

	BUSINESS ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215
		BUSINESS PHONE:		615.733.4731

	MAIL ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Imprimis Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20120301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSDEL PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20070912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bywater Resources, Inc
		DATE OF NAME CHANGE:	20060421
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:HROW="http://harrowinc.com/20220331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_07F_XDX_form10q.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_HROW_harrowinc.com_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001360214 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_SquareFoot_0_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityCentralIndexKey">0001360214</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-03-31" id="xdx2ixbrl0124" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:GainLossOnForgivenessOfDebt" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0247" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0305" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0317" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0375" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:GainLossOnForgivenessOfDebt" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-03-31" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted" contextRef="From2022-01-01to2022-03-31" id="xdx2ixbrl0550" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:InvestmentPaidInKindInterest" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_MeltPharmaceuticalsIncMember" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_SurfaceOphthalmicsIncMember" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31_custom_TransferOfProfitMember" id="xdx2ixbrl0644" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_us-gaap_LicenseMember" id="xdx2ixbrl0646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember" id="xdx2ixbrl0666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31_custom_MeltPharmaceuticalsIncMember" id="xdx2ixbrl0667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31_custom_SurfaceOphthalmicsIncMember" id="xdx2ixbrl0712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2021-12-31" id="xdx2ixbrl0748" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2022-03-31_us-gaap_PatentsMember" id="xdx2ixbrl0842" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2022-03-31_custom_LicensesMember" id="xdx2ixbrl0852" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-03-31_us-gaap_TrademarksMember" id="xdx2ixbrl0860" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2022-03-31_us-gaap_TrademarksMember" id="xdx2ixbrl0862" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2022-03-31_custom_NewDrugApplicationsMember" id="xdx2ixbrl0872" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember" id="xdx2ixbrl0884" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2022-03-31_us-gaap_TradeNamesMember" id="xdx2ixbrl0894" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31_us-gaap_TradeNamesMember" id="xdx2ixbrl0896" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2022-03-31_custom_NonCompetitionClauseMember" id="xdx2ixbrl0906" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31_custom_NonCompetitionClauseMember" id="xdx2ixbrl0908" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2022-03-31_custom_StatePharmacyLicensesMember" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2022-03-31" id="xdx2ixbrl0924" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-03-31_custom_NewDrugApplicationsMember" id="xdx2ixbrl0937" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2022-03-31_srt_MinimumMember_custom_OfficeAndLaboratorySpaceMember" format="ixt-sec:duryear" id="xdx2ixbrl1033" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">1</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember" id="xdx2ixbrl1204" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember" id="xdx2ixbrl1206" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember" id="xdx2ixbrl1250" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1418" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1420" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1426" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1428" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember" id="xdx2ixbrl1448" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember" id="xdx2ixbrl1450" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember" id="xdx2ixbrl1452" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-03-31_custom_EmployeesMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="xdx2ixbrl1480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-03-31_custom_ConsultantMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="xdx2ixbrl1486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="hrow-20220331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CommonStock0.001ParValuePerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">HROW:CommonStock0.001ParValuePerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_ProductSalesNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:ProductSalesNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_ProductSalesNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:ProductSalesNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_OtherRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:OtherRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_OtherRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:OtherRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsUnvestedRSUsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsUnvestedRSUsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_EtonPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_srt_MaximumMember_custom_EtonPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EtonPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_EtonPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">HROW:LoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">HROW:LoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember_custom_SurfaceOphthalmicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CommissionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:CommissionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_CommissionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:CommissionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_TransferOfProfitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:TransferOfProfitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_TransferOfProfitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:TransferOfProfitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-012019-02-28_custom_ManagementServicesAgreementMember_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-01</xbrli:startDate>
        <xbrli:endDate>2019-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_MeltLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:MeltLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_custom_MeltLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:MeltLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ManagementServicesAgreementMember_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SurfaceOphthalmicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_CapitalizedInternalUseSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CapitalizedInternalUseSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CapitalizedInternalUseSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CapitalizedInternalUseSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ThirdPartySoftwareLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:ThirdPartySoftwareLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ThirdPartySoftwareLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:ThirdPartySoftwareLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CapitalizedSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CapitalizedSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_CapitalizedSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CapitalizedSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MinimumMember_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MaximumMember_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_NewDrugApplicationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NewDrugApplicationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_NewDrugApplicationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NewDrugApplicationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MinimumMember_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MaximumMember_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MinimumMember_custom_NonCompetitionClauseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MaximumMember_custom_NonCompetitionClauseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_NonCompetitionClauseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_StatePharmacyLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_StatePharmacyLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_NewDrugApplicationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NewDrugApplicationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-31_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-30_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-04-30_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-312026-02-01_srt_ScenarioForecastMember_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-31</xbrli:startDate>
        <xbrli:endDate>2026-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member2184750">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_srt_MinimumMember_custom_OfficeAndLaboratorySpaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">HROW:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_srt_MaximumMember_custom_OfficeAndLaboratorySpaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">HROW:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_CarlsbadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:CarlsbadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_CarlsbadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:CarlsbadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_LedgewoodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_LedgewoodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_LedgewoodMember_custom_LeaseAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LeaseAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_NashvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:NashvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_NashvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:NashvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_MarkLBaumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MarkLBaumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-012019-02-28_custom_AndrewRBollMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:AndrewRBollMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-01</xbrli:startDate>
        <xbrli:endDate>2019-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28_custom_AndrewRBollMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:AndrewRBollMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-012019-02-28_custom_JohnPSaharekMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:JohnPSaharekMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-01</xbrli:startDate>
        <xbrli:endDate>2019-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28_custom_JohnPSaharekMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:JohnPSaharekMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-012019-02-28_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-01</xbrli:startDate>
        <xbrli:endDate>2019-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_StockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesAndConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_StockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_StockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_UnvestedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_UnvestedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_UnvestedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_SubsidiaryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:SubsidiaryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SubsidiaryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:SubsidiaryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionPlanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_StockOptionPlanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_StockOptionPlanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_OptionsEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_RangeTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_RangeTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmployeesMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_EmployeesMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmployeesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_EmployeesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_DirectorMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_srt_DirectorMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_ConsultantMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_ConsultantMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-012017-04-30_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_KlarityLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_KlarityLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_KlarityLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_KlarityLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_InjectableAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_InjectableAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_InjectableAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_InjectableAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_DexycuAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:DexycuAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_DexycuAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:DexycuAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_SalesAndMarketingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MinimumMember_custom_SalesAndMarketingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_srt_MaximumMember_custom_SalesAndMarketingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SalesAndMarketingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_AssetPurchaseLicenseAndRelatedAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:AssetPurchaseLicenseAndRelatedAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_AssetPurchaseLicenseAndRelatedAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:AssetPurchaseLicenseAndRelatedAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-07-31_custom_SinteticaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SinteticaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-07-31_custom_DueWithinThirtyDaysMember_custom_SinteticaAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:DueWithinThirtyDaysMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SinteticaAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SinteticaAgreementMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SinteticaAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-012021-08-31_custom_WakamotoAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:WakamotoAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-01</xbrli:startDate>
        <xbrli:endDate>2021-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_TwoProductConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:TwoProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_TwoProductConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:TwoProductConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">HROW:ThreeMainSuppliersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">HROW:ThreeMainSuppliersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="SquareFoot">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_906_edei--DocumentType_c20220101__20220331_zXYxqL9ugqkc"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span id="xdx_90F_edei--DocumentQuarterlyReport_c20220101__20220331_zsv39jIFbxCk"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_907_edei--DocumentPeriodEndDate_c20220101__20220331_zRmnznyUHgzf"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, <span id="xdx_90F_edei--DocumentFiscalYearFocus_c20220101__20220331_zkOPJwt8FROb"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span id="xdx_908_edei--DocumentTransitionReport_c20220101__20220331_zyrPfCbUoeEb"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from ___________ to _____________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number: <span id="xdx_900_edei--EntityFileNumber_c20220101__20220331_zbXkC5p0Yos"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityFileNumber">001-35814</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_908_edei--EntityRegistrantName_c20220101__20220331_zBS1SiF4NMYh"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityRegistrantName">Harrow
Health, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20220101__20220331_zeUvN0QHGyve"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20220101__20220331_zmGDYhXjkm74"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityTaxIdentificationNumber">45-0567010</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20220101__20220331_zNpZDe864zzi"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine1">102
                                            Woodmont Blvd.</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20220101__20220331_zqWN2UfW1fce"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine2">Suite 610</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressCityOrTown_c20220101__20220331_zXF2VTN0iBlk"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressCityOrTown">Nashville</ix:nonNumeric></span>,
    <span id="xdx_905_edei--EntityAddressStateOrProvince_c20220101__20220331_zb4TMrrv5XF7"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Tennessee</ix:nonNumeric> </span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20220101__20220331_zEvAY7IdP54c"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityAddressPostalZipCode">37205</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--CityAreaCode_c20220101__20220331_zmjvcWCdLyUj"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:CityAreaCode">(615)</ix:nonNumeric></span>
<span id="xdx_905_edei--LocalPhoneNumber_c20220101__20220331_z1KXwqvRtyLi"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:LocalPhoneNumber">733-4730</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    on exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValuePerShareMember_zGVLunURlnda"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_CommonStock0.001ParValuePerShareMember" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValuePerShareMember_zNdJXavdweT9"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_CommonStock0.001ParValuePerShareMember" name="dei:TradingSymbol">HROW</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_90D_edei--SecurityExchangeName_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValuePerShareMember_zbMLnhJ4iGo1"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_CommonStock0.001ParValuePerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Global Market</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--Sec8.625SeniorNotesDue2026Member_zAqvgFG1mdRe"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member" name="dei:Security12bTitle">8.625%
    Senior Notes due 2026</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--Sec8.625SeniorNotesDue2026Member_zttXYEC9uGId"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member" name="dei:TradingSymbol">HROWL</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_904_edei--SecurityExchangeName_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--Sec8.625SeniorNotesDue2026Member_zfeFu3AfuX6i"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Global Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90A_edei--EntityCurrentReportingStatus_c20220101__20220331_zxU76Maksde4"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746;  No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_900_edei--EntityInteractiveDataCurrent_c20220101__20220331_zlz115aXJil6"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746;  No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 30%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 5%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityFilerCategory_c20220101__20220331_z2jrZTaHl3Z1"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9746;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntitySmallBusiness_c20220101__20220331_zQff9Lg20iNg"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20220101__20220331_zL4Wo9hAP9pc"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744;   <span id="xdx_902_edei--EntityShellCompany_c20220101__20220331_zXGKiE6a9lJb"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 4, 2022, there were <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_pid_c20220504_z5BKY7eUmQh8"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-05-04" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,031,127</ix:nonFraction></span> shares of the registrant&#8217;s common stock, $0.001 par value, outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HARROW
HEALTH, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Table
of Contents</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
    I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ka_001">FINANCIAL INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ka_002">Financial Statements (unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_001">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">25</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_002">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">33</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_003">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">33</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
    II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_004">OTHER INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_005">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_006">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_007">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_008">Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_009">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_010">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_011">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sur_012">Signatures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">35</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ka_001"></span>FINANCIAL
INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ka_002"></span>Item
1. Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HARROW
HEALTH, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_zHAp1NnptIL6" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20220331_z8drN9g5P2Oe" style="text-align: center">March 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20211231_zH0EKm3Bibw9" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zDg8cjHUpZIg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrentAbstract_i01B_zUlgekldjlac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i02I_maACz7Za_zgNnKBtTcIZd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,948,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,167,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShortTermInvestments_i02I_maACz7Za_zvJT7sN49wmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Investment in Eton Pharmaceuticals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,642,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,503,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsReceivableNetCurrent_i02I_maACz7Za_zYh82ge31kD3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,995,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,470,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryNet_i02I_maACz7Za_zXXF70bwunTb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,396,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,217,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACz7Za_zSjz16no7Gfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,334,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,305,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtACz7Za_maAzZGD_zalRm8rjF918" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,315,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,662,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzZGD_zrOpj9hm9pOk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,968,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,141,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CapitalizedComputerSoftwareNet_i01I_maAzZGD_zOKyIP5pNOS5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capitalized software costs, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,471,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,313,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzZGD_zP3pxk36SWu" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,847,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,935,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maAzZGD_zch3Bv9M0vc6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,415,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,813,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--InvestmentsAndOtherNoncurrentAssetsOne_i01I_maAzZGD_zHuhVhxhomQa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment in Melt Pharmaceuticals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="HROW:InvestmentsAndOtherNoncurrentAssetsOne" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,247,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="HROW:InvestmentsAndOtherNoncurrentAssetsOne" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,133,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Goodwill_i01I_maAzZGD_zk4DtaZeuVQc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">332,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">332,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtAzZGD_zcxRobYlbpG4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,595,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,329,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zt7YllEF2xUl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B_zJOdAJzU3F9g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzAXy_zxE5bTxmqmxf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,758,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,337,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maLCzAXy_zmoTaAisMbMg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued payroll and related liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,948,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,089,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ContractWithCustomerLiabilityCurrent_i02I_maLCzAXy_zZYcbWASKr94" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred revenue and customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzAXy_zNjRoQfNgS9i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current portion of operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLCzAXy_ztXczn2IL8Ta" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Current portion of finance lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzAXy_maLzSWb_zHPVExpq1aM6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,182,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,722,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzSWb_z7oPUSY9flQ" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease obligations, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,823,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,012,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_i01I_maLzSWb_zcy9z0FBdiYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease obligations, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LongTermNotesPayable_i01I_maLzSWb_zBF6HHyTIhD7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loans payable, net of current portion and unamortized debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,847,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,654,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Liabilities_i01TI_mtLzSWb_maLASEzHYb_zIV4P6DhX0jh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,859,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,398,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzHYb_zejPyxZ8yBh9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0124">&#160;</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_i01B_z4pDEMGtpva2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_i02I_maSEzs6m_zlVwR0x79i04" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Common stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220331_z4J9a1u8oHw8" title="Common stock, par value"><span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zOvbkCWCQluj" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20220331_zRNWWpV8B0ah" title="Common stock, sharess authorized"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_z6GKYeACFIV3" title="Common stock, sharess authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20220331_zk2Kvc5czpd2" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20220331_zMVrz0U5Mpqd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,031,127</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20211231_zGjZF1yQMw0j" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_z3PojKAqzwa9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,902,763</ix:nonFraction></ix:nonFraction></span></span> shares issued
    and outstanding at March 31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_maSEzs6m_zqCNuhSw8EBh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,909,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,666,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzs6m_zlR9YgKykoz5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,845,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">95,407,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_i02TI_mtSEzs6m_maSEIPAz5Hg_zmYQeCzbJq09" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">TOTAL HARROW HEALTH STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,091,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,286,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--MinorityInterest_i02I_maSEIPAz5Hg_zG5K7B3aPfyl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Noncontrolling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">355,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">355,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_mtSEIPAz5Hg_maLASEzHYb_z8PUfbk9N8j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">TOTAL STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,736,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,931,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzHYb_zdp3j95VBeSf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,595,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,329,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HARROW
HEALTH, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_zdZTNdfo0woh" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20220331_zsaWNXQ7J98k" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210331_z6oYMgR3eOG5" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">For the</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">Three Months Ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenuesAbstract_iB_zBxQh777mk8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zYQ4ncqH1vyf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Product sales, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_ProductSalesNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,340,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31_custom_ProductSalesNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,948,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_zErIiLJ66n1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_OtherRevenuesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,780,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31_custom_OtherRevenuesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">495,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzFnc_zMKKLAc0k8fd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Total revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,443,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_iN_di_msGPzFnc_zzNdh1igux3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,963,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,770,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--GrossProfit_iT_mtGPzFnc_maOILzDK7_zbNDiaIO7HZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,157,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,673,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpensesAbstract_iB_zoexvP5MIn1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOEzpuv_zi2AF6I9QuI4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,398,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,164,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzpuv_zXAZL4OfsIN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">658,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">592,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpenses_i01T_mtOEzpuv_msOILzDK7_zH6YGoPpUMPb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,056,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,756,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_mtOILzDK7_maILFCOzzNq_znTsVOoJ5UQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Income from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,101,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,917,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zKdunKHepLX" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpense_i01N_di_msNIEzJJW_z5OCbMfjpMsh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,792,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">513,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--EquityInLossesOfUnconsolidatedEntities_i01N_di_msNIEzJJW_zFTMms55HLQ4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Equity in losses of unconsolidated entities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="HROW:EquityInLossesOfUnconsolidatedEntities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,886,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="HROW:EquityInLossesOfUnconsolidatedEntities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--GainLossOnInvestments_i01_maNIEzJJW_zlurOFeHVWw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investment gain (loss) from Eton Pharmaceuticals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,835,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--GainLossOnForgivenessOfDebt_i01_maNIEzJJW_zWSpDkcxQA66" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Gain on forgiveness of PPP loan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0212">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="HROW:GainLossOnForgivenessOfDebt" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,967,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_i01T_maILFCOzzNq_mtNIEzJJW_zmKddwH3zcml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,539,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,700,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzzNq_maNILATzSdT_zB0iNa4cqoo" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">(Loss) income before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,438,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILATzSdT_zU4zsxETIml1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0221">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0222">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_mtNILATzSdT_zgdlnbGnWIWc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,438,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_zi23VfonR6P9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic net (loss) income per share of common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.09</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_zJfjW9OlOvqh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Diluted net (loss) income per share of common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.09</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zh6YXbFgztD5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average number of shares of common stock
    outstanding, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,226,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,019,255</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_ziOZjrwhTSx3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average number of shares of common stock outstanding, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,226,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,480,622</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HARROW
HEALTH, INC. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Three Months Ended March 31, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_zILDLMn880a7" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 12pt">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zlmpVBmvyQol" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zrTz6gPZS2n1" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zCBaQ5IGwHzf" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z1BIZxT2PdBa" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_custom--TotalHarrowHealthIncStockholdersEquityMember_zc768amorGE1" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zmxFKcpBRVL7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B9_zAX6ZakzumA8" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-size: 12pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total<br />
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
    Health, Inc.</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total<br />
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non</span></p>
                                                                      <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlling</span></p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Par</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-in</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&#8217;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&#8217;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_435_c20210101__20210331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zV2O6cGJJTi9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Balance at December 31, 2020</td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zJo7WHU5aGE5" title="Beginning Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0247">&#160;</span>-
                                            </span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>$</td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0239">&#160;</span>-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuIPxxl7tnA5" title="Beginning Balance, shares" style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,749,875</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,557,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">77,400,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,183,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">355,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,828,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock in connection with:</td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_zXABJvoCiNPb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercise of employee options</td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo0EnzoWZVig" title="Exercise of employee options, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,301</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0256">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zsYql3sPSPBc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Vesting of RSUs</td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbOYkO2dbIh6" title="Vesting of RSUs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">230,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0265">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueOther_zGpzo98o2xA" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Shares withheld related to net share settlement of equity awards</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0271">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesOther_iN_pid_di_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlK7QA0b2hEi" title="Shares withheld related to net share settlement of equity awards, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zyxTTRf4CLac" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">855,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">855,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">855,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zQkWAndz7NXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net income</td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43D_c20210101__20210331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zscWqFDOX5W1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zAwyHnTKZ4H2" title="Ending Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxD5URwY6tQ3" title="Ending Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,983,676</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,382,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">77,183,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,225,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">355,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,870,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_433_c20220101__20220331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zEMlGipYIO19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2021</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zPflH7YOJXx6" title="Beginning Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU88jAy1e1G8" title="Beginning Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,902,763</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,666,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">95,407,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,286,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">355,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,931,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock in connection with:</td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_z8UkIJaSdiOc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercise of employee options</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlPIdUsfb9p7" title="Exercise of employee options, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,986</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zt9sl9NRqYmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Vesting of RSUs</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeT8080OTOCe" title="Vesting of RSUs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zyzkeGeJQnH4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Shares withheld related to net share settlement of equity awards</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesOther_iN_pid_di_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zstLr1PRFhN7" title="Shares withheld related to net share settlement of equity awards, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,622</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">776,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">777,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">777,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zeeQ7A7Q3Pc5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,016,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,016,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,016,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_z4J6tunj3g8d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,438,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,438,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,438,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_434_c20220101__20220331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zLpnFMVPBEug" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2022</td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_ztWyQwJAGGE" title="Ending Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz9c9gPfzpJa" title="Ending Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,031,127</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,909,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,845,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,091,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">355,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,736,000</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HARROW
HEALTH, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_zcNwDggghNMb" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20220331_zKXzoVBEhk96" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20210101__20210331_z0ebwobVbRvf" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">For the Three Months Ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z3FEs0LlcCR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_maNCPBUzDt2_zQOusTq9po62" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net (loss) income</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,438,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zxYHvDYXklKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net (loss) income to net cash provided by operating
    activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DepreciationAndAmortization_i02_maNCPBUzDt2_zut4TZJ97BM6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">419,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AmortizationOfIntangibleAssets_i02_maNCPBUzDt2_zMEC5YNvIpWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">404,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzDt2_zPVTSEYT15xj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProvisionForDoubtfulAccounts_i02_maNCPBUzDt2_zyyHJ2iloWv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Provision for bad debt expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maNCPBUzDt2_zGs1LeybCDd4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt issuance costs and discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainLossOnForgivenessOfDebt_i02N_di_msNCPBUzDt2_zgX9b8uXKrD2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gain on forgiveness of PPP loan</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="HROW:GainLossOnForgivenessOfDebt" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,967,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--GainLossOnInvestments_i02N_di_msNCPBUzDt2_zPeLJifGGWPb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Investment (gain) loss from investment in Eton</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,835,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--EquityInLossesOfUnconsolidatedEntities_i02_maNCPBUzDt2_zLkFDBaBNvmd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Equity in losses of unconsolidated entities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="HROW:EquityInLossesOfUnconsolidatedEntities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,886,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="HROW:EquityInLossesOfUnconsolidatedEntities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensation_i02_maNCPBUzDt2_zv0yHT85cSod" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,016,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">855,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i02B_zN6zgJgvTCj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzDt2_zlr4FrLWAOG2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,535,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">610,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msNCPBUzDt2_z3UBtzykMBGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">534,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzDt2_z5Yhm9SJEfKd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maNCPBUzDt2_zlZUhk2NP9wg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,105,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i03_maNCPBUzDt2_z7pgyjXHJ0Sj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accrued payroll and related liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,141,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">684,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i03_maNCPBUzDt2_z1j8Eey9eoJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Deferred revenue and customer deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzDt2_maCCERCzjNX_zoTCzjkifpze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">NET CASH PROVIDED BY OPERATING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">967,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,208,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_ztjIdQ8maCZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUzBHo_zZRJIJGMOB5e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Investment in patent and trademark assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzBHo_zqNKCiRSje1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Purchases of property, plant and equipment and capitalized software development costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">404,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzBHo_maCCERCzjNX_zcQN3pnyGno1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">NET CASH USED IN INVESTING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">410,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">224,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zwW7igrokLAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msNCPBUzgER_zwOi4bGJhBOa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Payments on finance lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msNCPBUzgER_zoCBxIbFVVwl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Principal payment on SWK loan</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzgER_zws1y4mLKo4d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Proceeds from the exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--PaymentOfTaxesForVestingOfRestrictedStockUnit_i01_maNCPBUzgER_zNIJIKZb0Ugl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Payment of taxes upon vesting of RSUs and exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="HROW:PaymentOfTaxesForVestingOfRestrictedStockUnit" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">777,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="HROW:PaymentOfTaxesForVestingOfRestrictedStockUnit" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzgER_maCCERCzjNX_zWU68WykCxLc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">NET CASH USED IN FINANCING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">776,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">781,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzjNX_z3qgxuPFbX5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">219,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,203,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zTDR1CI7J4Fk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,167,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,301,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_ztdRYlgznx4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,948,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,504,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract_iB_zoy1SjIsFwP" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01E_zMMtAVlm2zt7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,948,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,304,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RestrictedCash_i01E_zm9oqhrHH4uj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_i01E_zRWV4eEVJOAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,948,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,504,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zxEk4OkPnlri" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaidNet_i01_zCxuyjR5OLYa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestPaidNet_i01_znR3w9bVweA5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,617,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">415,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_i01B_zJf4f4zePmUe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_i02_z9AFGP1OQNdh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Right-of-use assets obtained in exchange for new operating
    lease obligations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br />&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HARROW
HEALTH, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Three Months Ended March 31, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_801_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zscPxO6FEhjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_828_zFbnycVysiwh">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
and Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise
requires, the &#8220;Company&#8221; or &#8220;Harrow&#8221;) is an ophthalmic-focused healthcare company that specializes in the development,
production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through
its subsidiaries and deconsolidated companies. The Company owns one of the nation&#8217;s leading ophthalmology-focused pharmaceutical
businesses, ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has non-controlling equity positions in Surface Ophthalmics,
Inc. (&#8220;Surface&#8221;) and Melt Pharmaceuticals, Inc. (&#8220;Melt&#8221;), both companies that began as subsidiaries of Harrow.
In 2020, Harrow created Visionology, Inc. (&#8220;Visionology&#8221;), which launched a digital eye health platform business during 2021.
Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles
generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the
rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes
required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring
adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31,
2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any other period.
For further information, refer to the Company&#8217;s audited consolidated financial statements and footnotes thereto included in the
Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned
subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity
(&#8220;VIE&#8221;) model to determine whether the Company is the primary beneficiary of that entity&#8217;s operations. If an entity
is not deemed to be a VIE, the Company consolidates entities in which it holds and/or controls, directly or indirectly, more than
50% of the voting rights. All intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zZ5oQA7dB0k3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_827_zgt6Mo8oOVxa">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents an update for the three months ended March 31, 2022 to the significant accounting policies described in the Company&#8217;s
Annual Report on Form 10-K for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:RisksUncertaintiesAndLiquidityPolicyTextBlock"><p id="xdx_842_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zlikh7k4Jfld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z61yL2WHWdw">Risks,
Uncertainties and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company&#8217;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result
of regulatory guidelines or inspections, this may have a material impact on the Company&#8217;s financial condition, liquidity and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGEhHZSPonzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zkwHcxaMbNAi">Segments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to shifts in the Company&#8217;s strategic plans to further focus on growing the Company&#8217;s ImprimisRx business and suspension of
activities related to starting up development-stage pharmaceutical companies, along with changes to the Company&#8217;s organizational
and internal reporting structure, beginning in January 2022 management no longer evaluates the Company&#8217;s business in two segments
and instead focuses on the performance of the business as a single operating business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_z09jDRTdzUM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zK97u56dXbd8">Basic
and Diluted Net (Loss) Income per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net (loss) income per common share is computed by dividing net (loss) income attributable to common stockholders for the period by the
weighted average number of common shares outstanding during the period. Diluted net (loss) income per share is computed by dividing the
net (loss) income attributable to common stockholders for the period by the weighted average number of common and common equivalent shares,
such as stock options, restricted stock units (&#8220;RSUs&#8221;) and warrants, outstanding during the period. Common equivalent shares
(using the treasury stock method) from stock options, unvested RSUs and warrants were <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zi4YTngRCKDb" title="Antidilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-03-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,546,200</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zgKWeI7wFAOg" title="Antidilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-03-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,486,678</ix:nonFraction></span> at March 31, 2022 and 2021,
respectively. For the three months ended March 31, 2022, the common equivalent shares are excluded in the calculation of diluted net
loss per share because the effect is anti-dilutive. Included in the basic and diluted net (loss) income per share calculation were RSUs
awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number
of shares underlying vested RSUs at March 31, 2022 and 2021 was <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNOovaasI2H1" title="Number of shares vestted, RSUs"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,405</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZzIAkghWppk" title="Number of shares vestted, RSUs"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-01-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">223,219</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNS0kGC3Spqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the computation of basic net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zIK2wVYRcfJb" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20220331_zPZjySBbpEEb" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20210331_zK9PGkctLRE2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zBSHDqd9SEe6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc. common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,438,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zVkFlIgL0agf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Denominator - weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,226,819</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,019,255</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_zedkPD5L7Keb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.09</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zZdBqJnX6MLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:DilutedCommonEquivalentSharesTableTextBlock"><p id="xdx_89A_ecustom--DilutedCommonEquivalentSharesTableTextBlock_ztS6hUdeceP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2021, the Company had net income. As a result, the Company computed diluted net income per share using
the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent
shares for the three months ended March 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zGv4Ux4CkOL9" style="display: none">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20210331_zKlwQtQ6UHne" style="text-align: center; font-weight: bold">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Diluted shares related to: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEluRcHYzuv1" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%">Warrants </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 30%; text-align: right"><ix:nonFraction name="us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted" contextRef="From2021-01-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">576,275</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLmA3bQlDFui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Stock options </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted" contextRef="From2021-01-012021-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">885,092</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,461,367</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zEDTRvbryULd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:DilutedNetIncomePerShareTableTextBlock"><p id="xdx_898_ecustom--DilutedNetIncomePerShareTableTextBlock_zTLSbJwFaYn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the computation of diluted net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zbQUI7vKVAsf" style="display: none">SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20220331_zhckyztUZ068" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210331_zME873UuxLr3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,438,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zxoBmqdXKAv3" style="vertical-align: bottom; background-color: White">
    <td>Denominator &#8211; weighted average number of shares outstanding, basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,226,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,019,255</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_pid_z2WDYs3HKDoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,461,367</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z5Rl0ws6trN2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted earnings per share computation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,226,819</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,480,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zXD2dSROWCph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.09</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z8eqhiriI7Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_zsDCERs0SWaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zpB9pPdiNes3">Investment in Eton Pharmaceuticals, Inc.</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, the Company owned <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zTJupoqpHCG3" title="Number of shares owned"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-03-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,982,000</ix:nonFraction></span> shares of Eton common stock, which represents less than <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zd5SBrhuUHQd" title="Equity Method Investment, Ownership Percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-03-31_srt_MaximumMember_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of the equity interests of
Eton. At March 31, 2022, the fair market value of Eton&#8217;s common stock was $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zirbFSENtIKi" title="Shares price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-03-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.36</ix:nonFraction></span> per share. In accordance with the Accounting Standards
Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets
and Financial Liabilities</i>, the Company recorded an unrealized investment gain (loss) from its Eton common stock position of $<span id="xdx_907_eus-gaap--UnrealizedGainLossOnInvestments_c20220101__20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_z9IFkdPVayS6" title="Unrealized Gain (Loss) on Investments"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2022-01-012022-03-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,000</ix:nonFraction></span>
and $(<span id="xdx_90C_eus-gaap--UnrealizedGainLossOnInvestments_c20210101__20210331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zPiVkWlbQTT3" title="Unrealized Gain (Loss) on Investments"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2021-01-012021-03-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,835,000</ix:nonFraction></span>) during the three months ended March 31, 2022 and 2021, respectively, related to the change in fair market value of its
investment in Eton during the measurement period. As of March 31, 2022, the fair market value of the Company&#8217;s investment in Eton
was $<span id="xdx_901_eus-gaap--InvestmentOwnedAtFairValue_iI_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zCD3tr1mWRee" title="Investment owned, at fair value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2022-03-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,642,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:InvestmentOnePolicyTextBlock"><p id="xdx_841_ecustom--InvestmentOnePolicyTextBlock_z7ZR2aiQoUZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUPoGjZBwjMd">Investment
in Melt Pharmaceuticals, Inc. &#8211; Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company owns <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zX1EQ0YC1wZ9" title="Number of shares owned"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500,000</ix:nonFraction></span> shares of common stock of Melt (representing approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z744nHYvrDi8" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">46</ix:nonFraction></span>% of the equity interests as of March 31, 2022). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests
in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant
influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this
method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying
amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31,
2021, the Company reduced the carrying value of its common stock investment in Melt to $<span id="xdx_906_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkYZt5lFNR76" title="Reduction in common stock investment"><ix:nonFraction name="HROW:ReductionInCommonStockInvestment" contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as a result of the Company recording its share
of equity losses in Melt since its deconsolidation in 2019. As of March 31, 2022 and at the time of entering into the Melt Loan Agreement
(see Note 4), the Company owned <span id="xdx_905_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBYyKHO8OWw9" title="Investment Interest Rate"><ix:nonFraction name="us-gaap:InvestmentInterestRate" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of Melt&#8217;s indebtedness. Following the reduction of the carrying value of the Company&#8217;s
common stock investment in Melt to $<span id="xdx_904_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zEXoazSP5uqg" title="Reduction in common stock investment"><ix:nonFraction name="HROW:ReductionInCommonStockInvestment" contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, the Company began recording <span id="xdx_90D_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKy0RGpMjbR3" title="Investment Interest Rate"><ix:nonFraction name="us-gaap:InvestmentInterestRate" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the equity method losses of Melt, based on its ownership of
Melt&#8217;s total indebtedness. In addition, the Company treats interest paid in kind on the Melt Loan Agreement as an in-substance
capital contribution and reduces its investment in Melt accordingly, rather than recording interest income. The Company has no other
requirements to advance funds to Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember" escape="true" name="us-gaap:InvestmentTableTextBlock"><p id="xdx_890_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zHDKezjlAzC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s investments in Melt as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zOu6gAVnfeab" style="display: none">SCHEDULE OF INVESTMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Cost</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Share of Equity</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Paid-in-Kind</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">In-substance Capital</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Basis</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Method Losses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> Contributions</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; text-align: justify">Common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBkl2EaRCDC4" title="Cost Basis" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,810,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqfd0vzn9Si" title="Share of Equity Method Losses" style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,810,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJhT7QPahy73" title="Paid in Kind Interest" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;$</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Loan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z36QM1txxHVg" title="Cost Basis" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_za6GSpCvubZ7" title="Share of Equity Method Losses" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,253,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXBKSmtqYxvk" title="Paid in Kind Interest" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="HROW:InvestmentPaidInKindInterest" contextRef="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkJgzLHOo4wi" title="In Substance Capital Contributions" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InvestmentCompanyCommittedCapital" contextRef="From2022-01-012022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXiD29Wvcgr8" title="Net Carrying Value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,247,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6dIETxaG9Ad" title="Cost Basis" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,310,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSjrHuJ5eGWi" title="Share of Equity Method Losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,063,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zZE5JbYjMrNf" title="Paid in Kind Interest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="HROW:InvestmentPaidInKindInterest" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zhg3MW8XrTdi" title="In Substance Capital Contributions" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:InvestmentCompanyCommittedCapital" contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,021,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zWU9pjd23XQi" title="Net Carrying Value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,247,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zS3V4anqotQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022 and 2021, the Company recorded $<span id="xdx_903_eus-gaap--DueFromRelatedParties_iI_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zSpqwczV4Jd1"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2021-03-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">due from Melt for reimbursable expenses and
amounts payable pursuant to a Management Services Agreement between the Company and Melt (the &#8220;Melt MSA&#8221;), which are included
in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 4 for more information and related party disclosure regarding Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:InvestmentTwoPolicyTextBlock"><p id="xdx_845_ecustom--InvestmentTwoPolicyTextBlock_zsSi1v7tD1ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zXyiO94KHvEf">Investment
in Surface Ophthalmics, Inc. &#8211; Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company owns <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zwq1TJ9qFRKf" title="Number of shares owned"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500,000</ix:nonFraction></span> common shares of Surface (representing approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zM7tBbks44u2"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of Surface&#8217;s equity interests following the closing
of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as
management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions
of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts
the carrying amount of its investment in Surface accordingly. The Company&#8217;s share of earnings and losses are based on the Company&#8217;s
ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company
reduced its common stock investment in Surface to $<span id="xdx_90B_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zn44rm9BzRZ5" title="Reduction in common stock investment"><ix:nonFraction name="HROW:ReductionInCommonStockInvestment" contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as a result of the Company recording its share of equity losses of Surface. The
Company has no other investments in Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember" escape="true" name="us-gaap:InvestmentTableTextBlock"><p id="xdx_894_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zgWdLIjhxxte" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s investment in Surface as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zyVpPQIkwx7b" style="display: none">SCHEDULE OF INVESTMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Cost</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Share of Equity</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Basis</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Method Losses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zXw7lKRQkQXb" title="Cost basis" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,320,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zilG9GbPwS9c" title="Share of Equity Method Losses" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,320,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z4ThatYSP1Mf" title="Net carrying value" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zLCrX4mbCnW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 5 for more information and related party disclosure regarding Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:EquityMethodInvestmentsPolicy"><p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zqjQq2ALREy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zwQT0bcs6oUa">Impairment
of Equity Method Investments and Note Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company&#8217;s equity method
investments and note receivable may be other than temporarily impaired. Indicators include financial condition, operating performance,
and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate
both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is
determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity
method investments and note receivable. At March 31, 2022 and December 31, 2021, no indicators of impairment existed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_zqml2A6lcRm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_82C_zUB9vZOxnvQl">REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for contracts with customers in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606, <i>Revenues
from Contracts with Customers.</i> The Company has two primary streams of revenue: (1) revenue recognized from its sale of products within
pharmacy services and (2) revenue recognized from intellectual property license and asset purchase agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product
Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sells prescription drugs directly through its pharmacy and outsourcing facility. Revenue from the Company&#8217;s pharmacy services
includes: (i) the portion of the price the client pays directly to the Company, net of any volume-related or other discounts paid back
to the client, (ii) the price paid to the Company by individuals, and (iii) customer copayments made directly to the pharmacy network.
Sales taxes are not included in revenue. Following the core principles of ASC 606, the Company has identified the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the performance obligations in the contract: The order received contains the performance obligations to be met, in almost all cases
    the product the customer is wishing to receive. If we are unable to be meet the performance obligations the customer is notified.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    the transaction price: the transaction price is based on the product being sold to the customer, and any related customer discounts.
    These amounts are pre-determined and built into the Company&#8217;s order management software.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate
    the transaction price to the performance obligations in the contract: The transaction price associated with the product(s) being
    ordered is allocated according to the pre-determined amounts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize
    revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing facility
    the performance obligation has been met.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following revenue recognition policy has been established for the Company&#8217;s pharmacy services:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
generated from prescription or office use drugs sold by the Company&#8217;s pharmacies and outsourcing facility are recognized when the
prescription is shipped. At the time of shipment, the pharmacy services has performed substantially all of its obligations under its
client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4) is based
on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of
those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and allowances
and other adjustments are provided for in the same period during which the related sales are recorded and are based on actual returns
history. The rate of returns is analyzed annually to determine historical returns experience. If the historical data we use to calculate
these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination
is made and revenues in that period could be materially affected. The Company will defer any revenues received for a product that has
not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been
delivered and no refund will be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Commission
Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into an agreement whereby it is paid a fee calculated based on sales the Company generates from a pharmaceutical
product that is owned by a third party. The revenue earned from this arrangement is recognized at the time a customer has ordered the
pharmaceutical product and it has shipped from the third party (or one of its distributors or affiliates), at which point there is no
future performance obligation required by the Company and no consequential continuing involvement on the Company&#8217;s part to recognize
the associated revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transfer
of Acquired Product Profit Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into an agreement whereby it purchased the exclusive commercial rights to assets associated with certain ophthalmic
products from another pharmaceutical company (the &#8220;Seller&#8221;). During a temporary, six month transition period, the Seller
will continue to manufacture and market these products and transfer the net profit from the sale of the products to the Company. The
revenue recognized by the Company from the transfer of net profit is recognized at the time profit from the products sales has been calculated
by the Seller and confirmed by the Company, typically on a monthly basis, at which point there is no future performance obligation required
by the Company and no consequential continuing involvement on the Company&#8217;s part to recognize the associated revenue. On
a quarterly basis, the Seller invoices the Company for all credits and reimbursements (&#8220;Chargebacks&#8221;) made to customers related
to the products. The Company uses historical actual experience to estimate Chargebacks associated with the net profit transferred. The
estimate is recorded as a reduction in revenues in the Company&#8217;s condensed consolidated statements of operations and
accounts receivable in the condensed consolidated balance sheets, at the time the revenue is recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intellectual
Property License Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently holds five intellectual property licenses and related agreements in which the Company has agreed to license or sell
to a customer with the right to access the Company&#8217;s intellectual property. License arrangements may consist of non-refundable
upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds,
technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue
of which is recognized at the point in time that the performance obligation is met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-refundable
fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part
of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation
and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the
compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the
patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has
continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable
fee has no utility to the licensee and that are separate and independent of the Company&#8217;s performance under the other elements
of the arrangement. In addition, if the Company&#8217;s continued involvement is required, through research and development services
that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then
such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are
recognized on a straight-line basis over the applicable term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zQXOsddbBOpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
disaggregated by revenue source for the three months ended March 31, 2022 and 2021, consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zR6gEyzvRMdk" style="display: none">SCHEDULE
OF DISAGGREGATED REVENUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49A_20220101__20220331_zOW4uD1SJ9Wg" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td id="xdx_492_20210101__20210331_zKieTB8t8vh" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Three Months Ended March 31,</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zs9nSw8zPHWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Product sales, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_ProductSalesNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,340,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31_custom_ProductSalesNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,948,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CommissionsMember_zkkGsAEXACH8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_CommissionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,320,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31_custom_CommissionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfProfitMember_zMZB6cpbgOQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Transfer of profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-03-31_custom_TransferOfProfitMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">460,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zJcXuvzPmRbk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">License</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total revenues</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,443,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zSi1dO87BCGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
revenue and customer deposits at March 31, 2022 and December 31, 2021 were $<span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20220331_zQGircum5OW8" title="Deferred revenue and customer deposits"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20211231_zy2KvS7fIh9k" title="Deferred revenue and customer deposits"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></span>, respectively. All deferred revenue and
customer deposit amounts at December 31, 2021 were recognized as revenue during the three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"><p id="xdx_802_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zHi0IBPSSDzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_822_zz2QFfqdg3f5">INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2018, the Company entered into an asset purchase agreement with Melt (the &#8220;Melt Asset Purchase Agreement&#8221;). Pursuant
to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company
to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively,
the &#8220;Melt Products&#8221;). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make mid-single digit royalty
payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2019, the Company and Melt entered into the Melt MSA, whereby the Company provides to Melt certain administrative services and
support, including bookkeeping, web services and human resources related activities, and Melt is required to pay the Company a monthly
amount of $<span id="xdx_902_eus-gaap--AdministrativeFeesExpense_c20190201__20190228__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zYzzITmK6fg2" title="Administrative Fees Expense"><ix:nonFraction name="us-gaap:AdministrativeFeesExpense" contextRef="From2019-02-012019-02-28_custom_ManagementServicesAgreementMember_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span>. As of March 31, 2022 and December 31, 2021, the Company was due $<span id="xdx_909_eus-gaap--DueFromRelatedParties_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zphIuyLIzUVf" title="Due from Related Parties"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DueFromRelatedParties_iI_c20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zPXKy8zvmjwc" title="Due from Related Parties"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,000</ix:nonFraction></span>, respectively, from Melt for reimbursable
expenses and amounts due under the Melt MSA. Melt did not make any payments to the Company during the three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer, Mark L. Baum, was previously a member of the Melt board of directors until his resignation during
the year ended December 31, 2021. Following Mr. Baum&#8217;s departure, the Company no longer has any representation on Melt&#8217;s
board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zSRRrC0Q5zwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed results of operations information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z209h09UDAti" style="display: none">SCHEDULE OF CONDENSED INCOME STATEMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zTXh8GiQ2iEg" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zlupJ2JUKVsj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Three Months Ended <br />
March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zO2i2yFigoSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revenues, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zq6rdl3psRmg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Loss from operations</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,337,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,099,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zDluIhJtlKhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,337,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,099,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zkzfTCylfvdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:ScheduleOfCondensedBalanceSheetOneTableTextBlock"><p id="xdx_896_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zcLzu4bOoxG" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed balance sheet information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z9dE8G2IDlo1" style="display: none">SCHEDULE OF CONDENSED BALANCE SHEET</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zDUDBDUYrHH" style="font-weight: bold; text-align: center">At March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zdqnypoLIcSd" style="font-weight: bold; text-align: center">At December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_iI_zy0cOf4VxwId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,025,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,278,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsNoncurrent_iI_zpSoeNsopG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">360,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iI_zxGkTHwP6UY" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,385,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,278,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_iI_zijkfMkukffk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,313,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,732,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zzgVUbOyOtfk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total preferred stock and stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,928,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,454,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zV9uxU49tu1i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,385,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,278,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zPnNZPkxSWj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Melt
Note Receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2021, the Company entered into a loan and security agreement in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_z76ZyWU7MJm5" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-09-30_custom_MeltLoanAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,500,000</ix:nonFraction></span> (the &#8220;Melt Loan Agreement&#8221;),
as lender, with Melt, as borrower. Amounts borrowed under the Melt Loan Agreement bear interest at twelve and one-half percent (<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zL0Q8dYygfGb" title="Debt instrument interest rate stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-09-30_custom_MeltLoanAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.50</ix:nonFraction></span>%)
per annum, which interest can be paid in-kind at the option of Melt until the maturity date. The Melt Loan Agreement permits Melt to
pay interest only on the principal amount loaned thereunder through the term and all amounts owed will be due and payable on September
1, 2022. Melt may elect to prepay all, but not less than all, of the amounts owed prior to the maturity date at any time without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melt
has granted the Company a security interest in substantially all of its personal property, rights and assets, including intellectual
property rights, to secure the payment of all amounts owed under the Melt Loan Agreement. The Melt Loan Agreement contains customary
representations, warranties and covenants, including covenants by Melt limiting additional indebtedness, liens, mergers and acquisitions,
dispositions, investments, distributions, subordinated debt, and transactions with affiliates. The Melt Loan Agreement includes customary
events of default, and upon the occurrence of an event of default (subject to cure periods for certain events of default), all amounts
owed by Melt thereunder may be declared immediately due and payable by the Company, and the interest rate on the loan may be increased
by three percent (<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_c20210901__20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zeiY1tnPbW9g" title="Increase in interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-09-012021-09-30_custom_MeltLoanAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>%) per annum. See Note 17 regarding an Amendment to the Melt Loan Agreement entered into in April 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Melt Loan Agreement, the Company and Melt entered into a Right of First Refusal Agreement providing the Company with
the right, but not the obligation, to match any offer received by Melt associated with the commercial rights to any of Melt&#8217;s drug
candidates for a period of five years following the effective date of the Melt Loan Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net funds received by Melt excluded $<span id="xdx_900_ecustom--AccountsReceivableTransferredToNoteReceivable_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKbAYGZuugX5" title="Accounts receivable transferred to note receivable"><ix:nonFraction name="HROW:AccountsReceivableTransferredToNoteReceivable" contextRef="AsOf2022-03-31_custom_ManagementServicesAgreementMember_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">908,000</ix:nonFraction></span> for amounts owed to the Company for reimbursable expenses and amounts due under the Melt
MSA prior to the effective date of the note receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock"><p id="xdx_805_ecustom--InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_zLbaooG7A5h1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_82B_zvcnQ6oDQcg8">INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the &#8220;Surface License
Agreements&#8221;). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual
property and related rights associated with Surface&#8217;s drug candidates (collectively, the &#8220;Surface Products&#8221;). Surface
is required to make mid-single digit royalty payments to the Company on net sales of the Surface Products while any patent rights remain
outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, the Company owned <span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z1OaSPehDWOg" title="Number of shares owned"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500,000</ix:nonFraction></span> shares of Surface common stock (representing approximately <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zNeDLCgLGzJg" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of Surface&#8217;s issued
and outstanding equity interests). A Company director, Richard L. Lindstrom, and the Company&#8217;s Chief Executive Officer, Mark L.
Baum, are directors of Surface. Dr. Lindstrom is a principal of Flying L Partners, an affiliate of an investor who purchased Surface
Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock"><p id="xdx_894_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zaFV5yfixqbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed results of operations information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z2nUHKSrPoQ9" style="display: none">SUMMARY OF CONDENSED INCOME STATEMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zz5eImx0Xajl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20210331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_ziQe1WCBizti" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zVIAmgsK7HXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenues, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_zprMrtaFqUF3" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,996,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,831,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zphBbIINa2Ri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,996,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,831,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zMpvraidM3Gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><p id="xdx_896_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zUaMI08gdbJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed balance sheet information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z9DYOciFWKzj" style="display: none">SUMMARY OF CONDENSED BALANCE SHEET</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z3UrTE5lRVuj" style="font-weight: bold; text-align: center">At March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zLOGRTHliMve" style="font-weight: bold; text-align: center">At December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zzNlI7Tuqx78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,920,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,731,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_ziWygcHThLl4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">411,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Assets_iI_zb1jhBCUKvOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,331,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,143,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_iI_zW41pp0YzM9e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,937,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,514,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_iI_zSTgmyTpzVXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total preferred stock and stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,394,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,629,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zjmufASaortk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,331,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,143,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zzdpIa8zujMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_zt88CVBUsn25" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_827_zx7MFXHDumO3">INVENTORIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zpTcmZWigGsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of March 31, 2022 and
December 31, 2021 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zmtyr5FMbDN" style="display: none">SCHEDULE OF INVENTORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220331_zYFocsw1bgsd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231_zkHMuC7NR4Qd" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maINz1vg_zySRv7C76sIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,441,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,441,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz1vg_zWPXVndX7Xtf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InventoryFinishedGoods_iI_maINz1vg_zqeRsVxcnJNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,911,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,776,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryNet_iTI_mtINz1vg_z184sO7uAeNb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,396,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,217,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zbHGu2CAcbx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:OtherAssetsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OtherAssetsDisclosureTextBlock_zaj16JKOlCph" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_827_z2xc96AyvzYb">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqPEeLwq7fn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets at March 31, 2022 and December 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zZSMDZgP1N8" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220331_zy4KO0UM0EP2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zgo4Qsrvmrha" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidInsurance_iI_maPEAOAz7FJ_zI4cUnolEfl6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">455,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">728,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueFromRelatedParties_iI_maPEAOAz7FJ_zD5GgvX3f5Tj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Melt Pharmaceuticals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz7FJ_zl8dctplNAx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">757,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAssetsCurrent_iI_maPEAOAz7FJ_zlNBpP9ltbJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz7FJ_z6aGjli0D5u2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,334,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,305,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zfvovfD58w4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmcBUIuHVOZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_82B_zomMZUsLtIQb">PROPERTY, PLANT AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_ze1CgIm54nx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment at March 31, 2022 and December 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z6k2VxD3GSXj" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220331_zQM2Nq6qjxH3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zXofIOFnnmD8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ComputerHardwareGross_iI_maPPAEGzWKe_zPEZ9JFh67Tc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Computer hardware</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="HROW:ComputerHardwareGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">786,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="HROW:ComputerHardwareGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">772,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzWKe_zRnW5IVCP8Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">521,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzWKe_zVK4Z1UYQ24h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,142,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,056,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzWKe_z7WADUw264m9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,728,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,703,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzWKe_maPPAENzhZF_z1eE7Kmoyhw4" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif">Property, plant and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,177,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,974,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzhZF_zIHsffSgMWq6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,209,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,833,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzhZF_zXT8mQxmtbF4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,968,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,141,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zWIPmnj55Vy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2022 and 2021, depreciation related to the property, plant and equipment was $<span id="xdx_90D_eus-gaap--Depreciation_c20220101__20220331_zDGQkceFrj79" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">376,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--Depreciation_c20210101__20210331_zaIXip8Nf6yk" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,000</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:CapitalizedSoftwareDevelopmentCostsTextBlock"><p id="xdx_806_ecustom--CapitalizedSoftwareDevelopmentCostsTextBlock_zeW7yI8Yifh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_828_zp1UEkocrbZ1">CAPITALIZED SOFTWARE DEVELOPMENT COSTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:CapitalizedSoftwareDevelopmentCostsTableTextBlock"><p id="xdx_893_ecustom--CapitalizedSoftwareDevelopmentCostsTableTextBlock_zf7Seo6HJNB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
software development costs at March 31, 2022 and December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zhjRVbjWx1Ua" style="display: none">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220331_zzPoBne899Hc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zcGkC3TN8Z9g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedInternalUseSoftwareMember_zFvHdjm73Ydc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Capitalized internal-use software development costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2022-03-31_custom_CapitalizedInternalUseSoftwareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">942,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2021-12-31_custom_CapitalizedInternalUseSoftwareMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">942,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_zTJ2NFmQbAQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Acquired third-party software license for internal-use</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2022-03-31_custom_ThirdPartySoftwareLicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2021-12-31_custom_ThirdPartySoftwareLicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzJkV_zDJR8Ism6H71" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total gross capitalized software for internal-use</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,101,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,101,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzJkV_zXqLvHTMLooa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">612,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCCSNzJkV_zwoNzydOMbOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Capitalized internal-use software in process</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="HROW:CapitalizedComputerSoftwareInternalUseInProcess" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">982,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="HROW:CapitalizedComputerSoftwareInternalUseInProcess" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">781,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzJkV_zB3D3Db34jZ1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Total
    finite lived intangible assets net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,471,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,313,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zsCaBt9E1Rua" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded amortization expense of $<span id="xdx_90C_eus-gaap--AdjustmentForAmortization_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zsM8waAgqnL6" title="Amortization"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2022-01-012022-03-31_custom_CapitalizedSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--AdjustmentForAmortization_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zNni26PVYxtj" title="Amortization"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2021-01-012021-03-31_custom_CapitalizedSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000</ix:nonFraction></span> related to capitalized software development costs during the three months
ended March 31, 2022 and 2021, respectively.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_807_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zmmgBScvSRZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_824_zipuKZp8kpFj">INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zJjWYWQsjHwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s intangible assets at March 31, 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zxgFjxmDBBYl" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 12pt">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Amortization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Periods</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(in years)</b></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Cost</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Accumulated</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Amortization</b></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Impairment</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Carrying Value</b></p></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjf5wF2iXy15" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_srt_MinimumMember_us-gaap_PatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17</ix:nonNumeric></span>-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zImd8lINgrh8" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_srt_MaximumMember_us-gaap_PatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">19</ix:nonNumeric></span> </span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zehbq1WeiU88" title="Cost" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-03-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">972,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlfJmIfFhxQ1" title="Accumulated amortization" style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-03-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0Q4yhmF9Q7k" title="Impairment" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfzZMRiuoT1a" title="Net Carrying value" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">875,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Licenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeWgyYGFESy6" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_LicensesMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvVKD9f6aP9" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-03-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zNCzPEzPr34l" title="Accumulated amortization" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-03-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIbS2fmM6rCg" title="Impairment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_znlesKjCSMDh" title="Net Carrying value" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trademarks</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0koJpf1xUZ3" title="Finite-Lived Intangible Assets, Amortization Method"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_TrademarksMember" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod">Indefinite</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zKpTejnk0qC8" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-03-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zll2HXJ0YgI" title="Accumulated amortization" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV2aw1rKd6tj" title="Impairment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zMOochU6dJvk" title="Net Carrying value" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquired NDAs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zVYdkm2FSXd2" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_NewDrugApplicationsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zHlU0qDpkfKg" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-03-31_custom_NewDrugApplicationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,635,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z820THJtV2P2" title="Accumulated amortization" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-03-31_custom_NewDrugApplicationsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">341,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zjQW5qUswlHe" title="Impairment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z36noIcOlKVe" title="Net Carrying value" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31_custom_NewDrugApplicationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,294,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Customer relationships</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zirZ8X0bocTk" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_srt_MinimumMember_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">3</ix:nonNumeric></span>-<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zfVV8Q3e0TGc" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_srt_MaximumMember_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">15</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z3NDMTXnz9wj" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,519,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zOfTiUUyw7l4" title="Accumulated amortization" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">619,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ztUO2SvFO869" title="Impairment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2r5IfCrgA5l" title="Net Carrying value" style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">900,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Trade name</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zdn33BHgRTy4" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_TradeNamesMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z48sa9Y7Jmk9" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-03-31_us-gaap_TradeNamesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEBqLhqiMHi3" title="Accumulated amortization" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-03-31_us-gaap_TradeNamesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQp1niDP54wb" title="Impairment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zDx1gHu34EDc" title="Net Carrying value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-competition clause</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zgP1zPts6wP2" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_srt_MinimumMember_custom_NonCompetitionClauseMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">3</ix:nonNumeric></span>-<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zNE9e9WAUqxe" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_srt_MaximumMember_custom_NonCompetitionClauseMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">4</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zhfab4dWaoQc" title="Cost" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-03-31_custom_NonCompetitionClauseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z9rGoZWRSmFj" title="Accumulated amortization" style="text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-03-31_custom_NonCompetitionClauseMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zURC90oOrve3" title="Impairment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zdGWNGcngprj" title="Net Carrying value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">State pharmacy licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zh2wHWe5SxT" title="Amortization periods (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_StatePharmacyLicensesMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">25</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z0fWDQZkeYHi" title="Cost" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-03-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z84Dqt7Mr6H" title="Accumulated amortization" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-03-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zQEqyTorbf13" title="Impairment" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z68nKa56dLyh" title="Net Carrying value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331_zwGvikTRgpW4" title="Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,549,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331_zDPdx6zi9o73" title="Accumulated amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,134,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331_zVlxrwN2Ltr" title="Impairment" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331_zZgmAs7pThp8" title="Net Carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,415,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z5smofGy2AMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zK2eZFjQVHj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for intangible assets for the three months ended March 31, 2022 and 2021 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zCTvexaauAP5" style="display: none">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 12pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49E_20220101__20220331_z6zAM7UfccS5" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49A_20210101__20210331_zx49Vo3S5zyh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the <br />Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 12pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z3GoaCK4TD9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-03-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-03-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z45HYDtJNJWj" style="vertical-align: bottom; background-color: White">
    <td>Licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-03-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-03-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zMnd9cp9n6i7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Acquired NDAs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-03-31_custom_NewDrugApplicationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zTrMaLbIZt4l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-03-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-03-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AmortizationOfIntangibleAssets_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of intangible assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">404,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A0_zYEUDHOOap46" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zjlC3on5YG66" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
future amortization expense for the Company&#8217;s intangible assets at March 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zIpkGufjwR6l" style="display: none">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20220331_ze3p2LvbPte" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzqfW_zwUaRFyNHO4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,194,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzqfW_zWx02eONrfp5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,592,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzqfW_zF3bJUCAECSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,592,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzqfW_zzrN7DtMlStj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,592,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzqfW_zmRF1aGHsh6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,595,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzqfW_zjqyFLM7MD0c" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,590,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzqfW_z01D7vJLeYRi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,155,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zRwLv4zr47b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_800_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z4w1lYBZiLwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_828_zsAXwb4jHwjg">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zxQmhsPtaNV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and accrued expenses at March 31, 2022 and December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zNMn0zIbKer5" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220331_zm7ufVjUs2rj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zsCiPMOqwvxb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALziP7_zvw8orfBEi35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,595,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,174,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALziP7_zvs71AC3YS6f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAALziP7_z2487muc3H55" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,114,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,114,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALziP7_z19Vj5yde983" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Total accounts payable and accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,758,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,337,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z6uu52gggDVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zEMSq80cdcle" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. <span id="xdx_82F_zPhxnX7D3ZO5">DEBT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>8.625%
Senior Notes Due 2026</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, the Company closed an offering of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z7AbIkzW0PF" title="Debt principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-04-30_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span> aggregate principal amount of 8.625% senior notes due April 2026, and in May
2021 issued an additional $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210501__20210531__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zct5JwrPOzEl" title="Additional notes issued"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" contextRef="From2021-05-012021-05-31_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> of such notes pursuant to the full exercise of the underwriters&#8217; option to purchase additional
notes (collectively, the &#8220;April Notes&#8221;). The April Notes were sold to investors at a par value of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z24EbCdbOpee" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.00</ix:nonFraction></span> per April Note and
the offering resulted in net proceeds to the Company of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20210401__20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zTGtOHrCFAy8" title="Proceeds from issuance of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2021-04-012021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,909,000</ix:nonFraction></span> after deducting underwriting discounts and commissions
and expenses of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zUQMBPVHvF7j" title="Debt issuance costs and discounts"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,091,000</ix:nonFraction></span>. In June 2021, in a further issuance of the April Notes, the Company sold an additional $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210601__20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zxU5DUR2JMYf" title="Additional notes issued"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" contextRef="From2021-06-012021-06-30_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span> aggregate
principal amount of such notes (the &#8220;June Notes,&#8221; and together with the April Notes, the &#8220;Notes&#8221;), at a price
of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z7WgrBDVN1Sk" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.75</ix:nonFraction></span> per June Note, with interest of $<span id="xdx_906_eus-gaap--InterestExpenseDebt_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z7okaq6cV78b" title="Interest expense, debt"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2021-06-012021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,000</ix:nonFraction></span> on the June Notes being accrued from April 20, 2021 as of the date of issuance. The
June offering resulted in net proceeds to the Company of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zoJvGAuYq45l" title="Proceeds from issuance of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2021-06-012021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,164,000</ix:nonFraction></span> after deducting underwriting discounts and commissions
and expenses of $<span id="xdx_907_eus-gaap--DeferredFinanceCostsNet_iI_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zkpskDAkEgKb" title="Debt issuance costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,158,000</ix:nonFraction></span> and a premium on note issuance of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedPremium_iI_c20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zUCv1UfBrWXl" title="Premium on issuance of debt"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedPremium" contextRef="AsOf2021-06-30_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">322,000</ix:nonFraction></span>. The June Notes are treated as a single series with the April Notes
under the indenture governing the April Notes, dated as of April 20, 2021, and have the same terms as the April Notes (other than the
initial offering price and issue date). The Notes are senior unsecured obligations of the Company and rank equally in right of payment
with all of our other existing and future senior unsecured and unsubordinated indebtedness. The Notes are effectively subordinated in
right of payment to all of the Company&#8217;s existing and future secured indebtedness and structurally subordinated to all existing
and future indebtedness of the Company&#8217;s subsidiaries, including trade payables. The Notes bear interest at a rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zYy8qMEUq0qh" title="Debt instrument, interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-04-012021-04-30_custom_Sec8.625SeniorNotesDue2026Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.625</ix:nonFraction></span>% per
annum. Interest on the Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing
on July 31, 2021. The Notes will mature on April 30, 2026. The issuance costs were recorded as a debt discount and are being amortized
as interest expense, net of the amortization of the premium on note issuance, over the term of the Notes using the effective interest
rate method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to February 1, 2026, the Company may, at its option, redeem the Notes, in whole at any time or in part from time to time, at a <span id="xdx_904_eus-gaap--DebtInstrumentRedemptionDescription_c20260131__20260201__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z9v9N2OofIHc" title="Debt instrument, redemption, description"><ix:nonNumeric contextRef="From2026-01-312026-02-01_srt_ScenarioForecastMember_custom_Sec8.625SeniorNotesDue2026Member" name="us-gaap:DebtInstrumentRedemptionDescription">redemption
price equal to 100% of the principal amount of the Notes to be redeemed</ix:nonNumeric></span>, plus a make-whole amount, if any, plus accrued and unpaid interest
to, but excluding, the date of redemption. The Company may redeem the Notes for cash in whole or in part at any time at our option on
or after February 1, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest
to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense related to the Notes totaled $<span id="xdx_908_eus-gaap--InterestExpenseOtherLongTermDebt_c20220101__20220331__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zWFNvBrw0ux6" title="Interest Expense, debt"><ix:nonFraction name="us-gaap:InterestExpenseOtherLongTermDebt" contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member2184750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,810,000</ix:nonFraction></span> for the three months ended March 31, 2022, and included amortization of debt issuance
costs and discount of $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20220331__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z4AIqJGy45hc" title="Amortization of debt issuance costs and discount"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member2184750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,000</ix:nonFraction></span> for three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zeXit3iAI55j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, future minimum payments under the Company&#8217;s debt were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zCaoB1YgDg5" style="display: none">SUMMARY OF FUTURE MINIMUM PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220331_zjCFRn231Vyf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maLTDz3L0_zRx4HQB7fzoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,852,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDz3L0_z3s7cGJj8Ukb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,469,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDz3L0_zgidYMhRg0u2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,469,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDz3L0_zaK6kVZsAHE3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,469,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDz3L0_zHWTd4zld0i2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,158,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz3L0_zPXXi5uAvz85" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total minimum payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,417,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_zNwMlipFUgD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,417,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DebtInstrumentCarryingAmount_iI_zAs5CTtwXl8i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_z9wdwKyKH6N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized discount, net of premium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,153,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermNotesPayable_iI_z7Ost3bAP696" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Notes payable, net of unamortized discount</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,847,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zq8GuC4BsL37" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock"><p id="xdx_80F_ecustom--LesseeOperatingLeaseAndFinanceLeaseTextBlock_zGDXUysbF93b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13. <span id="xdx_821_zPB6DIhnzvca">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and laboratory space under non-cancelable operating leases listed below. These lease agreements have remaining
terms between <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtYxL_c20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zXDguXswy201" title="Lease term::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl1033">one</span></span> to <span id="xdx_909_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zvc7MO7kr8mi" title="Lease term"><ix:nonNumeric contextRef="AsOf2022-03-31_srt_MaximumMember_custom_OfficeAndLaboratorySpaceMember" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">five years</ix:nonNumeric></span> and contain various clauses for renewal at the Company&#8217;s option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    operating lease for <span id="xdx_905_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220331__srt--StatementGeographicalAxis__custom--CarlsbadMember_zVnNYGLr1TP9" title="Area of Land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2022-03-31_custom_CarlsbadMember" format="ixt:numdotdecimal" decimals="INF" unitRef="SquareFoot">5,789</ix:nonFraction></span> square feet of office space in Carlsbad, California, which commenced in January 2022 and will expire in
    <span id="xdx_90E_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220331__srt--StatementGeographicalAxis__custom--CarlsbadMember_zVX6TPuvkiYf" title="Lease expiration date description"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_CarlsbadMember" name="HROW:LeaseExpirationDateDescription">July 2027</ix:nonNumeric></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    operating lease for <span id="xdx_90A_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_zMHwbDQ9V0Z2" title="Area of Land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2022-03-31_custom_LedgewoodMember" format="ixt:numdotdecimal" decimals="INF" unitRef="SquareFoot">35,326</ix:nonFraction></span> square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in <span id="xdx_905_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_zdaCGfEnL1Sj" title="Lease expiration date description"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_LedgewoodMember" name="HROW:LeaseExpirationDateDescription">July 2026</ix:nonNumeric></span>, with
    <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_zHYsyAjH2RPe" title="Lease term, option to extend"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_LedgewoodMember" name="us-gaap:LesseeOperatingLeaseOptionToExtend">an option to extend the term for two additional five-year periods.</ix:nonNumeric></span> This includes an amendment that was made effective July 2020 that
    extended the term of the original lease and added <span id="xdx_90D_ecustom--AdditionalAreaOfLand_uSquareFoot_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_znyv5Utz8Hb8" title="Additional square footage"><ix:nonFraction name="HROW:AdditionalAreaOfLand" contextRef="From2022-01-012022-03-31_custom_LedgewoodMember" format="ixt:numdotdecimal" decimals="INF" unitRef="SquareFoot">1,400</ix:nonFraction></span> of additional square footage to the lease and another amendment entered into
    in May 2021 that extended the term of the lease to July 2027 and added <span id="xdx_905_ecustom--AdditionalAreaOfLand_uSquareFoot_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zRmAUfKpx3uf"><ix:nonFraction name="HROW:AdditionalAreaOfLand" contextRef="From2022-01-012022-03-31_custom_LedgewoodMember_custom_LeaseAmendmentMember" format="ixt:numdotdecimal" decimals="INF" unitRef="SquareFoot">8,900</ix:nonFraction></span> square feet of space.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    operating lease for <span id="xdx_900_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220331__srt--StatementGeographicalAxis__custom--NashvilleMember_zqSieIigKnX4" title="Area of Land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2022-03-31_custom_NashvilleMember" format="ixt:numdotdecimal" decimals="INF" unitRef="SquareFoot">5,500</ix:nonFraction></span> square feet of office space in Nashville, Tennessee that expires in <span id="xdx_90B_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220331__srt--StatementGeographicalAxis__custom--NashvilleMember_zYPPIxvqIbYj" title="Lease expiration date description"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_NashvilleMember" name="HROW:LeaseExpirationDateDescription">December 2024</ix:nonNumeric></span>, with <span id="xdx_905_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220331__srt--StatementGeographicalAxis__custom--NashvilleMember_zfF1QUHasLok" title="Lease term, option to extend"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_NashvilleMember" name="us-gaap:LesseeOperatingLeaseOptionToExtend">an option to extend
    the term for two additional five-year periods.</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases
held by the Company were <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_ztl0PM4oOc5c" title="Operating lease, weighted average discount rate, percentage"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.34</ix:nonFraction></span>% and <span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_zsIySPSGadud" title="Operating lease, weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-03-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">13.45</ix:nonNumeric></span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022 and 2021, cash paid for amounts included for the operating lease liabilities was $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20220101__20220331_zahSIJ03sK82" title="Operating lease, payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--OperatingLeasePayments_c20210101__20210331_zKzDWl8IAjZd" title="Operating lease, payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,000</ix:nonFraction></span>,
respectively, and the Company recorded operating lease expense of $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20220101__20220331_zUSJ7GDzos6j" title="Operating lease, expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">238,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20210101__20210331_zUZ0ryx2mjE1" title="Operating lease, expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">261,000</ix:nonFraction></span>, included in selling, general and administrative
expenses, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIhB5Bo97Zf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
lease payments under operating leases as of March 31, 2022 were as follows<b>: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B7_zPoLj2em0lGd" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20220331_z465aRPQBoD9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzIyO_zBtXXYhn7tc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 78%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzIyO_zQqVxQs35Pqg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">944,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzIyO_zqp51RqLT0d2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">970,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzIyO_zNzee68udGmg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">796,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzIyO_z6mRREQj8QPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzIyO_zywaK7VJ0MB4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="HROW:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,648,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzIyO_zv9lk9ryrXX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,823,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zRrNnz7HqX56" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: amount representing interest payments</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,555,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zENYyAG2FZbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,268,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zByQzP6YkDx" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: current portion, operating lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zSX1Nsg0f066" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities, net of current portion</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,823,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zNL0InFA7iFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has a finance lease that is included in its lease accounting but is not considered significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock"><p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zZQa6S4wHoec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
lease payments under the non-cancelable finance lease as of March 31, 2022 were as follows<b>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B8_zsZDJjr1TXN8" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220331_z6NLuqyySe12" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzZHK_zOncHOuLhKv4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 78%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzZHK_z54SOZeYTSOg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzZHK_z8a2vj9fIy9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzZHK_z5EFggVfzLRi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zddcqHmbwAb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseLiability_iI_zICmpzDaD6Qd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_z6KSxa1ddWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zbP0upLRnTj6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zaDiFaZZBxRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, the incremental borrowing rate and the remaining lease term for the finance lease held by the Company were <span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_zbgmS1m3Zmq" title="Finance lease, weighted average discount rate, percentage"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.36</ix:nonFraction></span>% and
<span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_z4aewc4aXczk" title="Finance lease, weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-03-31" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">1.83</ix:nonNumeric></span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2022 and 2021, depreciation expense related to the equipment held under the finance lease obligation
was $<span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20220101__20220331_zrIVlnGHbS6k" title="Amortization"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AdjustmentForAmortization_c20210101__20210331_zS52QDR5EAtb" title="Amortization"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2022 and 2021, cash paid and expense recognized for interest expense related to the finance lease obligation
was $<span id="xdx_904_eus-gaap--FinanceLeaseInterestExpense_c20220101__20220331_zhPb1tjbZMjb" title="Finance lease, interest expense"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--FinanceLeaseInterestExpense_c20210101__20210331_ziaLFQcwq431" title="Finance lease, interest expense"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_801_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zOJ4Lp2zbyD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14. <span id="xdx_82C_zShQsrSKYg8c">STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022 and December 31, 2021, the Company had <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_z4S8wiSqSe6j" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20220331_zP1z2UZ1JrWh" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of preferred stock, $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zAOVPOwGKd6e" title="Preferred stock, par or stated value per share"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220331_z2CZYnreRvx1" title="Preferred stock, par or stated value per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, authorized and <span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20211231_z4YKaKETbf03" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231_zoDCjAc9gh72" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20220331_zrSlVymUgmoj" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20220331_zErtlpKbPVWf" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares
of preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z0KyBxngLjr2" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,594</ix:nonFraction></span> shares of common stock to Mark L. Baum, the Company&#8217;s Chief Executive
Officer, upon the cashless exercise of options to purchase <span id="xdx_907_ecustom--CashlessExerciseOfOptionsShares_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zZo6M5cxeTT4" title="Cashless exercise of options, shares"><ix:nonFraction name="HROW:CashlessExerciseOfOptionsShares" contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span> shares at an exercise price of $<span id="xdx_907_ecustom--CashlessExerciseOfOptionsPricePerShares_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zAMxKz24FNLh" title="Cashless exercise of options, price per shares"><ix:nonFraction name="HROW:CashlessExerciseOfOptionsPricePerShares" contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.40</ix:nonFraction></span> per share. The Company withheld
from Mr. Baum <span id="xdx_90F_ecustom--CommonStockWithheldOnCashlessExercise_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zLQ7iW9Jiig7" title="Common stock withheld on cashless exercise"><ix:nonFraction name="HROW:CommonStockWithheldOnCashlessExercise" contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,014</ix:nonFraction></span> shares as consideration for the cashless exercise and an additional <span id="xdx_90C_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z7FsYO4vfI59" title="Common stock withheld for payroll tax withholdings, shares"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsShares" contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,392</ix:nonFraction></span> shares for payroll tax obligations totaling
$<span id="xdx_908_ecustom--CommonStockWithheldForPayrollTaxWithholdings_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zkIaTLBgLD11" title="Common stock withheld for payroll tax withholdings, value"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdings" contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20190201__20190228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zydEd7Xb509g" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2019-02-012019-02-28_custom_AndrewRBollMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span>
RSUs granted in February 2019 to Andrew R. Boll, the Company&#8217;s Chief Financial Officer, vested, and in February 2022, the Company
issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zzbNiozXKIf4" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-012022-02-28_custom_AndrewRBollMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,395</ix:nonFraction></span> shares of common stock to Mr. Boll, net of <span id="xdx_90A_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zt70HWgvvUv5" title="Common stock withheld for payroll tax withholdings, shares"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsShares" contextRef="From2022-02-012022-02-28_custom_AndrewRBollMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,605</ix:nonFraction></span> shares of common stock withheld for payroll tax withholdings totaling
$<span id="xdx_904_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_z4pGwaYZ3sk2" title="Common stock withheld for payroll tax withholdings, value"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsValue" contextRef="From2022-02-012022-02-28_custom_AndrewRBollMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20190201__20190228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_z2kalpzJQZpd" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-02-012019-02-28_custom_JohnPSaharekMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span>
RSUs granted in February 2019 to John P. Saharek, the President of ImprimisRx, vested, and in February 2022, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zjppP1MaKh3e" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-012022-02-28_custom_JohnPSaharekMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,077</ix:nonFraction></span>
shares of common stock to Mr. Saharek, net of <span id="xdx_90D_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zIJqqPnPKrQ1" title="Common stock withheld for payroll tax withholdings, shares"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsShares" contextRef="From2022-02-012022-02-28_custom_JohnPSaharekMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,923</ix:nonFraction></span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_907_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_z1vXs3m7Fqye" title="Common stock withheld for payroll tax withholdings, value"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsValue" contextRef="From2022-02-012022-02-28_custom_JohnPSaharekMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20190201__20190228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkJo5qJn91nh" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-02-012019-02-28_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></span>
RSUs granted in February 2019 vested, and in February 2022, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgE73FhjhcC8" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-012022-02-28_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,298</ix:nonFraction></span> shares of common stock, net of <span id="xdx_901_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyLpsIrtGqgd" title="Common stock withheld for payroll tax withholdings, shares"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsShares" contextRef="From2022-02-012022-02-28_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,702</ix:nonFraction></span> shares of
common stock withheld for payroll tax withholdings totaling $<span id="xdx_90E_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsKdV4ZRjD0j" title="Common stock withheld for payroll tax withholdings, value"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsValue" contextRef="From2022-02-012022-02-28_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDtQPIuVIAig" title="Number of shares isssued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> shares of common stock and received net proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0mPvATYj27i" title="Proceeds from purchase of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></span> upon the exercise
of options to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTPUdlFcse5k" title="Number of options to purchase common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> shares of common stock with exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjoyUAjR1Psf" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.95</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyB4Arl7Or48" title="Number of shares isssued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,644</ix:nonFraction></span> shares of the Company&#8217;s common stock underlying RSUs issued to directors vested, but
the issuance and delivery of these shares are deferred until the applicable director resigns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Option Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 17, 2007, the Company&#8217;s Board of Directors and stockholders adopted the Company&#8217;s 2007 Incentive Stock and Awards
Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended,
the &#8220;2007 Plan&#8221;). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this
plan; however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or
are otherwise cancelled/forfeited. On June 13, 2017, the Company&#8217;s Board of Directors and stockholders adopted the Company&#8217;s
2017 Incentive Stock and Awards Plan which was subsequently amended on June 3, 2021 (as amended, the &#8220;2017 Plan&#8221; together
with the 2007 Plan, the &#8220;Plans&#8221;). As of March 31, 2022, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_z9oEijQMSALc" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-03-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock. The purposes of the Plans are to attract and retain directors, officers, consultants, advisors
and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such
persons in the Company&#8217;s development and financial success. Under the Plans, the Company is authorized to issue incentive stock
options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified stock options, restricted
stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company&#8217;s Board of Directors.
The Company had <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_zBcD4jG6Tda3" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-03-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,229,399</ix:nonFraction></span> shares available for future issuances under the 2017 Plan at March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zJxL6dHkZQWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity under the Plans for the three months ended March 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zMfNdnqJrHK8" style="display: none">SCHEDULE
OF STOCK OPTION PLAN ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Options outstanding &#8211; January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zs71DclQBMOi" title="Number of shares, outstanding, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,039,546</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLUzVHvgl5I2" title="Weighted average exercise price, outstanding, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.52</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZATxOBiSMpi" title="Number of shares, options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">170,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zlaZ40dISsag" title="Weighted average exercise price, options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpIw669FcMr9" title="Number of shares, options exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWIYBRJqmDg4" title="Weighted average exercise price, options exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zn1WOUkuwpdb" title="Number of shares, options cancelled/forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1204">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwd9Fh04h5wf" title="Weighted average exercise price, options cancelled/forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding &#8211; March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zbwxm1CFj9hk" title="Number of shares, outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,083,796</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJAW0Gkj0JT5" title="Weighted average exercise price, outstanding, ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.76</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWKDp5ZBcODh" title="Weighted average. remaining contractual life, options outstanding"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.01</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLu9Zj8MW3w7" title="Aggregate intrinsic value, options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,781,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z6Cbdb4qDJS3" title="Number of shares, options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,408,629</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVAAOR1EgGog" title="Weighted average exercise price, options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.29</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVC7vOFHuPik" title="Weighted average. remaining contractual life, options exercisable"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.61</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOPPtIdiFQZ6" title="Aggregate intrinsic value, options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,639,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zDrp9jBJ4UJj" title="Number of shares, options vested and expected to vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,083,796</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJ0KwgTMUvgg" title="Weighted average exercise price, options vested and expected to vest" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.76</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zMibHxxV6Hv7" title="Weighted average. remaining contractual life, options vested and expected to vest"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">5.01</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zshFV23Z9Zx6" title="Aggregate intrinsic value, options vested and expected to vest" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,781,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zXUWPVUGjh52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would
have been received by option holders if all option holders had exercised and immediately sold all shares underlying options with an exercise
price lower than the market price on March 31, 2022, based on the closing price of the Company&#8217;s common stock of $<span id="xdx_905_ecustom--ClosingPriceOfCommonStockPricePerShare_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zojVTmb68O4c" title="Closing price of common stock price per share"><ix:nonFraction name="HROW:ClosingPriceOfCommonStockPricePerShare" contextRef="AsOf2022-03-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.82</ix:nonFraction></span> on that
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, the Company granted stock options to certain employees and a consultant. The stock options were
granted with an exercise price equal to the current market price of the Company&#8217;s common stock, as reported by the securities exchange
on which the common stock was then listed, at the grant date and have contractual terms of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zR2pjA0e6qkl" title="Weighted avg. remaining contractual life, options exercisable"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">10</ix:nonNumeric></span> years. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_z1TB1lhRy9cb" title="Share-based compensation arrangement by share-based payment award, plan modification, description and terms"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">Vesting terms for options granted
to employees during the three months ended March 31, 2022 included the following vesting schedule: 25% of the shares subject to the option
vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest
and become exercisable quarterly in equal installments thereafter over three years. Certain option awards provide for accelerated vesting
if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term
of options granted to employees and directors was determined in accordance with the &#8220;simplified approach,&#8221; as the Company
has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free
interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time
of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual
effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of <span id="xdx_900_ecustom--ForfeitureFactorPercentage_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zbxUNmZfSSr4" title="Forfeiture factor, percentage"><ix:nonFraction name="HROW:ForfeitureFactorPercentage" contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%. These
factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing
these assumptions, the fair value is determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z8zpcMEUVIpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions
used for valuing options granted to employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zg1IQqPsufYg" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zmdp4Om773Kf" title="Weighted-average fair value of options granted" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.65</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected terms (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zzbfrGSUFxKa" title="Expected terms (in years)"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.11</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zGSII0nQ7aL7" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zN27WN8Tdig6" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.54</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zomvtOcMH8d3" title="Dividend yield" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zoQg66NxAmMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1gh4Ptrwfo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about stock options outstanding and exercisable at March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="xdx_8B2_zfz4KwQGn4je" style="display: none">SCHEDULE OF STOCK OPTION
OUTSTANDING AND EXERCISABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life in Years</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY8PqxlEtXn7" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span>
- $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMsCdx2YF4Y4" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.73</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ztQo68yEhXz9" title="Number of Options Outstanding" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">312,887</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z24q1PU3O8E5" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.70</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zodfpNIeuAmf" title="Weighted Average Exercise Price" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zakIb0ukmuJk" title="Number Exercisable" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">312,887</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcB7TuUOL1of" title="Weighted Average Exercisable Exercise Price" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSGj6KDekUT3" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.23</ix:nonFraction></span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z32dxiErRQc3" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.60</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2SSYXXsSL3c" title="Number of Options Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">313,068</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zT25n5tfd1Di" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">4.84</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z7pxyjABYlCf" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z75oIeqX9ei5" title="Number Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">312,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1ux0QJvYD9e" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zlbZvTHqfLBj" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.76</ix:nonFraction></span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z3BhakphXJ9k" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zX4NmiL2kUs1" title="Number of Options Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXwXMGWvh39c" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.95</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDklN5SIoJB8" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.49</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIeS6xa7bWP6" title="Number Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,906</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zARkKud69mYc" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zpVFjXx6hG55" title="Range of Exercise Prices"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.95</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zN5BPH4Uc7V2" title="Number of Options Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">370,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRW91QoQ5nlh" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeFourMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">4.00</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zMZRx6loRkk4" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zAUALSjauKM5" title="Number Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">370,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUYTQ9ezDwW8" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.95</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrJcySqDeen9" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.08</ix:nonFraction></span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zmvR4WUmEaR4" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.30</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zYOWjPHdfYTf" title="Number of Options Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">578,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zDzGhG9ubpS5" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeFiveMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.71</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zzScQ2irwIHf" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zlKKSuX3bH7g" title="Number Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525,027</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zehLvUJ9aqHf" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.85</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zFssEYVhEJM" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.81</ix:nonFraction></span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zH3KbASX2QE" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.37</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_ziQGewB6CGqe" title="Number of Options Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">388,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF8rAJAetFX2" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeSixMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">6.27</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zx6zFKvNQDGe" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zhPb9Lacstl1" title="Number Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">297,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zJoNEGvO2ZV1" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zn9AbrBJBnbl" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.52</ix:nonFraction></span> - $<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zEce5kFGZrvl" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.79</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zxCWmPlRVlI2" title="Number of Options Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">221,823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zBLTyxICahH" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeSevenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.33</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zdvSnIExzeek" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.61</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zlhNBpCrBIJ9" title="Number Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,323</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z8lHdRdM1aMc" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.66</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUXgtrH3q953" title="Range of Exercise Prices"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.87</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_znmaby7QTmIf" title="Number of Options Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zXGSd2oC62af" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeEightMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">3.33</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z6WLssJ6mn58" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zxBXQ4JYDdJ2" title="Number Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z3g2WSdXUIQk" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.87</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zj12WIIF2rRj" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.89</ix:nonFraction></span> - $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJi9FRnGOXN7" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.98</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zoairg7hWZmf" title="Number of Options Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">92,673</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBCoLK9aiOO3" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeNineMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.47</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z4hEfdWECo01" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z8nMzmM2dE43" title="Number Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zy8b5igvA4cb" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zHoL7MUV5Whf" title="Range of Exercise Prices"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-03-31_custom_RangeTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.99</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zJ0ibE8PHbv2" title="Number of Options Outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31_custom_RangeTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZVNxrAu0CM7" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_RangeTenMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">1.09</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zA4Ck5wftYM6" title="Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31_custom_RangeTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.99</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zeg9x30DOTdi" title="Number Exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31_custom_RangeTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zog13riGQFGl" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_custom_RangeTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.99</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331_zAfyYlfe5RY8" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span> - $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331_z1jNkg6szbWk" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.99</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331_ztowcNr96WXj" title="Number of Options Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,083,796</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zFIPCqRg02Ll" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.01</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331_zVXgHCyBuZf9" title="Weighted Average Exercise Price" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.76</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331_zjnnezu8CiSk" title="Number Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,408,629</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331_z69dsw8Z2T91" title="Weighted Average Exercisable Exercise Price" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.29</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zfyJxnHYScU9" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, there was approximately $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_z7uywyQlhDo2" title="Unrecognized compensation expense related to unvested stock options granted under the plan"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-03-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,806,000</ix:nonFraction></span> of total unrecognized compensation expense related to unvested stock options granted
under the Plans. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zKkdIitsaAJe" title="Expense expected to recognize over the weighted-average remaining vesting period"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">4.89</ix:nonNumeric></span> years. The stock-based
compensation for all stock options was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_z0xAYBlVaSga" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zP0ydY76AsDa" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">452,000</ix:nonFraction></span> during the three months ended March 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of options exercised during the three months ended March 31, 2022 was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zMaTUvdj7FHa" title="Intrinsic value of options exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">745,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units/Performance Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU
awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria.
The grant date fair value of the RSUs, which has been determined based upon the market value of the Company&#8217;s common stock on the
grant date, is expensed over the vesting period of the RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zL3Fov38ZLo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s RSU activity (including performance stock units) and related information for the three months ended March
31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zKxp5nlKRWpa" style="display: none">SCHEDULE
OF RESTRICTED STOCK UNITS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">RSUs unvested - January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeoqiQU4Cum4" title="Number of RSUs unvested, Outstanding, Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,233,202</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMeeYIVkYgVk" title="Weighted Average Grant Date Fair Value, Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.78</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RSUs granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjfsiSlInzFe" title="Number of RSUs granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAOkPaieR8jh" title="Weighted Average Grant Date Fair Value, RSUs granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">RSUs vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbN62HMPlyWc" title="Number of RSUs vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,644</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znDhB7QraFv2" title="Weighted Average Grant Date Fair Value, RSUs vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.57</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFgbIgWQ0s8" title="Number of RSUs cancelled/forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTYSEKP7aTDl" title="Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">RSUs unvested at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgbEvmKQ2qDb" title="Number of RSUs unvested, Outstanding, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,088,558</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuXzSXRNnJ9" title="Weighted Average Grant Date Fair Value, Ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.79</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zblHekinWO1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zhC5lpryASM6" title="Unrecognized compensation expense related to unvested stock options granted under the plan"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-03-31_custom_UnvestedRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,756,000</ix:nonFraction></span>, which is expected
to be recognized over a weighted-average period of <span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zHgIYywusSIl" title="Expense expected to recognize over the weighted-average remaining vesting period"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_UnvestedRSUMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.33</ix:nonNumeric></span> years, based on estimated and actual vesting schedules of the applicable RSUs.
The stock-based compensation for RSUs during the three months ended March 31, 2022 and 2021 was $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zHxcx6c0WDwe" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_UnvestedRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,744,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20210101__20210331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zgPK0efEAbAk" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31_custom_UnvestedRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company issues warrants to purchase shares of the Company&#8217;s common stock to investors, lenders, underwriters
and other non-employees for services rendered or to be rendered in the future, or pursuant to settlement agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo5ixYfyrQ2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of warrant activity for the three months ended March 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_ztvBORS9irK" style="display: none">SCHEDULE
OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Shares Subject</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">to Warrants Outstanding</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants outstanding - January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPb4Gb1Jz4vc" title="Number of Shares Warrants Outstanding, beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">373,847</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyGJANhyi5j3" title="Weighted Average. Exercise Price, Outstanding, beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrPyFoX9mwK9" title="Number of Shares Warrants Outstanding, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zakui8Qwm8b3" title="Share-based Payment Award, Non-Option Equity Instruments, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6IT4LIzQJ9k" title=" Share-based Payment Award, Non-Option Equity Instruments, Expirations" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1452">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHFQiAJFEfSd" title="Number of Shares Warrants Outstanding, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">373,847</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBIycJQy98z2" title="Weighted Average. Exercise Price, Outstanding, Ending balance" style="text-align: right"><ix:nonFraction name="HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2022-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z8S1ubqxtvD1" title="Weighted average remaining contractual life of the outstanding warrants in years"><ix:nonNumeric contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="HROW:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1">2.3</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zRbkYHtlAY7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="HROW:ScheduleofWarrantsOutstandingTableTextBlock"><p id="xdx_897_ecustom--ScheduleofWarrantsOutstandingTableTextBlock_z1jBO3cal1o3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding and exercisable as of March 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmlBmUS0EVja" style="display: none">SCHEDULE
OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Series</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left">Lender warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_900_ecustom--WarrantsIssuanceDate_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z6ZFhmiEdv9a" title="Issue Date"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_LenderWarrantsMember" format="ixt:datemonthdayyear" name="HROW:WarrantsIssuanceDate">7/19/2017</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z8wZbmYFXGWf" title="Warrants Outstanding" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-03-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">373,847</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zlmFP81pJi6a" title="Exercise Price" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-03-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zw8drB9B6Ihc" title="Expiration Date"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_LenderWarrantsMember" format="ixt:datemonthdayyear" name="HROW:WarrantsAndRightsOutstandingMaturityDates">7/19/2024</ix:nonNumeric></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zamDE5I7GWfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiary
Stock-Based Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_zIxxPL6DdzFh" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-03-31_custom_SubsidiaryStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20210101__20210331__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_z0IGk0lzu2Kl" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-03-31_custom_SubsidiaryStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,000</ix:nonFraction></span> in stock-based compensation expense related to subsidiary stock options during the three months ended
March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z4vPgSO6nvK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_ziDMPJsYYPw5" style="display: none">SCHEDULE
OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20220331_zSewNhZ8RMs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20210331_zeZ6gdo90dU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zzZCTPKEA8A5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31_custom_EmployeesMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,676,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-03-31_custom_EmployeesMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">755,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkxhkmCyw9Qe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employees &#8211; research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31_custom_EmployeesMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1480">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVUcNHC5VAfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Directors - selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31_srt_DirectorMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-03-31_srt_DirectorMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z1PYRObGnws1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Consultants &#8211; research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-03-31_custom_ConsultantMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1486">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zuRtxErxv2Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,016,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">855,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbmEPjPSzl7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15. <span id="xdx_82C_z2mC8CTirizl">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Other</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make claims
or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial disputes.
Any of these claims could subject the Company to litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
and Professional Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize
traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any
given time reflects current market conditions, including cost and availability, when the policy is written.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the indemnification provisions contained in the Company&#8217;s governing documents, the Company generally enters into separate
indemnification agreements with each of the Company&#8217;s directors and officers. These agreements require the Company, among other
things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys&#8217; fees, judgments, fines
and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual&#8217;s status
or service as the Company&#8217;s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly
fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the
individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors
in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for
any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred
any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed
consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Klarity
License Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a license agreement in April 2017, as amended in April 2018 (the &#8220;Klarity License Agreement&#8221;), with
Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed
certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic
solution Klarity designed to protect and rehabilitate the ocular surface (the &#8220;Klarity Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z6d1CLBuRVcj" title="Royalty payment description"><ix:nonNumeric contextRef="From2017-04-012017-04-30_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember" name="HROW:RoyaltyPaymentDescription">Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of
net sales, dependent upon the final formulation of the Klarity Product sold</ix:nonNumeric></span>. In addition, the Company was required to make certain milestone
payments to Dr. Lindstrom. All of the above referenced milestone payments were payable at the Company&#8217;s election in cash or shares
of the Company&#8217;s restricted common stock. Payments totaling $<span id="xdx_90A_ecustom--MilestonePaymentInCash_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zSTYSntkUSXk" title="Milestone payment in cash"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="AsOf2022-03-31_custom_KlarityLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> and $<span id="xdx_905_ecustom--MilestonePaymentInCash_iI_c20210331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zYMWpbnK2gWj" title="Milestone payment in cash"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="AsOf2021-03-31_custom_KlarityLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span> were made during the three months ended March 31,
2022 and 2021, respectively. $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_z7aVcoOiVGn4" title="Royalty expenses"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2022-01-012022-03-31_custom_KlarityLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zNQyED0RiQ5k" title="Royalty expenses"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-01-012021-03-31_custom_KlarityLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span> were incurred as royalty expenses during the three months ended March 31, 2022 and 2021,
respectively, and was included in accounts payable to Dr. Lindstrom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Injectable
Asset Purchase Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the Company entered into an asset purchase agreement (the &#8220;Lindstrom APA&#8221;) with Dr. Lindstrom, a member of
its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights
from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the &#8220;Lindstrom Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Lindstrom APA, <span id="xdx_904_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z7yTs6ZVHQud" title="Royalty payment description"><ix:nonNumeric contextRef="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" name="HROW:RoyaltyPaymentDescription">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales,
dependent upon the final formulation and patent protection of the Lindstrom Product sold</ix:nonNumeric></span>. In addition, the Company is required to make
certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_90C_ecustom--InitialMilestonePayment_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zEM577gDs0Wb" title="Initial milestone payment"><ix:nonFraction name="HROW:InitialMilestonePayment" contextRef="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction></span> upon execution of the Lindstrom APA. Dr. Lindstrom
was paid $<span id="xdx_908_ecustom--MilestonePaymentInCash_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_ziRMRumqWQmd" title="Milestone payment in cash"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="AsOf2022-03-31_custom_InjectableAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--MilestonePaymentInCash_iI_c20210331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zfHnAnS1qFT8"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="AsOf2021-03-31_custom_InjectableAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span> in cash during the three months ended March 31, 2022 and 2021, respectively. The Company incurred $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zWuOSPbCmOCb" title="Royalty expenses"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2022-01-012022-03-31_custom_InjectableAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span> and
$<span id="xdx_901_eus-gaap--RoyaltyExpense_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zigytNiKJVQi" title="Royalty expenses"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-01-012021-03-31_custom_InjectableAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span> for royalty expenses related to the Lindstrom APA during the three months ended March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Eyepoint
Commercial Alliance Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the &#8220;Dexycu
Agreement&#8221;) with Eyepoint Pharmaceuticals, Inc. (&#8220;Eyepoint&#8221;), pursuant to which Eyepoint granted the Company the non-exclusive
right to co-promote DEXYCU<sup>&#174;</sup> (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation
following ocular surgery in the United States.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the <span style="background-color: white">Dexycu Agreement</span>, Eyepoint will pay the Company a fee calculated based on the quarterly
sales of DEXYCU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms of the <span style="background-color: white">Dexycu
Agreement</span>, the Company shall use commercially reasonable efforts to promote and market DEXYCU in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span style="background-color: white">Dexycu Agreement</span> expires on <span id="xdx_903_ecustom--CommissionExpirationDate_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zze7YtRgsA4i"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_DexycuAgreementMember" format="ixt:datemonthdayyearen" name="HROW:CommissionExpirationDate">August 1, 2025</ix:nonNumeric></span>, subject to early termination in accordance with
the terms set forth therein. Either party may terminate the <span style="background-color: white">Dexycu Agreement, subject to specified
notice periods and limitations,</span> in the event of (i) uncured material breach by the other party or (ii) if DEXYCU ceases to have
&#8220;pass-through&#8221; payment status. In addition, subject to certain limitations, the Company may terminate the <span style="background-color: white">Dexycu
Agreement</span> (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a change
of control. Eyepoint may terminate the <span style="background-color: white">Dexycu Agreement</span>, subject to specified notice periods
and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods. During the three months
ended March 31, 2022 and 2021, the Company recorded $<span id="xdx_90E_ecustom--CommissionRevenues_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zrC3cpRCRtn3" title="Commission revenues"><ix:nonFraction name="HROW:CommissionRevenues" contextRef="From2022-01-012022-03-31_custom_DexycuAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,320,000</ix:nonFraction></span> and $<span id="xdx_900_ecustom--CommissionRevenues_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zTIo62ADmUWh" title="Commission revenues"><ix:nonFraction name="HROW:CommissionRevenues" contextRef="From2021-01-012021-03-31_custom_DexycuAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485,000</ix:nonFraction></span>, respectively, in commission revenues related to the Dexycu
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered various sales and marketing agreements with certain organizations to provide exclusive and non-exclusive sales and
marketing representation services to Harrow in select geographies in the U.S. in connection with the Company&#8217;s ophthalmic pharmaceutical
compounded formulations or related products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--DescriptionForCommissionPayments_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zahTbaz2FEKb" title="Description for commission payments"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_SalesAndMarketingAgreementsMember" name="HROW:DescriptionForCommissionPayments">Under
the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to <span id="xdx_90A_ecustom--CommissionPaymentsPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zkVqI9bjFDbk" title="Commission payments percentage"><ix:nonFraction name="HROW:CommissionPaymentsPercentage" contextRef="From2022-01-012022-03-31_srt_MinimumMember_custom_SalesAndMarketingAgreementsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% - <span id="xdx_90B_ecustom--CommissionPaymentsPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_z4LuF0bzkmY1" title="Commission payments percentage"><ix:nonFraction name="HROW:CommissionPaymentsPercentage" contextRef="From2022-01-012022-03-31_srt_MaximumMember_custom_SalesAndMarketingAgreementsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% of
net sales for products above and beyond the initial existing sales amounts</ix:nonNumeric></span>. In addition, the Company is required to make periodic milestone
payments to certain organizations in shares of the Company&#8217;s restricted common stock if net sales in the assigned territory reach
certain future levels by the end of their terms. Commission expenses of $<span id="xdx_90F_eus-gaap--SalesCommissionsAndFees_pn3n3_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zGeVmRm8NCIb" title="Commission expenses"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2022-01-012022-03-31_custom_SalesAndMarketingAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,047,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--SalesCommissionsAndFees_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zolAxgvIbau" title="Commission expenses"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2021-01-012021-03-31_custom_SalesAndMarketingAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">804,000</ix:nonFraction></span> were incurred under these agreements during the three months ended March 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset
Purchase, License and Related Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related
parties (the &#8220;Inventors&#8221;) through multiple asset purchase agreements, license agreements, strategic agreements and commission
agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for
the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize
a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual
property and drug development opportunities presented by these Inventors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based
on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first
patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the
Company files the first investigational new drug application (&#8220;IND&#8221;) with the U.S. Food and Drug Administration (&#8220;FDA&#8221;)
for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within
30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual
property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or
licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company&#8217;s
development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the
Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where
data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property,
the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to
the Inventors. During the three months ended March 31, 2022 and 2021, $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zz2PtmNcJcX5" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2022-01-012022-03-31_custom_AssetPurchaseLicenseAndRelatedAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zYZDO92reQzi" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-01-012021-03-31_custom_AssetPurchaseLicenseAndRelatedAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,000</ix:nonFraction></span> were incurred under these agreements as royalty
expenses, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sintetica
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, the Company entered into a License and Supply Agreement (the &#8220;Sintetica Agreement&#8221;) with Sintetica S.A. (&#8220;Sintetica&#8221;),
pursuant to which Sintetica granted the Company the exclusive license and marketing rights to its patented ophthalmic drug candidate
(&#8220;AMP-100&#8221;) in the U.S. and Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Sintetica Agreement, the Company will pay Sintetica a per unit transfer price to supply AMP-100, along with a per unit royalty
for units sold. The Company is required to pay Sintetica up to $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_c20210701__20210731__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zLKCsCkfo5ph" title="Royalty payments"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2021-07-012021-07-31_custom_SinteticaAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000,000</ix:nonFraction></span> in one-time milestone payments including a $<span id="xdx_906_eus-gaap--PaymentsForRoyalties_c20210701__20210731__srt--StatementScenarioAxis__custom--DueWithinThirtyDaysMember__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zboQTHWuHZek" title="Royalty payments"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2021-07-012021-07-31_custom_DueWithinThirtyDaysMember_custom_SinteticaAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> payment
(the &#8220;Upfront Payment&#8221;) due within 30 days of signing the Sintetica Agreement and the balance of payments due upon achievement
of certain regulatory and commercial milestones. Under the terms of the Sintetica Agreement, Sintetica will be responsible for regulatory
filings for AMP-100 in the U.S. The Upfront Payment along with an additional milestone payment of $<span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7626tFCAxkg"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2021-01-012021-12-31_custom_SinteticaAgreementMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,117,000</ix:nonFraction></span> was paid and recorded as
a R&amp;D expenses during the year ended December 31, 2021. For the three months ended March 31, 2022, no amounts have been paid or accrued
under the Sintetica agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations, the term of the Sintetica Agreement is ten years, and allows for a ten-year extension if certain sales thresholds
are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wakamoto
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
August 2021, the Company entered into a License Agreement and a Basic Sale and Purchase Agreement (together, the &#8220;Wakamoto Agreements&#8221;)
with Wakamoto Pharmaceutical Co., Ltd. (&#8220;Wakamoto&#8221;), pursuant to which Wakamoto granted the Company the exclusive license
and marketing rights to its ophthalmic drug candidate (&#8220;MAQ-100&#8221;) in the U.S. and Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the <span style="background-color: white">Wakamoto </span>Agreements, Wakamoto will supply MAQ-100 to the Company, and the Company
will pay Wakamoto a per unit transfer price to supply MAQ-100. In addition, the Company is required to pay Wakamoto various one-time
milestone payments totaling up to $<span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--WakamotoAgreementMember_zGLq77pOpHY1" title="Payment for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2021-08-012021-08-31_custom_WakamotoAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> upon the achievement of certain regulatory milestones and up to $<span id="xdx_909_ecustom--CommercialPaymentsForRoyalties_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--WakamotoAgreementMember_zfumzQTDWiJb" title="Commercial payments for royalties"><ix:nonFraction name="HROW:CommercialPaymentsForRoyalties" contextRef="From2021-08-012021-08-31_custom_WakamotoAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,200,000</ix:nonFraction></span> upon the achievement
of certain commercial milestones. Under the terms of the Agreements, the Company will be responsible for regulatory filings and fees
for MAQ-100 in the U.S. and Canada. Through March 31, 2022, no amounts have been paid or accrued under the Wakamoto agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations, the term of the Agreements is for five years from the date of the FDA&#8217;s market approval of MAQ-100 and
allows for a five-year extension if certain unit sales thresholds are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Presbyopia
Asset Purchase Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the Company entered into an asset purchase agreement (the &#8220;Presbyopia APA&#8221;) with Richard L. Lindstrom, M.D.,
a member of its Board of Directors. Pursuant to the terms of the Presbyopia APA, the Company acquired certain intellectual property and
related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic topical product to treat presbyopia
(the &#8220;Presbyopia Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Presbyopia Product, <span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z7Q763ZNmQ62"><ix:nonNumeric contextRef="From2019-12-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" name="HROW:RoyaltyPaymentDescription">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales,
dependent upon the final formulation and patent protection of the Presbyopia Product sold</ix:nonNumeric></span>. Dr. Lindstrom was paid $<span id="xdx_903_ecustom--MilestonePaymentInCash_iI_pn3n3_c20220331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zbRHq0ZChKOk" title="Milestone payment in cash"><span id="xdx_906_ecustom--MilestonePaymentInCash_iI_pn3n3_c20210331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zzFarbzhcbg" title="Milestone payment in cash"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="AsOf2022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="AsOf2021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> in cash during the
periods ended March 31, 2022 and 2021, and was due $<span id="xdx_901_ecustom--MilestonePaymentsOnPayables_iI_pn3n3_c20220331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zgFoBNxDxh3h" title="Milestone payments on payables"><span id="xdx_902_ecustom--MilestonePaymentsOnPayables_iI_pn3n3_c20210331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zJCOqJNO0Iy8" title="Milestone payments on payables"><ix:nonFraction name="HROW:MilestonePaymentsOnPayables" contextRef="AsOf2022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="HROW:MilestonePaymentsOnPayables" contextRef="AsOf2021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> at March 31, 2022 and 2021. The Company incurred $<span id="xdx_905_eus-gaap--RoyaltyExpense_pn3n3_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zqAnyd65PQB7" title="Royalty expense"><span id="xdx_901_eus-gaap--RoyaltyExpense_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zdwMCGfRnTxd" title="Royalty expense"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2022-01-012022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-01-012021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> for royalty expenses related
to the Presbyopia APA during the periods ended March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_808_eus-gaap--ConcentrationRiskDisclosureTextBlock_zaB4iy0Cwgk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16. <span id="xdx_827_zhZ9f4d7GrN1">CONCENTRATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two products that each comprised more than 10% of total revenues. These products collectively accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zqUQoz088484"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-03-31_custom_TwoProductConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zNvYt9MOXRSj"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-03-31_custom_TwoProductConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">36</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenues during the three months ended March
31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the
Company&#8217;s total pharmacy sales during the three months ended March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zOBkC85bSFj7" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74</ix:nonFraction></span>% and
<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zluRvfoBDKd5" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82</ix:nonFraction></span>% of active pharmaceutical ingredient purchases during the three months ended March 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zX6rswmRDxQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17. <span id="xdx_829_zOVUgaCJPov4">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has performed an evaluation of events occurring subsequent to March 31, 2022 through the filing date of this Quarterly Report.
Based on its evaluation, no events other than those described below need to be disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conditional
Melt Loan Amendment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br />
In April 2022, the Company entered into a First Amendment (the &#8220;Amendment&#8221;) to its loan and security agreement previously
entered into on September 1, 2021 with Melt. The Amendment provides for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--DescripitionOfLoanAmendment_c20220401__20220430__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4NsIwAzfXQ7" title="Descripition of loan amendment"><ix:nonNumeric contextRef="From2022-04-012022-04-30_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember" name="HROW:DescripitionOfLoanAmendment">Melt
    is required to maintain a minimum cash balance of $7,000,000 for one (1) year following the effective date of the Amendment; and
    a minimum cash balance of $5,000,000 at all times after the one year anniversary of the effective date of the Amendment</ix:nonNumeric></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    maturity date by which all amounts owed under the loan agreement are payable was extended to September 1, 2026, unless otherwise
    accelerated pursuant to the terms of the loan agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    definition of Material Adverse Effect was amended so that such an effect will be deemed to have occurred if the data from the phase
    2 study of MELT-300 fails to demonstrate the benefit of the combination MELT-300 study drug versus the individual components of the
    same MELT-300 study drug, as reasonably determined by the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    effectiveness of the Amendment is subject to, among other conditions, Melt consummating a qualifying financing of a minimum amount
    of $<span id="xdx_904_ecustom--MinimumAmountOfFinancing_c20220831__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJpTmHOjbn45" title="Minimum amount of financing"><ix:nonFraction name="HROW:MinimumAmountOfFinancing" contextRef="AsOf2022-08-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span> from third party investors by August 31, 2022.</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_81E_zsGYrOKTZrDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ka_003"></span><span id="sur_001"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited
condensed consolidated financial statements and the related notes thereto contained in Part I, Item 1 of this Quarterly Report on Form
10-Q (this &#8220;Quarterly Report&#8221;). Our condensed consolidated financial statements have been prepared and, unless otherwise
stated, the information derived therefrom as presented in this discussion and analysis is presented, in accordance with accounting principles
generally accepted in the United States of America (&#8220;GAAP&#8221;).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>The
information contained in this Quarterly Report is not a complete description of our business or the risks associated with an investment
in our common stock. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in
our other reports filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including our Annual Report on Form
10-K for the fiscal year ended December 31, 2021 and subsequent reports, which discuss our business in greater detail. As used in this
discussion and analysis, unless the context indicates otherwise, the terms the &#8220;Company,&#8221; &#8220;Harrow,&#8221; &#8220;we,&#8221;
&#8220;us&#8221; and &#8220;our&#8221; refer to Harrow Health, Inc. and its consolidated subsidiaries, consisting of ImprimisRx, LLC,
ImprimisRx NJ, LLC dba ImprimisRx, Imprimis NJOF, LLC, and Imprimis Pharmaceuticals USA, LLC. In this discussion and analysis, we refer
to our consolidated subsidiaries ImprimisRx, LLC, ImprimisRx NJ, LLC and Imprimis NJOF, LLC collectively as &#8220;ImprimisRx.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>In
addition to historical information, the following discussion contains forward-looking statements regarding future events and our future
performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;will,&#8221; &#8220;may,&#8221;
&#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;forecasts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or
other comparable terminology. All statements made in this Quarterly Report other than statements of historical fact are forward-looking
statements. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions
with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual
results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause
actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, risks related
to: the impact of the COVID-19 pandemic on our financial condition, liquidity or results of operations; our ability to successfully implement
our business plan, develop and commercialize our proprietary formulations in a timely manner or at all, identify and acquire additional
proprietary formulations, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit
and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions
and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities
and pharmacies; general economic and business conditions; regulatory and legal risks and uncertainties related to our pharmacy operations
and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations
and compounding pharmacies generally; and the other risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in
Part II, Item 1A of this Quarterly Report and in our other filings with the SEC. You should not place undue reliance on forward-looking
statements. Forward-looking statements speak only as of the date they are made and, except as required by law, we undertake no obligation
to revise or publicly update any forward-looking statement for any reason.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are an ophthalmic-focused healthcare company. Our business specializes in the development, production, sale, and distribution of innovative
prescription medications that offer unique competitive advantages and serve unmet needs in the marketplace through our subsidiaries and
deconsolidated companies. We own and operate ImprimisRx, one of the nation&#8217;s leading ophthalmology-focused pharmaceutical businesses,
and Visionology, Inc. (&#8220;Visionology&#8221;), a direct-to-consumer digital eyecare subsidiary. In addition, we also have non-controlling
equity positions in Surface Ophthalmics, Inc. (&#8220;Surface&#8221;) and Melt Pharmaceuticals, Inc. (&#8220;Melt&#8221;), both companies
that began as subsidiaries of Harrow and were subsequently deconsolidated. We also own royalty rights in various drug candidates being
developed by Surface and Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ImprimisRx</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ImprimisRx
is our ophthalmology-focused prescription pharmaceutical business. From its inception in 2014, ImprimisRx, which consists of integrated
research and development, production, dispensing/distribution, sales, marketing, and customer serve capabilities, has offered physician
customers and their patients access to critical medicines to meet their clinical needs. Initially, ImprimisRx focused exclusively on
compounded medications to serve needs unmet by commercially available drugs. We make our formulations available at prices that are, in
most cases, lower than non-customized commercial drugs. ImprimisRx&#8217;s customer base has grown to include more than 10,000 U.S. eyecare
dedicated prescribers and institutions. Our current ophthalmology formulary includes over twenty compounded formulations, many of which
are patented or patent-pending, and are customizable for the specific needs of a patient. Some of our compounded medications are various
combinations of drugs formulated into one bottle and others are preservative free formulations. Depending on the formulation, the regulations
of a specific state, and ultimately, the needs of the patient, ImprimisRx products may be dispensed as patient-specific medications from
our 503A pharmacy, or for in-office use, or made according to current good manufacturing practices (or &#8220;cGMPs&#8221;) or other
FDA-guidance documents, in our FDA-registered New Jersey outsourcing facility (&#8220;NJOF&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Over
the past two years, in order to more fully serve the needs of our growing customer base, we have invested in broadening ImprimisRx&#8217;s
product portfolio to include FDA-approved products. Our investments in this regard have led to commercial partnerships to sell DEXYCU&#174;
and Avenova, the acquisition of two later stage drug candidates, and the recent acquisition of U.S. rights to four FDA-approved ophthalmic
products. These transactions, and those we are continuing to pursue, are focused in eyecare pharmaceuticals. We believe that our continued
investments in these and other products will result in our ability to provide more physician prescribers and their patients with access
to a complete portfolio of affordable eyecare pharmaceuticals to address their clinical needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>DEXYCU&#174;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ImprimisRx
entered into a Commercial Alliance Agreement (the &#8220;Dexycu Agreement&#8221;) with Eyepoint Pharmaceuticals, Inc. (&#8220;Eyepoint&#8221;),
pursuant to which Eyepoint granted ImprimisRx the right to promote DEXYCU&#174; (dexamethasone intraocular suspension) 9% for the treatment
of post-operative inflammation following ocular surgery in the United States. Pursuant to the Dexycu Agreement, Eyepoint pays ImprimisRx
a fee that is calculated based on the quarterly sales of DEXYCU in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>IOPIDINE&#174;,
MAXITROL&#174;, MOXEZA&#174;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
December 2021, we acquired U.S. commercial rights to four FDA-approved ophthalmic medicines: IOPIDINE 1% and 0.5% (apraclonidine hydrochloride);
MAXITROL (neomycin/polymyxin B/dexamethasone) ophthalmic suspension; and MOXEZA (moxifloxacin hydrochloride). We believe by expanding
our product portfolio to include branded FDA-approved products, we will be uniquely positioned to leverage our ImprimisRx platform to
introduce unique lifecycle management strategies that could grow sales and address needs of our customers that we are unable to meet
with our other compounded product offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
the time of closing the acquisition of the four products, we agreed to a transitional period with the seller, which is expected to last
approximately six months following the closing of the transaction. During the transition period, the seller will continue to sell the
products and transfer the net profit to us. Following the transition period, we expect to have the products manufactured by third parties
and commercialize the products for the U.S. market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>AMP-100</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
July 2021, we acquired the exclusive marketing and supply rights to AMP-100 in the U.S. and Canada from Sintetica S.A. (&#8220;Sintetica&#8221;).
AMP-100 is a patented, ophthalmic topical anesthetic drug candidate. If FDA-approved, the active ingredient used in AMP-100 will be the
first approved use of this active ingredient in the U.S. ophthalmic market. A new drug application (&#8220;NDA&#8221;) for AMP-100 was
submitted by Sintetica to the FDA in the fourth quarter of 2021 and the FDA has assigned the application standard review and a Prescription
Drug User Fee Act (PDUFA) target action date of October 16, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>MAQ-100</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
August 2021, we acquired the exclusive marketing rights to MAQ-100 in the U.S. and Canada from Wakamoto Pharmaceutical Co., Ltd. (&#8220;Wakamoto&#8221;).
MAQ-100 is a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. MAQ-100 is marketed and sold by Wakamoto
in Japan as MaQaid&#174;. Following Japan&#8217;s Ministry of Health Labor and Welfare (&#8220;MHLW&#8221;) approval, MaQaid was launched
in Japan in 2010, indicated as an intravitreal injection for visualization for vitrectomy. Since its initial MHLW approval, the indication
for MaQaid was expanded to include (a) treatments for alleviation of diabetic macular edema, (b) macular edema associated with retinal
vein occlusion (or RVO), and (c) non-infectious uveitis. We intend to leverage the clinical data used for Japanese market approval of
MaQaid to support a clinical program and U.S. market NDA submission of MAQ-100 for visualization during vitrectomy. We intend to request
a meeting with FDA during the first half of 2022 to discuss our planned clinical program for MAQ-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
expect to acquire and/or develop additional FDA-approved/approvable ophthalmic products and product candidates that will allow us to
leverage our commercial infrastructure to promote, sell, and ultimately bring these products to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Visionology</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Visionology,
a direct-to-consumer digital eye health platform, leverages our experience in the ophthalmic pharmaceutical business as well as our relationships
with eyecare professionals across the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carved-Out
Businesses (De-Consolidated Businesses)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have ownership interests in Surface, Melt, and Eton Pharmaceuticals, Inc. (&#8220;Eton&#8221;) and hold royalty interests in some of
Surface&#8217;s and Melt&#8217;s drug candidates. These companies are pursuing market approval for their drug candidates under the FDCA,
including in some instances under the abbreviated pathway described in Section 505(b)(2), which permits the submission of a new drug
application (&#8220;NDA&#8221;) where at least some of the information required for approval comes from studies not conducted by or for
the applicant and for which the applicant has not obtained a right of reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Noncontrolling
Equity Interests</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Surface
Ophthalmics, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Surface
is a clinical-stage pharmaceutical company focused on development and commercialization of innovative therapeutics for ocular surface
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
January 2021, Surface announced positive top-line results from a Phase 2 trial of its drug candidate SURF-201, a 0.2% betamethasone,
preservative-free ophthalmic solution in the Klarity delivery vehicle for the treatment of post cataract surgery pain and inflammation.
According to the Surface results, SURF-201 was dosed twice daily, met its primary endpoints of absence of inflammation at both Day 8
and Day 15 and was found to be safe and well-tolerated by the patient group. In addition, a secondary endpoint showed almost 90% of patients
given SURF-201 were pain free at Day 15. Also in January 2021, Surface announced the first patient dosed in a head-to-head Phase 2 trial
for its drug candidate SURF-100 (mycophenolate sodium and betamethasone in Klarity vehicle) for the treatment of chronic dry eye disease.
In February 2021, Surface announced the first patient dosed in a Phase 2 trial for its drug candidate SURF-200 (betamethasone in Klarity
vehicle) for the treatment of episodic dry eye flares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
2018, Surface closed an offering of its Series A Preferred Stock. At that time, we lost our controlling interest and deconsolidated Surface
from our consolidated financial statements. During May, June and July of 2021, Surface closed an offering of its preferred stock at a
purchase price of $4.50 per share resulting in gross proceeds to Surface of approximately $25,000,000 (the &#8220;Surface Series B Offering&#8221;).
We own 3,500,000 shares of Surface common stock, which was approximately 20% of the equity and voting interests as of March 31, 2022.
Harrow owns mid-single digit royalty rights on net sales of SURF-100, SURF-200 and SURF-201.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Melt
Pharmaceuticals, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Melt
is a clinical-stage pharmaceutical company focused on the development and commercialization of proprietary non-intravenous, sedation
and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Melt intends to seek regulatory
approval for its proprietary technologies, where possible. In December 2018, we entered into an Asset Purchase Agreement with Melt (the
&#8220;Melt Asset Purchase Agreement&#8221;), pursuant to which Harrow assigned to Melt the underlying intellectual property for Melt&#8217;s
current pipeline, including its lead drug candidate MELT-300. The core intellectual property Melt owns is a patented series of combination
non-opioid sedation drug formulations that we estimate to have multitudinous applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">MELT-300
is a novel, sublingually delivered, non-IV, opioid-free drug candidate being developed for procedural sedation. Melt filed an investigational
new drug application (&#8220;IND&#8221;) with the FDA in June 2020 and began its clinical program for MELT-300. In February 2021, Melt
announced data from, and the successful completion of, its Phase 1 study. Melt began enrolling patients in its Phase 2 study for MELT-300
during the fourth quarter of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
January 2019, Melt closed an offering of its Series A Preferred Stock. At that time, we gave up our controlling interest and deconsolidated
Melt from our consolidated financial statements. We own 3,500,000 shares of Melt common stock, which was approximately 46% of the equity
and voting interests issued and outstanding as of March 31, 2022. In September 2021, we provided Melt with a senior secured loan with
a principle amount of $13,500,000, which is intended to fund the Phase 2 program of MELT-300. In connection with the loan, we were given
the right, but not the obligation, to match any offer received by Melt associated with the commercial rights to any of its drug candidates
for a period of five years. Melt is required to make mid-single digit royalty payments to the Company on net sales of MELT-300, while
any patent rights remain outstanding, subject to other conditions. Melt can require the Company to cease compounding like products at
the time of FDA approval of MELT-300. If approved, we do not expect a cessation of compounding like products to have a material impact
on our operations and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eton
Pharmaceuticals, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eton
is a commercial-stage orphan-disease focused pharmaceutical company developing and commercializing innovative drug products. Its product
portfolio and pipeline includes several products and drug candidates in various stages of development across a variety of dosage forms.
In May 2017, we gave up our controlling interest in Eton. We own 1,982,000 shares of Eton common stock, which is less than 10% of the
equity and voting interests issued and outstanding of Eton as of March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Factors
Affecting Our Performance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
believe the primary factors affecting our performance are our ability to increase revenues of our proprietary compounded formulations
and certain non-proprietary products, grow and gain operating efficiencies in our pharmacy operations, potential regulatory-related restrictions,
optimize pricing and obtain reimbursement options for our proprietary compounded formulations, and continue to pursue development and
commercialization opportunities for certain of our ophthalmology and other assets that we have not yet made commercially available as
compounded formulations. We believe we have built a tangible and intangible infrastructure that will allow us to scale revenues efficiently
in the near and long-term. All of these activities will require significant costs and other resources, which we may not have or be able
to obtain from operations or other sources. See &#8220;Liquidity and Capital Resources&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reimbursement
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dexycu
is covered under Medicare Part B, and we are developing drug candidates that we believe will be covered under Medicare Part B. New drugs
approved by the FDA that are used in surgeries performed in a hospital outpatient departments or ambulatory surgical centers may receive
a transitional pass-through reimbursement under Medicare, provided they meet certain criteria, including a &#8220;not insignificant&#8221;
cost criterion. Pass-through status allows for separate payment (i.e., outside the packaged payment rate for the surgical procedure)
under Medicare Part B, which consists of Medicare reimbursement for a drug based on a defined formula for calculating the minimum fee
that a manufacturer may charge for the drug. Under current regulations of the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;),
pass-through status applies for a period of three years; that is measured from the date Medicare makes its first pass-through payment
for the product, following which the product would be incorporated into the cataract bundled payment system, which could significantly
reduce the pricing for that product. Following expiration of pass-through status, under current CMS policy, non-opioid pain management
surgical drugs when used on Medicare Part B patients in an outpatient setting can qualify for ongoing separate payment. CMS&#8217; current
non-opioid separate payment policy, like other CMS policies, can be changed by CMS through its annual rulemaking and comment process.
We believe that CMS will continue its separate payment policy for non-opioid pain management surgical drugs, which has been in effect
since 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working with outside consultants to potentially gain an extension to the transitional payment system, or to separate the drug payment
from the bundled cataract surgery payment after the three-year transitional payment ends and continue to be reimbursed separately for
a longer period of time, potentially through patent life. Unless extended, Dexycu transitional pass-through reimbursement status will
expire on December 31, 2022, which will have an adverse impact on our commission revenues from this product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
proprietary ophthalmic compounded formulations are currently primarily available on a cash-pay basis. However, we expect that MOXEZA,
MAXITROL and IOPIDINE are, and we expect that other drug candidates we are developing, if approved, will be eligible for reimbursement
by third-party payors. We may devote time and other resources to seek reimbursement and patient pay opportunities for these and other
drug products and candidates. However, we may be unsuccessful in achieving these goals, as many third-party payors have imposed significant
challenges for products to be eligible for reimbursement in recent years. Moreover, third-party payors, including Medicare, are increasingly
attempting to contain health care costs by limiting coverage and the level of reimbursement for new drugs and by refusing, in some cases,
to provide coverage for uses of approved products for disease indications for which the FDA has not granted labeling approval. Further,
the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010
(collectively, the &#8220;Health Care Reform Law&#8221;), may have a considerable impact on the existing U.S. system for the delivery
and financing of health care and could conceivably have a </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">material
<span style="background-color: white">adverse effect on our business. As a result, reimbursement from Medicare, Medicaid and other third-party
payors may never be available for any of our products or, if available, may not be sufficient to allow us to sell the products on a competitive
basis and at desirable price points. We are communicating with government and third-party payors in order to make our drug products and
candidates available to more patients and at optimized pricing levels. However, if government and other third-party payors do not provide
adequate coverage and reimbursement levels for our drug products and candidates, the market acceptance and opportunity for them may be
limited.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19
Pandemic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
novel strain of coronavirus was first identified in Wuhan, China in December 2019. The disease caused by it, COVID-19, was declared a
global pandemic by the World Health Organization in March 2020. On March 18, 2020, CMS released guidance for U.S. healthcare providers
to limit all elective medical procedures in order to conserve personal protective equipment and limit exposure to COVID-19 during the
pendency of the pandemic. In addition to limiting elective medical procedures, many hospitals and other healthcare providers have strictly
limited access to their facilities during the pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global
supply chains and healthcare delivery, led to social distancing recommendation, and created significant volatility in financial markets.
In May 2020 and the following months, U.S. states and geographies began easing restrictions associated with the COVID-19 pandemic including
those restrictions related to elective procedures. We have since seen sales of our products return to near historical norms and trends
as restrictions associated with elective procedures and the COVID-19 pandemic have continued to ease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">However,
given the unprecedented and dynamic nature of the COVID-19 pandemic virus, including any mutations/variants, we may not be able to reasonably
estimate the impacts it may have on our financial condition, results of operations or cash flows in the future, especially if there are
new restrictions in elective procedures in the future which would have an adverse impact, which may be material, on our future revenues,
profitability and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br />
In April 2022, we entered into a First Amendment (the &#8220;Amendment&#8221;) to our loan and security agreement previously entered
into on September 1, 2021 with Melt. The Amendment provides for the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melt
    is required to maintain a minimum cash balance of $7,000,000 for one (1) year following the effective date of the Amendment; and
    a minimum cash balance of $5,000,000 at all times after the one year anniversary of the effective date of the Amendment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    maturity date by which all amounts owed under the loan agreement are payable was extended to September 1, 2026, unless otherwise
    accelerated pursuant to the terms of the loan agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    definition of Material Adverse Effect was amended so that such an effect will be deemed to have occurred if the data from the phase
    2 study of MELT-300 fails to demonstrate the benefit of the combination MELT-300 study drug versus the individual components of the
    same MELT-300 study drug, as reasonably determined by us.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    effectiveness of the Amendment is subject to, among other conditions, Melt consummating a qualifying financing of a minimum amount
    of $15,000,000 from third-party investors by August 31, 2022.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following period-to-period comparisons of our financial results for the three months ended March 31, 2022 and 2021, are not necessarily
indicative of results for the current period or any future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenues include amounts recorded from sales of proprietary compounded formulations, commissions from third parties and revenues received
from royalty payments owed to us pursuant to out-license arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following presents our revenues for the three months ended March 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$ Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left">Product sales, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">20,340,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,948,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,392,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Commission revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,320,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">485,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">835,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Transfer of profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">License revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,120,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,443,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,677,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in revenues between periods was related to an increase in sales volumes of our ophthalmology products, an increase in commissions
attributable to sales of Dexycu&#174; and transfer of profit from recently acquired products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
of Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cost of sales includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients,
personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements depreciation,
the write-off of obsolete inventory and other related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following presents our cost of sales for the three months ended March 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$ Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; padding-bottom: 2.5pt">Cost of sales</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">5,963,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">3,770,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">2,193,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in our cost of sales between periods was largely attributable to an increase in unit volumes sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gross
Profit and Margin</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$ Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Gross profit</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">16,157,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">11,673,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">4,484,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Gross margin</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">73.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">75.6</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.6</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decrease in gross margin between the three months ended March 31, 2022 and 2021 is primarily attributable to amortization of certain
intangible assets related to recently acquired products beginning in January 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling,
General and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
selling, general and administrative expenses include personnel costs, including wages and stock-based compensation, corporate facility
expenses, and investor relations, consulting, insurance, filing, legal and accounting fees and expenses as well as costs associated with
our marketing activities and sales of our proprietary compounded formulations and other non-proprietary pharmacy products and formulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following presents our selling, general and administrative expenses for the three months ended March 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$ Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Selling, general and administrative</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">13,398,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">8,164,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">5,234,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in selling, general and administrative expenses between periods was primarily attributable to an increase in compensation
expense related to an increase in stock-based compensation associated with performance stock units that were granted in July 2021,
an increase in consulting expenses associated with regulatory improvements and to support the transition of recent product acquisitions,
and increase in sales and marketing expenses related to new employee costs to support current sales and expected future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development (&#8220;R&amp;D&#8221;) expenses primarily include personnel costs, including wages and stock-based compensation,
expenses related to the development of intellectual property, investigator-initiated research and evaluations, formulation development,
acquired in-process R&amp;D and other costs related to the clinical development of our assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following presents our research and development expenses for the three months ended March 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$ Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Research and development</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">658,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">592,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">66,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, research and development expenses increased compared to the same period in 2021 primarily as a
result of increased costs associated with the clinical programs for AMP-100 and MAQ-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense, net was $1,792,000 for the three months ended March 31, 2022 compared to $513,000 for the same period in 2021. The increase
during the period ended March 31, 2022 compared to the same period in 2021 was primarily due to an increase in the outstanding principal
amount of our debt obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Equity
in Losses from Unconsolidated Entities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, we recorded a loss of $2,886,000 related to our share of losses in Melt compared to $1,319,000
for the same period last year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investment
Gain (Loss) from Eton</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded an unrealized gain of $139,000 related to the change in fair market value of Eton&#8217;s common stock during the three
months ended March 31, 2022. We recorded an unrealized loss of $2,835,000 related to the change in fair market value of Eton&#8217;s
common stock for the three months ended March 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gain
on Forgiveness of PPP Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2021, we recorded gain on forgiveness of PPP (as defined below) loan of $1,967,000 related to the forgiveness
of our $1,967,000 loan received pursuant to the Paycheck Protection Program (&#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief,
and Economic Security Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
(Loss) Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents our net (loss) income and per share net (loss) income for the three months ended March 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc. common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(2,438,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">217,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net (loss) income per share, basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.09</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash on hand at March 31, 2022 was $41,948,000, compared to $42,167,000 at December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Quarterly Report, we believe that cash and cash equivalents of $41,948,000 at March 31, 2022 will be sufficient to
sustain our planned level of operations and capital expenditures for at least the next 12 months. In addition, we may consider the sale
of certain assets including, but not limited to, part of, or all of, our investments in Eton, Surface, Melt, and/or any of our consolidated
subsidiaries. However, we may pursue acquisitions of revenue generating products, drug candidates or other strategic transactions that
involve large expenditures or we may experience growth more quickly or on a larger scale than we expect, any of which could result in
the depletion of capital resources more rapidly than anticipated and could require us to seek additional financing to support our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to use our current cash position and funds generated from our operations and any financing to pursue our business plan, which
includes developing and commercializing drug candidates, compounded formulations and technologies, integrating and developing our operations,
pursuing potential future strategic transactions as opportunities arise, including potential acquisitions of additional pharmacy, outsourcing
facilities, drug company and manufacturers, drug products, drug candidates, and/or assets or technologies, and otherwise fund our operations.
We may also use our resources to conduct clinical trials or other studies in support of our formulations or any drug candidate for which
we pursue FDA approval, to pursue additional development programs or to explore other development opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Flow</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides detailed information about our net cash flows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended March 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">967,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,208,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(410,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(224,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(776,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(781,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(219,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,203,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents and restricted cash at beginning of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,167,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,301,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash at end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">41,948,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,504,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by operating activities during the three months ended March 31, 2022 was $967,000 compared to $3,208,000 during the same
period in the prior year. The decrease in net cash provided by operating activities during the periods was mainly attributed to an increase
in our accounts receivable amounts and decrease in our accounts payable and accrued liabilities balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities during the three months ended March 31, 2022 was $410,000 compared to $224,000, during the same
period in the prior year. Cash used in investing activities in 2022 and 2021 was primarily associated with equipment and software purchases
and upgrades along with investments in our intellectual property portfolio</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities during the three months ended March 31, 2022 and 2021 was $776,000 and $781,000, respectively.
Cash used in financing activities during the three months ended March 31, 2022 was primarily related to payment of taxes upon vesting
of RSUs and exercise of stock options and principal payments on loans outstanding during the same period in the prior year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources
of Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal sources of cash consist of cash provided by operating activities from our ImprimisRx business, and recently, proceeds from
the sale of senior notes and a portion of our Eton common stock. We may also sell some or all of our ownership interests in Surface,
Melt or our subsidiaries, along with the some or all of the remaining portion of our Eton common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
changing trends and overall economic outlook in light of the COVID-19 pandemic, including the historic interim stay-at-home orders and
bans on elective surgeries, created uncertainty surrounding our operating outlook and may impact our future operating results if there
is a rise in COVID-19 related cases in the U.S. In addition, we may acquire new products, product candidates and/or businesses and, as
a result, we may need significant additional capital to support our business plan and fund our proposed business operations. We may receive
additional proceeds from the exercise of stock purchase warrants that are currently outstanding. We may also seek additional financing
from a variety of sources, including other equity or debt financings, funding from corporate partnerships or licensing arrangements,
sales of assets or any other financing transaction. If we issue equity or convertible debt securities to raise additional funds, our
existing stockholders may experience substantial dilution, and the newly issued equity or debt securities may have more favorable terms
or rights, preferences and privileges senior to those of our existing stockholders. If we raise additional funds through collaboration
or licensing arrangements or sales of assets, we may be required to relinquish potentially valuable rights to our product candidates
or proprietary technologies or formulations, or grant licenses on terms that are not favorable to us. If we raise funds by incurring
additional debt, we may be required to pay significant interest expenses and our leverage relative to our earnings or to our equity capitalization
may increase. Obtaining commercial loans, assuming they would be available, would increase our liabilities and future cash commitments
and may impose restrictions on our activities, such as the financial and operating covenants. Further, we may incur substantial costs
in pursuing future capital and/or financing transactions, including investment banking fees, legal fees, accounting fees, printing and
distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we
may issue, such as convertible notes and warrants, which would adversely impact our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to obtain financing when necessary as a result of, among other things, our performance, general economic conditions, conditions
in the pharmaceuticals and pharmacy industries, or our operating history, including our past bankruptcy proceedings. In addition, the
fact that we have a limited history of profitability could further impact the availability or cost to us of future financings. As a result,
sufficient funds may not be available when needed from any source or, if available, such funds may not be available on terms that are
acceptable to us. If we are unable to raise funds to satisfy our capital needs when needed, then we may need to forego pursuit of potentially
valuable development or acquisition opportunities, we may not be able to continue to operate our business pursuant to our business plan,
which would require us to modify our operations to reduce spending to a sustainable level by, among other things, delaying, scaling back
or eliminating some or all of our ongoing or planned investments in corporate infrastructure, business development, sales and marketing
and other activities, or we may be forced to discontinue our operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued and Adopted Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our condensed consolidated financial statements included in this Quarterly Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ka_004"></span><span id="sur_002"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_003"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evaluation
of Disclosure Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed
or submitted pursuant to the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated
to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions
regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our principal executive officer and principal financial officer, our management conducted
an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange
Act, as they existed on March 31, 2022. Based on this evaluation, our principal executive officer and principal financial officer have
concluded that our disclosure controls and procedures were effective to achieve their stated purpose as of March 31, 2022, the end of
the period covered by this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Controls over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the
quarter ended March 31, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial
reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_004"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OTHER
INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_005"></span>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">See
Note 15 to our condensed consolidated financial statements included in this Quarterly Report for information on various legal proceedings,
which is incorporated into this Item by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_006"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -49.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
addition to the other information contained in this Quarterly Report you should consider the risk factors and the other information in
our Annual Report on Form 10-K for the year ended December 31, 2021, including our audited financial statements and the related notes
and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; If any such risks actually
occur, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely
affected. In these circumstances, the market price of our common stock would likely decline and you may lose all or part of your investments.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_007"></span>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_008"></span>Item
3. Defaults Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_009"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_010"></span>Item
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_011"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>31.1*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Mark L. Baum, principal executive officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002.</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>31.2*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Andrew R. Boll, principal financial and accounting officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>32.1**</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by Mark L. Baum, principal executive officer, and Andrew R. Boll, principal financial and accounting officer.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>101.INS*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
    the Inline XBRL document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>101.SCH*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>101.CAL*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>101.DEF*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>101.LAB*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>101.PRE*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>104</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, has been formatted in Inline
    XBRL.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions
    of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sur_012"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Harrow
    Health, Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    May 5, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Mark L. Baum</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    L. Baum</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Andrew R. Boll</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    R. Boll</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></p>
                                                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
31.1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION
OF THE PRINCIPAL EXECUTIVE OFFICER UNDER</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
302 OF THE SARBANES-OXLEY ACT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">I,
Mark L. Baum, certify that:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this quarterly report on Form 10-Q of Harrow Health, Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in the report any change in this registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or
    persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 5, 2022</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark L. Baum</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    L. Baum</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">EXHIBIT
31.2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">CERTIFICATION
OF THE PRINCIPAL FINANCIAL OFFICER UNDER</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">SECTION
302 OF THE SARBANES-OXLEY ACT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">I,
Andrew R. Boll, certify that:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this quarterly report on Form 10-Q of Harrow Health, Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in the report any change in this registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or
    persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 5, 2022</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew R. Boll</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    R. Boll</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Chief
                                            Financial Officer</FONT></P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
REQUIRED BY<BR>
SECTION 1350 OF TITLE 18 OF THE UNITED STATES CODE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned hereby certifies in his capacity as the specified officer of
Harrow Health, Inc. (the &ldquo;Company&rdquo;), that, to the best of his knowledge, the Quarterly Report of the Company on Form 10-Q
for the fiscal quarter ended March 31, 2022 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities
Exchange Act of 1934, and that the information contained in such report fairly presents, in all material respects, the financial condition
and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 5, 2022 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark L. Baum </I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark L. Baum <I>Chief Executive Officer</I></FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 5, 2022 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew R. Boll </I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew R. Boll <I>Chief Financial Officer</I></FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial and Accounting Officer)</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed
filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>hrow-20220331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSEybP9z5Z8KekhvWB+bflqryosZA8N9S8sn6ZmATcM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:HROW="http://harrowinc.com/20220331" elementFormDefault="qualified" targetNamespace="http://harrowinc.com/20220331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://harrowinc.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation" id="DescriptionOfBusinessAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Revenues" id="Revenues">
	  <link:definition>00000009 - Disclosure - REVENUES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" id="InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions">
	  <link:definition>00000010 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" id="InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions">
	  <link:definition>00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Inventories" id="Inventories">
	  <link:definition>00000012 - Disclosure - INVENTORIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000013 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
	  <link:definition>00000014 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts" id="CapitalizedSoftwareDevelopmentCosts">
	  <link:definition>00000015 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
	  <link:definition>00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
	  <link:definition>00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Debt" id="Debt">
	  <link:definition>00000018 - Disclosure - DEBT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Leases" id="Leases">
	  <link:definition>00000019 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" id="StockholdersEquityAndStock-basedCompensation">
	  <link:definition>00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Concentrations" id="Concentrations">
	  <link:definition>00000022 - Disclosure - CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/RevenuesTables" id="RevenuesTables">
	  <link:definition>00000026 - Disclosure - REVENUES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" id="InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables">
	  <link:definition>00000027 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" id="InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables">
	  <link:definition>00000028 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InventoriesTables" id="InventoriesTables">
	  <link:definition>00000029 - Disclosure - INVENTORIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000030 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
	  <link:definition>00000031 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables" id="CapitalizedSoftwareDevelopmentCostsTables">
	  <link:definition>00000032 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
	  <link:definition>00000033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
	  <link:definition>00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/DebtTables" id="DebtTables">
	  <link:definition>00000035 - Disclosure - DEBT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000036 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" id="StockholdersEquityAndStock-basedCompensationTables">
	  <link:definition>00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" id="ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails">
	  <link:definition>00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" id="ScheduleOfDilutedCommonEquivalentSharesDetails">
	  <link:definition>00000039 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails" id="ScheduleOfDilutedNetIncomeLossPerSharesDetails">
	  <link:definition>00000040 - Disclosure - SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfInvestmentDetails" id="ScheduleOfInvestmentDetails">
	  <link:definition>00000041 - Disclosure - SCHEDULE OF INVESTMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" id="ScheduleOfDisaggregatedRevenueDetails">
	  <link:definition>00000043 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/RevenuesDetailsNarrative" id="RevenuesDetailsNarrative">
	  <link:definition>00000044 - Disclosure - REVENUES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" id="ScheduleOfCondensedIncomeStatementDetails">
	  <link:definition>00000045 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" id="ScheduleOfCondensedBalanceSheetDetails">
	  <link:definition>00000046 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" id="InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000047 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" id="SummaryOfCondensedIncomeStatementDetails">
	  <link:definition>00000048 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" id="SummaryOfCondensedBalanceSheetDetails">
	  <link:definition>00000049 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" id="InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000050 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfInventoriesDetails" id="ScheduleOfInventoriesDetails">
	  <link:definition>00000051 - Disclosure - SCHEDULE OF INVENTORIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
	  <link:definition>00000052 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" id="ScheduleOfPropertyPlantAndEquipmentDetails">
	  <link:definition>00000053 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" id="PropertyPlantAndEquipmentDetailsNarrative">
	  <link:definition>00000054 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" id="ScheduleOfFiniteLivedIntangibleAssetsDetails">
	  <link:definition>00000055 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative" id="CapitalizedSoftwareDevelopmentCostsDetailsNarrative">
	  <link:definition>00000056 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
	  <link:definition>00000057 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" id="ScheduleOfAmortizationExpensesForIntangibleAssetsDetails">
	  <link:definition>00000058 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" id="ScheduleOfEstimatedFutureAmortizationExpenseDetails">
	  <link:definition>00000059 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" id="ScheduleOfAccountsPayableAndAccruedExpensesDetails">
	  <link:definition>00000060 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" id="SummaryOfFutureMinimumPaymentsDetails">
	  <link:definition>00000061 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
	  <link:definition>00000062 - Disclosure - DEBT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" id="ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails">
	  <link:definition>00000063 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" id="ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails">
	  <link:definition>00000064 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000065 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" id="ScheduleOfStockOptionPlanActivityDetails">
	  <link:definition>00000066 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" id="ScheduleOfFairValueAssumptionsDetails">
	  <link:definition>00000067 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" id="ScheduleOfStockOptionOutstandingAndExercisableDetails">
	  <link:definition>00000068 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" id="ScheduleOfRestrictedStockUnitsActivityDetails">
	  <link:definition>00000069 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
	  <link:definition>00000070 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" id="ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails">
	  <link:definition>00000071 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" id="ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails">
	  <link:definition>00000072 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" id="StockholdersEquityAndStock-basedCompensationDetailsNarrative">
	  <link:definition>00000073 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000074 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ConcentrationsDetailsNarrative" id="ConcentrationsDetailsNarrative">
	  <link:definition>00000075 - Disclosure - CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="HROW_CommonStock0.001ParValuePerShareMember" name="CommonStock0.001ParValuePerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_Sec8.625SeniorNotesDue2026Member" name="Sec8.625SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ProductSalesNetMember" name="ProductSalesNetMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_OtherRevenuesMember" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_TotalHarrowHealthIncStockholdersEquityMember" name="TotalHarrowHealthIncStockholdersEquityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StockOptionsUnvestedRSUsAndWarrantsMember" name="StockOptionsUnvestedRSUsAndWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_EtonPharmaceuticalsIncMember" name="EtonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MeltPharmaceuticalsIncMember" name="MeltPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ManagementServicesAgreementMember" name="ManagementServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SurfaceOphthalmicsIncMember" name="SurfaceOphthalmicsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LoanMember" name="LoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommissionsMember" name="CommissionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_TransferOfProfitMember" name="TransferOfProfitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MeltLoanAgreementMember" name="MeltLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CapitalizedInternalUseSoftwareMember" name="CapitalizedInternalUseSoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ThirdPartySoftwareLicenseMember" name="ThirdPartySoftwareLicenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CapitalizedSoftwareDevelopmentCostsMember" name="CapitalizedSoftwareDevelopmentCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LicensesMember" name="LicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NewDrugApplicationsMember" name="NewDrugApplicationsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NonCompetitionClauseMember" name="NonCompetitionClauseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StatePharmacyLicensesMember" name="StatePharmacyLicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CarlsbadMember" name="CarlsbadMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LedgewoodMember" name="LedgewoodMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LeaseAmendmentMember" name="LeaseAmendmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NashvilleMember" name="NashvilleMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MarkLBaumMember" name="MarkLBaumMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AndrewRBollMember" name="AndrewRBollMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_JohnPSaharekMember" name="JohnPSaharekMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" name="TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StockOptionPlanMember" name="StockOptionPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_EmployeesAndConsultantMember" name="EmployeesAndConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_UnvestedRSUMember" name="UnvestedRSUMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SubsidiaryStockMember" name="SubsidiaryStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StockOptionPlanOneMember" name="StockOptionPlanOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_OptionsEmployeesMember" name="OptionsEmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeFourMember" name="RangeFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeFiveMember" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeSixMember" name="RangeSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeSevenMember" name="RangeSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeEightMember" name="RangeEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeNineMember" name="RangeNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeTenMember" name="RangeTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LenderWarrantsMember" name="LenderWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_KlarityLicenseAgreementMember" name="KlarityLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RichardLLindstromMDMember" name="RichardLLindstromMDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InjectableAssetPurchaseAgreementMember" name="InjectableAssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DexycuAgreementMember" name="DexycuAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SalesAndMarketingAgreementsMember" name="SalesAndMarketingAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AssetPurchaseLicenseAndRelatedAgreementsMember" name="AssetPurchaseLicenseAndRelatedAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SinteticaAgreementMember" name="SinteticaAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DueWithinThirtyDaysMember" name="DueWithinThirtyDaysMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_WakamotoAgreementMember" name="WakamotoAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_PresbyopiaAssetPurchaseAgreementMember" name="PresbyopiaAssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_TwoProductConcentrationRiskMember" name="TwoProductConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ThreeMainSuppliersMember" name="ThreeMainSuppliersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InvestmentsAndOtherNoncurrentAssetsOne" name="InvestmentsAndOtherNoncurrentAssetsOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_EquityInLossesOfUnconsolidatedEntities" name="EquityInLossesOfUnconsolidatedEntities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_GainLossOnForgivenessOfDebt" name="GainLossOnForgivenessOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit" name="PaymentOfTaxesForVestingOfRestrictedStockUnit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" name="ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" name="CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" name="DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" name="InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract" name="DisclosureCapitalizedSoftwareDevelopmentCostsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CapitalizedSoftwareDevelopmentCostsTextBlock" name="CapitalizedSoftwareDevelopmentCostsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock" name="LesseeOperatingLeaseAndFinanceLeaseTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" name="RisksUncertaintiesAndLiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InvestmentOnePolicyTextBlock" name="InvestmentOnePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InvestmentTwoPolicyTextBlock" name="InvestmentTwoPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DilutedCommonEquivalentSharesTableTextBlock" name="DilutedCommonEquivalentSharesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DilutedNetIncomePerShareTableTextBlock" name="DilutedNetIncomePerShareTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" name="ScheduleOfCondensedIncomeStatementOneTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" name="ScheduleOfCondensedBalanceSheetOneTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock" name="CapitalizedSoftwareDevelopmentCostsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ScheduleofWarrantsOutstandingTableTextBlock" name="ScheduleofWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InvestmentPaidInKindInterest" name="InvestmentPaidInKindInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ReductionInCommonStockInvestment" name="ReductionInCommonStockInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AccountsReceivableTransferredToNoteReceivable" name="AccountsReceivableTransferredToNoteReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ComputerHardwareGross" name="ComputerHardwareGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CapitalizedComputerSoftwareInternalUseInProcess" name="CapitalizedComputerSoftwareInternalUseInProcess" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_FiniteLivedIntangibleAssetsImpairment" name="FiniteLivedIntangibleAssetsImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LeaseExpirationDateDescription" name="LeaseExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AdditionalAreaOfLand" name="AdditionalAreaOfLand" nillable="true" xbrli:periodType="duration" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_WarrantsIssuanceDate" name="WarrantsIssuanceDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_WarrantsAndRightsOutstandingMaturityDates" name="WarrantsAndRightsOutstandingMaturityDates" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CashlessExerciseOfOptionsShares" name="CashlessExerciseOfOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CashlessExerciseOfOptionsPricePerShares" name="CashlessExerciseOfOptionsPricePerShares" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommonStockWithheldOnCashlessExercise" name="CommonStockWithheldOnCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommonStockWithheldForPayrollTaxWithholdingsShares" name="CommonStockWithheldForPayrollTaxWithholdingsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommonStockWithheldForPayrollTaxWithholdings" name="CommonStockWithheldForPayrollTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" name="CommonStockWithheldForPayrollTaxWithholdingsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ClosingPriceOfCommonStockPricePerShare" name="ClosingPriceOfCommonStockPricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ForfeitureFactorPercentage" name="ForfeitureFactorPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RoyaltyPaymentDescription" name="RoyaltyPaymentDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MilestonePaymentInCash" name="MilestonePaymentInCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InitialMilestonePayment" name="InitialMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommissionExpirationDate" name="CommissionExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommissionRevenues" name="CommissionRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DescriptionForCommissionPayments" name="DescriptionForCommissionPayments" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommissionPaymentsPercentage" name="CommissionPaymentsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommercialPaymentsForRoyalties" name="CommercialPaymentsForRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MilestonePaymentsOnPayables" name="MilestonePaymentsOnPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DescripitionOfLoanAmendment" name="DescripitionOfLoanAmendment" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MinimumAmountOfFinancing" name="MinimumAmountOfFinancing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_IssuanceOfCommonStockRelatedToVesting" name="IssuanceOfCommonStockRelatedToVesting" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_IssuanceOfCommonStockRelatedToVestingShares" name="IssuanceOfCommonStockRelatedToVestingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>hrow-20220331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrowinc.com/role/Cover" xlink:href="hrow-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheets" xlink:href="hrow-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:href="hrow-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfOperations" xlink:href="hrow-20220331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:href="hrow-20220331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfCashFlows" xlink:href="hrow-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="hrow-20220331.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Revenues" xlink:href="hrow-20220331.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" xlink:href="hrow-20220331.xsd#InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" xlink:href="hrow-20220331.xsd#InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Inventories" xlink:href="hrow-20220331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="hrow-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:href="hrow-20220331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts" xlink:href="hrow-20220331.xsd#CapitalizedSoftwareDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:href="hrow-20220331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:href="hrow-20220331.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Debt" xlink:href="hrow-20220331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Leases" xlink:href="hrow-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:href="hrow-20220331.xsd#StockholdersEquityAndStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:href="hrow-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Concentrations" xlink:href="hrow-20220331.xsd#Concentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEvents" xlink:href="hrow-20220331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesTables" xlink:href="hrow-20220331.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" xlink:href="hrow-20220331.xsd#InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" xlink:href="hrow-20220331.xsd#InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InventoriesTables" xlink:href="hrow-20220331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="hrow-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:href="hrow-20220331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables" xlink:href="hrow-20220331.xsd#CapitalizedSoftwareDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="hrow-20220331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="hrow-20220331.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtTables" xlink:href="hrow-20220331.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesTables" xlink:href="hrow-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:href="hrow-20220331.xsd#StockholdersEquityAndStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:href="hrow-20220331.xsd#ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfDilutedNetIncomeLossPerSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfInvestmentDetails" xlink:href="hrow-20220331.xsd#ScheduleOfInvestmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:href="hrow-20220331.xsd#ScheduleOfDisaggregatedRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:href="hrow-20220331.xsd#RevenuesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:href="hrow-20220331.xsd#ScheduleOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:href="hrow-20220331.xsd#ScheduleOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20220331.xsd#InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:href="hrow-20220331.xsd#SummaryOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:href="hrow-20220331.xsd#SummaryOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20220331.xsd#InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="hrow-20220331.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:href="hrow-20220331.xsd#PropertyPlantAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative" xlink:href="hrow-20220331.xsd#CapitalizedSoftwareDevelopmentCostsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="hrow-20220331.xsd#ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:href="hrow-20220331.xsd#SummaryOfFutureMinimumPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtDetailsNarrative" xlink:href="hrow-20220331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:href="hrow-20220331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:href="hrow-20220331.xsd#ScheduleOfStockOptionPlanActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:href="hrow-20220331.xsd#ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="hrow-20220331.xsd#ScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="hrow-20220331.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:href="hrow-20220331.xsd#ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:href="hrow-20220331.xsd#StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="hrow-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ConcentrationsDetailsNarrative" xlink:href="hrow-20220331.xsd#ConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:href="hrow-20220331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaapCapitalizedComputerSoftwareNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCapitalizedComputerSoftwareNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentsAndOtherNoncurrentAssetsOne" xlink:label="loc_HROWInvestmentsAndOtherNoncurrentAssetsOne" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_HROWInvestmentsAndOtherNoncurrentAssetsOne" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EquityInLossesOfUnconsolidatedEntities" xlink:label="loc_HROWEquityInLossesOfUnconsolidatedEntities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_HROWEquityInLossesOfUnconsolidatedEntities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_GainLossOnForgivenessOfDebt" xlink:label="loc_HROWGainLossOnForgivenessOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_HROWGainLossOnForgivenessOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_GainLossOnForgivenessOfDebt" xlink:label="loc_HROWGainLossOnForgivenessOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HROWGainLossOnForgivenessOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EquityInLossesOfUnconsolidatedEntities" xlink:label="loc_HROWEquityInLossesOfUnconsolidatedEntities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HROWEquityInLossesOfUnconsolidatedEntities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit" xlink:label="loc_HROWPaymentOfTaxesForVestingOfRestrictedStockUnit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_HROWPaymentOfTaxesForVestingOfRestrictedStockUnit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Revenues" xlink:title="00000009 - Disclosure - REVENUES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" xlink:title="00000010 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" xlink:title="00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Inventories" xlink:title="00000012 - Disclosure - INVENTORIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:title="00000014 - Disclosure - PROPERTY, PLANT AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts" xlink:title="00000015 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Debt" xlink:title="00000018 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Leases" xlink:title="00000019 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:title="00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Concentrations" xlink:title="00000022 - Disclosure - CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesTables" xlink:title="00000026 - Disclosure - REVENUES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" xlink:title="00000027 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" xlink:title="00000028 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InventoriesTables" xlink:title="00000029 - Disclosure - INVENTORIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000030 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:title="00000031 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables" xlink:title="00000032 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtTables" xlink:title="00000035 - Disclosure - DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesTables" xlink:title="00000036 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfInvestmentDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF INVESTMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:title="00000044 - Disclosure - REVENUES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000047 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:title="00000048 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:title="00000049 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000050 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000053 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ComputerHardwareGross" xlink:label="loc_HROWComputerHardwareGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_HROWComputerHardwareGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:title="00000054 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaapCapitalizedComputerSoftwareNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalizedComputerSoftwareNet" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalizedComputerSoftwareNet" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedComputerSoftwareInternalUseInProcess" xlink:label="loc_HROWCapitalizedComputerSoftwareInternalUseInProcess" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalizedComputerSoftwareNet" xlink:to="loc_HROWCapitalizedComputerSoftwareInternalUseInProcess" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative" xlink:title="00000056 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_HROWFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_HROWFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:title="00000061 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtDetailsNarrative" xlink:title="00000062 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_HROWLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_HROWLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:title="00000065 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:title="00000073 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000074 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ConcentrationsDetailsNarrative" xlink:title="00000075 - Disclosure - CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>hrow-20220331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrowinc.com/role/Cover" xlink:href="hrow-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheets" xlink:href="hrow-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:href="hrow-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfOperations" xlink:href="hrow-20220331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:href="hrow-20220331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfCashFlows" xlink:href="hrow-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="hrow-20220331.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Revenues" xlink:href="hrow-20220331.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" xlink:href="hrow-20220331.xsd#InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" xlink:href="hrow-20220331.xsd#InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Inventories" xlink:href="hrow-20220331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="hrow-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:href="hrow-20220331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts" xlink:href="hrow-20220331.xsd#CapitalizedSoftwareDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:href="hrow-20220331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:href="hrow-20220331.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Debt" xlink:href="hrow-20220331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Leases" xlink:href="hrow-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:href="hrow-20220331.xsd#StockholdersEquityAndStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:href="hrow-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Concentrations" xlink:href="hrow-20220331.xsd#Concentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEvents" xlink:href="hrow-20220331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesTables" xlink:href="hrow-20220331.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" xlink:href="hrow-20220331.xsd#InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" xlink:href="hrow-20220331.xsd#InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InventoriesTables" xlink:href="hrow-20220331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="hrow-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:href="hrow-20220331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables" xlink:href="hrow-20220331.xsd#CapitalizedSoftwareDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="hrow-20220331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="hrow-20220331.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtTables" xlink:href="hrow-20220331.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesTables" xlink:href="hrow-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:href="hrow-20220331.xsd#StockholdersEquityAndStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:href="hrow-20220331.xsd#ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfDilutedNetIncomeLossPerSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfInvestmentDetails" xlink:href="hrow-20220331.xsd#ScheduleOfInvestmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:href="hrow-20220331.xsd#ScheduleOfDisaggregatedRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:href="hrow-20220331.xsd#RevenuesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:href="hrow-20220331.xsd#ScheduleOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:href="hrow-20220331.xsd#ScheduleOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20220331.xsd#InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:href="hrow-20220331.xsd#SummaryOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:href="hrow-20220331.xsd#SummaryOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20220331.xsd#InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="hrow-20220331.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:href="hrow-20220331.xsd#PropertyPlantAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative" xlink:href="hrow-20220331.xsd#CapitalizedSoftwareDevelopmentCostsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="hrow-20220331.xsd#ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:href="hrow-20220331.xsd#SummaryOfFutureMinimumPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtDetailsNarrative" xlink:href="hrow-20220331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:href="hrow-20220331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:href="hrow-20220331.xsd#ScheduleOfStockOptionPlanActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:href="hrow-20220331.xsd#ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="hrow-20220331.xsd#ScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="hrow-20220331.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:href="hrow-20220331.xsd#ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:href="hrow-20220331.xsd#StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="hrow-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ConcentrationsDetailsNarrative" xlink:href="hrow-20220331.xsd#ConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:href="hrow-20220331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStock0.001ParValuePerShareMember" xlink:label="loc_HROWCommonStock0.001ParValuePerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_HROWCommonStock0.001ParValuePerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_Sec8.625SeniorNotesDue2026Member" xlink:label="loc_HROWSec8.625SeniorNotesDue2026Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_HROWSec8.625SeniorNotesDue2026Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ProductSalesNetMember" xlink:label="loc_HROWProductSalesNetMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWProductSalesNetMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_OtherRevenuesMember" xlink:label="loc_HROWOtherRevenuesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWOtherRevenuesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapOperatingExpenses_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapInterestExpense_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EquityInLossesOfUnconsolidatedEntities" xlink:label="loc_HROWEquityInLossesOfUnconsolidatedEntities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_HROWEquityInLossesOfUnconsolidatedEntities_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapGainLossOnInvestments_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_GainLossOnForgivenessOfDebt" xlink:label="loc_HROWGainLossOnForgivenessOfDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_HROWGainLossOnForgivenessOfDebt_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapNonoperatingIncomeExpense_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TotalHarrowHealthIncStockholdersEquityMember" xlink:label="loc_HROWTotalHarrowHealthIncStockholdersEquityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_HROWTotalHarrowHealthIncStockholdersEquityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Revenues" xlink:title="00000009 - Disclosure - REVENUES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" xlink:title="00000010 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" xlink:title="00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Inventories" xlink:title="00000012 - Disclosure - INVENTORIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:title="00000014 - Disclosure - PROPERTY, PLANT AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts" xlink:title="00000015 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Debt" xlink:title="00000018 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Leases" xlink:title="00000019 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:title="00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Concentrations" xlink:title="00000022 - Disclosure - CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DilutedCommonEquivalentSharesTableTextBlock" xlink:label="loc_HROWDilutedCommonEquivalentSharesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWDilutedCommonEquivalentSharesTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DilutedNetIncomePerShareTableTextBlock" xlink:label="loc_HROWDilutedNetIncomePerShareTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWDilutedNetIncomePerShareTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="loc_us-gaapInvestmentTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentTableTextBlock_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesTables" xlink:title="00000026 - Disclosure - REVENUES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" xlink:title="00000027 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" xlink:title="00000028 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InventoriesTables" xlink:title="00000029 - Disclosure - INVENTORIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000030 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:title="00000031 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables" xlink:title="00000032 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtTables" xlink:title="00000035 - Disclosure - DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesTables" xlink:title="00000036 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted" xlink:label="loc_us-gaapProFormaWeightedAverageSharesOutstandingDiluted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProFormaWeightedAverageSharesOutstandingDiluted_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfInvestmentDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF INVESTMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:label="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LoanMember" xlink:label="loc_HROWLoanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_HROWLoanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaapEquityMethodInvestmentAggregateCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentAggregateCost_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentPaidInKindInterest" xlink:label="loc_HROWInvestmentPaidInKindInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_HROWInvestmentPaidInKindInterest_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCommittedCapital" xlink:label="loc_us-gaapInvestmentCompanyCommittedCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_us-gaapInvestmentCompanyCommittedCapital_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_us-gaapInvestments_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:label="loc_HROWStockOptionsUnvestedRSUsAndWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_HROWStockOptionsUnvestedRSUsAndWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EtonPharmaceuticalsIncMember" xlink:label="loc_HROWEtonPharmaceuticalsIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWEtonPharmaceuticalsIncMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ManagementServicesAgreementMember" xlink:label="loc_HROWManagementServicesAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWManagementServicesAgreementMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharePrice_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ReductionInCommonStockInvestment" xlink:label="loc_HROWReductionInCommonStockInvestment_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_HROWReductionInCommonStockInvestment_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate" xlink:label="loc_us-gaapInvestmentInterestRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentInterestRate_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDueFromRelatedParties_140" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ProductSalesNetMember" xlink:label="loc_HROWProductSalesNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWProductSalesNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionsMember" xlink:label="loc_HROWCommissionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWCommissionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TransferOfProfitMember" xlink:label="loc_HROWTransferOfProfitMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWTransferOfProfitMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:title="00000044 - Disclosure - REVENUES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_30" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000047 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ManagementServicesAgreementMember" xlink:label="loc_HROWManagementServicesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWManagementServicesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltLoanAgreementMember" xlink:label="loc_HROWMeltLoanAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWMeltLoanAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="loc_us-gaapAdministrativeFeesExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdministrativeFeesExpense_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDueFromRelatedParties_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AccountsReceivableTransferredToNoteReceivable" xlink:label="loc_HROWAccountsReceivableTransferredToNoteReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_HROWAccountsReceivableTransferredToNoteReceivable_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:title="00000048 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:title="00000049 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_30" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000050 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF INVENTORIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000053 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:title="00000054 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedInternalUseSoftwareMember" xlink:label="loc_HROWCapitalizedInternalUseSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWCapitalizedInternalUseSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ThirdPartySoftwareLicenseMember" xlink:label="loc_HROWThirdPartySoftwareLicenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWThirdPartySoftwareLicenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedComputerSoftwareInternalUseInProcess" xlink:label="loc_HROWCapitalizedComputerSoftwareInternalUseInProcess_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_HROWCapitalizedComputerSoftwareInternalUseInProcess_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaapCapitalizedComputerSoftwareNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareNet_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative" xlink:title="00000056 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedSoftwareDevelopmentCostsMember" xlink:label="loc_HROWCapitalizedSoftwareDevelopmentCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWCapitalizedSoftwareDevelopmentCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LicensesMember" xlink:label="loc_HROWLicensesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWLicensesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NewDrugApplicationsMember" xlink:label="loc_HROWNewDrugApplicationsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWNewDrugApplicationsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NonCompetitionClauseMember" xlink:label="loc_HROWNonCompetitionClauseMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWNonCompetitionClauseMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StatePharmacyLicensesMember" xlink:label="loc_HROWStatePharmacyLicensesMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWStatePharmacyLicensesMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_FiniteLivedIntangibleAssetsImpairment" xlink:label="loc_HROWFiniteLivedIntangibleAssetsImpairment_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_HROWFiniteLivedIntangibleAssetsImpairment_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationMethod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationMethod_210" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LicensesMember" xlink:label="loc_HROWLicensesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWLicensesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NewDrugApplicationsMember" xlink:label="loc_HROWNewDrugApplicationsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWNewDrugApplicationsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:title="00000061 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtDetailsNarrative" xlink:title="00000062 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_Sec8.625SeniorNotesDue2026Member" xlink:label="loc_HROWSec8.625SeniorNotesDue2026Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_HROWSec8.625SeniorNotesDue2026Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="loc_us-gaapDebtInstrumentUnamortizedPremium_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedPremium_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaapDebtInstrumentRedemptionDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionDescription_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOtherLongTermDebt" xlink:label="loc_us-gaapInterestExpenseOtherLongTermDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseOtherLongTermDebt_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_120" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:title="00000065 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_OfficeAndLaboratorySpaceMember" xlink:label="loc_HROWOfficeAndLaboratorySpaceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_HROWOfficeAndLaboratorySpaceMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CarlsbadMember" xlink:label="loc_HROWCarlsbadMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWCarlsbadMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LedgewoodMember" xlink:label="loc_HROWLedgewoodMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWLedgewoodMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NashvilleMember" xlink:label="loc_HROWNashvilleMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWNashvilleMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LeaseAmendmentMember" xlink:label="loc_HROWLeaseAmendmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWLeaseAmendmentMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LeaseExpirationDateDescription" xlink:label="loc_HROWLeaseExpirationDateDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWLeaseExpirationDateDescription_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AdditionalAreaOfLand" xlink:label="loc_HROWAdditionalAreaOfLand_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWAdditionalAreaOfLand_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_130" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StockOptionPlanOneMember" xlink:label="loc_HROWStockOptionPlanOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWStockOptionPlanOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_40" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_OptionsEmployeesMember" xlink:label="loc_HROWOptionsEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWOptionsEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeOneMember" xlink:label="loc_HROWRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeTwoMember" xlink:label="loc_HROWRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeThreeMember" xlink:label="loc_HROWRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeFourMember" xlink:label="loc_HROWRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeFiveMember" xlink:label="loc_HROWRangeFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeSixMember" xlink:label="loc_HROWRangeSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeSevenMember" xlink:label="loc_HROWRangeSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeEightMember" xlink:label="loc_HROWRangeEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeNineMember" xlink:label="loc_HROWRangeNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeTenMember" xlink:label="loc_HROWRangeTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_230" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_230" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_230" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_230" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_HROWSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LenderWarrantsMember" xlink:label="loc_HROWLenderWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWLenderWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_WarrantsIssuanceDate" xlink:label="loc_HROWWarrantsIssuanceDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_HROWWarrantsIssuanceDate_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:label="loc_HROWWarrantsAndRightsOutstandingMaturityDates_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_HROWWarrantsAndRightsOutstandingMaturityDates_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EmployeesMember" xlink:label="loc_HROWEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ConsultantMember" xlink:label="loc_HROWConsultantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWConsultantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:title="00000073 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MarkLBaumMember" xlink:label="loc_HROWMarkLBaumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWMarkLBaumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AndrewRBollMember" xlink:label="loc_HROWAndrewRBollMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWAndrewRBollMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_JohnPSaharekMember" xlink:label="loc_HROWJohnPSaharekMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWJohnPSaharekMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StockOptionPlanMember" xlink:label="loc_HROWStockOptionPlanMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWStockOptionPlanMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_UnvestedRSUMember" xlink:label="loc_HROWUnvestedRSUMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWUnvestedRSUMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SubsidiaryStockMember" xlink:label="loc_HROWSubsidiaryStockMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWSubsidiaryStockMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EmployeesAndConsultantMember" xlink:label="loc_HROWEmployeesAndConsultantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesAndConsultantMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:label="loc_HROWTwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_HROWTwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CashlessExerciseOfOptionsShares" xlink:label="loc_HROWCashlessExerciseOfOptionsShares_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCashlessExerciseOfOptionsShares_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CashlessExerciseOfOptionsPricePerShares" xlink:label="loc_HROWCashlessExerciseOfOptionsPricePerShares_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCashlessExerciseOfOptionsPricePerShares_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldOnCashlessExercise" xlink:label="loc_HROWCommonStockWithheldOnCashlessExercise_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldOnCashlessExercise_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsShares" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsShares_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsShares_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdings_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdings_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ClosingPriceOfCommonStockPricePerShare" xlink:label="loc_HROWClosingPriceOfCommonStockPricePerShare_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWClosingPriceOfCommonStockPricePerShare_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_220" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_220" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ForfeitureFactorPercentage" xlink:label="loc_HROWForfeitureFactorPercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWForfeitureFactorPercentage_220" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_220" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_220" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_220" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_220" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000074 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_KlarityLicenseAgreementMember" xlink:label="loc_HROWKlarityLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWKlarityLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InjectableAssetPurchaseAgreementMember" xlink:label="loc_HROWInjectableAssetPurchaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWInjectableAssetPurchaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DexycuAgreementMember" xlink:label="loc_HROWDexycuAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWDexycuAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SalesAndMarketingAgreementsMember" xlink:label="loc_HROWSalesAndMarketingAgreementsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSalesAndMarketingAgreementsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AssetPurchaseLicenseAndRelatedAgreementsMember" xlink:label="loc_HROWAssetPurchaseLicenseAndRelatedAgreementsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWAssetPurchaseLicenseAndRelatedAgreementsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SinteticaAgreementMember" xlink:label="loc_HROWSinteticaAgreementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSinteticaAgreementMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_WakamotoAgreementMember" xlink:label="loc_HROWWakamotoAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWWakamotoAgreementMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:label="loc_HROWPresbyopiaAssetPurchaseAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWPresbyopiaAssetPurchaseAgreementMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RichardLLindstromMDMember" xlink:label="loc_HROWRichardLLindstromMDMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWRichardLLindstromMDMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DueWithinThirtyDaysMember" xlink:label="loc_HROWDueWithinThirtyDaysMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_HROWDueWithinThirtyDaysMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RoyaltyPaymentDescription" xlink:label="loc_HROWRoyaltyPaymentDescription_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWRoyaltyPaymentDescription_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MilestonePaymentInCash" xlink:label="loc_HROWMilestonePaymentInCash_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWMilestonePaymentInCash_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InitialMilestonePayment" xlink:label="loc_HROWInitialMilestonePayment_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWInitialMilestonePayment_280" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionExpirationDate" xlink:label="loc_HROWCommissionExpirationDate_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommissionExpirationDate_280" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionRevenues" xlink:label="loc_HROWCommissionRevenues_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommissionRevenues_280" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DescriptionForCommissionPayments" xlink:label="loc_HROWDescriptionForCommissionPayments_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWDescriptionForCommissionPayments_280" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionPaymentsPercentage" xlink:label="loc_HROWCommissionPaymentsPercentage_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommissionPaymentsPercentage_280" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees_280" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_280" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommercialPaymentsForRoyalties" xlink:label="loc_HROWCommercialPaymentsForRoyalties_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommercialPaymentsForRoyalties_280" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MilestonePaymentsOnPayables" xlink:label="loc_HROWMilestonePaymentsOnPayables_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWMilestonePaymentsOnPayables_280" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ConcentrationsDetailsNarrative" xlink:title="00000075 - Disclosure - CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TwoProductConcentrationRiskMember" xlink:label="loc_HROWTwoProductConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWTwoProductConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="loc_us-gaapCostOfGoodsProductLineMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfGoodsProductLineMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ThreeMainSuppliersMember" xlink:label="loc_HROWThreeMainSuppliersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_HROWThreeMainSuppliersMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DescripitionOfLoanAmendment" xlink:label="loc_HROWDescripitionOfLoanAmendment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HROWDescripitionOfLoanAmendment_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MinimumAmountOfFinancing" xlink:label="loc_HROWMinimumAmountOfFinancing_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HROWMinimumAmountOfFinancing_30" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>hrow-20220331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStock0.001ParValuePerShareMember" xlink:label="HROW_CommonStock0.001ParValuePerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStock0.001ParValuePerShareMember" xlink:to="HROW_CommonStock0.001ParValuePerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStock0.001ParValuePerShareMember_lbl" xml:lang="en-US">Common Stock, $0.001 Par Value Per Share [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_Sec8.625SeniorNotesDue2026Member" xlink:label="HROW_Sec8.625SeniorNotesDue2026Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_Sec8.625SeniorNotesDue2026Member" xlink:to="HROW_Sec8.625SeniorNotesDue2026Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_Sec8.625SeniorNotesDue2026Member_lbl" xml:lang="en-US">8.625% Senior Notes Due 2026 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ProductSalesNetMember" xlink:label="HROW_ProductSalesNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ProductSalesNetMember" xlink:to="HROW_ProductSalesNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ProductSalesNetMember_lbl" xml:lang="en-US">Product Sales, Net [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_OtherRevenuesMember" xlink:label="HROW_OtherRevenuesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OtherRevenuesMember" xlink:to="HROW_OtherRevenuesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_OtherRevenuesMember_lbl" xml:lang="en-US">Other Revenues [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TotalHarrowHealthIncStockholdersEquityMember" xlink:label="HROW_TotalHarrowHealthIncStockholdersEquityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TotalHarrowHealthIncStockholdersEquityMember" xlink:to="HROW_TotalHarrowHealthIncStockholdersEquityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_TotalHarrowHealthIncStockholdersEquityMember_lbl" xml:lang="en-US">Total Harrow Health, Inc. Stockholders' Equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:label="HROW_StockOptionsUnvestedRSUsAndWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:to="HROW_StockOptionsUnvestedRSUsAndWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StockOptionsUnvestedRSUsAndWarrantsMember_lbl" xml:lang="en-US">Stock Options, Unvested RSUs and Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EtonPharmaceuticalsIncMember" xlink:label="HROW_EtonPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EtonPharmaceuticalsIncMember" xlink:to="HROW_EtonPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_EtonPharmaceuticalsIncMember_lbl" xml:lang="en-US">Eton Pharmaceuticals, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="HROW_MeltPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MeltPharmaceuticalsIncMember" xlink:to="HROW_MeltPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MeltPharmaceuticalsIncMember_lbl" xml:lang="en-US">Melt Pharmaceuticals, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ManagementServicesAgreementMember" xlink:label="HROW_ManagementServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ManagementServicesAgreementMember" xlink:to="HROW_ManagementServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ManagementServicesAgreementMember_lbl" xml:lang="en-US">Management Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="HROW_SurfaceOphthalmicsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SurfaceOphthalmicsIncMember" xlink:to="HROW_SurfaceOphthalmicsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SurfaceOphthalmicsIncMember_lbl" xml:lang="en-US">Surface Ophthalmics, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LoanMember" xlink:label="HROW_LoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LoanMember" xlink:to="HROW_LoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LoanMember_lbl" xml:lang="en-US">Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionsMember" xlink:label="HROW_CommissionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionsMember" xlink:to="HROW_CommissionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommissionsMember_lbl" xml:lang="en-US">Commissions [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TransferOfProfitMember" xlink:label="HROW_TransferOfProfitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TransferOfProfitMember" xlink:to="HROW_TransferOfProfitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_TransferOfProfitMember_lbl" xml:lang="en-US">Transfer Of Profit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltLoanAgreementMember" xlink:label="HROW_MeltLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MeltLoanAgreementMember" xlink:to="HROW_MeltLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MeltLoanAgreementMember_lbl" xml:lang="en-US">Melt Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedInternalUseSoftwareMember" xlink:label="HROW_CapitalizedInternalUseSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedInternalUseSoftwareMember" xlink:to="HROW_CapitalizedInternalUseSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CapitalizedInternalUseSoftwareMember_lbl" xml:lang="en-US">Capitalized Internal Use Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ThirdPartySoftwareLicenseMember" xlink:label="HROW_ThirdPartySoftwareLicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ThirdPartySoftwareLicenseMember" xlink:to="HROW_ThirdPartySoftwareLicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ThirdPartySoftwareLicenseMember_lbl" xml:lang="en-US">Third Party Software License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedSoftwareDevelopmentCostsMember" xlink:label="HROW_CapitalizedSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedSoftwareDevelopmentCostsMember" xlink:to="HROW_CapitalizedSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CapitalizedSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Capitalized Software Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LicensesMember" xlink:label="HROW_LicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LicensesMember" xlink:to="HROW_LicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LicensesMember_lbl" xml:lang="en-US">Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US">Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NewDrugApplicationsMember" xlink:label="HROW_NewDrugApplicationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NewDrugApplicationsMember" xlink:to="HROW_NewDrugApplicationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NewDrugApplicationsMember_lbl" xml:lang="en-US">New Drug Applications [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeNamesMember_lbl" xml:lang="en-US">Trade Names [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NonCompetitionClauseMember" xlink:label="HROW_NonCompetitionClauseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NonCompetitionClauseMember" xlink:to="HROW_NonCompetitionClauseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NonCompetitionClauseMember_lbl" xml:lang="en-US">Non-Competition Clause [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StatePharmacyLicensesMember" xlink:label="HROW_StatePharmacyLicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StatePharmacyLicensesMember" xlink:to="HROW_StatePharmacyLicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StatePharmacyLicensesMember_lbl" xml:lang="en-US">State Pharmacy Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_OfficeAndLaboratorySpaceMember" xlink:label="HROW_OfficeAndLaboratorySpaceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OfficeAndLaboratorySpaceMember" xlink:to="HROW_OfficeAndLaboratorySpaceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US">Office and Laboratory Space [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CarlsbadMember" xlink:label="HROW_CarlsbadMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CarlsbadMember" xlink:to="HROW_CarlsbadMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CarlsbadMember_lbl" xml:lang="en-US">Carlsbad [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LedgewoodMember" xlink:label="HROW_LedgewoodMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LedgewoodMember" xlink:to="HROW_LedgewoodMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LedgewoodMember_lbl" xml:lang="en-US">Ledgewood [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LeaseAmendmentMember" xlink:label="HROW_LeaseAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LeaseAmendmentMember" xlink:to="HROW_LeaseAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LeaseAmendmentMember_lbl" xml:lang="en-US">Lease Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NashvilleMember" xlink:label="HROW_NashvilleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NashvilleMember" xlink:to="HROW_NashvilleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NashvilleMember_lbl" xml:lang="en-US">Nashville [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MarkLBaumMember" xlink:label="HROW_MarkLBaumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MarkLBaumMember" xlink:to="HROW_MarkLBaumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MarkLBaumMember_lbl" xml:lang="en-US">Mark L. Baum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AndrewRBollMember" xlink:label="HROW_AndrewRBollMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AndrewRBollMember" xlink:to="HROW_AndrewRBollMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AndrewRBollMember_lbl" xml:lang="en-US">Andrew R. Boll [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_JohnPSaharekMember" xlink:label="HROW_JohnPSaharekMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_JohnPSaharekMember" xlink:to="HROW_JohnPSaharekMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_JohnPSaharekMember_lbl" xml:lang="en-US">John P. Saharek [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:label="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:to="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_lbl" xml:lang="en-US">2017 Incentive Stock and Awards Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StockOptionPlanMember" xlink:label="HROW_StockOptionPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanMember" xlink:to="HROW_StockOptionPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StockOptionPlanMember_lbl" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EmployeesAndConsultantMember" xlink:label="HROW_EmployeesAndConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EmployeesAndConsultantMember" xlink:to="HROW_EmployeesAndConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_EmployeesAndConsultantMember_lbl" xml:lang="en-US">Employees and Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_UnvestedRSUMember" xlink:label="HROW_UnvestedRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_UnvestedRSUMember" xlink:to="HROW_UnvestedRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_UnvestedRSUMember_lbl" xml:lang="en-US">Unvested RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SubsidiaryStockMember" xlink:label="HROW_SubsidiaryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SubsidiaryStockMember" xlink:to="HROW_SubsidiaryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SubsidiaryStockMember_lbl" xml:lang="en-US">Subsidiary Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StockOptionPlanOneMember" xlink:label="HROW_StockOptionPlanOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanOneMember" xlink:to="HROW_StockOptionPlanOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HROW_StockOptionPlanOneMember_lbl" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_OptionsEmployeesMember" xlink:label="HROW_OptionsEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OptionsEmployeesMember" xlink:to="HROW_OptionsEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_OptionsEmployeesMember_lbl" xml:lang="en-US">Options Granted to Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeOneMember" xlink:label="HROW_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeOneMember" xlink:to="HROW_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeTwoMember" xlink:label="HROW_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeTwoMember" xlink:to="HROW_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeThreeMember" xlink:label="HROW_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeThreeMember" xlink:to="HROW_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeFourMember" xlink:label="HROW_RangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeFourMember" xlink:to="HROW_RangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeFiveMember" xlink:label="HROW_RangeFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeFiveMember" xlink:to="HROW_RangeFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeFiveMember_lbl" xml:lang="en-US">Range Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeSixMember" xlink:label="HROW_RangeSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeSixMember" xlink:to="HROW_RangeSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeSixMember_lbl" xml:lang="en-US">Range Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeSevenMember" xlink:label="HROW_RangeSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeSevenMember" xlink:to="HROW_RangeSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeSevenMember_lbl" xml:lang="en-US">Range Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeEightMember" xlink:label="HROW_RangeEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeEightMember" xlink:to="HROW_RangeEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeEightMember_lbl" xml:lang="en-US">Range Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeNineMember" xlink:label="HROW_RangeNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeNineMember" xlink:to="HROW_RangeNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeNineMember_lbl" xml:lang="en-US">Range Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeTenMember" xlink:label="HROW_RangeTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeTenMember" xlink:to="HROW_RangeTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeTenMember_lbl" xml:lang="en-US">Range Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LenderWarrantsMember" xlink:label="HROW_LenderWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LenderWarrantsMember" xlink:to="HROW_LenderWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LenderWarrantsMember_lbl" xml:lang="en-US">Lender Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EmployeesMember" xlink:label="HROW_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EmployeesMember" xlink:to="HROW_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ConsultantMember" xlink:label="HROW_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ConsultantMember" xlink:to="HROW_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ConsultantMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_KlarityLicenseAgreementMember" xlink:label="HROW_KlarityLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_KlarityLicenseAgreementMember" xlink:to="HROW_KlarityLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_KlarityLicenseAgreementMember_lbl" xml:lang="en-US">Klarity License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RichardLLindstromMDMember" xlink:label="HROW_RichardLLindstromMDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RichardLLindstromMDMember" xlink:to="HROW_RichardLLindstromMDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RichardLLindstromMDMember_lbl" xml:lang="en-US">Richard L. Lindstrom, M.D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InjectableAssetPurchaseAgreementMember" xlink:label="HROW_InjectableAssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InjectableAssetPurchaseAgreementMember" xlink:to="HROW_InjectableAssetPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InjectableAssetPurchaseAgreementMember_lbl" xml:lang="en-US">Injectable Asset Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DexycuAgreementMember" xlink:label="HROW_DexycuAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DexycuAgreementMember" xlink:to="HROW_DexycuAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DexycuAgreementMember_lbl" xml:lang="en-US">Dexycu Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SalesAndMarketingAgreementsMember" xlink:label="HROW_SalesAndMarketingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SalesAndMarketingAgreementsMember" xlink:to="HROW_SalesAndMarketingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SalesAndMarketingAgreementsMember_lbl" xml:lang="en-US">Sales and Marketing Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AssetPurchaseLicenseAndRelatedAgreementsMember" xlink:label="HROW_AssetPurchaseLicenseAndRelatedAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AssetPurchaseLicenseAndRelatedAgreementsMember" xlink:to="HROW_AssetPurchaseLicenseAndRelatedAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AssetPurchaseLicenseAndRelatedAgreementsMember_lbl" xml:lang="en-US">Asset Purchase, License and Related Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SinteticaAgreementMember" xlink:label="HROW_SinteticaAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SinteticaAgreementMember" xlink:to="HROW_SinteticaAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SinteticaAgreementMember_lbl" xml:lang="en-US">Sintetica Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DueWithinThirtyDaysMember" xlink:label="HROW_DueWithinThirtyDaysMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DueWithinThirtyDaysMember" xlink:to="HROW_DueWithinThirtyDaysMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DueWithinThirtyDaysMember_lbl" xml:lang="en-US">Due Within Thirty Days [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_WakamotoAgreementMember" xlink:label="HROW_WakamotoAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WakamotoAgreementMember" xlink:to="HROW_WakamotoAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_WakamotoAgreementMember_lbl" xml:lang="en-US">Wakamoto Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:label="HROW_PresbyopiaAssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:to="HROW_PresbyopiaAssetPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_PresbyopiaAssetPurchaseAgreementMember_lbl" xml:lang="en-US">Presbyopia Asset Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TwoProductConcentrationRiskMember" xlink:label="HROW_TwoProductConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TwoProductConcentrationRiskMember" xlink:to="HROW_TwoProductConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_TwoProductConcentrationRiskMember_lbl" xml:lang="en-US">Two Product Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="us-gaap_CostOfGoodsProductLineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl" xml:lang="en-US">Cost of Goods and Service, Product and Service Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ThreeMainSuppliersMember" xlink:label="HROW_ThreeMainSuppliersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ThreeMainSuppliersMember" xlink:to="HROW_ThreeMainSuppliersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ThreeMainSuppliersMember_lbl" xml:lang="en-US">Three Main Suppliers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Investment in Eton Pharmaceuticals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareNet" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xml:lang="en-US">Capitalized software costs, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentsAndOtherNoncurrentAssetsOne" xlink:label="HROW_InvestmentsAndOtherNoncurrentAssetsOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentsAndOtherNoncurrentAssetsOne" xlink:to="HROW_InvestmentsAndOtherNoncurrentAssetsOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InvestmentsAndOtherNoncurrentAssetsOne_lbl" xml:lang="en-US">Investment in Melt Pharmaceuticals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue and customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of finance lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease obligations, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligations, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Loans payable, net of current portion and unamortized debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 50,000,000 shares authorized, 27,031,127 and 26,902,763 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL HARROW HEALTH STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, sharess authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Income from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EquityInLossesOfUnconsolidatedEntities" xlink:label="HROW_EquityInLossesOfUnconsolidatedEntities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EquityInLossesOfUnconsolidatedEntities" xlink:to="HROW_EquityInLossesOfUnconsolidatedEntities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_EquityInLossesOfUnconsolidatedEntities_lbl" xml:lang="en-US">Equity in losses of unconsolidated entities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Investment gain (loss) from Eton Pharmaceuticals</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_GainLossOnForgivenessOfDebt" xlink:label="HROW_GainLossOnForgivenessOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_GainLossOnForgivenessOfDebt" xlink:to="HROW_GainLossOnForgivenessOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_GainLossOnForgivenessOfDebt_lbl" xml:lang="en-US">Gain on forgiveness of PPP loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">(Loss) income before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net (loss) income per share of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net (loss) income per share of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares of common stock outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares of common stock outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">Exercise of employee options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Exercise of employee options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of RSUs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares withheld related to net share settlement of equity awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares withheld related to net share settlement of equity awards, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash provided by operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for bad debt expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_GainLossOnForgivenessOfDebt" xlink:to="HROW_GainLossOnForgivenessOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_GainLossOnForgivenessOfDebt_2_lbl" xml:lang="en-US">Gain on forgiveness of PPP loan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnInvestments_2_lbl" xml:lang="en-US">Investment (gain) loss from investment in Eton</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EquityInLossesOfUnconsolidatedEntities" xlink:to="HROW_EquityInLossesOfUnconsolidatedEntities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_EquityInLossesOfUnconsolidatedEntities_2_lbl" xml:lang="en-US">Equity in losses of unconsolidated entities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued payroll and related liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue and customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Investment in patent and trademark assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property, plant and equipment and capitalized software development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payment on SWK loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit" xlink:label="HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit" xlink:to="HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit_lbl" xml:lang="en-US">Payment of taxes upon vesting of RSUs and exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH USED IN FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:label="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:to="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract_lbl" xml:lang="en-US">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:label="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:to="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:label="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:to="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Investment In Surface Ophthalmics Inc. - Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:label="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:to="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_lbl" xml:lang="en-US">INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:label="HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:to="HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract_lbl" xml:lang="en-US">Capitalized Software Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedSoftwareDevelopmentCostsTextBlock" xlink:label="HROW_CapitalizedSoftwareDevelopmentCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedSoftwareDevelopmentCostsTextBlock" xlink:to="HROW_CapitalizedSoftwareDevelopmentCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CapitalizedSoftwareDevelopmentCostsTextBlock_lbl" xml:lang="en-US">CAPITALIZED SOFTWARE DEVELOPMENT COSTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureLeasesAbstract" xlink:label="HROW_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DisclosureLeasesAbstract" xlink:to="HROW_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock" xlink:label="HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock" xlink:to="HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" xlink:label="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" xlink:to="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock_lbl" xml:lang="en-US">Risks, Uncertainties and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net (Loss) Income per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment in Eton Pharmaceuticals, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentOnePolicyTextBlock" xlink:label="HROW_InvestmentOnePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentOnePolicyTextBlock" xlink:to="HROW_InvestmentOnePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InvestmentOnePolicyTextBlock_lbl" xml:lang="en-US">Investment in Melt Pharmaceuticals, Inc. &#8211; Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentTwoPolicyTextBlock" xlink:label="HROW_InvestmentTwoPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentTwoPolicyTextBlock" xlink:to="HROW_InvestmentTwoPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InvestmentTwoPolicyTextBlock_lbl" xml:lang="en-US">Investment in Surface Ophthalmics, Inc. &#8211; Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Impairment of Equity Method Investments and Note Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DilutedCommonEquivalentSharesTableTextBlock" xlink:label="HROW_DilutedCommonEquivalentSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DilutedCommonEquivalentSharesTableTextBlock" xlink:to="HROW_DilutedCommonEquivalentSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DilutedCommonEquivalentSharesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DilutedNetIncomePerShareTableTextBlock" xlink:label="HROW_DilutedNetIncomePerShareTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DilutedNetIncomePerShareTableTextBlock" xlink:to="HROW_DilutedNetIncomePerShareTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DilutedNetIncomePerShareTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="us-gaap_InvestmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTableTextBlock" xlink:to="us-gaap_InvestmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVESTMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DISAGGREGATED REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:label="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:to="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CONDENSED INCOME STATEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:label="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:to="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CONDENSED BALANCE SHEET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF CONDENSED INCOME STATEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF CONDENSED BALANCE SHEET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock" xlink:label="HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock" xlink:to="HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF FUTURE MINIMUM PAYMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ScheduleofWarrantsOutstandingTableTextBlock" xlink:label="HROW_ScheduleofWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleofWarrantsOutstandingTableTextBlock" xlink:to="HROW_ScheduleofWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ScheduleofWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc. common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Denominator - weighted average number of shares outstanding, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net (loss) income per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted" xlink:label="us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted" xlink:to="us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted_lbl" xml:lang="en-US">Dilutive common equivalent shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3_lbl" xml:lang="en-US">Denominator &#8211; weighted average number of shares outstanding, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Number of shares used for diluted earnings per share computation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Net (loss) income per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_lbl" xml:lang="en-US">Investment Income [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_lbl" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="us-gaap_InvestmentOwnedAtCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xml:lang="en-US">Cost basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Share of Equity Method Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentPaidInKindInterest" xlink:label="HROW_InvestmentPaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentPaidInKindInterest" xlink:to="HROW_InvestmentPaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InvestmentPaidInKindInterest_lbl" xml:lang="en-US">Paid in Kind Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCommittedCapital" xlink:label="us-gaap_InvestmentCompanyCommittedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyCommittedCapital" xlink:to="us-gaap_InvestmentCompanyCommittedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentCompanyCommittedCapital_lbl" xml:lang="en-US">In Substance Capital Contributions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Net carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of shares vestted, RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Number of shares owned</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Shares price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xml:lang="en-US">Investment owned, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ReductionInCommonStockInvestment" xlink:label="HROW_ReductionInCommonStockInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ReductionInCommonStockInvestment" xlink:to="HROW_ReductionInCommonStockInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ReductionInCommonStockInvestment_lbl" xml:lang="en-US">Reduction in common stock investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Investment Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedParties_lbl" xml:lang="en-US">Due from Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Non-current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Total preferred stock and stockholders&#8217; deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xml:lang="en-US">Administrative Fees Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument interest rate stated percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Increase in interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AccountsReceivableTransferredToNoteReceivable" xlink:label="HROW_AccountsReceivableTransferredToNoteReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AccountsReceivableTransferredToNoteReceivable" xlink:to="HROW_AccountsReceivableTransferredToNoteReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AccountsReceivableTransferredToNoteReceivable_lbl" xml:lang="en-US">Accounts receivable transferred to note receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_3_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueFromRelatedParties_2_lbl" xml:lang="en-US">Due from Melt Pharmaceuticals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Deposits and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ComputerHardwareGross" xlink:label="HROW_ComputerHardwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ComputerHardwareGross" xlink:to="HROW_ComputerHardwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ComputerHardwareGross_lbl" xml:lang="en-US">Computer hardware</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Lab and pharmacy equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">&#160;Property, plant and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Total gross capitalized software for internal-use</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:to="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedComputerSoftwareInternalUseInProcess" xlink:label="HROW_CapitalizedComputerSoftwareInternalUseInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedComputerSoftwareInternalUseInProcess" xlink:to="HROW_CapitalizedComputerSoftwareInternalUseInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CapitalizedComputerSoftwareInternalUseInProcess_lbl" xml:lang="en-US">Capitalized internal-use software in process</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareNet" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_2_lbl" xml:lang="en-US">Total finite lived intangible assets net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Amortization periods (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_FiniteLivedIntangibleAssetsImpairment" xlink:label="HROW_FiniteLivedIntangibleAssetsImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FiniteLivedIntangibleAssetsImpairment" xlink:to="HROW_FiniteLivedIntangibleAssetsImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_FiniteLivedIntangibleAssetsImpairment_lbl" xml:lang="en-US">Impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net Carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total minimum payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Less: amount representing interest payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Notes payable, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Less: unamortized discount, net of premium</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermNotesPayable_2_lbl" xml:lang="en-US">Notes payable, net of unamortized discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Additional notes issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs and discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense, debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US">Premium on issuance of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt instrument, interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionDescription" xlink:to="us-gaap_DebtInstrumentRedemptionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xml:lang="en-US">Debt instrument, redemption, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOtherLongTermDebt" xlink:label="us-gaap_InterestExpenseOtherLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOtherLongTermDebt" xlink:to="us-gaap_InterestExpenseOtherLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOtherLongTermDebt_lbl" xml:lang="en-US">Interest Expense, debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DisclosureLeasesAbstract" xlink:to="HROW_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HROW_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Future Lease Payment Under Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: amount representing interest payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: current portion, operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DisclosureLeasesAbstract" xlink:to="HROW_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="HROW_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Future Lease Payment Under Finance Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: amount representing interest payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of future minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: current portion, finance lease obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Finance lease obligation, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LeaseExpirationDateDescription" xlink:label="HROW_LeaseExpirationDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LeaseExpirationDateDescription" xlink:to="HROW_LeaseExpirationDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LeaseExpirationDateDescription_lbl" xml:lang="en-US">Lease expiration date description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease term, option to extend</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AdditionalAreaOfLand" xlink:label="HROW_AdditionalAreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AdditionalAreaOfLand" xlink:to="HROW_AdditionalAreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AdditionalAreaOfLand_lbl" xml:lang="en-US">Additional square footage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating lease, weighted average discount rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease, payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease, expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance lease, weighted average discount rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance lease, weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Finance lease, interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of shares, options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, options cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options cancelled/forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average. remaining contractual life, options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average. remaining contractual life, options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares, options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average. remaining contractual life, options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected terms (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of Exercise Prices, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of Exercise Prices, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Average Exercisable Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of RSUs unvested, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of RSUs granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of RSUs cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of RSUs unvested, Outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Warrants Outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Average. Exercise Price, Outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares Warrants Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Share-based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares Warrants Outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Weighted Average. Exercise Price, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life of the outstanding warrants in years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_WarrantsIssuanceDate" xlink:label="HROW_WarrantsIssuanceDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WarrantsIssuanceDate" xlink:to="HROW_WarrantsIssuanceDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_WarrantsIssuanceDate_lbl" xml:lang="en-US">Issue Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:label="HROW_WarrantsAndRightsOutstandingMaturityDates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:to="HROW_WarrantsAndRightsOutstandingMaturityDates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_WarrantsAndRightsOutstandingMaturityDates_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par or stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares isssued</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CashlessExerciseOfOptionsShares" xlink:label="HROW_CashlessExerciseOfOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashlessExerciseOfOptionsShares" xlink:to="HROW_CashlessExerciseOfOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CashlessExerciseOfOptionsShares_lbl" xml:lang="en-US">Cashless exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CashlessExerciseOfOptionsPricePerShares" xlink:label="HROW_CashlessExerciseOfOptionsPricePerShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashlessExerciseOfOptionsPricePerShares" xlink:to="HROW_CashlessExerciseOfOptionsPricePerShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CashlessExerciseOfOptionsPricePerShares_lbl" xml:lang="en-US">Cashless exercise of options, price per shares</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldOnCashlessExercise" xlink:label="HROW_CommonStockWithheldOnCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldOnCashlessExercise" xlink:to="HROW_CommonStockWithheldOnCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStockWithheldOnCashlessExercise_lbl" xml:lang="en-US">Common stock withheld on cashless exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsShares" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdingsShares" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdingsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsShares_lbl" xml:lang="en-US">Common stock withheld for payroll tax withholdings, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdings_lbl" xml:lang="en-US">Common stock withheld for payroll tax withholdings, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of restricted stock units granted</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_lbl" xml:lang="en-US">Common stock withheld for payroll tax withholdings, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Number of restricted stock units granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ClosingPriceOfCommonStockPricePerShare" xlink:label="HROW_ClosingPriceOfCommonStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ClosingPriceOfCommonStockPricePerShare" xlink:to="HROW_ClosingPriceOfCommonStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ClosingPriceOfCommonStockPricePerShare_lbl" xml:lang="en-US">Closing price of common stock price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted avg. remaining contractual life, options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, plan modification, description and terms</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ForfeitureFactorPercentage" xlink:label="HROW_ForfeitureFactorPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ForfeitureFactorPercentage" xlink:to="HROW_ForfeitureFactorPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ForfeitureFactorPercentage_lbl" xml:lang="en-US">Forfeiture factor, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options granted under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Expense expected to recognize over the weighted-average remaining vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RoyaltyPaymentDescription" xlink:label="HROW_RoyaltyPaymentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RoyaltyPaymentDescription" xlink:to="HROW_RoyaltyPaymentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RoyaltyPaymentDescription_lbl" xml:lang="en-US">Royalty payment description</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MilestonePaymentInCash" xlink:label="HROW_MilestonePaymentInCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MilestonePaymentInCash" xlink:to="HROW_MilestonePaymentInCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MilestonePaymentInCash_lbl" xml:lang="en-US">Milestone payment in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty expense</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InitialMilestonePayment" xlink:label="HROW_InitialMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InitialMilestonePayment" xlink:to="HROW_InitialMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InitialMilestonePayment_lbl" xml:lang="en-US">Initial milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionExpirationDate" xlink:label="HROW_CommissionExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionExpirationDate" xlink:to="HROW_CommissionExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommissionExpirationDate_lbl" xml:lang="en-US">Commission expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionRevenues" xlink:label="HROW_CommissionRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionRevenues" xlink:to="HROW_CommissionRevenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommissionRevenues_lbl" xml:lang="en-US">Commission revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DescriptionForCommissionPayments" xlink:label="HROW_DescriptionForCommissionPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DescriptionForCommissionPayments" xlink:to="HROW_DescriptionForCommissionPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DescriptionForCommissionPayments_lbl" xml:lang="en-US">Description for commission payments</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionPaymentsPercentage" xlink:label="HROW_CommissionPaymentsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionPaymentsPercentage" xlink:to="HROW_CommissionPaymentsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommissionPaymentsPercentage_lbl" xml:lang="en-US">Commission payments percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="us-gaap_SalesCommissionsAndFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesCommissionsAndFees_lbl" xml:lang="en-US">Commission expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payment for royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommercialPaymentsForRoyalties" xlink:label="HROW_CommercialPaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommercialPaymentsForRoyalties" xlink:to="HROW_CommercialPaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommercialPaymentsForRoyalties_lbl" xml:lang="en-US">Commercial payments for royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MilestonePaymentsOnPayables" xlink:label="HROW_MilestonePaymentsOnPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MilestonePaymentsOnPayables" xlink:to="HROW_MilestonePaymentsOnPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MilestonePaymentsOnPayables_lbl" xml:lang="en-US">Milestone payments on payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DescripitionOfLoanAmendment" xlink:label="HROW_DescripitionOfLoanAmendment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DescripitionOfLoanAmendment" xlink:to="HROW_DescripitionOfLoanAmendment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DescripitionOfLoanAmendment_lbl" xml:lang="en-US">Descripition of loan amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MinimumAmountOfFinancing" xlink:label="HROW_MinimumAmountOfFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MinimumAmountOfFinancing" xlink:to="HROW_MinimumAmountOfFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MinimumAmountOfFinancing_lbl" xml:lang="en-US">Minimum amount of financing</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_Sec8.625SeniorNotesDue2026Member" xlink:to="HROW_Sec8.625SeniorNotesDue2026Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_Sec8.625SeniorNotesDue2026Member_doc" xml:lang="en-US">8.625% Senior Notes due 2026 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStock0.001ParValuePerShareMember" xlink:to="HROW_CommonStock0.001ParValuePerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStock0.001ParValuePerShareMember_doc" xml:lang="en-US">Common Stock, $0.001 par value per share [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentsAndOtherNoncurrentAssetsOne" xlink:to="HROW_InvestmentsAndOtherNoncurrentAssetsOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InvestmentsAndOtherNoncurrentAssetsOne_doc" xml:lang="en-US">Investments and other noncurrent assets one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EquityInLossesOfUnconsolidatedEntities" xlink:to="HROW_EquityInLossesOfUnconsolidatedEntities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_EquityInLossesOfUnconsolidatedEntities_doc" xml:lang="en-US">Equity in losses of unconsolidated entities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_GainLossOnForgivenessOfDebt" xlink:to="HROW_GainLossOnForgivenessOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_GainLossOnForgivenessOfDebt_doc" xml:lang="en-US">Gain Loss On Forgiveness Of Debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ProductSalesNetMember" xlink:to="HROW_ProductSalesNetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ProductSalesNetMember_doc" xml:lang="en-US">Product Sales Net [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TotalHarrowHealthIncStockholdersEquityMember" xlink:to="HROW_TotalHarrowHealthIncStockholdersEquityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_TotalHarrowHealthIncStockholdersEquityMember_doc" xml:lang="en-US">Total harrow health inc stockholders equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_IssuanceOfCommonStockRelatedToVesting" xlink:label="HROW_IssuanceOfCommonStockRelatedToVesting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IssuanceOfCommonStockRelatedToVesting" xlink:to="HROW_IssuanceOfCommonStockRelatedToVesting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_IssuanceOfCommonStockRelatedToVesting_doc" xml:lang="en-US">Issuance Of Common Stock Related To Vesting.</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_IssuanceOfCommonStockRelatedToVestingShares" xlink:label="HROW_IssuanceOfCommonStockRelatedToVestingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IssuanceOfCommonStockRelatedToVestingShares" xlink:to="HROW_IssuanceOfCommonStockRelatedToVestingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_IssuanceOfCommonStockRelatedToVestingShares_doc" xml:lang="en-US">Issuance Of Common Stock Related To Vesting Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:to="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract_doc" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restriced Cash At End Of Period Abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:to="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_doc" xml:lang="en-US">Cash Cash Equivalents And Restricted Cash At End Of Period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit" xlink:to="HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit_doc" xml:lang="en-US">Payment of taxes for vesting of restricted stock unit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" xlink:to="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock_doc" xml:lang="en-US">Risks Uncertainties And Liquidity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentOnePolicyTextBlock" xlink:to="HROW_InvestmentOnePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InvestmentOnePolicyTextBlock_doc" xml:lang="en-US">Investment One [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentTwoPolicyTextBlock" xlink:to="HROW_InvestmentTwoPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InvestmentTwoPolicyTextBlock_doc" xml:lang="en-US">Investment Two [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DilutedCommonEquivalentSharesTableTextBlock" xlink:to="HROW_DilutedCommonEquivalentSharesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DilutedCommonEquivalentSharesTableTextBlock_doc" xml:lang="en-US">Diluted Common Equivalent Shares [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DilutedNetIncomePerShareTableTextBlock" xlink:to="HROW_DilutedNetIncomePerShareTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DilutedNetIncomePerShareTableTextBlock_doc" xml:lang="en-US">Diluted Net Income Per Share [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MeltPharmaceuticalsIncMember" xlink:to="HROW_MeltPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MeltPharmaceuticalsIncMember_doc" xml:lang="en-US">Melt Pharmaceuticals Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:to="HROW_StockOptionsUnvestedRSUsAndWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StockOptionsUnvestedRSUsAndWarrantsMember_doc" xml:lang="en-US">Stock Options, Unvested RSUs and Warrants [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentPaidInKindInterest" xlink:to="HROW_InvestmentPaidInKindInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InvestmentPaidInKindInterest_doc" xml:lang="en-US">Investment paid in kind interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EtonPharmaceuticalsIncMember" xlink:to="HROW_EtonPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_EtonPharmaceuticalsIncMember_doc" xml:lang="en-US">Eton Pharmaceuticals, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ReductionInCommonStockInvestment" xlink:to="HROW_ReductionInCommonStockInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ReductionInCommonStockInvestment_doc" xml:lang="en-US">Reduction in common stock investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LoanMember" xlink:to="HROW_LoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LoanMember_doc" xml:lang="en-US">Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionsMember" xlink:to="HROW_CommissionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommissionsMember_doc" xml:lang="en-US">Commissions [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TransferOfProfitMember" xlink:to="HROW_TransferOfProfitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_TransferOfProfitMember_doc" xml:lang="en-US">Transfer Of Profit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:to="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock_doc" xml:lang="en-US">Schedule Of condensed Income Statement One [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:to="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock_doc" xml:lang="en-US">Schedule Of condensed Balance Sheet One [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ManagementServicesAgreementMember" xlink:to="HROW_ManagementServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ManagementServicesAgreementMember_doc" xml:lang="en-US">Management Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MeltLoanAgreementMember" xlink:to="HROW_MeltLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MeltLoanAgreementMember_doc" xml:lang="en-US">Melt Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AccountsReceivableTransferredToNoteReceivable" xlink:to="HROW_AccountsReceivableTransferredToNoteReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AccountsReceivableTransferredToNoteReceivable_doc" xml:lang="en-US">Accounts receivable transferred to note receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:to="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_doc" xml:lang="en-US">Investments And Agreements Related Party Transactions [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ComputerHardwareGross" xlink:to="HROW_ComputerHardwareGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ComputerHardwareGross_doc" xml:lang="en-US">Computer hardware gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedSoftwareDevelopmentCostsTextBlock" xlink:to="HROW_CapitalizedSoftwareDevelopmentCostsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CapitalizedSoftwareDevelopmentCostsTextBlock_doc" xml:lang="en-US">Capitalized Software Development Costs [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock" xlink:to="HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock_doc" xml:lang="en-US">Capitalized Software Development Costs [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedInternalUseSoftwareMember" xlink:to="HROW_CapitalizedInternalUseSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CapitalizedInternalUseSoftwareMember_doc" xml:lang="en-US">Capitalized Internal Use Software [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ThirdPartySoftwareLicenseMember" xlink:to="HROW_ThirdPartySoftwareLicenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ThirdPartySoftwareLicenseMember_doc" xml:lang="en-US">Third Party Software License [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedComputerSoftwareInternalUseInProcess" xlink:to="HROW_CapitalizedComputerSoftwareInternalUseInProcess_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CapitalizedComputerSoftwareInternalUseInProcess_doc" xml:lang="en-US">Capitalized computer software internal use in process.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CapitalizedSoftwareDevelopmentCostsMember" xlink:to="HROW_CapitalizedSoftwareDevelopmentCostsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CapitalizedSoftwareDevelopmentCostsMember_doc" xml:lang="en-US">Capitalized Software Development Costs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LicensesMember" xlink:to="HROW_LicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LicensesMember_doc" xml:lang="en-US">Licenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NonCompetitionClauseMember" xlink:to="HROW_NonCompetitionClauseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NonCompetitionClauseMember_doc" xml:lang="en-US">Non-Competition Clause [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StatePharmacyLicensesMember" xlink:to="HROW_StatePharmacyLicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StatePharmacyLicensesMember_doc" xml:lang="en-US">State Pharmacy Licenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NewDrugApplicationsMember" xlink:to="HROW_NewDrugApplicationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NewDrugApplicationsMember_doc" xml:lang="en-US">New Drug Applications [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FiniteLivedIntangibleAssetsImpairment" xlink:to="HROW_FiniteLivedIntangibleAssetsImpairment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_FiniteLivedIntangibleAssetsImpairment_doc" xml:lang="en-US">Finite lived intangible assets impairment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_doc" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock" xlink:to="HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock_doc" xml:lang="en-US">Lessee Operating Lease And Finance Lease [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CarlsbadMember" xlink:to="HROW_CarlsbadMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CarlsbadMember_doc" xml:lang="en-US">Carlsbad [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OfficeAndLaboratorySpaceMember" xlink:to="HROW_OfficeAndLaboratorySpaceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_OfficeAndLaboratorySpaceMember_doc" xml:lang="en-US">Office and Laboratory Space [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LeaseExpirationDateDescription" xlink:to="HROW_LeaseExpirationDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LeaseExpirationDateDescription_doc" xml:lang="en-US">Lease expiration date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LedgewoodMember" xlink:to="HROW_LedgewoodMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LedgewoodMember_doc" xml:lang="en-US">Ledgewood [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AdditionalAreaOfLand" xlink:to="HROW_AdditionalAreaOfLand_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AdditionalAreaOfLand_doc" xml:lang="en-US">Additional area of land.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LeaseAmendmentMember" xlink:to="HROW_LeaseAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LeaseAmendmentMember_doc" xml:lang="en-US">Lease Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NashvilleMember" xlink:to="HROW_NashvilleMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NashvilleMember_doc" xml:lang="en-US">Nashville [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MarkLBaumMember" xlink:to="HROW_MarkLBaumMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MarkLBaumMember_doc" xml:lang="en-US">Mark L. Baum [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldOnCashlessExercise" xlink:to="HROW_CommonStockWithheldOnCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStockWithheldOnCashlessExercise_doc" xml:lang="en-US">Common stock withheld on cashless exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdingsShares" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdingsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsShares_doc" xml:lang="en-US">Common stock withheld for payroll tax withholdings, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AndrewRBollMember" xlink:to="HROW_AndrewRBollMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AndrewRBollMember_doc" xml:lang="en-US">Andrew R. Boll [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_doc" xml:lang="en-US">Common stock withheld for payroll tax withholdings, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_JohnPSaharekMember" xlink:to="HROW_JohnPSaharekMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_JohnPSaharekMember_doc" xml:lang="en-US">John P. Saharek [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:to="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_doc" xml:lang="en-US">2017 Incentive Stock and Awards Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanOneMember" xlink:to="HROW_StockOptionPlanOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StockOptionPlanOneMember_doc" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ClosingPriceOfCommonStockPricePerShare" xlink:to="HROW_ClosingPriceOfCommonStockPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ClosingPriceOfCommonStockPricePerShare_doc" xml:lang="en-US">Closing price of common stock price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanMember" xlink:to="HROW_StockOptionPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StockOptionPlanMember_doc" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EmployeesAndConsultantMember" xlink:to="HROW_EmployeesAndConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_EmployeesAndConsultantMember_doc" xml:lang="en-US">Employees and Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ForfeitureFactorPercentage" xlink:to="HROW_ForfeitureFactorPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ForfeitureFactorPercentage_doc" xml:lang="en-US">Forfeiture factor, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OptionsEmployeesMember" xlink:to="HROW_OptionsEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_OptionsEmployeesMember_doc" xml:lang="en-US">Options Granted to Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeOneMember" xlink:to="HROW_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeOneMember_doc" xml:lang="en-US">Range One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RoyaltyPaymentDescription" xlink:to="HROW_RoyaltyPaymentDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RoyaltyPaymentDescription_doc" xml:lang="en-US">Royalty payment description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_KlarityLicenseAgreementMember" xlink:to="HROW_KlarityLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_KlarityLicenseAgreementMember_doc" xml:lang="en-US">Klarity License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RichardLLindstromMDMember" xlink:to="HROW_RichardLLindstromMDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RichardLLindstromMDMember_doc" xml:lang="en-US">Richard L. Lindstrom, M.D [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MilestonePaymentInCash" xlink:to="HROW_MilestonePaymentInCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MilestonePaymentInCash_doc" xml:lang="en-US">Milestone payment in cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InjectableAssetPurchaseAgreementMember" xlink:to="HROW_InjectableAssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InjectableAssetPurchaseAgreementMember_doc" xml:lang="en-US">Injectable Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionExpirationDate" xlink:to="HROW_CommissionExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommissionExpirationDate_doc" xml:lang="en-US">Commission expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DexycuAgreementMember" xlink:to="HROW_DexycuAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DexycuAgreementMember_doc" xml:lang="en-US">Dexycu Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionRevenues" xlink:to="HROW_CommissionRevenues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommissionRevenues_doc" xml:lang="en-US">Commission revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DescriptionForCommissionPayments" xlink:to="HROW_DescriptionForCommissionPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DescriptionForCommissionPayments_doc" xml:lang="en-US">Description for commission payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SalesAndMarketingAgreementsMember" xlink:to="HROW_SalesAndMarketingAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SalesAndMarketingAgreementsMember_doc" xml:lang="en-US">Sales and Marketing Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionPaymentsPercentage" xlink:to="HROW_CommissionPaymentsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommissionPaymentsPercentage_doc" xml:lang="en-US">Commission payments, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_UnvestedRSUMember" xlink:to="HROW_UnvestedRSUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_UnvestedRSUMember_doc" xml:lang="en-US">Unvested RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SubsidiaryStockMember" xlink:to="HROW_SubsidiaryStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SubsidiaryStockMember_doc" xml:lang="en-US">Subsidiary Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WarrantsIssuanceDate" xlink:to="HROW_WarrantsIssuanceDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_WarrantsIssuanceDate_doc" xml:lang="en-US">Warrants issuance date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LenderWarrantsMember" xlink:to="HROW_LenderWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LenderWarrantsMember_doc" xml:lang="en-US">Lender Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:to="HROW_WarrantsAndRightsOutstandingMaturityDates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_WarrantsAndRightsOutstandingMaturityDates_doc" xml:lang="en-US">Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AssetPurchaseLicenseAndRelatedAgreementsMember" xlink:to="HROW_AssetPurchaseLicenseAndRelatedAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AssetPurchaseLicenseAndRelatedAgreementsMember_doc" xml:lang="en-US">Asset Purchase, License and Related Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WakamotoAgreementMember" xlink:to="HROW_WakamotoAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_WakamotoAgreementMember_doc" xml:lang="en-US">Wakamoto Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommercialPaymentsForRoyalties" xlink:to="HROW_CommercialPaymentsForRoyalties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommercialPaymentsForRoyalties_doc" xml:lang="en-US">Commercial payments for royalties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:to="HROW_PresbyopiaAssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_PresbyopiaAssetPurchaseAgreementMember_doc" xml:lang="en-US">Presbyopia Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MilestonePaymentsOnPayables" xlink:to="HROW_MilestonePaymentsOnPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MilestonePaymentsOnPayables_doc" xml:lang="en-US">Milestone payments on payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashlessExerciseOfOptionsShares" xlink:to="HROW_CashlessExerciseOfOptionsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CashlessExerciseOfOptionsShares_doc" xml:lang="en-US">Cashless exercise of options shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashlessExerciseOfOptionsPricePerShares" xlink:to="HROW_CashlessExerciseOfOptionsPricePerShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CashlessExerciseOfOptionsPricePerShares_doc" xml:lang="en-US">Cashless exercise of options price per shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdings_doc" xml:lang="en-US">Common stock withheld for payroll tax withholdings, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeTwoMember" xlink:to="HROW_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeTwoMember_doc" xml:lang="en-US">Range Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeThreeMember" xlink:to="HROW_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeThreeMember_doc" xml:lang="en-US">Range Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeFourMember" xlink:to="HROW_RangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeFourMember_doc" xml:lang="en-US">Range Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeFiveMember" xlink:to="HROW_RangeFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeFiveMember_doc" xml:lang="en-US">Range Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeSixMember" xlink:to="HROW_RangeSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeSixMember_doc" xml:lang="en-US">Range Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeSevenMember" xlink:to="HROW_RangeSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeSevenMember_doc" xml:lang="en-US">Range Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeEightMember" xlink:to="HROW_RangeEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeEightMember_doc" xml:lang="en-US">Range Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeNineMember" xlink:to="HROW_RangeNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeNineMember_doc" xml:lang="en-US">Range Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeTenMember" xlink:to="HROW_RangeTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeTenMember_doc" xml:lang="en-US">Range Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleofWarrantsOutstandingTableTextBlock" xlink:to="HROW_ScheduleofWarrantsOutstandingTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ScheduleofWarrantsOutstandingTableTextBlock_doc" xml:lang="en-US">Schedule of Warrants Outstanding [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EmployeesMember" xlink:to="HROW_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ConsultantMember" xlink:to="HROW_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ConsultantMember_doc" xml:lang="en-US">Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DescripitionOfLoanAmendment" xlink:to="HROW_DescripitionOfLoanAmendment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DescripitionOfLoanAmendment_doc" xml:lang="en-US">Descripition of loan amendment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MinimumAmountOfFinancing" xlink:to="HROW_MinimumAmountOfFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MinimumAmountOfFinancing_doc" xml:lang="en-US">Minimum amount of financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TwoProductConcentrationRiskMember" xlink:to="HROW_TwoProductConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_TwoProductConcentrationRiskMember_doc" xml:lang="en-US">Two Product Concentration Risk [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ThreeMainSuppliersMember" xlink:to="HROW_ThreeMainSuppliersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ThreeMainSuppliersMember_doc" xml:lang="en-US">Three Main Suppliers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InitialMilestonePayment" xlink:to="HROW_InitialMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InitialMilestonePayment_doc" xml:lang="en-US">Initial milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SinteticaAgreementMember" xlink:to="HROW_SinteticaAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SinteticaAgreementMember_doc" xml:lang="en-US">Sintetica Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DueWithinThirtyDaysMember" xlink:to="HROW_DueWithinThirtyDaysMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DueWithinThirtyDaysMember_doc" xml:lang="en-US">Due Within Thirty Days [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SurfaceOphthalmicsIncMember" xlink:to="HROW_SurfaceOphthalmicsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SurfaceOphthalmicsIncMember_doc" xml:lang="en-US">Surface Ophthalmics, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OtherRevenuesMember" xlink:to="HROW_OtherRevenuesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_OtherRevenuesMember_doc" xml:lang="en-US">Other Revenues [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanOneMember" xlink:to="HROW_StockOptionPlanOneMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StockOptionPlanOneMember_3_lbl" xml:lang="en-US">Stock Option Plan [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_3_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:to="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_3_lbl" xml:lang="en-US">CashCashEquivalentsAndRestrictedCashAtEndOfPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_2_lbl" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyCommittedCapital" xlink:to="us-gaap_InvestmentCompanyCommittedCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyCommittedCapital_2_lbl" xml:lang="en-US">Investment Company, Committed Capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:to="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_2_lbl" xml:lang="en-US">Capitalized Computer Software, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_2_lbl" xml:lang="en-US">Interest Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_3_lbl" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_4_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_3_lbl" xml:lang="en-US">CommonStockWithheldForPayrollTaxWithholdingsValue</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>hrow-20220331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrowinc.com/role/Cover" xlink:href="hrow-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheets" xlink:href="hrow-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:href="hrow-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfOperations" xlink:href="hrow-20220331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:href="hrow-20220331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfCashFlows" xlink:href="hrow-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="hrow-20220331.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Revenues" xlink:href="hrow-20220331.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" xlink:href="hrow-20220331.xsd#InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" xlink:href="hrow-20220331.xsd#InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Inventories" xlink:href="hrow-20220331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="hrow-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:href="hrow-20220331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts" xlink:href="hrow-20220331.xsd#CapitalizedSoftwareDevelopmentCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:href="hrow-20220331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:href="hrow-20220331.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Debt" xlink:href="hrow-20220331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Leases" xlink:href="hrow-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:href="hrow-20220331.xsd#StockholdersEquityAndStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:href="hrow-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Concentrations" xlink:href="hrow-20220331.xsd#Concentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEvents" xlink:href="hrow-20220331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesTables" xlink:href="hrow-20220331.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" xlink:href="hrow-20220331.xsd#InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" xlink:href="hrow-20220331.xsd#InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InventoriesTables" xlink:href="hrow-20220331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="hrow-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:href="hrow-20220331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables" xlink:href="hrow-20220331.xsd#CapitalizedSoftwareDevelopmentCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="hrow-20220331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="hrow-20220331.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtTables" xlink:href="hrow-20220331.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesTables" xlink:href="hrow-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:href="hrow-20220331.xsd#StockholdersEquityAndStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:href="hrow-20220331.xsd#ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfDilutedNetIncomeLossPerSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfInvestmentDetails" xlink:href="hrow-20220331.xsd#ScheduleOfInvestmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="hrow-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:href="hrow-20220331.xsd#ScheduleOfDisaggregatedRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:href="hrow-20220331.xsd#RevenuesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:href="hrow-20220331.xsd#ScheduleOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:href="hrow-20220331.xsd#ScheduleOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20220331.xsd#InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:href="hrow-20220331.xsd#SummaryOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:href="hrow-20220331.xsd#SummaryOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20220331.xsd#InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="hrow-20220331.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:href="hrow-20220331.xsd#PropertyPlantAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative" xlink:href="hrow-20220331.xsd#CapitalizedSoftwareDevelopmentCostsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="hrow-20220331.xsd#ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:href="hrow-20220331.xsd#SummaryOfFutureMinimumPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtDetailsNarrative" xlink:href="hrow-20220331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:href="hrow-20220331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:href="hrow-20220331.xsd#ScheduleOfStockOptionPlanActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:href="hrow-20220331.xsd#ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="hrow-20220331.xsd#ScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="hrow-20220331.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:href="hrow-20220331.xsd#ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:href="hrow-20220331.xsd#ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:href="hrow-20220331.xsd#StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="hrow-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ConcentrationsDetailsNarrative" xlink:href="hrow-20220331.xsd#ConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:href="hrow-20220331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStock0.001ParValuePerShareMember" xlink:label="loc_HROWCommonStock0.001ParValuePerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_HROWCommonStock0.001ParValuePerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_Sec8.625SeniorNotesDue2026Member" xlink:label="loc_HROWSec8.625SeniorNotesDue2026Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_HROWSec8.625SeniorNotesDue2026Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaapCapitalizedComputerSoftwareNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentsAndOtherNoncurrentAssetsOne" xlink:label="loc_HROWInvestmentsAndOtherNoncurrentAssetsOne" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_HROWInvestmentsAndOtherNoncurrentAssetsOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ProductSalesNetMember" xlink:label="loc_HROWProductSalesNetMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWProductSalesNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_OtherRevenuesMember" xlink:label="loc_HROWOtherRevenuesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWOtherRevenuesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EquityInLossesOfUnconsolidatedEntities" xlink:label="loc_HROWEquityInLossesOfUnconsolidatedEntities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_HROWEquityInLossesOfUnconsolidatedEntities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_GainLossOnForgivenessOfDebt" xlink:label="loc_HROWGainLossOnForgivenessOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_HROWGainLossOnForgivenessOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TotalHarrowHealthIncStockholdersEquityMember" xlink:label="loc_HROWTotalHarrowHealthIncStockholdersEquityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_HROWTotalHarrowHealthIncStockholdersEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_GainLossOnForgivenessOfDebt" xlink:label="loc_HROWGainLossOnForgivenessOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_HROWGainLossOnForgivenessOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EquityInLossesOfUnconsolidatedEntities" xlink:label="loc_HROWEquityInLossesOfUnconsolidatedEntities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_HROWEquityInLossesOfUnconsolidatedEntities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit" xlink:label="loc_HROWPaymentOfTaxesForVestingOfRestrictedStockUnit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_HROWPaymentOfTaxesForVestingOfRestrictedStockUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:label="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:label="loc_HROWCashCashEquivalentsAndRestrictedCashAtEndOfPeriod" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:to="loc_HROWCashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Revenues" xlink:title="00000009 - Disclosure - REVENUES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions" xlink:title="00000010 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions" xlink:title="00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:label="loc_HROWInvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:to="loc_HROWInvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Inventories" xlink:title="00000012 - Disclosure - INVENTORIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:title="00000014 - Disclosure - PROPERTY, PLANT AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts" xlink:title="00000015 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:label="loc_HROWDisclosureCapitalizedSoftwareDevelopmentCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedSoftwareDevelopmentCostsTextBlock" xlink:label="loc_HROWCapitalizedSoftwareDevelopmentCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:to="loc_HROWCapitalizedSoftwareDevelopmentCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Debt" xlink:title="00000018 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Leases" xlink:title="00000019 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureLeasesAbstract" xlink:label="loc_HROWDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock" xlink:label="loc_HROWLesseeOperatingLeaseAndFinanceLeaseTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_HROWLesseeOperatingLeaseAndFinanceLeaseTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:title="00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Concentrations" xlink:title="00000022 - Disclosure - CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" xlink:label="loc_HROWRisksUncertaintiesAndLiquidityPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWRisksUncertaintiesAndLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInvestmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentOnePolicyTextBlock" xlink:label="loc_HROWInvestmentOnePolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWInvestmentOnePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentTwoPolicyTextBlock" xlink:label="loc_HROWInvestmentTwoPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWInvestmentTwoPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DilutedCommonEquivalentSharesTableTextBlock" xlink:label="loc_HROWDilutedCommonEquivalentSharesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWDilutedCommonEquivalentSharesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DilutedNetIncomePerShareTableTextBlock" xlink:label="loc_HROWDilutedNetIncomePerShareTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWDilutedNetIncomePerShareTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="loc_us-gaapInvestmentTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesTables" xlink:title="00000026 - Disclosure - REVENUES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables" xlink:title="00000027 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:label="loc_HROWScheduleOfCondensedIncomeStatementOneTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_HROWScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:label="loc_HROWScheduleOfCondensedBalanceSheetOneTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_HROWScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables" xlink:title="00000028 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:to="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:to="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InventoriesTables" xlink:title="00000029 - Disclosure - INVENTORIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000030 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_HROWScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_HROWScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:title="00000031 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables" xlink:title="00000032 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:label="loc_HROWDisclosureCapitalizedSoftwareDevelopmentCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock" xlink:label="loc_HROWCapitalizedSoftwareDevelopmentCostsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:to="loc_HROWCapitalizedSoftwareDevelopmentCostsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtTables" xlink:title="00000035 - Disclosure - DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesTables" xlink:title="00000036 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureLeasesAbstract" xlink:label="loc_HROWDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ScheduleofWarrantsOutstandingTableTextBlock" xlink:label="loc_HROWScheduleofWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_HROWScheduleofWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted" xlink:label="loc_us-gaapProFormaWeightedAverageSharesOutstandingDiluted" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProFormaWeightedAverageSharesOutstandingDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted" xlink:label="loc_us-gaapProFormaWeightedAverageSharesOutstandingDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapProFormaWeightedAverageSharesOutstandingDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfInvestmentDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF INVESTMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:label="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:label="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LoanMember" xlink:label="loc_HROWLoanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_HROWLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaapEquityMethodInvestmentAggregateCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentAggregateCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InvestmentPaidInKindInterest" xlink:label="loc_HROWInvestmentPaidInKindInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_HROWInvestmentPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCommittedCapital" xlink:label="loc_us-gaapInvestmentCompanyCommittedCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_us-gaapInvestmentCompanyCommittedCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:label="loc_HROWStockOptionsUnvestedRSUsAndWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_HROWStockOptionsUnvestedRSUsAndWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EtonPharmaceuticalsIncMember" xlink:label="loc_HROWEtonPharmaceuticalsIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWEtonPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ManagementServicesAgreementMember" xlink:label="loc_HROWManagementServicesAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWManagementServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ReductionInCommonStockInvestment" xlink:label="loc_HROWReductionInCommonStockInvestment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_HROWReductionInCommonStockInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate" xlink:label="loc_us-gaapInvestmentInterestRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ProductSalesNetMember" xlink:label="loc_HROWProductSalesNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWProductSalesNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionsMember" xlink:label="loc_HROWCommissionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWCommissionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TransferOfProfitMember" xlink:label="loc_HROWTransferOfProfitMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWTransferOfProfitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:title="00000044 - Disclosure - REVENUES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000047 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ManagementServicesAgreementMember" xlink:label="loc_HROWManagementServicesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWManagementServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltLoanAgreementMember" xlink:label="loc_HROWMeltLoanAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWMeltLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="loc_us-gaapAdministrativeFeesExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdministrativeFeesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AccountsReceivableTransferredToNoteReceivable" xlink:label="loc_HROWAccountsReceivableTransferredToNoteReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_HROWAccountsReceivableTransferredToNoteReceivable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:title="00000048 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:title="00000049 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000050 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SurfaceOphthalmicsIncMember" xlink:label="loc_HROWSurfaceOphthalmicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfaceOphthalmicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000053 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ComputerHardwareGross" xlink:label="loc_HROWComputerHardwareGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_HROWComputerHardwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:title="00000054 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:label="loc_HROWDisclosureCapitalizedSoftwareDevelopmentCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedInternalUseSoftwareMember" xlink:label="loc_HROWCapitalizedInternalUseSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWCapitalizedInternalUseSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ThirdPartySoftwareLicenseMember" xlink:label="loc_HROWThirdPartySoftwareLicenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWThirdPartySoftwareLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedComputerSoftwareInternalUseInProcess" xlink:label="loc_HROWCapitalizedComputerSoftwareInternalUseInProcess" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_HROWCapitalizedComputerSoftwareInternalUseInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaapCapitalizedComputerSoftwareNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapCapitalizedComputerSoftwareNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative" xlink:title="00000056 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:label="loc_HROWDisclosureCapitalizedSoftwareDevelopmentCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureCapitalizedSoftwareDevelopmentCostsAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CapitalizedSoftwareDevelopmentCostsMember" xlink:label="loc_HROWCapitalizedSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWCapitalizedSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LicensesMember" xlink:label="loc_HROWLicensesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NewDrugApplicationsMember" xlink:label="loc_HROWNewDrugApplicationsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWNewDrugApplicationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NonCompetitionClauseMember" xlink:label="loc_HROWNonCompetitionClauseMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWNonCompetitionClauseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StatePharmacyLicensesMember" xlink:label="loc_HROWStatePharmacyLicensesMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWStatePharmacyLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_FiniteLivedIntangibleAssetsImpairment" xlink:label="loc_HROWFiniteLivedIntangibleAssetsImpairment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_HROWFiniteLivedIntangibleAssetsImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationMethod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationMethod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LicensesMember" xlink:label="loc_HROWLicensesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NewDrugApplicationsMember" xlink:label="loc_HROWNewDrugApplicationsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWNewDrugApplicationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_HROWFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_HROWFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:title="00000061 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtDetailsNarrative" xlink:title="00000062 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_Sec8.625SeniorNotesDue2026Member" xlink:label="loc_HROWSec8.625SeniorNotesDue2026Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_HROWSec8.625SeniorNotesDue2026Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="loc_us-gaapDebtInstrumentUnamortizedPremium" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaapDebtInstrumentRedemptionDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOtherLongTermDebt" xlink:label="loc_us-gaapInterestExpenseOtherLongTermDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseOtherLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureLeasesAbstract" xlink:label="loc_HROWDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_HROWLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_HROWLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:title="00000064 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureLeasesAbstract" xlink:label="loc_HROWDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:title="00000065 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DisclosureLeasesAbstract" xlink:label="loc_HROWDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_OfficeAndLaboratorySpaceMember" xlink:label="loc_HROWOfficeAndLaboratorySpaceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_HROWOfficeAndLaboratorySpaceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CarlsbadMember" xlink:label="loc_HROWCarlsbadMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWCarlsbadMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LedgewoodMember" xlink:label="loc_HROWLedgewoodMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWLedgewoodMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_NashvilleMember" xlink:label="loc_HROWNashvilleMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWNashvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LeaseAmendmentMember" xlink:label="loc_HROWLeaseAmendmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWLeaseAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LeaseExpirationDateDescription" xlink:label="loc_HROWLeaseExpirationDateDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWLeaseExpirationDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AdditionalAreaOfLand" xlink:label="loc_HROWAdditionalAreaOfLand" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWAdditionalAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StockOptionPlanOneMember" xlink:label="loc_HROWStockOptionPlanOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWStockOptionPlanOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_OptionsEmployeesMember" xlink:label="loc_HROWOptionsEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWOptionsEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeOneMember" xlink:label="loc_HROWRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeTwoMember" xlink:label="loc_HROWRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeThreeMember" xlink:label="loc_HROWRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeFourMember" xlink:label="loc_HROWRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeFiveMember" xlink:label="loc_HROWRangeFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeSixMember" xlink:label="loc_HROWRangeSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeSevenMember" xlink:label="loc_HROWRangeSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeEightMember" xlink:label="loc_HROWRangeEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeNineMember" xlink:label="loc_HROWRangeNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RangeTenMember" xlink:label="loc_HROWRangeTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_HROWSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_LenderWarrantsMember" xlink:label="loc_HROWLenderWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWLenderWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_WarrantsIssuanceDate" xlink:label="loc_HROWWarrantsIssuanceDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_HROWWarrantsIssuanceDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:label="loc_HROWWarrantsAndRightsOutstandingMaturityDates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_HROWWarrantsAndRightsOutstandingMaturityDates" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EmployeesMember" xlink:label="loc_HROWEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ConsultantMember" xlink:label="loc_HROWConsultantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:title="00000073 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MarkLBaumMember" xlink:label="loc_HROWMarkLBaumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWMarkLBaumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AndrewRBollMember" xlink:label="loc_HROWAndrewRBollMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWAndrewRBollMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_JohnPSaharekMember" xlink:label="loc_HROWJohnPSaharekMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWJohnPSaharekMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_StockOptionPlanMember" xlink:label="loc_HROWStockOptionPlanMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWStockOptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_UnvestedRSUMember" xlink:label="loc_HROWUnvestedRSUMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWUnvestedRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SubsidiaryStockMember" xlink:label="loc_HROWSubsidiaryStockMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWSubsidiaryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_EmployeesAndConsultantMember" xlink:label="loc_HROWEmployeesAndConsultantMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesAndConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:label="loc_HROWTwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_HROWTwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CashlessExerciseOfOptionsShares" xlink:label="loc_HROWCashlessExerciseOfOptionsShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCashlessExerciseOfOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CashlessExerciseOfOptionsPricePerShares" xlink:label="loc_HROWCashlessExerciseOfOptionsPricePerShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCashlessExerciseOfOptionsPricePerShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldOnCashlessExercise" xlink:label="loc_HROWCommonStockWithheldOnCashlessExercise" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldOnCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsShares" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdings" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ClosingPriceOfCommonStockPricePerShare" xlink:label="loc_HROWClosingPriceOfCommonStockPricePerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWClosingPriceOfCommonStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ForfeitureFactorPercentage" xlink:label="loc_HROWForfeitureFactorPercentage" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWForfeitureFactorPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000074 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_KlarityLicenseAgreementMember" xlink:label="loc_HROWKlarityLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWKlarityLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InjectableAssetPurchaseAgreementMember" xlink:label="loc_HROWInjectableAssetPurchaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWInjectableAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DexycuAgreementMember" xlink:label="loc_HROWDexycuAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWDexycuAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SalesAndMarketingAgreementsMember" xlink:label="loc_HROWSalesAndMarketingAgreementsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSalesAndMarketingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_AssetPurchaseLicenseAndRelatedAgreementsMember" xlink:label="loc_HROWAssetPurchaseLicenseAndRelatedAgreementsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWAssetPurchaseLicenseAndRelatedAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_SinteticaAgreementMember" xlink:label="loc_HROWSinteticaAgreementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSinteticaAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_WakamotoAgreementMember" xlink:label="loc_HROWWakamotoAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWWakamotoAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:label="loc_HROWPresbyopiaAssetPurchaseAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWPresbyopiaAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RichardLLindstromMDMember" xlink:label="loc_HROWRichardLLindstromMDMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWRichardLLindstromMDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DueWithinThirtyDaysMember" xlink:label="loc_HROWDueWithinThirtyDaysMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_HROWDueWithinThirtyDaysMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_RoyaltyPaymentDescription" xlink:label="loc_HROWRoyaltyPaymentDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWRoyaltyPaymentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MilestonePaymentInCash" xlink:label="loc_HROWMilestonePaymentInCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWMilestonePaymentInCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_InitialMilestonePayment" xlink:label="loc_HROWInitialMilestonePayment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWInitialMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionExpirationDate" xlink:label="loc_HROWCommissionExpirationDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommissionExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionRevenues" xlink:label="loc_HROWCommissionRevenues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommissionRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DescriptionForCommissionPayments" xlink:label="loc_HROWDescriptionForCommissionPayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWDescriptionForCommissionPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommissionPaymentsPercentage" xlink:label="loc_HROWCommissionPaymentsPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommissionPaymentsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_CommercialPaymentsForRoyalties" xlink:label="loc_HROWCommercialPaymentsForRoyalties" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommercialPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MilestonePaymentsOnPayables" xlink:label="loc_HROWMilestonePaymentsOnPayables" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWMilestonePaymentsOnPayables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ConcentrationsDetailsNarrative" xlink:title="00000075 - Disclosure - CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_TwoProductConcentrationRiskMember" xlink:label="loc_HROWTwoProductConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWTwoProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="loc_us-gaapCostOfGoodsProductLineMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfGoodsProductLineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_ThreeMainSuppliersMember" xlink:label="loc_HROWThreeMainSuppliersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_HROWThreeMainSuppliersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_DescripitionOfLoanAmendment" xlink:label="loc_HROWDescripitionOfLoanAmendment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HROWDescripitionOfLoanAmendment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20220331.xsd#HROW_MinimumAmountOfFinancing" xlink:label="loc_HROWMinimumAmountOfFinancing" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HROWMinimumAmountOfFinancing" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505574456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Harrow
Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001360214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0567010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">102
                                            Woodmont Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(615)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-4730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,031,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=HROW_CommonStock0.001ParValuePerShareMember', window );">Common Stock, $0.001 Par Value Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HROW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=HROW_Sec8.625SeniorNotesDue2026Member', window );">8.625% Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">8.625%
    Senior Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HROWL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=HROW_CommonStock0.001ParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=HROW_CommonStock0.001ParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=HROW_Sec8.625SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=HROW_Sec8.625SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198506767576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 41,948,000<span></span>
</td>
<td class="nump">$ 42,167,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investment in Eton Pharmaceuticals</a></td>
<td class="nump">8,642,000<span></span>
</td>
<td class="nump">8,503,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">5,995,000<span></span>
</td>
<td class="nump">4,470,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">4,396,000<span></span>
</td>
<td class="nump">4,217,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,334,000<span></span>
</td>
<td class="nump">1,305,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">62,315,000<span></span>
</td>
<td class="nump">60,662,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,968,000<span></span>
</td>
<td class="nump">3,141,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Capitalized software costs, net</a></td>
<td class="nump">1,471,000<span></span>
</td>
<td class="nump">1,313,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">6,847,000<span></span>
</td>
<td class="nump">5,935,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">15,415,000<span></span>
</td>
<td class="nump">15,813,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentsAndOtherNoncurrentAssetsOne', window );">Investment in Melt Pharmaceuticals</a></td>
<td class="nump">8,247,000<span></span>
</td>
<td class="nump">11,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">332,000<span></span>
</td>
<td class="nump">332,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">97,595,000<span></span>
</td>
<td class="nump">98,329,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,758,000<span></span>
</td>
<td class="nump">6,337,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related liabilities</a></td>
<td class="nump">1,948,000<span></span>
</td>
<td class="nump">3,089,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue and customer deposits</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease obligations</a></td>
<td class="nump">445,000<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease obligations</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,182,000<span></span>
</td>
<td class="nump">9,722,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, net of current portion</a></td>
<td class="nump">6,823,000<span></span>
</td>
<td class="nump">6,012,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations, net of current portion</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Loans payable, net of current portion and unamortized debt discount</a></td>
<td class="nump">71,847,000<span></span>
</td>
<td class="nump">71,654,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">87,859,000<span></span>
</td>
<td class="nump">87,398,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 50,000,000 shares authorized, 27,031,127 and 26,902,763 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">107,909,000<span></span>
</td>
<td class="nump">106,666,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(97,845,000)<span></span>
</td>
<td class="num">(95,407,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL HARROW HEALTH STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">10,091,000<span></span>
</td>
<td class="nump">11,286,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(355,000)<span></span>
</td>
<td class="num">(355,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">9,736,000<span></span>
</td>
<td class="nump">10,931,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 97,595,000<span></span>
</td>
<td class="nump">$ 98,329,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_InvestmentsAndOtherNoncurrentAssetsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments and other noncurrent assets one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_InvestmentsAndOtherNoncurrentAssetsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504039432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, sharess authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,031,127<span></span>
</td>
<td class="nump">26,902,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,031,127<span></span>
</td>
<td class="nump">26,902,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505390104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 22,120,000<span></span>
</td>
<td class="nump">$ 15,443,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="num">(5,963,000)<span></span>
</td>
<td class="num">(3,770,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">16,157,000<span></span>
</td>
<td class="nump">11,673,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">13,398,000<span></span>
</td>
<td class="nump">8,164,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">658,000<span></span>
</td>
<td class="nump">592,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,056,000<span></span>
</td>
<td class="nump">8,756,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">2,101,000<span></span>
</td>
<td class="nump">2,917,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(1,792,000)<span></span>
</td>
<td class="num">(513,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_EquityInLossesOfUnconsolidatedEntities', window );">Equity in losses of unconsolidated entities</a></td>
<td class="num">(2,886,000)<span></span>
</td>
<td class="num">(1,319,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Investment gain (loss) from Eton Pharmaceuticals</a></td>
<td class="nump">139,000<span></span>
</td>
<td class="num">(2,835,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_GainLossOnForgivenessOfDebt', window );">Gain on forgiveness of PPP loan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,967,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(4,539,000)<span></span>
</td>
<td class="num">(2,700,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="num">(2,438,000)<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to common stockholders</a></td>
<td class="num">$ (2,438,000)<span></span>
</td>
<td class="nump">$ 217,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share of common stock</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share of common stock</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares of common stock outstanding, basic</a></td>
<td class="nump">27,226,819<span></span>
</td>
<td class="nump">26,019,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares of common stock outstanding, diluted</a></td>
<td class="nump">27,226,819<span></span>
</td>
<td class="nump">27,480,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_ProductSalesNetMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 20,340,000<span></span>
</td>
<td class="nump">$ 14,948,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_OtherRevenuesMember', window );">Other Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,780,000<span></span>
</td>
<td class="nump">$ 495,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_EquityInLossesOfUnconsolidatedEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity in losses of unconsolidated entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_EquityInLossesOfUnconsolidatedEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_GainLossOnForgivenessOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Loss On Forgiveness Of Debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_GainLossOnForgivenessOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_ProductSalesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_ProductSalesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198502331848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total Harrow Health, Inc. Stockholders' Equity [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 104,557,000<span></span>
</td>
<td class="num">$ (77,400,000)<span></span>
</td>
<td class="nump">$ 27,183,000<span></span>
</td>
<td class="num">$ (355,000)<span></span>
</td>
<td class="nump">$ 26,828,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,749,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Exercise of employee options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Exercise of employee options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares withheld related to net share settlement of equity awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares withheld related to net share settlement of equity awards, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">855,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">855,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">855,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">217,000<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">217,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">105,382,000<span></span>
</td>
<td class="num">(77,183,000)<span></span>
</td>
<td class="nump">28,225,000<span></span>
</td>
<td class="num">(355,000)<span></span>
</td>
<td class="nump">27,870,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,983,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">106,666,000<span></span>
</td>
<td class="num">(95,407,000)<span></span>
</td>
<td class="nump">11,286,000<span></span>
</td>
<td class="num">(355,000)<span></span>
</td>
<td class="nump">10,931,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">26,902,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Exercise of employee options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Exercise of employee options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of RSUs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares withheld related to net share settlement of equity awards</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">(776,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(777,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(777,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares withheld related to net share settlement of equity awards, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,622)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,016,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,016,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,016,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,438,000)<span></span>
</td>
<td class="num">(2,438,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,438,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 107,909,000<span></span>
</td>
<td class="num">$ (97,845,000)<span></span>
</td>
<td class="nump">$ 10,091,000<span></span>
</td>
<td class="num">$ (355,000)<span></span>
</td>
<td class="nump">$ 9,736,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,031,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198506682392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (2,438,000)<span></span>
</td>
<td class="nump">$ 217,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">419,000<span></span>
</td>
<td class="nump">464,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">404,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">124,000<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt expense</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discount</a></td>
<td class="nump">193,000<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_GainLossOnForgivenessOfDebt', window );">Gain on forgiveness of PPP loan</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,967,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Investment (gain) loss from investment in Eton</a></td>
<td class="num">(139,000)<span></span>
</td>
<td class="nump">2,835,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_EquityInLossesOfUnconsolidatedEntities', window );">Equity in losses of unconsolidated entities</a></td>
<td class="nump">2,886,000<span></span>
</td>
<td class="nump">1,319,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,016,000<span></span>
</td>
<td class="nump">855,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,535,000)<span></span>
</td>
<td class="num">(610,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(179,000)<span></span>
</td>
<td class="num">(534,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(29,000)<span></span>
</td>
<td class="num">(32,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">369,000<span></span>
</td>
<td class="nump">1,105,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and related liabilities</a></td>
<td class="num">(1,141,000)<span></span>
</td>
<td class="num">(684,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue and customer deposits</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="num">(63,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY OPERATING ACTIVITIES</a></td>
<td class="nump">967,000<span></span>
</td>
<td class="nump">3,208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Investment in patent and trademark assets</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment and capitalized software development costs</a></td>
<td class="num">(404,000)<span></span>
</td>
<td class="num">(211,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(410,000)<span></span>
</td>
<td class="num">(224,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease obligations</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payment on SWK loan</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(750,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit', window );">Payment of taxes upon vesting of RSUs and exercise of stock options</a></td>
<td class="num">(777,000)<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED IN FINANCING ACTIVITIES</a></td>
<td class="num">(776,000)<span></span>
</td>
<td class="num">(781,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="num">(219,000)<span></span>
</td>
<td class="nump">2,203,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period</a></td>
<td class="nump">42,167,000<span></span>
</td>
<td class="nump">4,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period</a></td>
<td class="nump">41,948,000<span></span>
</td>
<td class="nump">6,504,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract', window );"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">41,948,000<span></span>
</td>
<td class="nump">6,304,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD</a></td>
<td class="nump">41,948,000<span></span>
</td>
<td class="nump">6,504,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,617,000<span></span>
</td>
<td class="nump">415,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease obligations</a></td>
<td class="nump">$ 1,036,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Cash Equivalents And Restricted Cash At End Of Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_EquityInLossesOfUnconsolidatedEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity in losses of unconsolidated entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_EquityInLossesOfUnconsolidatedEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_GainLossOnForgivenessOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Loss On Forgiveness Of Debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_GainLossOnForgivenessOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of taxes for vesting of restricted stock unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Cash Cash Equivalents And Restriced Cash At End Of Period Abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503863880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_801_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zscPxO6FEhjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_828_zFbnycVysiwh">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
and Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise
requires, the &#8220;Company&#8221; or &#8220;Harrow&#8221;) is an ophthalmic-focused healthcare company that specializes in the development,
production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through
its subsidiaries and deconsolidated companies. The Company owns one of the nation&#8217;s leading ophthalmology-focused pharmaceutical
businesses, ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has non-controlling equity positions in Surface Ophthalmics,
Inc. (&#8220;Surface&#8221;) and Melt Pharmaceuticals, Inc. (&#8220;Melt&#8221;), both companies that began as subsidiaries of Harrow.
In 2020, Harrow created Visionology, Inc. (&#8220;Visionology&#8221;), which launched a digital eye health platform business during 2021.
Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles
generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the
rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes
required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring
adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31,
2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any other period.
For further information, refer to the Company&#8217;s audited consolidated financial statements and footnotes thereto included in the
Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned
subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity
(&#8220;VIE&#8221;) model to determine whether the Company is the primary beneficiary of that entity&#8217;s operations. If an entity
is not deemed to be a VIE, the Company consolidates entities in which it holds and/or controls, directly or indirectly, more than
50% of the voting rights. All intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503806472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zZ5oQA7dB0k3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_827_zgt6Mo8oOVxa">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents an update for the three months ended March 31, 2022 to the significant accounting policies described in the Company&#8217;s
Annual Report on Form 10-K for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zlikh7k4Jfld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z61yL2WHWdw">Risks,
Uncertainties and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company&#8217;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result
of regulatory guidelines or inspections, this may have a material impact on the Company&#8217;s financial condition, liquidity and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGEhHZSPonzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zkwHcxaMbNAi">Segments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to shifts in the Company&#8217;s strategic plans to further focus on growing the Company&#8217;s ImprimisRx business and suspension of
activities related to starting up development-stage pharmaceutical companies, along with changes to the Company&#8217;s organizational
and internal reporting structure, beginning in January 2022 management no longer evaluates the Company&#8217;s business in two segments
and instead focuses on the performance of the business as a single operating business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_z09jDRTdzUM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zK97u56dXbd8">Basic
and Diluted Net (Loss) Income per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net (loss) income per common share is computed by dividing net (loss) income attributable to common stockholders for the period by the
weighted average number of common shares outstanding during the period. Diluted net (loss) income per share is computed by dividing the
net (loss) income attributable to common stockholders for the period by the weighted average number of common and common equivalent shares,
such as stock options, restricted stock units (&#8220;RSUs&#8221;) and warrants, outstanding during the period. Common equivalent shares
(using the treasury stock method) from stock options, unvested RSUs and warrants were <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zi4YTngRCKDb" title="Antidilutive securities">5,546,200</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zgKWeI7wFAOg" title="Antidilutive securities">5,486,678</span> at March 31, 2022 and 2021,
respectively. For the three months ended March 31, 2022, the common equivalent shares are excluded in the calculation of diluted net
loss per share because the effect is anti-dilutive. Included in the basic and diluted net (loss) income per share calculation were RSUs
awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number
of shares underlying vested RSUs at March 31, 2022 and 2021 was <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNOovaasI2H1" title="Number of shares vestted, RSUs">277,405</span> and <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZzIAkghWppk" title="Number of shares vestted, RSUs">223,219</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNS0kGC3Spqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the computation of basic net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zIK2wVYRcfJb" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20220331_zPZjySBbpEEb" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20210331_zK9PGkctLRE2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zBSHDqd9SEe6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc. common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(2,438,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">217,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zVkFlIgL0agf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Denominator - weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,226,819</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,019,255</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_zedkPD5L7Keb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zZdBqJnX6MLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_ecustom--DilutedCommonEquivalentSharesTableTextBlock_ztS6hUdeceP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2021, the Company had net income. As a result, the Company computed diluted net income per share using
the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent
shares for the three months ended March 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zGv4Ux4CkOL9" style="display: none">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20210331_zKlwQtQ6UHne" style="text-align: center; font-weight: bold">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Diluted shares related to: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEluRcHYzuv1" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%">Warrants </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 30%; text-align: right">576,275</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLmA3bQlDFui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Stock options </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">885,092</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,461,367</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zEDTRvbryULd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--DilutedNetIncomePerShareTableTextBlock_zTLSbJwFaYn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the computation of diluted net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zbQUI7vKVAsf" style="display: none">SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20220331_zhckyztUZ068" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210331_zME873UuxLr3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(2,438,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">217,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zxoBmqdXKAv3" style="vertical-align: bottom; background-color: White">
    <td>Denominator &#8211; weighted average number of shares outstanding, basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,226,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,019,255</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_pid_z2WDYs3HKDoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,461,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z5Rl0ws6trN2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted earnings per share computation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,226,819</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,480,622</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zXD2dSROWCph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_z8eqhiriI7Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_zsDCERs0SWaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zpB9pPdiNes3">Investment in Eton Pharmaceuticals, Inc.</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, the Company owned <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zTJupoqpHCG3" title="Number of shares owned">1,982,000</span> shares of Eton common stock, which represents less than <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zd5SBrhuUHQd" title="Equity Method Investment, Ownership Percentage">10</span>% of the equity interests of
Eton. At March 31, 2022, the fair market value of Eton&#8217;s common stock was $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zirbFSENtIKi" title="Shares price">4.36</span> per share. In accordance with the Accounting Standards
Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets
and Financial Liabilities</i>, the Company recorded an unrealized investment gain (loss) from its Eton common stock position of $<span id="xdx_907_eus-gaap--UnrealizedGainLossOnInvestments_c20220101__20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_z9IFkdPVayS6" title="Unrealized Gain (Loss) on Investments">139,000</span>
and $(<span id="xdx_90C_eus-gaap--UnrealizedGainLossOnInvestments_c20210101__20210331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zPiVkWlbQTT3" title="Unrealized Gain (Loss) on Investments">2,835,000</span>) during the three months ended March 31, 2022 and 2021, respectively, related to the change in fair market value of its
investment in Eton during the measurement period. As of March 31, 2022, the fair market value of the Company&#8217;s investment in Eton
was $<span id="xdx_901_eus-gaap--InvestmentOwnedAtFairValue_iI_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zCD3tr1mWRee" title="Investment owned, at fair value">8,642,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--InvestmentOnePolicyTextBlock_z7ZR2aiQoUZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUPoGjZBwjMd">Investment
in Melt Pharmaceuticals, Inc. &#8211; Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company owns <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zX1EQ0YC1wZ9" title="Number of shares owned">3,500,000</span> shares of common stock of Melt (representing approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z744nHYvrDi8" title="Ownership percentage">46</span>% of the equity interests as of March 31, 2022). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests
in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant
influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this
method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying
amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31,
2021, the Company reduced the carrying value of its common stock investment in Melt to $<span id="xdx_906_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkYZt5lFNR76" title="Reduction in common stock investment">0</span> as a result of the Company recording its share
of equity losses in Melt since its deconsolidation in 2019. As of March 31, 2022 and at the time of entering into the Melt Loan Agreement
(see Note 4), the Company owned <span id="xdx_905_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBYyKHO8OWw9" title="Investment Interest Rate">100</span>% of Melt&#8217;s indebtedness. Following the reduction of the carrying value of the Company&#8217;s
common stock investment in Melt to $<span id="xdx_904_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zEXoazSP5uqg" title="Reduction in common stock investment">0</span>, the Company began recording <span id="xdx_90D_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKy0RGpMjbR3" title="Investment Interest Rate">100</span>% of the equity method losses of Melt, based on its ownership of
Melt&#8217;s total indebtedness. In addition, the Company treats interest paid in kind on the Melt Loan Agreement as an in-substance
capital contribution and reduces its investment in Melt accordingly, rather than recording interest income. The Company has no other
requirements to advance funds to Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zHDKezjlAzC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s investments in Melt as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zOu6gAVnfeab" style="display: none">SCHEDULE OF INVESTMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Cost</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Share of Equity</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Paid-in-Kind</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">In-substance Capital</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Basis</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Method Losses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> Contributions</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; text-align: justify">Common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBkl2EaRCDC4" style="width: 14%; text-align: right" title="Cost Basis">5,810,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqfd0vzn9Si" style="width: 14%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJhT7QPahy73" style="width: 14%; text-align: right" title="Paid in Kind Interest"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;$</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Loan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z36QM1txxHVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost Basis">13,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_za6GSpCvubZ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses">(5,253,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXBKSmtqYxvk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Paid in Kind Interest">1,021,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkJgzLHOo4wi" style="border-bottom: Black 1.5pt solid; text-align: right" title="In Substance Capital Contributions">(1,021,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXiD29Wvcgr8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value">8,247,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6dIETxaG9Ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis">19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSjrHuJ5eGWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(11,063,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zZE5JbYjMrNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest">1,021,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zhg3MW8XrTdi" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions">(1,021,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zWU9pjd23XQi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">8,247,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zS3V4anqotQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022 and 2021, the Company recorded $<span id="xdx_903_eus-gaap--DueFromRelatedParties_iI_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zSpqwczV4Jd1">30,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">due from Melt for reimbursable expenses and
amounts payable pursuant to a Management Services Agreement between the Company and Melt (the &#8220;Melt MSA&#8221;), which are included
in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 4 for more information and related party disclosure regarding Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_ecustom--InvestmentTwoPolicyTextBlock_zsSi1v7tD1ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zXyiO94KHvEf">Investment
in Surface Ophthalmics, Inc. &#8211; Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company owns <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zwq1TJ9qFRKf" title="Number of shares owned">3,500,000</span> common shares of Surface (representing approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zM7tBbks44u2">20</span>% of Surface&#8217;s equity interests following the closing
of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as
management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions
of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts
the carrying amount of its investment in Surface accordingly. The Company&#8217;s share of earnings and losses are based on the Company&#8217;s
ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company
reduced its common stock investment in Surface to $<span id="xdx_90B_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zn44rm9BzRZ5" title="Reduction in common stock investment">0</span> as a result of the Company recording its share of equity losses of Surface. The
Company has no other investments in Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zgWdLIjhxxte" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s investment in Surface as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zyVpPQIkwx7b" style="display: none">SCHEDULE OF INVESTMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Cost</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Share of Equity</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Basis</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Method Losses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zXw7lKRQkQXb" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Cost basis">5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zilG9GbPwS9c" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Share of Equity Method Losses">(5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z4ThatYSP1Mf" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Net carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zLCrX4mbCnW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 5 for more information and related party disclosure regarding Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zqjQq2ALREy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zwQT0bcs6oUa">Impairment
of Equity Method Investments and Note Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company&#8217;s equity method
investments and note receivable may be other than temporarily impaired. Indicators include financial condition, operating performance,
and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate
both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is
determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity
method investments and note receivable. At March 31, 2022 and December 31, 2021, no indicators of impairment existed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504877080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_zqml2A6lcRm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_82C_zUB9vZOxnvQl">REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for contracts with customers in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606, <i>Revenues
from Contracts with Customers.</i> The Company has two primary streams of revenue: (1) revenue recognized from its sale of products within
pharmacy services and (2) revenue recognized from intellectual property license and asset purchase agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product
Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sells prescription drugs directly through its pharmacy and outsourcing facility. Revenue from the Company&#8217;s pharmacy services
includes: (i) the portion of the price the client pays directly to the Company, net of any volume-related or other discounts paid back
to the client, (ii) the price paid to the Company by individuals, and (iii) customer copayments made directly to the pharmacy network.
Sales taxes are not included in revenue. Following the core principles of ASC 606, the Company has identified the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the performance obligations in the contract: The order received contains the performance obligations to be met, in almost all cases
    the product the customer is wishing to receive. If we are unable to be meet the performance obligations the customer is notified.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    the transaction price: the transaction price is based on the product being sold to the customer, and any related customer discounts.
    These amounts are pre-determined and built into the Company&#8217;s order management software.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate
    the transaction price to the performance obligations in the contract: The transaction price associated with the product(s) being
    ordered is allocated according to the pre-determined amounts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize
    revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing facility
    the performance obligation has been met.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following revenue recognition policy has been established for the Company&#8217;s pharmacy services:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
generated from prescription or office use drugs sold by the Company&#8217;s pharmacies and outsourcing facility are recognized when the
prescription is shipped. At the time of shipment, the pharmacy services has performed substantially all of its obligations under its
client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4) is based
on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of
those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and allowances
and other adjustments are provided for in the same period during which the related sales are recorded and are based on actual returns
history. The rate of returns is analyzed annually to determine historical returns experience. If the historical data we use to calculate
these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination
is made and revenues in that period could be materially affected. The Company will defer any revenues received for a product that has
not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been
delivered and no refund will be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Commission
Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into an agreement whereby it is paid a fee calculated based on sales the Company generates from a pharmaceutical
product that is owned by a third party. The revenue earned from this arrangement is recognized at the time a customer has ordered the
pharmaceutical product and it has shipped from the third party (or one of its distributors or affiliates), at which point there is no
future performance obligation required by the Company and no consequential continuing involvement on the Company&#8217;s part to recognize
the associated revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transfer
of Acquired Product Profit Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into an agreement whereby it purchased the exclusive commercial rights to assets associated with certain ophthalmic
products from another pharmaceutical company (the &#8220;Seller&#8221;). During a temporary, six month transition period, the Seller
will continue to manufacture and market these products and transfer the net profit from the sale of the products to the Company. The
revenue recognized by the Company from the transfer of net profit is recognized at the time profit from the products sales has been calculated
by the Seller and confirmed by the Company, typically on a monthly basis, at which point there is no future performance obligation required
by the Company and no consequential continuing involvement on the Company&#8217;s part to recognize the associated revenue. On
a quarterly basis, the Seller invoices the Company for all credits and reimbursements (&#8220;Chargebacks&#8221;) made to customers related
to the products. The Company uses historical actual experience to estimate Chargebacks associated with the net profit transferred. The
estimate is recorded as a reduction in revenues in the Company&#8217;s condensed consolidated statements of operations and
accounts receivable in the condensed consolidated balance sheets, at the time the revenue is recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intellectual
Property License Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently holds five intellectual property licenses and related agreements in which the Company has agreed to license or sell
to a customer with the right to access the Company&#8217;s intellectual property. License arrangements may consist of non-refundable
upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds,
technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue
of which is recognized at the point in time that the performance obligation is met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-refundable
fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part
of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation
and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the
compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the
patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has
continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable
fee has no utility to the licensee and that are separate and independent of the Company&#8217;s performance under the other elements
of the arrangement. In addition, if the Company&#8217;s continued involvement is required, through research and development services
that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then
such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are
recognized on a straight-line basis over the applicable term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zQXOsddbBOpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
disaggregated by revenue source for the three months ended March 31, 2022 and 2021, consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zR6gEyzvRMdk" style="display: none">SCHEDULE
OF DISAGGREGATED REVENUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49A_20220101__20220331_zOW4uD1SJ9Wg" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td id="xdx_492_20210101__20210331_zKieTB8t8vh" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Three Months Ended March 31,</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zs9nSw8zPHWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Product sales, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">20,340,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14,948,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CommissionsMember_zkkGsAEXACH8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,320,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">485,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfProfitMember_zMZB6cpbgOQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Transfer of profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zJcXuvzPmRbk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">License</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total revenues</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,120,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,443,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zSi1dO87BCGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
revenue and customer deposits at March 31, 2022 and December 31, 2021 were $<span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20220331_zQGircum5OW8" title="Deferred revenue and customer deposits">23,000</span> and $<span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20211231_zy2KvS7fIh9k" title="Deferred revenue and customer deposits">16,000</span>, respectively. All deferred revenue and
customer deposit amounts at December 31, 2021 were recognized as revenue during the three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503946632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_802_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zHi0IBPSSDzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_822_zz2QFfqdg3f5">INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2018, the Company entered into an asset purchase agreement with Melt (the &#8220;Melt Asset Purchase Agreement&#8221;). Pursuant
to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company
to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively,
the &#8220;Melt Products&#8221;). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make mid-single digit royalty
payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2019, the Company and Melt entered into the Melt MSA, whereby the Company provides to Melt certain administrative services and
support, including bookkeeping, web services and human resources related activities, and Melt is required to pay the Company a monthly
amount of $<span id="xdx_902_eus-gaap--AdministrativeFeesExpense_c20190201__20190228__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zYzzITmK6fg2" title="Administrative Fees Expense">10,000</span>. As of March 31, 2022 and December 31, 2021, the Company was due $<span id="xdx_909_eus-gaap--DueFromRelatedParties_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zphIuyLIzUVf" title="Due from Related Parties">70,000</span> and $<span id="xdx_903_eus-gaap--DueFromRelatedParties_iI_c20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zPXKy8zvmjwc" title="Due from Related Parties">48,000</span>, respectively, from Melt for reimbursable
expenses and amounts due under the Melt MSA. Melt did not make any payments to the Company during the three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer, Mark L. Baum, was previously a member of the Melt board of directors until his resignation during
the year ended December 31, 2021. Following Mr. Baum&#8217;s departure, the Company no longer has any representation on Melt&#8217;s
board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zSRRrC0Q5zwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed results of operations information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z209h09UDAti" style="display: none">SCHEDULE OF CONDENSED INCOME STATEMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zTXh8GiQ2iEg" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zlupJ2JUKVsj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Three Months Ended <br/>
March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zO2i2yFigoSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revenues, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zq6rdl3psRmg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Loss from operations</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(3,337,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(1,099,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zDluIhJtlKhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,337,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,099,000</td><td style="text-align: left">)</td></tr>
  </table>

<p id="xdx_8A9_zkzfTCylfvdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zcLzu4bOoxG" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed balance sheet information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z9dE8G2IDlo1" style="display: none">SCHEDULE OF CONDENSED BALANCE SHEET</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zDUDBDUYrHH" style="font-weight: bold; text-align: center">At March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zdqnypoLIcSd" style="font-weight: bold; text-align: center">At December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_iI_zy0cOf4VxwId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,025,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,278,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsNoncurrent_iI_zpSoeNsopG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">360,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iI_zxGkTHwP6UY" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,385,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,278,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_iI_zijkfMkukffk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,313,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,732,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zzgVUbOyOtfk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total preferred stock and stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,928,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,454,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zV9uxU49tu1i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,385,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,278,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zPnNZPkxSWj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Melt
Note Receivable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2021, the Company entered into a loan and security agreement in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_z76ZyWU7MJm5" title="Principal amount">13,500,000</span> (the &#8220;Melt Loan Agreement&#8221;),
as lender, with Melt, as borrower. Amounts borrowed under the Melt Loan Agreement bear interest at twelve and one-half percent (<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zL0Q8dYygfGb" title="Debt instrument interest rate stated percentage">12.50</span>%)
per annum, which interest can be paid in-kind at the option of Melt until the maturity date. The Melt Loan Agreement permits Melt to
pay interest only on the principal amount loaned thereunder through the term and all amounts owed will be due and payable on September
1, 2022. Melt may elect to prepay all, but not less than all, of the amounts owed prior to the maturity date at any time without penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melt
has granted the Company a security interest in substantially all of its personal property, rights and assets, including intellectual
property rights, to secure the payment of all amounts owed under the Melt Loan Agreement. The Melt Loan Agreement contains customary
representations, warranties and covenants, including covenants by Melt limiting additional indebtedness, liens, mergers and acquisitions,
dispositions, investments, distributions, subordinated debt, and transactions with affiliates. The Melt Loan Agreement includes customary
events of default, and upon the occurrence of an event of default (subject to cure periods for certain events of default), all amounts
owed by Melt thereunder may be declared immediately due and payable by the Company, and the interest rate on the loan may be increased
by three percent (<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_c20210901__20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zeiY1tnPbW9g" title="Increase in interest rate">3</span>%) per annum. See Note 17 regarding an Amendment to the Melt Loan Agreement entered into in April 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Melt Loan Agreement, the Company and Melt entered into a Right of First Refusal Agreement providing the Company with
the right, but not the obligation, to match any offer received by Melt associated with the commercial rights to any of Melt&#8217;s drug
candidates for a period of five years following the effective date of the Melt Loan Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net funds received by Melt excluded $<span id="xdx_900_ecustom--AccountsReceivableTransferredToNoteReceivable_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKbAYGZuugX5" title="Accounts receivable transferred to note receivable">908,000</span> for amounts owed to the Company for reimbursable expenses and amounts due under the Melt
MSA prior to the effective date of the note receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503976744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract', window );"><strong>Investment In Surface Ophthalmics Inc. - Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock', window );">INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_805_ecustom--InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_zLbaooG7A5h1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_82B_zvcnQ6oDQcg8">INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the &#8220;Surface License
Agreements&#8221;). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual
property and related rights associated with Surface&#8217;s drug candidates (collectively, the &#8220;Surface Products&#8221;). Surface
is required to make mid-single digit royalty payments to the Company on net sales of the Surface Products while any patent rights remain
outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, the Company owned <span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z1OaSPehDWOg" title="Number of shares owned">3,500,000</span> shares of Surface common stock (representing approximately <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zNeDLCgLGzJg" title="Ownership percentage">20</span>% of Surface&#8217;s issued
and outstanding equity interests). A Company director, Richard L. Lindstrom, and the Company&#8217;s Chief Executive Officer, Mark L.
Baum, are directors of Surface. Dr. Lindstrom is a principal of Flying L Partners, an affiliate of an investor who purchased Surface
Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_894_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zaFV5yfixqbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed results of operations information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z2nUHKSrPoQ9" style="display: none">SUMMARY OF CONDENSED INCOME STATEMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zz5eImx0Xajl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20210331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_ziQe1WCBizti" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zVIAmgsK7HXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenues, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_zprMrtaFqUF3" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(1,996,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(2,831,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zphBbIINa2Ri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,996,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,831,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AC_zMpvraidM3Gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zUaMI08gdbJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed balance sheet information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z9DYOciFWKzj" style="display: none">SUMMARY OF CONDENSED BALANCE SHEET</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z3UrTE5lRVuj" style="font-weight: bold; text-align: center">At March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zLOGRTHliMve" style="font-weight: bold; text-align: center">At December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zzNlI7Tuqx78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,920,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">21,731,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_ziWygcHThLl4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">411,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">412,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Assets_iI_zb1jhBCUKvOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,331,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,143,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_iI_zW41pp0YzM9e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,937,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,514,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_iI_zSTgmyTpzVXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total preferred stock and stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,394,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,629,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zjmufASaortk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,331,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,143,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zzdpIa8zujMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Agreements Related Party Transactions [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503945672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_zt88CVBUsn25" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_827_zx7MFXHDumO3">INVENTORIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zpTcmZWigGsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of March 31, 2022 and
December 31, 2021 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zmtyr5FMbDN" style="display: none">SCHEDULE OF INVENTORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220331_zYFocsw1bgsd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231_zkHMuC7NR4Qd" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maINz1vg_zySRv7C76sIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,441,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,441,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz1vg_zWPXVndX7Xtf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InventoryFinishedGoods_iI_maINz1vg_zqeRsVxcnJNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,911,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,776,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryNet_iTI_mtINz1vg_z184sO7uAeNb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,396,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,217,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zbHGu2CAcbx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503915560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OtherAssetsDisclosureTextBlock_zaj16JKOlCph" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_827_z2xc96AyvzYb">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqPEeLwq7fn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets at March 31, 2022 and December 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zZSMDZgP1N8" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220331_zy4KO0UM0EP2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zgo4Qsrvmrha" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidInsurance_iI_maPEAOAz7FJ_zI4cUnolEfl6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">455,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">728,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueFromRelatedParties_iI_maPEAOAz7FJ_zD5GgvX3f5Tj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Melt Pharmaceuticals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz7FJ_zl8dctplNAx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">757,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAssetsCurrent_iI_maPEAOAz7FJ_zlNBpP9ltbJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz7FJ_z6aGjli0D5u2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,334,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,305,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zfvovfD58w4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503965976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmcBUIuHVOZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_82B_zomMZUsLtIQb">PROPERTY, PLANT AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_ze1CgIm54nx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment at March 31, 2022 and December 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z6k2VxD3GSXj" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220331_zQM2Nq6qjxH3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zXofIOFnnmD8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ComputerHardwareGross_iI_maPPAEGzWKe_zPEZ9JFh67Tc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Computer hardware</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">786,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">772,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzWKe_zRnW5IVCP8Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">521,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">443,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzWKe_zVK4Z1UYQ24h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,142,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,056,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzWKe_z7WADUw264m9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,728,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,703,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzWKe_maPPAENzhZF_z1eE7Kmoyhw4" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif">Property, plant and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,177,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,974,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzhZF_zIHsffSgMWq6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,209,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,833,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzhZF_zXT8mQxmtbF4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,968,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,141,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zWIPmnj55Vy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2022 and 2021, depreciation related to the property, plant and equipment was $<span id="xdx_90D_eus-gaap--Depreciation_c20220101__20220331_zDGQkceFrj79" title="Depreciation and amortization">376,000</span> and $<span id="xdx_907_eus-gaap--Depreciation_c20210101__20210331_zaIXip8Nf6yk" title="Depreciation and amortization">436,000</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503870856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZED SOFTWARE DEVELOPMENT COSTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract', window );"><strong>Capitalized Software Development Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CapitalizedSoftwareDevelopmentCostsTextBlock', window );">CAPITALIZED SOFTWARE DEVELOPMENT COSTS</a></td>
<td class="text"><p id="xdx_806_ecustom--CapitalizedSoftwareDevelopmentCostsTextBlock_zeW7yI8Yifh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_828_zp1UEkocrbZ1">CAPITALIZED SOFTWARE DEVELOPMENT COSTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--CapitalizedSoftwareDevelopmentCostsTableTextBlock_zf7Seo6HJNB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
software development costs at March 31, 2022 and December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zhjRVbjWx1Ua" style="display: none">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220331_zzPoBne899Hc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zcGkC3TN8Z9g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedInternalUseSoftwareMember_zFvHdjm73Ydc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Capitalized internal-use software development costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">942,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">942,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_zTJ2NFmQbAQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Acquired third-party software license for internal-use</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzJkV_zDJR8Ism6H71" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total gross capitalized software for internal-use</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,101,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,101,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzJkV_zXqLvHTMLooa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(612,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(569,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCCSNzJkV_zwoNzydOMbOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Capitalized internal-use software in process</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">982,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">781,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzJkV_zB3D3Db34jZ1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Total
    finite lived intangible assets net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,471,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,313,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zsCaBt9E1Rua" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded amortization expense of $<span id="xdx_90C_eus-gaap--AdjustmentForAmortization_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zsM8waAgqnL6" title="Amortization">43,000</span> and $<span id="xdx_904_eus-gaap--AdjustmentForAmortization_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zNni26PVYxtj" title="Amortization">28,000</span> related to capitalized software development costs during the three months
ended March 31, 2022 and 2021, respectively.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CapitalizedSoftwareDevelopmentCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized Software Development Costs [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CapitalizedSoftwareDevelopmentCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503960520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text"><p id="xdx_807_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zmmgBScvSRZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_824_zipuKZp8kpFj">INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zJjWYWQsjHwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s intangible assets at March 31, 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zxgFjxmDBBYl" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 12pt">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Amortization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Periods</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(in years)</b></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Cost</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Accumulated</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Amortization</b></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Impairment</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Carrying Value</b></p></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjf5wF2iXy15" title="Amortization periods (in years)">17</span>-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zImd8lINgrh8" title="Amortization periods (in years)">19</span> </span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zehbq1WeiU88" style="width: 9%; text-align: right" title="Cost">972,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlfJmIfFhxQ1" style="width: 9%; text-align: right" title="Accumulated amortization">(97,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0Q4yhmF9Q7k" style="width: 9%; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfzZMRiuoT1a" style="width: 9%; text-align: right" title="Net Carrying value">875,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Licenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeWgyYGFESy6" title="Amortization periods (in years)">20</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvVKD9f6aP9" style="text-align: right" title="Cost">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zNCzPEzPr34l" style="text-align: right" title="Accumulated amortization">(15,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIbS2fmM6rCg" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_znlesKjCSMDh" style="text-align: right" title="Net Carrying value">85,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trademarks</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0koJpf1xUZ3" title="Finite-Lived Intangible Assets, Amortization Method">Indefinite</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zKpTejnk0qC8" style="text-align: right" title="Cost">260,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zll2HXJ0YgI" style="text-align: right" title="Accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV2aw1rKd6tj" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zMOochU6dJvk" style="text-align: right" title="Net Carrying value">260,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquired NDAs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zVYdkm2FSXd2" title="Amortization periods (in years)">10</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zHlU0qDpkfKg" style="text-align: right" title="Cost">13,635,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z820THJtV2P2" style="text-align: right" title="Accumulated amortization">(341,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zjQW5qUswlHe" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z36noIcOlKVe" style="text-align: right" title="Net Carrying value">13,294,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Customer relationships</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zirZ8X0bocTk" title="Amortization periods (in years)">3</span>-<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zfVV8Q3e0TGc" title="Amortization periods (in years)">15</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z3NDMTXnz9wj" style="text-align: right" title="Cost">1,519,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zOfTiUUyw7l4" style="text-align: right" title="Accumulated amortization">(619,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ztUO2SvFO869" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2r5IfCrgA5l" style="text-align: right" title="Net Carrying value">900,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Trade name</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zdn33BHgRTy4" title="Amortization periods (in years)">5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z48sa9Y7Jmk9" style="text-align: right" title="Cost">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEBqLhqiMHi3" style="text-align: right" title="Accumulated amortization">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQp1niDP54wb" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zDx1gHu34EDc" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-competition clause</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zgP1zPts6wP2" title="Amortization periods (in years)">3</span>-<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zNE9e9WAUqxe" title="Amortization periods (in years)">4</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zhfab4dWaoQc" style="text-align: right" title="Cost">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z9rGoZWRSmFj" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zURC90oOrve3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zdGWNGcngprj" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">State pharmacy licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zh2wHWe5SxT" title="Amortization periods (in years)">25</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z0fWDQZkeYHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z84Dqt7Mr6H" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zQEqyTorbf13" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z68nKa56dLyh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331_zwGvikTRgpW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">16,549,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331_zDPdx6zi9o73" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(1,134,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331_zVlxrwN2Ltr" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331_zZgmAs7pThp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">15,415,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z5smofGy2AMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zK2eZFjQVHj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for intangible assets for the three months ended March 31, 2022 and 2021 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zCTvexaauAP5" style="display: none">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 12pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49E_20220101__20220331_z6zAM7UfccS5" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49A_20210101__20210331_zx49Vo3S5zyh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the <br/>Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 12pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z3GoaCK4TD9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">22,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z45HYDtJNJWj" style="vertical-align: bottom; background-color: White">
    <td>Licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zMnd9cp9n6i7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Acquired NDAs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">341,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zTrMaLbIZt4l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AmortizationOfIntangibleAssets_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of intangible assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">404,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A0_zYEUDHOOap46" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zjlC3on5YG66" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
future amortization expense for the Company&#8217;s intangible assets at March 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zIpkGufjwR6l" style="display: none">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20220331_ze3p2LvbPte" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzqfW_zwUaRFyNHO4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,194,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzqfW_zWx02eONrfp5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,592,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzqfW_zF3bJUCAECSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,592,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzqfW_zzrN7DtMlStj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,592,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzqfW_zmRF1aGHsh6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,595,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzqfW_zjqyFLM7MD0c" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,590,000</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzqfW_z01D7vJLeYRi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,155,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zRwLv4zr47b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503935896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z4w1lYBZiLwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_828_zsAXwb4jHwjg">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zxQmhsPtaNV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and accrued expenses at March 31, 2022 and December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zNMn0zIbKer5" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220331_zm7ufVjUs2rj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zsCiPMOqwvxb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALziP7_zvw8orfBEi35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,595,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,174,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALziP7_zvs71AC3YS6f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAALziP7_z2487muc3H55" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,114,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,114,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALziP7_z19Vj5yde983" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Total accounts payable and accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,758,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,337,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_z6uu52gggDVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503837272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zEMSq80cdcle" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. <span id="xdx_82F_zPhxnX7D3ZO5">DEBT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>8.625%
Senior Notes Due 2026</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, the Company closed an offering of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z7AbIkzW0PF" title="Debt principal amount">50,000,000</span> aggregate principal amount of 8.625% senior notes due April 2026, and in May
2021 issued an additional $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210501__20210531__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zct5JwrPOzEl" title="Additional notes issued">5,000,000</span> of such notes pursuant to the full exercise of the underwriters&#8217; option to purchase additional
notes (collectively, the &#8220;April Notes&#8221;). The April Notes were sold to investors at a par value of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z24EbCdbOpee" title="Share price">25.00</span> per April Note and
the offering resulted in net proceeds to the Company of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20210401__20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zTGtOHrCFAy8" title="Proceeds from issuance of debt">51,909,000</span> after deducting underwriting discounts and commissions
and expenses of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zUQMBPVHvF7j" title="Debt issuance costs and discounts">3,091,000</span>. In June 2021, in a further issuance of the April Notes, the Company sold an additional $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210601__20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zxU5DUR2JMYf" title="Additional notes issued">20,000,000</span> aggregate
principal amount of such notes (the &#8220;June Notes,&#8221; and together with the April Notes, the &#8220;Notes&#8221;), at a price
of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z7WgrBDVN1Sk" title="Share price">25.75</span> per June Note, with interest of $<span id="xdx_906_eus-gaap--InterestExpenseDebt_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z7okaq6cV78b" title="Interest expense, debt">278,000</span> on the June Notes being accrued from April 20, 2021 as of the date of issuance. The
June offering resulted in net proceeds to the Company of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zoJvGAuYq45l" title="Proceeds from issuance of debt">19,164,000</span> after deducting underwriting discounts and commissions
and expenses of $<span id="xdx_907_eus-gaap--DeferredFinanceCostsNet_iI_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zkpskDAkEgKb" title="Debt issuance costs">1,158,000</span> and a premium on note issuance of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedPremium_iI_c20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zUCv1UfBrWXl" title="Premium on issuance of debt">322,000</span>. The June Notes are treated as a single series with the April Notes
under the indenture governing the April Notes, dated as of April 20, 2021, and have the same terms as the April Notes (other than the
initial offering price and issue date). The Notes are senior unsecured obligations of the Company and rank equally in right of payment
with all of our other existing and future senior unsecured and unsubordinated indebtedness. The Notes are effectively subordinated in
right of payment to all of the Company&#8217;s existing and future secured indebtedness and structurally subordinated to all existing
and future indebtedness of the Company&#8217;s subsidiaries, including trade payables. The Notes bear interest at a rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zYy8qMEUq0qh" title="Debt instrument, interest rate">8.625</span>% per
annum. Interest on the Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing
on July 31, 2021. The Notes will mature on April 30, 2026. The issuance costs were recorded as a debt discount and are being amortized
as interest expense, net of the amortization of the premium on note issuance, over the term of the Notes using the effective interest
rate method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to February 1, 2026, the Company may, at its option, redeem the Notes, in whole at any time or in part from time to time, at a <span id="xdx_904_eus-gaap--DebtInstrumentRedemptionDescription_c20260131__20260201__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z9v9N2OofIHc" title="Debt instrument, redemption, description">redemption
price equal to 100% of the principal amount of the Notes to be redeemed</span>, plus a make-whole amount, if any, plus accrued and unpaid interest
to, but excluding, the date of redemption. The Company may redeem the Notes for cash in whole or in part at any time at our option on
or after February 1, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest
to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense related to the Notes totaled $<span id="xdx_908_eus-gaap--InterestExpenseOtherLongTermDebt_c20220101__20220331__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zWFNvBrw0ux6" title="Interest Expense, debt">1,810,000</span> for the three months ended March 31, 2022, and included amortization of debt issuance
costs and discount of $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20220331__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z4AIqJGy45hc" title="Amortization of debt issuance costs and discount">193,000</span> for three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zeXit3iAI55j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, future minimum payments under the Company&#8217;s debt were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zCaoB1YgDg5" style="display: none">SUMMARY OF FUTURE MINIMUM PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220331_zjCFRn231Vyf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maLTDz3L0_zRx4HQB7fzoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,852,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDz3L0_z3s7cGJj8Ukb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,469,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDz3L0_zgidYMhRg0u2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,469,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDz3L0_zaK6kVZsAHE3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,469,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDz3L0_zHWTd4zld0i2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,158,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz3L0_zPXXi5uAvz85" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total minimum payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,417,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_zNwMlipFUgD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,417,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DebtInstrumentCarryingAmount_iI_zAs5CTtwXl8i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_z9wdwKyKH6N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized discount, net of premium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,153,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermNotesPayable_iI_z7Ost3bAP696" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Notes payable, net of unamortized discount</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71,847,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zq8GuC4BsL37" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503860552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80F_ecustom--LesseeOperatingLeaseAndFinanceLeaseTextBlock_zGDXUysbF93b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13. <span id="xdx_821_zPB6DIhnzvca">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and laboratory space under non-cancelable operating leases listed below. These lease agreements have remaining
terms between <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtYxL_c20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zXDguXswy201" title="Lease term::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl1033">one</span></span> to <span id="xdx_909_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zvc7MO7kr8mi" title="Lease term">five years</span> and contain various clauses for renewal at the Company&#8217;s option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    operating lease for <span id="xdx_905_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220331__srt--StatementGeographicalAxis__custom--CarlsbadMember_zVnNYGLr1TP9" title="Area of Land">5,789</span> square feet of office space in Carlsbad, California, which commenced in January 2022 and will expire in
    <span id="xdx_90E_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220331__srt--StatementGeographicalAxis__custom--CarlsbadMember_zVX6TPuvkiYf" title="Lease expiration date description">July 2027</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    operating lease for <span id="xdx_90A_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_zMHwbDQ9V0Z2" title="Area of Land">35,326</span> square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in <span id="xdx_905_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_zdaCGfEnL1Sj" title="Lease expiration date description">July 2026</span>, with
    <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_zHYsyAjH2RPe" title="Lease term, option to extend">an option to extend the term for two additional five-year periods.</span> This includes an amendment that was made effective July 2020 that
    extended the term of the original lease and added <span id="xdx_90D_ecustom--AdditionalAreaOfLand_uSquareFoot_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_znyv5Utz8Hb8" title="Additional square footage">1,400</span> of additional square footage to the lease and another amendment entered into
    in May 2021 that extended the term of the lease to July 2027 and added <span id="xdx_905_ecustom--AdditionalAreaOfLand_uSquareFoot_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zRmAUfKpx3uf">8,900</span> square feet of space.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    operating lease for <span id="xdx_900_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220331__srt--StatementGeographicalAxis__custom--NashvilleMember_zqSieIigKnX4" title="Area of Land">5,500</span> square feet of office space in Nashville, Tennessee that expires in <span id="xdx_90B_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220331__srt--StatementGeographicalAxis__custom--NashvilleMember_zYPPIxvqIbYj" title="Lease expiration date description">December 2024</span>, with <span id="xdx_905_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220331__srt--StatementGeographicalAxis__custom--NashvilleMember_zfF1QUHasLok" title="Lease term, option to extend">an option to extend
    the term for two additional five-year periods.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases
held by the Company were <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_ztl0PM4oOc5c" title="Operating lease, weighted average discount rate, percentage">6.34</span>% and <span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_zsIySPSGadud" title="Operating lease, weighted average remaining lease term">13.45</span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022 and 2021, cash paid for amounts included for the operating lease liabilities was $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20220101__20220331_zahSIJ03sK82" title="Operating lease, payments">166,000</span> and $<span id="xdx_903_eus-gaap--OperatingLeasePayments_c20210101__20210331_zKzDWl8IAjZd" title="Operating lease, payments">251,000</span>,
respectively, and the Company recorded operating lease expense of $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20220101__20220331_zUSJ7GDzos6j" title="Operating lease, expense">238,000</span> and $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20210101__20210331_zUZ0ryx2mjE1" title="Operating lease, expense">261,000</span>, included in selling, general and administrative
expenses, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIhB5Bo97Zf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
lease payments under operating leases as of March 31, 2022 were as follows<b>: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B7_zPoLj2em0lGd" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20220331_z465aRPQBoD9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzIyO_zBtXXYhn7tc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 78%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">655,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzIyO_zQqVxQs35Pqg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">944,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzIyO_zqp51RqLT0d2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">970,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzIyO_zNzee68udGmg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">796,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzIyO_z6mRREQj8QPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">810,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzIyO_zywaK7VJ0MB4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,648,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzIyO_zv9lk9ryrXX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,823,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zRrNnz7HqX56" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: amount representing interest payments</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,555,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zENYyAG2FZbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,268,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zByQzP6YkDx" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: current portion, operating lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(445,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zSX1Nsg0f066" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities, net of current portion</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,823,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zNL0InFA7iFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has a finance lease that is included in its lease accounting but is not considered significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zZQa6S4wHoec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
lease payments under the non-cancelable finance lease as of March 31, 2022 were as follows<b>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B8_zsZDJjr1TXN8" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220331_z6NLuqyySe12" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzZHK_zOncHOuLhKv4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 78%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">6,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzZHK_z54SOZeYTSOg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzZHK_z8a2vj9fIy9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzZHK_z5EFggVfzLRi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zddcqHmbwAb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseLiability_iI_zICmpzDaD6Qd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_z6KSxa1ddWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zbP0upLRnTj6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zaDiFaZZBxRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, the incremental borrowing rate and the remaining lease term for the finance lease held by the Company were <span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_zbgmS1m3Zmq" title="Finance lease, weighted average discount rate, percentage">6.36</span>% and
<span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_z4aewc4aXczk" title="Finance lease, weighted average remaining lease term">1.83</span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2022 and 2021, depreciation expense related to the equipment held under the finance lease obligation
was $<span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20220101__20220331_zrIVlnGHbS6k" title="Amortization">2,000</span> and $<span id="xdx_907_eus-gaap--AdjustmentForAmortization_c20210101__20210331_zS52QDR5EAtb" title="Amortization">2,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2022 and 2021, cash paid and expense recognized for interest expense related to the finance lease obligation
was $<span id="xdx_904_eus-gaap--FinanceLeaseInterestExpense_c20220101__20220331_zhPb1tjbZMjb" title="Finance lease, interest expense">0</span> and $<span id="xdx_90F_eus-gaap--FinanceLeaseInterestExpense_c20210101__20210331_ziaLFQcwq431" title="Finance lease, interest expense">1,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease And Finance Lease [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504878472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_801_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zOJ4Lp2zbyD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14. <span id="xdx_82C_zShQsrSKYg8c">STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022 and December 31, 2021, the Company had <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_z4S8wiSqSe6j" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20220331_zP1z2UZ1JrWh" title="Preferred stock, shares authorized">5,000,000</span></span> shares of preferred stock, $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zAOVPOwGKd6e" title="Preferred stock, par or stated value per share"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220331_z2CZYnreRvx1" title="Preferred stock, par or stated value per share">0.001</span></span> par value, authorized and <span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20211231_z4YKaKETbf03" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231_zoDCjAc9gh72" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20220331_zrSlVymUgmoj" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20220331_zErtlpKbPVWf" title="Preferred stock, shares outstanding">no</span></span></span></span> shares
of preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z0KyBxngLjr2" title="Number of common stock issued">53,594</span> shares of common stock to Mark L. Baum, the Company&#8217;s Chief Executive
Officer, upon the cashless exercise of options to purchase <span id="xdx_907_ecustom--CashlessExerciseOfOptionsShares_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zZo6M5cxeTT4" title="Cashless exercise of options, shares">125,000</span> shares at an exercise price of $<span id="xdx_907_ecustom--CashlessExerciseOfOptionsPricePerShares_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zAMxKz24FNLh" title="Cashless exercise of options, price per shares">2.40</span> per share. The Company withheld
from Mr. Baum <span id="xdx_90F_ecustom--CommonStockWithheldOnCashlessExercise_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zLQ7iW9Jiig7" title="Common stock withheld on cashless exercise">36,014</span> shares as consideration for the cashless exercise and an additional <span id="xdx_90C_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z7FsYO4vfI59" title="Common stock withheld for payroll tax withholdings, shares">35,392</span> shares for payroll tax obligations totaling
$<span id="xdx_908_ecustom--CommonStockWithheldForPayrollTaxWithholdings_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zkIaTLBgLD11" title="Common stock withheld for payroll tax withholdings, value">295,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20190201__20190228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zydEd7Xb509g" title="Number of restricted stock units granted">50,000</span>
RSUs granted in February 2019 to Andrew R. Boll, the Company&#8217;s Chief Financial Officer, vested, and in February 2022, the Company
issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zzbNiozXKIf4" title="Number of common stock issued">29,395</span> shares of common stock to Mr. Boll, net of <span id="xdx_90A_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zt70HWgvvUv5" title="Common stock withheld for payroll tax withholdings, shares">20,605</span> shares of common stock withheld for payroll tax withholdings totaling
$<span id="xdx_904_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_z4pGwaYZ3sk2" title="Common stock withheld for payroll tax withholdings, value">162,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20190201__20190228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_z2kalpzJQZpd" title="Number of restricted stock units granted">50,000</span>
RSUs granted in February 2019 to John P. Saharek, the President of ImprimisRx, vested, and in February 2022, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zjppP1MaKh3e" title="Number of common stock issued">24,077</span>
shares of common stock to Mr. Saharek, net of <span id="xdx_90D_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zIJqqPnPKrQ1" title="Common stock withheld for payroll tax withholdings, shares">25,923</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_907_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_z1vXs3m7Fqye" title="Common stock withheld for payroll tax withholdings, value">204,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20190201__20190228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkJo5qJn91nh" title="Number of restricted stock units granted">35,000</span>
RSUs granted in February 2019 vested, and in February 2022, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgE73FhjhcC8" title="Number of common stock issued">20,298</span> shares of common stock, net of <span id="xdx_901_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyLpsIrtGqgd" title="Common stock withheld for payroll tax withholdings, shares">14,702</span> shares of
common stock withheld for payroll tax withholdings totaling $<span id="xdx_90E_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsKdV4ZRjD0j" title="Common stock withheld for payroll tax withholdings, value">116,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDtQPIuVIAig" title="Number of shares isssued">1,000</span> shares of common stock and received net proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0mPvATYj27i" title="Proceeds from purchase of common stock">4,000</span> upon the exercise
of options to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTPUdlFcse5k" title="Number of options to purchase common stock">1,000</span> shares of common stock with exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjoyUAjR1Psf" title="Exercise price">3.95</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyB4Arl7Or48" title="Number of shares isssued">9,644</span> shares of the Company&#8217;s common stock underlying RSUs issued to directors vested, but
the issuance and delivery of these shares are deferred until the applicable director resigns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Option Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 17, 2007, the Company&#8217;s Board of Directors and stockholders adopted the Company&#8217;s 2007 Incentive Stock and Awards
Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended,
the &#8220;2007 Plan&#8221;). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this
plan; however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or
are otherwise cancelled/forfeited. On June 13, 2017, the Company&#8217;s Board of Directors and stockholders adopted the Company&#8217;s
2017 Incentive Stock and Awards Plan which was subsequently amended on June 3, 2021 (as amended, the &#8220;2017 Plan&#8221; together
with the 2007 Plan, the &#8220;Plans&#8221;). As of March 31, 2022, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_z9oEijQMSALc" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">6,000,000</span>
shares of the Company&#8217;s common stock. The purposes of the Plans are to attract and retain directors, officers, consultants, advisors
and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such
persons in the Company&#8217;s development and financial success. Under the Plans, the Company is authorized to issue incentive stock
options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified stock options, restricted
stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company&#8217;s Board of Directors.
The Company had <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_zBcD4jG6Tda3" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant">2,229,399</span> shares available for future issuances under the 2017 Plan at March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zJxL6dHkZQWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity under the Plans for the three months ended March 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zMfNdnqJrHK8" style="display: none">SCHEDULE
OF STOCK OPTION PLAN ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Options outstanding &#8211; January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zs71DclQBMOi" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance">3,039,546</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLUzVHvgl5I2" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">5.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZATxOBiSMpi" style="text-align: right" title="Number of shares, options granted">170,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zlaZ40dISsag" style="text-align: right" title="Weighted average exercise price, options granted">7.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpIw669FcMr9" style="text-align: right" title="Number of shares, options exercised">(126,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWIYBRJqmDg4" style="text-align: right" title="Weighted average exercise price, options exercised">2.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zn1WOUkuwpdb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1204">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwd9Fh04h5wf" style="text-align: right" title="Weighted average exercise price, options cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding &#8211; March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zbwxm1CFj9hk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">3,083,796</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJAW0Gkj0JT5" style="text-align: right" title="Weighted average exercise price, outstanding, ending balance">5.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWKDp5ZBcODh" title="Weighted average. remaining contractual life, options outstanding">5.01</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLu9Zj8MW3w7" style="text-align: right" title="Aggregate intrinsic value, options outstanding">4,781,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z6Cbdb4qDJS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,408,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVAAOR1EgGog" style="text-align: right" title="Weighted average exercise price, options exercisable">5.29</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVC7vOFHuPik" title="Weighted average. remaining contractual life, options exercisable">4.61</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOPPtIdiFQZ6" style="text-align: right" title="Aggregate intrinsic value, options exercisable">4,639,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zDrp9jBJ4UJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">3,083,796</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJ0KwgTMUvgg" style="text-align: right" title="Weighted average exercise price, options vested and expected to vest">5.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zMibHxxV6Hv7" title="Weighted average. remaining contractual life, options vested and expected to vest">5.01</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zshFV23Z9Zx6" style="text-align: right" title="Aggregate intrinsic value, options vested and expected to vest">4,781,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zXUWPVUGjh52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would
have been received by option holders if all option holders had exercised and immediately sold all shares underlying options with an exercise
price lower than the market price on March 31, 2022, based on the closing price of the Company&#8217;s common stock of $<span id="xdx_905_ecustom--ClosingPriceOfCommonStockPricePerShare_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zojVTmb68O4c" title="Closing price of common stock price per share">6.82</span> on that
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022, the Company granted stock options to certain employees and a consultant. The stock options were
granted with an exercise price equal to the current market price of the Company&#8217;s common stock, as reported by the securities exchange
on which the common stock was then listed, at the grant date and have contractual terms of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zR2pjA0e6qkl" title="Weighted avg. remaining contractual life, options exercisable">10</span> years. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_z1TB1lhRy9cb" title="Share-based compensation arrangement by share-based payment award, plan modification, description and terms">Vesting terms for options granted
to employees during the three months ended March 31, 2022 included the following vesting schedule: 25% of the shares subject to the option
vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest
and become exercisable quarterly in equal installments thereafter over three years. Certain option awards provide for accelerated vesting
if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term
of options granted to employees and directors was determined in accordance with the &#8220;simplified approach,&#8221; as the Company
has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free
interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time
of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual
effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of <span id="xdx_900_ecustom--ForfeitureFactorPercentage_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zbxUNmZfSSr4" title="Forfeiture factor, percentage">10</span>%. These
factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing
these assumptions, the fair value is determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z8zpcMEUVIpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions
used for valuing options granted to employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zg1IQqPsufYg" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zmdp4Om773Kf" style="width: 18%; text-align: right" title="Weighted-average fair value of options granted">4.65</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected terms (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zzbfrGSUFxKa" title="Expected terms (in years)">6.11</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zGSII0nQ7aL7" title="Expected volatility">70</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zN27WN8Tdig6" title="Risk-free interest rate, minimum">1.54</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zomvtOcMH8d3" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zoQg66NxAmMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1gh4Ptrwfo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about stock options outstanding and exercisable at March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="xdx_8B2_zfz4KwQGn4je" style="display: none">SCHEDULE OF STOCK OPTION
OUTSTANDING AND EXERCISABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life in Years</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY8PqxlEtXn7" title="Range of Exercise Prices, minimum">1.47</span>
- $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMsCdx2YF4Y4" title="Range of Exercise Prices, maximum">1.73</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ztQo68yEhXz9" style="width: 13%; text-align: right" title="Number of Options Outstanding">312,887</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z24q1PU3O8E5" title="Weighted Average Remaining Contractual Life in Years">5.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zodfpNIeuAmf" style="width: 13%; text-align: right" title="Weighted Average Exercise Price">1.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zakIb0ukmuJk" style="width: 13%; text-align: right" title="Number Exercisable">312,887</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcB7TuUOL1of" style="width: 13%; text-align: right" title="Weighted Average Exercisable Exercise Price">1.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSGj6KDekUT3" title="Range of Exercise Prices, minimum">2.23</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z32dxiErRQc3" title="Range of Exercise Prices, maximum">2.60</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2SSYXXsSL3c" style="text-align: right" title="Number of Options Outstanding">313,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zT25n5tfd1Di" title="Weighted Average Remaining Contractual Life in Years">4.84</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z7pxyjABYlCf" style="text-align: right" title="Weighted Average Exercise Price">2.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z75oIeqX9ei5" style="text-align: right" title="Number Exercisable">312,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1ux0QJvYD9e" style="text-align: right" title="Weighted Average Exercisable Exercise Price">2.26</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zlbZvTHqfLBj" title="Range of Exercise Prices, minimum">2.76</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z3BhakphXJ9k" title="Range of Exercise Prices, maximum">3.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zX4NmiL2kUs1" style="text-align: right" title="Number of Options Outstanding">25,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXwXMGWvh39c" title="Weighted Average Remaining Contractual Life in Years">7.95</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDklN5SIoJB8" style="text-align: right" title="Weighted Average Exercise Price">3.49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIeS6xa7bWP6" style="text-align: right" title="Number Exercisable">12,906</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zARkKud69mYc" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zpVFjXx6hG55" title="Range of Exercise Prices">3.95</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zN5BPH4Uc7V2" style="text-align: right" title="Number of Options Outstanding">370,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRW91QoQ5nlh" title="Weighted Average Remaining Contractual Life in Years">4.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zMZRx6loRkk4" style="text-align: right" title="Weighted Average Exercise Price">3.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zAUALSjauKM5" style="text-align: right" title="Number Exercisable">370,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUYTQ9ezDwW8" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.95</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrJcySqDeen9" title="Range of Exercise Prices, minimum">4.08</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zmvR4WUmEaR4" title="Range of Exercise Prices, maximum">6.30</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zYOWjPHdfYTf" style="text-align: right" title="Number of Options Outstanding">578,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zDzGhG9ubpS5" title="Weighted Average Remaining Contractual Life in Years">5.71</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zzScQ2irwIHf" style="text-align: right" title="Weighted Average Exercise Price">5.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zlKKSuX3bH7g" style="text-align: right" title="Number Exercisable">525,027</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zehLvUJ9aqHf" style="text-align: right" title="Weighted Average Exercisable Exercise Price">5.85</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zFssEYVhEJM" title="Range of Exercise Prices, minimum">6.81</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zH3KbASX2QE" title="Range of Exercise Prices, maximum">7.37</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_ziQGewB6CGqe" style="text-align: right" title="Number of Options Outstanding">388,995</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF8rAJAetFX2" title="Weighted Average Remaining Contractual Life in Years">6.27</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zx6zFKvNQDGe" style="text-align: right" title="Weighted Average Exercise Price">7.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zhPb9Lacstl1" style="text-align: right" title="Number Exercisable">297,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zJoNEGvO2ZV1" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zn9AbrBJBnbl" title="Range of Exercise Prices, minimum">7.52</span> - $<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zEce5kFGZrvl" title="Range of Exercise Prices, maximum">7.79</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zxCWmPlRVlI2" style="text-align: right" title="Number of Options Outstanding">221,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zBLTyxICahH" title="Weighted Average Remaining Contractual Life in Years">8.33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zdvSnIExzeek" style="text-align: right" title="Weighted Average Exercise Price">7.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zlhNBpCrBIJ9" style="text-align: right" title="Number Exercisable">49,323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z8lHdRdM1aMc" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.66</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUXgtrH3q953" title="Range of Exercise Prices">7.87</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_znmaby7QTmIf" style="text-align: right" title="Number of Options Outstanding">600,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zXGSd2oC62af" title="Weighted Average Remaining Contractual Life in Years">3.33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z6WLssJ6mn58" style="text-align: right" title="Weighted Average Exercise Price">7.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zxBXQ4JYDdJ2" style="text-align: right" title="Number Exercisable">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z3g2WSdXUIQk" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.87</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zj12WIIF2rRj" title="Range of Exercise Prices, minimum">7.89</span> - $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJi9FRnGOXN7" title="Range of Exercise Prices, maximum">8.98</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zoairg7hWZmf" style="text-align: right" title="Number of Options Outstanding">92,673</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBCoLK9aiOO3" title="Weighted Average Remaining Contractual Life in Years">7.47</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z4hEfdWECo01" style="text-align: right" title="Weighted Average Exercise Price">8.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z8nMzmM2dE43" style="text-align: right" title="Number Exercisable">48,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zy8b5igvA4cb" style="text-align: right" title="Weighted Average Exercisable Exercise Price">8.22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zHoL7MUV5Whf" title="Range of Exercise Prices">8.99</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zJ0ibE8PHbv2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZVNxrAu0CM7" title="Weighted Average Remaining Contractual Life in Years">1.09</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zA4Ck5wftYM6" style="text-align: right" title="Weighted Average Exercise Price">8.99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zeg9x30DOTdi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zog13riGQFGl" style="text-align: right" title="Weighted Average Exercisable Exercise Price">8.99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331_zAfyYlfe5RY8" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331_z1jNkg6szbWk" title="Range of Exercise Prices, maximum">8.99</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331_ztowcNr96WXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding">3,083,796</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zFIPCqRg02Ll" title="Weighted Average Remaining Contractual Life in Years">5.01</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331_zVXgHCyBuZf9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price">5.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331_zjnnezu8CiSk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">2,408,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331_z69dsw8Z2T91" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">5.29</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zfyJxnHYScU9" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, there was approximately $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_z7uywyQlhDo2" title="Unrecognized compensation expense related to unvested stock options granted under the plan">1,806,000</span> of total unrecognized compensation expense related to unvested stock options granted
under the Plans. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zKkdIitsaAJe" title="Expense expected to recognize over the weighted-average remaining vesting period">4.89</span> years. The stock-based
compensation for all stock options was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_z0xAYBlVaSga" title="Stock-based compensation">272,000</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zP0ydY76AsDa" title="Stock-based compensation">452,000</span> during the three months ended March 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of options exercised during the three months ended March 31, 2022 was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zMaTUvdj7FHa" title="Intrinsic value of options exercised">745,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units/Performance Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU
awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria.
The grant date fair value of the RSUs, which has been determined based upon the market value of the Company&#8217;s common stock on the
grant date, is expensed over the vesting period of the RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zL3Fov38ZLo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s RSU activity (including performance stock units) and related information for the three months ended March
31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zKxp5nlKRWpa" style="display: none">SCHEDULE
OF RESTRICTED STOCK UNITS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">RSUs unvested - January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeoqiQU4Cum4" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">2,233,202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMeeYIVkYgVk" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">6.78</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RSUs granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjfsiSlInzFe" style="text-align: right" title="Number of RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAOkPaieR8jh" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">RSUs vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbN62HMPlyWc" style="text-align: right" title="Number of RSUs vested">(144,644</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znDhB7QraFv2" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">6.57</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFgbIgWQ0s8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTYSEKP7aTDl" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">RSUs unvested at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgbEvmKQ2qDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">2,088,558</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuXzSXRNnJ9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">6.79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zblHekinWO1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zhC5lpryASM6" title="Unrecognized compensation expense related to unvested stock options granted under the plan">8,756,000</span>, which is expected
to be recognized over a weighted-average period of <span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zHgIYywusSIl" title="Expense expected to recognize over the weighted-average remaining vesting period">1.33</span> years, based on estimated and actual vesting schedules of the applicable RSUs.
The stock-based compensation for RSUs during the three months ended March 31, 2022 and 2021 was $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zHxcx6c0WDwe" title="Stock-based compensation">1,744,000</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20210101__20210331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zgPK0efEAbAk" title="Stock-based compensation">346,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company issues warrants to purchase shares of the Company&#8217;s common stock to investors, lenders, underwriters
and other non-employees for services rendered or to be rendered in the future, or pursuant to settlement agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo5ixYfyrQ2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of warrant activity for the three months ended March 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_ztvBORS9irK" style="display: none">SCHEDULE
OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Shares Subject</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">to Warrants Outstanding</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants outstanding - January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPb4Gb1Jz4vc" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">373,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyGJANhyi5j3" style="width: 16%; text-align: right" title="Weighted Average. Exercise Price, Outstanding, beginning balance">2.08</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrPyFoX9mwK9" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zakui8Qwm8b3" style="text-align: right" title="Share-based Payment Award, Non-Option Equity Instruments, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6IT4LIzQJ9k" style="border-bottom: Black 1.5pt solid; text-align: right" title=" Share-based Payment Award, Non-Option Equity Instruments, Expirations"><span style="-sec-ix-hidden: xdx2ixbrl1452">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHFQiAJFEfSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding, Ending balance">373,847</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBIycJQy98z2" style="text-align: right" title="Weighted Average. Exercise Price, Outstanding, Ending balance">2.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z8S1ubqxtvD1" title="Weighted average remaining contractual life of the outstanding warrants in years">2.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zRbkYHtlAY7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--ScheduleofWarrantsOutstandingTableTextBlock_z1jBO3cal1o3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding and exercisable as of March 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmlBmUS0EVja" style="display: none">SCHEDULE
OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Series</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left">Lender warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_900_ecustom--WarrantsIssuanceDate_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z6ZFhmiEdv9a" title="Issue Date">7/19/2017</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z8wZbmYFXGWf" style="width: 14%; text-align: right" title="Warrants Outstanding">373,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zlmFP81pJi6a" style="width: 14%; text-align: right" title="Exercise Price">2.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zw8drB9B6Ihc" title="Expiration Date">7/19/2024</span></td></tr>
  </table>

<p id="xdx_8AE_zamDE5I7GWfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiary
Stock-Based Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_zIxxPL6DdzFh" title="Stock-based compensation">0</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20210101__20210331__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_z0IGk0lzu2Kl" title="Stock-based compensation">57,000</span> in stock-based compensation expense related to subsidiary stock options during the three months ended
March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z4vPgSO6nvK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_ziDMPJsYYPw5" style="display: none">SCHEDULE
OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20220331_zSewNhZ8RMs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20210331_zeZ6gdo90dU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zzZCTPKEA8A5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,676,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">755,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkxhkmCyw9Qe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employees &#8211; research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1480">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVUcNHC5VAfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Directors - selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z1PYRObGnws1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Consultants &#8211; research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1486">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zuRtxErxv2Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,016,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">855,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504875688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbmEPjPSzl7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15. <span id="xdx_82C_z2mC8CTirizl">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Other</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make claims
or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial disputes.
Any of these claims could subject the Company to litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
and Professional Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize
traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any
given time reflects current market conditions, including cost and availability, when the policy is written.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the indemnification provisions contained in the Company&#8217;s governing documents, the Company generally enters into separate
indemnification agreements with each of the Company&#8217;s directors and officers. These agreements require the Company, among other
things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys&#8217; fees, judgments, fines
and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual&#8217;s status
or service as the Company&#8217;s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly
fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the
individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors
in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for
any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred
any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed
consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Klarity
License Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a license agreement in April 2017, as amended in April 2018 (the &#8220;Klarity License Agreement&#8221;), with
Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed
certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic
solution Klarity designed to protect and rehabilitate the ocular surface (the &#8220;Klarity Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z6d1CLBuRVcj" title="Royalty payment description">Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of
net sales, dependent upon the final formulation of the Klarity Product sold</span>. In addition, the Company was required to make certain milestone
payments to Dr. Lindstrom. All of the above referenced milestone payments were payable at the Company&#8217;s election in cash or shares
of the Company&#8217;s restricted common stock. Payments totaling $<span id="xdx_90A_ecustom--MilestonePaymentInCash_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zSTYSntkUSXk" title="Milestone payment in cash">30,000</span> and $<span id="xdx_905_ecustom--MilestonePaymentInCash_iI_c20210331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zYMWpbnK2gWj" title="Milestone payment in cash">35,000</span> were made during the three months ended March 31,
2022 and 2021, respectively. $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_z7aVcoOiVGn4" title="Royalty expenses">71,000</span> and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zNQyED0RiQ5k" title="Royalty expenses">35,000</span> were incurred as royalty expenses during the three months ended March 31, 2022 and 2021,
respectively, and was included in accounts payable to Dr. Lindstrom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Injectable
Asset Purchase Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the Company entered into an asset purchase agreement (the &#8220;Lindstrom APA&#8221;) with Dr. Lindstrom, a member of
its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights
from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the &#8220;Lindstrom Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Lindstrom APA, <span id="xdx_904_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z7yTs6ZVHQud" title="Royalty payment description">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales,
dependent upon the final formulation and patent protection of the Lindstrom Product sold</span>. In addition, the Company is required to make
certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_90C_ecustom--InitialMilestonePayment_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zEM577gDs0Wb" title="Initial milestone payment">33,000</span> upon execution of the Lindstrom APA. Dr. Lindstrom
was paid $<span id="xdx_908_ecustom--MilestonePaymentInCash_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_ziRMRumqWQmd" title="Milestone payment in cash">8,000</span> and $<span id="xdx_90D_ecustom--MilestonePaymentInCash_iI_c20210331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zfHnAnS1qFT8">7,000</span> in cash during the three months ended March 31, 2022 and 2021, respectively. The Company incurred $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zWuOSPbCmOCb" title="Royalty expenses">7,000</span> and
$<span id="xdx_901_eus-gaap--RoyaltyExpense_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zigytNiKJVQi" title="Royalty expenses">7,000</span> for royalty expenses related to the Lindstrom APA during the three months ended March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Eyepoint
Commercial Alliance Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the &#8220;Dexycu
Agreement&#8221;) with Eyepoint Pharmaceuticals, Inc. (&#8220;Eyepoint&#8221;), pursuant to which Eyepoint granted the Company the non-exclusive
right to co-promote DEXYCU<sup>&#174;</sup> (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation
following ocular surgery in the United States.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the <span style="background-color: white">Dexycu Agreement</span>, Eyepoint will pay the Company a fee calculated based on the quarterly
sales of DEXYCU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms of the <span style="background-color: white">Dexycu
Agreement</span>, the Company shall use commercially reasonable efforts to promote and market DEXYCU in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span style="background-color: white">Dexycu Agreement</span> expires on <span id="xdx_903_ecustom--CommissionExpirationDate_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zze7YtRgsA4i">August 1, 2025</span>, subject to early termination in accordance with
the terms set forth therein. Either party may terminate the <span style="background-color: white">Dexycu Agreement, subject to specified
notice periods and limitations,</span> in the event of (i) uncured material breach by the other party or (ii) if DEXYCU ceases to have
&#8220;pass-through&#8221; payment status. In addition, subject to certain limitations, the Company may terminate the <span style="background-color: white">Dexycu
Agreement</span> (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a change
of control. Eyepoint may terminate the <span style="background-color: white">Dexycu Agreement</span>, subject to specified notice periods
and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods. During the three months
ended March 31, 2022 and 2021, the Company recorded $<span id="xdx_90E_ecustom--CommissionRevenues_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zrC3cpRCRtn3" title="Commission revenues">1,320,000</span> and $<span id="xdx_900_ecustom--CommissionRevenues_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zTIo62ADmUWh" title="Commission revenues">485,000</span>, respectively, in commission revenues related to the Dexycu
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered various sales and marketing agreements with certain organizations to provide exclusive and non-exclusive sales and
marketing representation services to Harrow in select geographies in the U.S. in connection with the Company&#8217;s ophthalmic pharmaceutical
compounded formulations or related products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--DescriptionForCommissionPayments_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zahTbaz2FEKb" title="Description for commission payments">Under
the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to <span id="xdx_90A_ecustom--CommissionPaymentsPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zkVqI9bjFDbk" title="Commission payments percentage">10</span>% - <span id="xdx_90B_ecustom--CommissionPaymentsPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_z4LuF0bzkmY1" title="Commission payments percentage">14</span>% of
net sales for products above and beyond the initial existing sales amounts</span>. In addition, the Company is required to make periodic milestone
payments to certain organizations in shares of the Company&#8217;s restricted common stock if net sales in the assigned territory reach
certain future levels by the end of their terms. Commission expenses of $<span id="xdx_90F_eus-gaap--SalesCommissionsAndFees_pn3n3_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zGeVmRm8NCIb" title="Commission expenses">1,047,000</span> and $<span id="xdx_90A_eus-gaap--SalesCommissionsAndFees_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zolAxgvIbau" title="Commission expenses">804,000</span> were incurred under these agreements during the three months ended March 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset
Purchase, License and Related Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related
parties (the &#8220;Inventors&#8221;) through multiple asset purchase agreements, license agreements, strategic agreements and commission
agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for
the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize
a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual
property and drug development opportunities presented by these Inventors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based
on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first
patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the
Company files the first investigational new drug application (&#8220;IND&#8221;) with the U.S. Food and Drug Administration (&#8220;FDA&#8221;)
for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within
30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual
property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or
licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company&#8217;s
development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the
Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where
data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property,
the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to
the Inventors. During the three months ended March 31, 2022 and 2021, $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zz2PtmNcJcX5" title="Royalty expense">213,000</span> and $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zYZDO92reQzi" title="Royalty expense">232,000</span> were incurred under these agreements as royalty
expenses, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sintetica
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, the Company entered into a License and Supply Agreement (the &#8220;Sintetica Agreement&#8221;) with Sintetica S.A. (&#8220;Sintetica&#8221;),
pursuant to which Sintetica granted the Company the exclusive license and marketing rights to its patented ophthalmic drug candidate
(&#8220;AMP-100&#8221;) in the U.S. and Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Sintetica Agreement, the Company will pay Sintetica a per unit transfer price to supply AMP-100, along with a per unit royalty
for units sold. The Company is required to pay Sintetica up to $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_c20210701__20210731__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zLKCsCkfo5ph" title="Royalty payments">18,000,000</span> in one-time milestone payments including a $<span id="xdx_906_eus-gaap--PaymentsForRoyalties_c20210701__20210731__srt--StatementScenarioAxis__custom--DueWithinThirtyDaysMember__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zboQTHWuHZek" title="Royalty payments">5,000,000</span> payment
(the &#8220;Upfront Payment&#8221;) due within 30 days of signing the Sintetica Agreement and the balance of payments due upon achievement
of certain regulatory and commercial milestones. Under the terms of the Sintetica Agreement, Sintetica will be responsible for regulatory
filings for AMP-100 in the U.S. The Upfront Payment along with an additional milestone payment of $<span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7626tFCAxkg">3,117,000</span> was paid and recorded as
a R&amp;D expenses during the year ended December 31, 2021. For the three months ended March 31, 2022, no amounts have been paid or accrued
under the Sintetica agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations, the term of the Sintetica Agreement is ten years, and allows for a ten-year extension if certain sales thresholds
are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wakamoto
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
August 2021, the Company entered into a License Agreement and a Basic Sale and Purchase Agreement (together, the &#8220;Wakamoto Agreements&#8221;)
with Wakamoto Pharmaceutical Co., Ltd. (&#8220;Wakamoto&#8221;), pursuant to which Wakamoto granted the Company the exclusive license
and marketing rights to its ophthalmic drug candidate (&#8220;MAQ-100&#8221;) in the U.S. and Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the <span style="background-color: white">Wakamoto </span>Agreements, Wakamoto will supply MAQ-100 to the Company, and the Company
will pay Wakamoto a per unit transfer price to supply MAQ-100. In addition, the Company is required to pay Wakamoto various one-time
milestone payments totaling up to $<span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--WakamotoAgreementMember_zGLq77pOpHY1" title="Payment for royalties">2,000,000</span> upon the achievement of certain regulatory milestones and up to $<span id="xdx_909_ecustom--CommercialPaymentsForRoyalties_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--WakamotoAgreementMember_zfumzQTDWiJb" title="Commercial payments for royalties">6,200,000</span> upon the achievement
of certain commercial milestones. Under the terms of the Agreements, the Company will be responsible for regulatory filings and fees
for MAQ-100 in the U.S. and Canada. Through March 31, 2022, no amounts have been paid or accrued under the Wakamoto agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations, the term of the Agreements is for five years from the date of the FDA&#8217;s market approval of MAQ-100 and
allows for a five-year extension if certain unit sales thresholds are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Presbyopia
Asset Purchase Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the Company entered into an asset purchase agreement (the &#8220;Presbyopia APA&#8221;) with Richard L. Lindstrom, M.D.,
a member of its Board of Directors. Pursuant to the terms of the Presbyopia APA, the Company acquired certain intellectual property and
related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic topical product to treat presbyopia
(the &#8220;Presbyopia Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Presbyopia Product, <span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z7Q763ZNmQ62">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales,
dependent upon the final formulation and patent protection of the Presbyopia Product sold</span>. Dr. Lindstrom was paid $<span id="xdx_903_ecustom--MilestonePaymentInCash_iI_pn3n3_c20220331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zbRHq0ZChKOk" title="Milestone payment in cash"><span id="xdx_906_ecustom--MilestonePaymentInCash_iI_pn3n3_c20210331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zzFarbzhcbg" title="Milestone payment in cash">0</span></span> in cash during the
periods ended March 31, 2022 and 2021, and was due $<span id="xdx_901_ecustom--MilestonePaymentsOnPayables_iI_pn3n3_c20220331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zgFoBNxDxh3h" title="Milestone payments on payables"><span id="xdx_902_ecustom--MilestonePaymentsOnPayables_iI_pn3n3_c20210331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zJCOqJNO0Iy8" title="Milestone payments on payables">0</span></span> at March 31, 2022 and 2021. The Company incurred $<span id="xdx_905_eus-gaap--RoyaltyExpense_pn3n3_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zqAnyd65PQB7" title="Royalty expense"><span id="xdx_901_eus-gaap--RoyaltyExpense_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zdwMCGfRnTxd" title="Royalty expense">0</span></span> for royalty expenses related
to the Presbyopia APA during the periods ended March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198598246632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--ConcentrationRiskDisclosureTextBlock_zaB4iy0Cwgk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
16. <span id="xdx_827_zhZ9f4d7GrN1">CONCENTRATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two products that each comprised more than 10% of total revenues. These products collectively accounted for <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zqUQoz088484">32</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zNvYt9MOXRSj">36</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of revenues during the three months ended March
31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the
Company&#8217;s total pharmacy sales during the three months ended March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zOBkC85bSFj7" title="Concentration risk percentage">74</span>% and
<span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zluRvfoBDKd5" title="Concentration risk percentage">82</span>% of active pharmaceutical ingredient purchases during the three months ended March 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503976744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zX6rswmRDxQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
17. <span id="xdx_829_zOVUgaCJPov4">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has performed an evaluation of events occurring subsequent to March 31, 2022 through the filing date of this Quarterly Report.
Based on its evaluation, no events other than those described below need to be disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conditional
Melt Loan Amendment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
In April 2022, the Company entered into a First Amendment (the &#8220;Amendment&#8221;) to its loan and security agreement previously
entered into on September 1, 2021 with Melt. The Amendment provides for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--DescripitionOfLoanAmendment_c20220401__20220430__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4NsIwAzfXQ7" title="Descripition of loan amendment">Melt
    is required to maintain a minimum cash balance of $7,000,000 for one (1) year following the effective date of the Amendment; and
    a minimum cash balance of $5,000,000 at all times after the one year anniversary of the effective date of the Amendment</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    maturity date by which all amounts owed under the loan agreement are payable was extended to September 1, 2026, unless otherwise
    accelerated pursuant to the terms of the loan agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    definition of Material Adverse Effect was amended so that such an effect will be deemed to have occurred if the data from the phase
    2 study of MELT-300 fails to demonstrate the benefit of the combination MELT-300 study drug versus the individual components of the
    same MELT-300 study drug, as reasonably determined by the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    effectiveness of the Amendment is subject to, among other conditions, Melt consummating a qualifying financing of a minimum amount
    of $<span id="xdx_904_ecustom--MinimumAmountOfFinancing_c20220831__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJpTmHOjbn45" title="Minimum amount of financing">15,000,000</span> from third party investors by August 31, 2022.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504223192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock', window );">Risks, Uncertainties and Liquidity</a></td>
<td class="text"><p id="xdx_842_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zlikh7k4Jfld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z61yL2WHWdw">Risks,
Uncertainties and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company&#8217;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result
of regulatory guidelines or inspections, this may have a material impact on the Company&#8217;s financial condition, liquidity and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGEhHZSPonzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zkwHcxaMbNAi">Segments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to shifts in the Company&#8217;s strategic plans to further focus on growing the Company&#8217;s ImprimisRx business and suspension of
activities related to starting up development-stage pharmaceutical companies, along with changes to the Company&#8217;s organizational
and internal reporting structure, beginning in January 2022 management no longer evaluates the Company&#8217;s business in two segments
and instead focuses on the performance of the business as a single operating business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net (Loss) Income per Common Share</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_z09jDRTdzUM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zK97u56dXbd8">Basic
and Diluted Net (Loss) Income per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net (loss) income per common share is computed by dividing net (loss) income attributable to common stockholders for the period by the
weighted average number of common shares outstanding during the period. Diluted net (loss) income per share is computed by dividing the
net (loss) income attributable to common stockholders for the period by the weighted average number of common and common equivalent shares,
such as stock options, restricted stock units (&#8220;RSUs&#8221;) and warrants, outstanding during the period. Common equivalent shares
(using the treasury stock method) from stock options, unvested RSUs and warrants were <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zi4YTngRCKDb" title="Antidilutive securities">5,546,200</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zgKWeI7wFAOg" title="Antidilutive securities">5,486,678</span> at March 31, 2022 and 2021,
respectively. For the three months ended March 31, 2022, the common equivalent shares are excluded in the calculation of diluted net
loss per share because the effect is anti-dilutive. Included in the basic and diluted net (loss) income per share calculation were RSUs
awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number
of shares underlying vested RSUs at March 31, 2022 and 2021 was <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNOovaasI2H1" title="Number of shares vestted, RSUs">277,405</span> and <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZzIAkghWppk" title="Number of shares vestted, RSUs">223,219</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNS0kGC3Spqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the computation of basic net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zIK2wVYRcfJb" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20220331_zPZjySBbpEEb" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20210331_zK9PGkctLRE2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zBSHDqd9SEe6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc. common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(2,438,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">217,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zVkFlIgL0agf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Denominator - weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,226,819</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,019,255</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_zedkPD5L7Keb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zZdBqJnX6MLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_ecustom--DilutedCommonEquivalentSharesTableTextBlock_ztS6hUdeceP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2021, the Company had net income. As a result, the Company computed diluted net income per share using
the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent
shares for the three months ended March 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zGv4Ux4CkOL9" style="display: none">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20210331_zKlwQtQ6UHne" style="text-align: center; font-weight: bold">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Diluted shares related to: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEluRcHYzuv1" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%">Warrants </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 30%; text-align: right">576,275</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLmA3bQlDFui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Stock options </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">885,092</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,461,367</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zEDTRvbryULd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--DilutedNetIncomePerShareTableTextBlock_zTLSbJwFaYn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the computation of diluted net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zbQUI7vKVAsf" style="display: none">SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20220331_zhckyztUZ068" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210331_zME873UuxLr3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(2,438,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">217,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zxoBmqdXKAv3" style="vertical-align: bottom; background-color: White">
    <td>Denominator &#8211; weighted average number of shares outstanding, basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,226,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,019,255</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_pid_z2WDYs3HKDoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,461,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z5Rl0ws6trN2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted earnings per share computation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,226,819</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,480,622</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zXD2dSROWCph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_z8eqhiriI7Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment in Eton Pharmaceuticals, Inc.</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_zsDCERs0SWaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zpB9pPdiNes3">Investment in Eton Pharmaceuticals, Inc.</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, the Company owned <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zTJupoqpHCG3" title="Number of shares owned">1,982,000</span> shares of Eton common stock, which represents less than <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zd5SBrhuUHQd" title="Equity Method Investment, Ownership Percentage">10</span>% of the equity interests of
Eton. At March 31, 2022, the fair market value of Eton&#8217;s common stock was $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zirbFSENtIKi" title="Shares price">4.36</span> per share. In accordance with the Accounting Standards
Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets
and Financial Liabilities</i>, the Company recorded an unrealized investment gain (loss) from its Eton common stock position of $<span id="xdx_907_eus-gaap--UnrealizedGainLossOnInvestments_c20220101__20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_z9IFkdPVayS6" title="Unrealized Gain (Loss) on Investments">139,000</span>
and $(<span id="xdx_90C_eus-gaap--UnrealizedGainLossOnInvestments_c20210101__20210331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zPiVkWlbQTT3" title="Unrealized Gain (Loss) on Investments">2,835,000</span>) during the three months ended March 31, 2022 and 2021, respectively, related to the change in fair market value of its
investment in Eton during the measurement period. As of March 31, 2022, the fair market value of the Company&#8217;s investment in Eton
was $<span id="xdx_901_eus-gaap--InvestmentOwnedAtFairValue_iI_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zCD3tr1mWRee" title="Investment owned, at fair value">8,642,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentOnePolicyTextBlock', window );">Investment in Melt Pharmaceuticals, Inc. &#8211; Related Party</a></td>
<td class="text"><p id="xdx_841_ecustom--InvestmentOnePolicyTextBlock_z7ZR2aiQoUZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zUPoGjZBwjMd">Investment
in Melt Pharmaceuticals, Inc. &#8211; Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company owns <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zX1EQ0YC1wZ9" title="Number of shares owned">3,500,000</span> shares of common stock of Melt (representing approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z744nHYvrDi8" title="Ownership percentage">46</span>% of the equity interests as of March 31, 2022). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests
in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant
influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this
method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying
amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31,
2021, the Company reduced the carrying value of its common stock investment in Melt to $<span id="xdx_906_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkYZt5lFNR76" title="Reduction in common stock investment">0</span> as a result of the Company recording its share
of equity losses in Melt since its deconsolidation in 2019. As of March 31, 2022 and at the time of entering into the Melt Loan Agreement
(see Note 4), the Company owned <span id="xdx_905_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBYyKHO8OWw9" title="Investment Interest Rate">100</span>% of Melt&#8217;s indebtedness. Following the reduction of the carrying value of the Company&#8217;s
common stock investment in Melt to $<span id="xdx_904_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zEXoazSP5uqg" title="Reduction in common stock investment">0</span>, the Company began recording <span id="xdx_90D_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKy0RGpMjbR3" title="Investment Interest Rate">100</span>% of the equity method losses of Melt, based on its ownership of
Melt&#8217;s total indebtedness. In addition, the Company treats interest paid in kind on the Melt Loan Agreement as an in-substance
capital contribution and reduces its investment in Melt accordingly, rather than recording interest income. The Company has no other
requirements to advance funds to Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zHDKezjlAzC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s investments in Melt as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zOu6gAVnfeab" style="display: none">SCHEDULE OF INVESTMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Cost</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Share of Equity</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Paid-in-Kind</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">In-substance Capital</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Basis</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Method Losses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> Contributions</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; text-align: justify">Common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBkl2EaRCDC4" style="width: 14%; text-align: right" title="Cost Basis">5,810,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqfd0vzn9Si" style="width: 14%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJhT7QPahy73" style="width: 14%; text-align: right" title="Paid in Kind Interest"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;$</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Loan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z36QM1txxHVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost Basis">13,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_za6GSpCvubZ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses">(5,253,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXBKSmtqYxvk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Paid in Kind Interest">1,021,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkJgzLHOo4wi" style="border-bottom: Black 1.5pt solid; text-align: right" title="In Substance Capital Contributions">(1,021,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXiD29Wvcgr8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value">8,247,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6dIETxaG9Ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis">19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSjrHuJ5eGWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(11,063,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zZE5JbYjMrNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest">1,021,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zhg3MW8XrTdi" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions">(1,021,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zWU9pjd23XQi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">8,247,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zS3V4anqotQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2022 and 2021, the Company recorded $<span id="xdx_903_eus-gaap--DueFromRelatedParties_iI_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zSpqwczV4Jd1">30,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">due from Melt for reimbursable expenses and
amounts payable pursuant to a Management Services Agreement between the Company and Melt (the &#8220;Melt MSA&#8221;), which are included
in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 4 for more information and related party disclosure regarding Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentTwoPolicyTextBlock', window );">Investment in Surface Ophthalmics, Inc. &#8211; Related Party</a></td>
<td class="text"><p id="xdx_845_ecustom--InvestmentTwoPolicyTextBlock_zsSi1v7tD1ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zXyiO94KHvEf">Investment
in Surface Ophthalmics, Inc. &#8211; Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company owns <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zwq1TJ9qFRKf" title="Number of shares owned">3,500,000</span> common shares of Surface (representing approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zM7tBbks44u2">20</span>% of Surface&#8217;s equity interests following the closing
of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as
management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions
of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts
the carrying amount of its investment in Surface accordingly. The Company&#8217;s share of earnings and losses are based on the Company&#8217;s
ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company
reduced its common stock investment in Surface to $<span id="xdx_90B_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zn44rm9BzRZ5" title="Reduction in common stock investment">0</span> as a result of the Company recording its share of equity losses of Surface. The
Company has no other investments in Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zgWdLIjhxxte" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s investment in Surface as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zyVpPQIkwx7b" style="display: none">SCHEDULE OF INVESTMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Cost</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Share of Equity</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Basis</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Method Losses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zXw7lKRQkQXb" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Cost basis">5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zilG9GbPwS9c" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Share of Equity Method Losses">(5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z4ThatYSP1Mf" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Net carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zLCrX4mbCnW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 5 for more information and related party disclosure regarding Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Impairment of Equity Method Investments and Note Receivable</a></td>
<td class="text"><p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zqjQq2ALREy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zwQT0bcs6oUa">Impairment
of Equity Method Investments and Note Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company&#8217;s equity method
investments and note receivable may be other than temporarily impaired. Indicators include financial condition, operating performance,
and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate
both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is
determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity
method investments and note receivable. At March 31, 2022 and December 31, 2021, no indicators of impairment existed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_InvestmentOnePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment One [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_InvestmentOnePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_InvestmentTwoPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Two [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_InvestmentTwoPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks Uncertainties And Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504234408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNS0kGC3Spqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the computation of basic net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zIK2wVYRcfJb" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20220331_zPZjySBbpEEb" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20210331_zK9PGkctLRE2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zBSHDqd9SEe6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc. common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(2,438,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">217,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zVkFlIgL0agf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Denominator - weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,226,819</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,019,255</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_zedkPD5L7Keb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DilutedCommonEquivalentSharesTableTextBlock', window );">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</a></td>
<td class="text"><p id="xdx_89A_ecustom--DilutedCommonEquivalentSharesTableTextBlock_ztS6hUdeceP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2021, the Company had net income. As a result, the Company computed diluted net income per share using
the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent
shares for the three months ended March 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zGv4Ux4CkOL9" style="display: none">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20210331_zKlwQtQ6UHne" style="text-align: center; font-weight: bold">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Diluted shares related to: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEluRcHYzuv1" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%">Warrants </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 30%; text-align: right">576,275</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLmA3bQlDFui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Stock options </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">885,092</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,461,367</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DilutedNetIncomePerShareTableTextBlock', window );">SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES</a></td>
<td class="text"><p id="xdx_898_ecustom--DilutedNetIncomePerShareTableTextBlock_zTLSbJwFaYn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the computation of diluted net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zbQUI7vKVAsf" style="display: none">SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20220331_zhckyztUZ068" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210331_zME873UuxLr3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(2,438,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">217,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zxoBmqdXKAv3" style="vertical-align: bottom; background-color: White">
    <td>Denominator &#8211; weighted average number of shares outstanding, basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,226,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,019,255</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_pid_z2WDYs3HKDoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,461,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z5Rl0ws6trN2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted earnings per share computation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,226,819</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,480,622</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zXD2dSROWCph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.09</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">SCHEDULE OF INVESTMENT</a></td>
<td class="text"><p id="xdx_890_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zHDKezjlAzC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s investments in Melt as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zOu6gAVnfeab" style="display: none">SCHEDULE OF INVESTMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Cost</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Share of Equity</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Paid-in-Kind</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">In-substance Capital</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Basis</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Method Losses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> Contributions</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; text-align: justify">Common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBkl2EaRCDC4" style="width: 14%; text-align: right" title="Cost Basis">5,810,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqfd0vzn9Si" style="width: 14%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJhT7QPahy73" style="width: 14%; text-align: right" title="Paid in Kind Interest"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;$</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Loan</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z36QM1txxHVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost Basis">13,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_za6GSpCvubZ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses">(5,253,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXBKSmtqYxvk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Paid in Kind Interest">1,021,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkJgzLHOo4wi" style="border-bottom: Black 1.5pt solid; text-align: right" title="In Substance Capital Contributions">(1,021,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXiD29Wvcgr8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value">8,247,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6dIETxaG9Ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis">19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSjrHuJ5eGWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(11,063,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zZE5JbYjMrNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest">1,021,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zhg3MW8XrTdi" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions">(1,021,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zWU9pjd23XQi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">8,247,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember', window );">Surface Ophthalmics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">SCHEDULE OF INVESTMENT</a></td>
<td class="text"><p id="xdx_894_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zgWdLIjhxxte" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s investment in Surface as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zyVpPQIkwx7b" style="display: none">SCHEDULE OF INVESTMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Cost</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Share of Equity</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Basis</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Method Losses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zXw7lKRQkQXb" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Cost basis">5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zilG9GbPwS9c" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Share of Equity Method Losses">(5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z4ThatYSP1Mf" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Net carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DilutedCommonEquivalentSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Diluted Common Equivalent Shares [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DilutedCommonEquivalentSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DilutedNetIncomePerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Diluted Net Income Per Share [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DilutedNetIncomePerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503915000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">SCHEDULE OF DISAGGREGATED REVENUE</a></td>
<td class="text"><p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zQXOsddbBOpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
disaggregated by revenue source for the three months ended March 31, 2022 and 2021, consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zR6gEyzvRMdk" style="display: none">SCHEDULE
OF DISAGGREGATED REVENUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49A_20220101__20220331_zOW4uD1SJ9Wg" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td id="xdx_492_20210101__20210331_zKieTB8t8vh" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Three Months Ended March 31,</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zs9nSw8zPHWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Product sales, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">20,340,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14,948,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CommissionsMember_zkkGsAEXACH8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Commissions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,320,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">485,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfProfitMember_zMZB6cpbgOQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Transfer of profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zJcXuvzPmRbk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">License</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total revenues</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,120,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,443,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504239960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock', window );">SCHEDULE OF CONDENSED INCOME STATEMENT</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zSRRrC0Q5zwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed results of operations information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z209h09UDAti" style="display: none">SCHEDULE OF CONDENSED INCOME STATEMENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zTXh8GiQ2iEg" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zlupJ2JUKVsj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the Three Months Ended <br/>
March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zO2i2yFigoSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revenues, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zq6rdl3psRmg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Loss from operations</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(3,337,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(1,099,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zDluIhJtlKhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,337,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,099,000</td><td style="text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock', window );">SCHEDULE OF CONDENSED BALANCE SHEET</a></td>
<td class="text"><p id="xdx_896_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zcLzu4bOoxG" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed balance sheet information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z9dE8G2IDlo1" style="display: none">SCHEDULE OF CONDENSED BALANCE SHEET</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zDUDBDUYrHH" style="font-weight: bold; text-align: center">At March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zdqnypoLIcSd" style="font-weight: bold; text-align: center">At December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_iI_zy0cOf4VxwId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,025,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,278,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsNoncurrent_iI_zpSoeNsopG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">360,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iI_zxGkTHwP6UY" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,385,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,278,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_iI_zijkfMkukffk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,313,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,732,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zzgVUbOyOtfk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total preferred stock and stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,928,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,454,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zV9uxU49tu1i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,385,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,278,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of condensed Balance Sheet One [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of condensed Income Statement One [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503800552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract', window );"><strong>Investment In Surface Ophthalmics Inc. - Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">SUMMARY OF CONDENSED INCOME STATEMENT</a></td>
<td class="text"><p id="xdx_894_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zaFV5yfixqbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed results of operations information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_z2nUHKSrPoQ9" style="display: none">SUMMARY OF CONDENSED INCOME STATEMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zz5eImx0Xajl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20210331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_ziQe1WCBizti" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zVIAmgsK7HXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Revenues, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_zprMrtaFqUF3" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(1,996,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(2,831,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zphBbIINa2Ri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,996,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,831,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">SUMMARY OF CONDENSED BALANCE SHEET</a></td>
<td class="text"><p id="xdx_896_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zUaMI08gdbJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed balance sheet information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z9DYOciFWKzj" style="display: none">SUMMARY OF CONDENSED BALANCE SHEET</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z3UrTE5lRVuj" style="font-weight: bold; text-align: center">At March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20211231__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zLOGRTHliMve" style="font-weight: bold; text-align: center">At December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zzNlI7Tuqx78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,920,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">21,731,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_ziWygcHThLl4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">411,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">412,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Assets_iI_zb1jhBCUKvOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,331,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,143,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_iI_zW41pp0YzM9e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,937,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,514,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_iI_zSTgmyTpzVXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total preferred stock and stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,394,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,629,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zjmufASaortk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,331,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,143,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503824360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">SCHEDULE OF INVENTORIES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zpTcmZWigGsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of March 31, 2022 and
December 31, 2021 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zmtyr5FMbDN" style="display: none">SCHEDULE OF INVENTORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220331_zYFocsw1bgsd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20211231_zkHMuC7NR4Qd" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maINz1vg_zySRv7C76sIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,441,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,441,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz1vg_zWPXVndX7Xtf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InventoryFinishedGoods_iI_maINz1vg_zqeRsVxcnJNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,911,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,776,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryNet_iTI_mtINz1vg_z184sO7uAeNb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,396,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,217,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503983368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqPEeLwq7fn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets at March 31, 2022 and December 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zZSMDZgP1N8" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220331_zy4KO0UM0EP2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zgo4Qsrvmrha" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidInsurance_iI_maPEAOAz7FJ_zI4cUnolEfl6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">455,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">728,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueFromRelatedParties_iI_maPEAOAz7FJ_zD5GgvX3f5Tj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from Melt Pharmaceuticals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz7FJ_zl8dctplNAx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">757,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAssetsCurrent_iI_maPEAOAz7FJ_zlNBpP9ltbJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz7FJ_z6aGjli0D5u2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,334,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,305,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503950136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_ze1CgIm54nx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment at March 31, 2022 and December 31, 2021, consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z6k2VxD3GSXj" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220331_zQM2Nq6qjxH3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zXofIOFnnmD8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ComputerHardwareGross_iI_maPPAEGzWKe_zPEZ9JFh67Tc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Computer hardware</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">786,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">772,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzWKe_zRnW5IVCP8Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">521,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">443,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzWKe_zVK4Z1UYQ24h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,142,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,056,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzWKe_z7WADUw264m9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,728,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,703,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzWKe_maPPAENzhZF_z1eE7Kmoyhw4" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif">Property, plant and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,177,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,974,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzhZF_zIHsffSgMWq6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,209,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,833,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzhZF_zXT8mQxmtbF4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,968,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,141,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503958840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract', window );"><strong>Capitalized Software Development Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_893_ecustom--CapitalizedSoftwareDevelopmentCostsTableTextBlock_zf7Seo6HJNB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
software development costs at March 31, 2022 and December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zhjRVbjWx1Ua" style="display: none">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220331_zzPoBne899Hc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_zcGkC3TN8Z9g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedInternalUseSoftwareMember_zFvHdjm73Ydc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Capitalized internal-use software development costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">942,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">942,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_zTJ2NFmQbAQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Acquired third-party software license for internal-use</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzJkV_zDJR8Ism6H71" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total gross capitalized software for internal-use</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,101,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,101,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzJkV_zXqLvHTMLooa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(612,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(569,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCCSNzJkV_zwoNzydOMbOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Capitalized internal-use software in process</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">982,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">781,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzJkV_zB3D3Db34jZ1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Total
    finite lived intangible assets net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,471,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,313,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized Software Development Costs [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198508686888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zJjWYWQsjHwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s intangible assets at March 31, 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zxgFjxmDBBYl" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 12pt">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Amortization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Periods</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(in years)</b></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Cost</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Accumulated</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Amortization</b></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Impairment</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Carrying Value</b></p></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjf5wF2iXy15" title="Amortization periods (in years)">17</span>-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zImd8lINgrh8" title="Amortization periods (in years)">19</span> </span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zehbq1WeiU88" style="width: 9%; text-align: right" title="Cost">972,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlfJmIfFhxQ1" style="width: 9%; text-align: right" title="Accumulated amortization">(97,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0Q4yhmF9Q7k" style="width: 9%; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfzZMRiuoT1a" style="width: 9%; text-align: right" title="Net Carrying value">875,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Licenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeWgyYGFESy6" title="Amortization periods (in years)">20</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvVKD9f6aP9" style="text-align: right" title="Cost">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zNCzPEzPr34l" style="text-align: right" title="Accumulated amortization">(15,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIbS2fmM6rCg" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_znlesKjCSMDh" style="text-align: right" title="Net Carrying value">85,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trademarks</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0koJpf1xUZ3" title="Finite-Lived Intangible Assets, Amortization Method">Indefinite</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zKpTejnk0qC8" style="text-align: right" title="Cost">260,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zll2HXJ0YgI" style="text-align: right" title="Accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV2aw1rKd6tj" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zMOochU6dJvk" style="text-align: right" title="Net Carrying value">260,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Acquired NDAs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zVYdkm2FSXd2" title="Amortization periods (in years)">10</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zHlU0qDpkfKg" style="text-align: right" title="Cost">13,635,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z820THJtV2P2" style="text-align: right" title="Accumulated amortization">(341,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zjQW5qUswlHe" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z36noIcOlKVe" style="text-align: right" title="Net Carrying value">13,294,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Customer relationships</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zirZ8X0bocTk" title="Amortization periods (in years)">3</span>-<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zfVV8Q3e0TGc" title="Amortization periods (in years)">15</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z3NDMTXnz9wj" style="text-align: right" title="Cost">1,519,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zOfTiUUyw7l4" style="text-align: right" title="Accumulated amortization">(619,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ztUO2SvFO869" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2r5IfCrgA5l" style="text-align: right" title="Net Carrying value">900,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Trade name</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zdn33BHgRTy4" title="Amortization periods (in years)">5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z48sa9Y7Jmk9" style="text-align: right" title="Cost">5,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEBqLhqiMHi3" style="text-align: right" title="Accumulated amortization">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQp1niDP54wb" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zDx1gHu34EDc" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-competition clause</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zgP1zPts6wP2" title="Amortization periods (in years)">3</span>-<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zNE9e9WAUqxe" title="Amortization periods (in years)">4</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zhfab4dWaoQc" style="text-align: right" title="Cost">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z9rGoZWRSmFj" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zURC90oOrve3" style="text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zdGWNGcngprj" style="text-align: right" title="Net Carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">State pharmacy licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zh2wHWe5SxT" title="Amortization periods (in years)">25</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z0fWDQZkeYHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z84Dqt7Mr6H" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zQEqyTorbf13" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z68nKa56dLyh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331_zwGvikTRgpW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">16,549,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331_zDPdx6zi9o73" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(1,134,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331_zVlxrwN2Ltr" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331_zZgmAs7pThp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">15,415,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zK2eZFjQVHj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for intangible assets for the three months ended March 31, 2022 and 2021 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zCTvexaauAP5" style="display: none">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 12pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49E_20220101__20220331_z6zAM7UfccS5" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" id="xdx_49A_20210101__20210331_zx49Vo3S5zyh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the <br/>Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 12pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2021</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z3GoaCK4TD9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">22,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z45HYDtJNJWj" style="vertical-align: bottom; background-color: White">
    <td>Licenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zMnd9cp9n6i7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Acquired NDAs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">341,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zTrMaLbIZt4l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AmortizationOfIntangibleAssets_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of intangible assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">404,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zjlC3on5YG66" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
future amortization expense for the Company&#8217;s intangible assets at March 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zIpkGufjwR6l" style="display: none">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20220331_ze3p2LvbPte" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzqfW_zwUaRFyNHO4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,194,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzqfW_zWx02eONrfp5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,592,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzqfW_zF3bJUCAECSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,592,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzqfW_zzrN7DtMlStj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,592,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzqfW_zmRF1aGHsh6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,595,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzqfW_zjqyFLM7MD0c" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,590,000</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzqfW_z01D7vJLeYRi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,155,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503935336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zxQmhsPtaNV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and accrued expenses at March 31, 2022 and December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zNMn0zIbKer5" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220331_zm7ufVjUs2rj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20211231_zsCiPMOqwvxb" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALziP7_zvw8orfBEi35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,595,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,174,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALziP7_zvs71AC3YS6f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAALziP7_z2487muc3H55" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,114,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,114,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALziP7_z19Vj5yde983" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Total accounts payable and accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,758,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,337,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503842584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">SUMMARY OF FUTURE MINIMUM PAYMENTS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zeXit3iAI55j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, future minimum payments under the Company&#8217;s debt were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zCaoB1YgDg5" style="display: none">SUMMARY OF FUTURE MINIMUM PAYMENTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220331_zjCFRn231Vyf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maLTDz3L0_zRx4HQB7fzoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,852,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDz3L0_z3s7cGJj8Ukb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,469,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDz3L0_zgidYMhRg0u2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,469,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDz3L0_zaK6kVZsAHE3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,469,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDz3L0_zHWTd4zld0i2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,158,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz3L0_zPXXi5uAvz85" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total minimum payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,417,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_zNwMlipFUgD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,417,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DebtInstrumentCarryingAmount_iI_zAs5CTtwXl8i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_z9wdwKyKH6N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized discount, net of premium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,153,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermNotesPayable_iI_z7Ost3bAP696" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Notes payable, net of unamortized discount</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71,847,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505274216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIhB5Bo97Zf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
lease payments under operating leases as of March 31, 2022 were as follows<b>: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B7_zPoLj2em0lGd" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20220331_z465aRPQBoD9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzIyO_zBtXXYhn7tc7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 78%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">655,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzIyO_zQqVxQs35Pqg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">944,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzIyO_zqp51RqLT0d2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">970,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzIyO_zNzee68udGmg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">796,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzIyO_z6mRREQj8QPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">810,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzIyO_zywaK7VJ0MB4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,648,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzIyO_zv9lk9ryrXX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,823,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zRrNnz7HqX56" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: amount representing interest payments</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,555,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zENYyAG2FZbi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,268,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zByQzP6YkDx" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: current portion, operating lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(445,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zSX1Nsg0f066" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities, net of current portion</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,823,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</a></td>
<td class="text"><p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zZQa6S4wHoec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
lease payments under the non-cancelable finance lease as of March 31, 2022 were as follows<b>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B8_zsZDJjr1TXN8" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220331_z6NLuqyySe12" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzZHK_zOncHOuLhKv4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 78%">Remainder of 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">6,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzZHK_z54SOZeYTSOg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzZHK_z8a2vj9fIy9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzZHK_z5EFggVfzLRi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zddcqHmbwAb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseLiability_iI_zICmpzDaD6Qd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_z6KSxa1ddWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zbP0upLRnTj6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198500364888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zJxL6dHkZQWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of stock option activity under the Plans for the three months ended March 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zMfNdnqJrHK8" style="display: none">SCHEDULE
OF STOCK OPTION PLAN ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Options outstanding &#8211; January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zs71DclQBMOi" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance">3,039,546</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLUzVHvgl5I2" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">5.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZATxOBiSMpi" style="text-align: right" title="Number of shares, options granted">170,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zlaZ40dISsag" style="text-align: right" title="Weighted average exercise price, options granted">7.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpIw669FcMr9" style="text-align: right" title="Number of shares, options exercised">(126,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWIYBRJqmDg4" style="text-align: right" title="Weighted average exercise price, options exercised">2.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zn1WOUkuwpdb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1204">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwd9Fh04h5wf" style="text-align: right" title="Weighted average exercise price, options cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding &#8211; March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zbwxm1CFj9hk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">3,083,796</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJAW0Gkj0JT5" style="text-align: right" title="Weighted average exercise price, outstanding, ending balance">5.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWKDp5ZBcODh" title="Weighted average. remaining contractual life, options outstanding">5.01</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLu9Zj8MW3w7" style="text-align: right" title="Aggregate intrinsic value, options outstanding">4,781,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z6Cbdb4qDJS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,408,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVAAOR1EgGog" style="text-align: right" title="Weighted average exercise price, options exercisable">5.29</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVC7vOFHuPik" title="Weighted average. remaining contractual life, options exercisable">4.61</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOPPtIdiFQZ6" style="text-align: right" title="Aggregate intrinsic value, options exercisable">4,639,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zDrp9jBJ4UJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">3,083,796</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJ0KwgTMUvgg" style="text-align: right" title="Weighted average exercise price, options vested and expected to vest">5.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zMibHxxV6Hv7" title="Weighted average. remaining contractual life, options vested and expected to vest">5.01</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zshFV23Z9Zx6" style="text-align: right" title="Aggregate intrinsic value, options vested and expected to vest">4,781,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z8zpcMEUVIpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions
used for valuing options granted to employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zg1IQqPsufYg" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zmdp4Om773Kf" style="width: 18%; text-align: right" title="Weighted-average fair value of options granted">4.65</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected terms (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zzbfrGSUFxKa" title="Expected terms (in years)">6.11</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zGSII0nQ7aL7" title="Expected volatility">70</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zN27WN8Tdig6" title="Risk-free interest rate, minimum">1.54</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zomvtOcMH8d3" style="text-align: right" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1250">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1gh4Ptrwfo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about stock options outstanding and exercisable at March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span id="xdx_8B2_zfz4KwQGn4je" style="display: none">SCHEDULE OF STOCK OPTION
OUTSTANDING AND EXERCISABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life in Years</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY8PqxlEtXn7" title="Range of Exercise Prices, minimum">1.47</span>
- $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMsCdx2YF4Y4" title="Range of Exercise Prices, maximum">1.73</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ztQo68yEhXz9" style="width: 13%; text-align: right" title="Number of Options Outstanding">312,887</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z24q1PU3O8E5" title="Weighted Average Remaining Contractual Life in Years">5.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zodfpNIeuAmf" style="width: 13%; text-align: right" title="Weighted Average Exercise Price">1.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zakIb0ukmuJk" style="width: 13%; text-align: right" title="Number Exercisable">312,887</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcB7TuUOL1of" style="width: 13%; text-align: right" title="Weighted Average Exercisable Exercise Price">1.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSGj6KDekUT3" title="Range of Exercise Prices, minimum">2.23</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z32dxiErRQc3" title="Range of Exercise Prices, maximum">2.60</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2SSYXXsSL3c" style="text-align: right" title="Number of Options Outstanding">313,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zT25n5tfd1Di" title="Weighted Average Remaining Contractual Life in Years">4.84</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z7pxyjABYlCf" style="text-align: right" title="Weighted Average Exercise Price">2.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z75oIeqX9ei5" style="text-align: right" title="Number Exercisable">312,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1ux0QJvYD9e" style="text-align: right" title="Weighted Average Exercisable Exercise Price">2.26</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zlbZvTHqfLBj" title="Range of Exercise Prices, minimum">2.76</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z3BhakphXJ9k" title="Range of Exercise Prices, maximum">3.50</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zX4NmiL2kUs1" style="text-align: right" title="Number of Options Outstanding">25,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXwXMGWvh39c" title="Weighted Average Remaining Contractual Life in Years">7.95</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDklN5SIoJB8" style="text-align: right" title="Weighted Average Exercise Price">3.49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIeS6xa7bWP6" style="text-align: right" title="Number Exercisable">12,906</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zARkKud69mYc" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.48</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zpVFjXx6hG55" title="Range of Exercise Prices">3.95</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zN5BPH4Uc7V2" style="text-align: right" title="Number of Options Outstanding">370,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRW91QoQ5nlh" title="Weighted Average Remaining Contractual Life in Years">4.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zMZRx6loRkk4" style="text-align: right" title="Weighted Average Exercise Price">3.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zAUALSjauKM5" style="text-align: right" title="Number Exercisable">370,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUYTQ9ezDwW8" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.95</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrJcySqDeen9" title="Range of Exercise Prices, minimum">4.08</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zmvR4WUmEaR4" title="Range of Exercise Prices, maximum">6.30</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zYOWjPHdfYTf" style="text-align: right" title="Number of Options Outstanding">578,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zDzGhG9ubpS5" title="Weighted Average Remaining Contractual Life in Years">5.71</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zzScQ2irwIHf" style="text-align: right" title="Weighted Average Exercise Price">5.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zlKKSuX3bH7g" style="text-align: right" title="Number Exercisable">525,027</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zehLvUJ9aqHf" style="text-align: right" title="Weighted Average Exercisable Exercise Price">5.85</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zFssEYVhEJM" title="Range of Exercise Prices, minimum">6.81</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zH3KbASX2QE" title="Range of Exercise Prices, maximum">7.37</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_ziQGewB6CGqe" style="text-align: right" title="Number of Options Outstanding">388,995</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF8rAJAetFX2" title="Weighted Average Remaining Contractual Life in Years">6.27</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zx6zFKvNQDGe" style="text-align: right" title="Weighted Average Exercise Price">7.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zhPb9Lacstl1" style="text-align: right" title="Number Exercisable">297,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zJoNEGvO2ZV1" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zn9AbrBJBnbl" title="Range of Exercise Prices, minimum">7.52</span> - $<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zEce5kFGZrvl" title="Range of Exercise Prices, maximum">7.79</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zxCWmPlRVlI2" style="text-align: right" title="Number of Options Outstanding">221,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zBLTyxICahH" title="Weighted Average Remaining Contractual Life in Years">8.33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zdvSnIExzeek" style="text-align: right" title="Weighted Average Exercise Price">7.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zlhNBpCrBIJ9" style="text-align: right" title="Number Exercisable">49,323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z8lHdRdM1aMc" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.66</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUXgtrH3q953" title="Range of Exercise Prices">7.87</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_znmaby7QTmIf" style="text-align: right" title="Number of Options Outstanding">600,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zXGSd2oC62af" title="Weighted Average Remaining Contractual Life in Years">3.33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z6WLssJ6mn58" style="text-align: right" title="Weighted Average Exercise Price">7.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zxBXQ4JYDdJ2" style="text-align: right" title="Number Exercisable">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z3g2WSdXUIQk" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.87</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zj12WIIF2rRj" title="Range of Exercise Prices, minimum">7.89</span> - $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJi9FRnGOXN7" title="Range of Exercise Prices, maximum">8.98</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zoairg7hWZmf" style="text-align: right" title="Number of Options Outstanding">92,673</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBCoLK9aiOO3" title="Weighted Average Remaining Contractual Life in Years">7.47</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z4hEfdWECo01" style="text-align: right" title="Weighted Average Exercise Price">8.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z8nMzmM2dE43" style="text-align: right" title="Number Exercisable">48,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zy8b5igvA4cb" style="text-align: right" title="Weighted Average Exercisable Exercise Price">8.22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zHoL7MUV5Whf" title="Range of Exercise Prices">8.99</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zJ0ibE8PHbv2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZVNxrAu0CM7" title="Weighted Average Remaining Contractual Life in Years">1.09</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zA4Ck5wftYM6" style="text-align: right" title="Weighted Average Exercise Price">8.99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zeg9x30DOTdi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">180,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zog13riGQFGl" style="text-align: right" title="Weighted Average Exercisable Exercise Price">8.99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331_zAfyYlfe5RY8" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331_z1jNkg6szbWk" title="Range of Exercise Prices, maximum">8.99</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331_ztowcNr96WXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding">3,083,796</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zFIPCqRg02Ll" title="Weighted Average Remaining Contractual Life in Years">5.01</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331_zVXgHCyBuZf9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price">5.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331_zjnnezu8CiSk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">2,408,629</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331_z69dsw8Z2T91" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">5.29</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zL3Fov38ZLo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s RSU activity (including performance stock units) and related information for the three months ended March
31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zKxp5nlKRWpa" style="display: none">SCHEDULE
OF RESTRICTED STOCK UNITS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">RSUs unvested - January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeoqiQU4Cum4" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">2,233,202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMeeYIVkYgVk" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">6.78</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RSUs granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjfsiSlInzFe" style="text-align: right" title="Number of RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAOkPaieR8jh" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">RSUs vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbN62HMPlyWc" style="text-align: right" title="Number of RSUs vested">(144,644</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znDhB7QraFv2" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">6.57</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFgbIgWQ0s8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1426">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTYSEKP7aTDl" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">RSUs unvested at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgbEvmKQ2qDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">2,088,558</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuXzSXRNnJ9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">6.79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANTS ACTIVITY</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo5ixYfyrQ2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of warrant activity for the three months ended March 31, 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_ztvBORS9irK" style="display: none">SCHEDULE
OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Shares Subject</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">to Warrants Outstanding</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants outstanding - January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPb4Gb1Jz4vc" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">373,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyGJANhyi5j3" style="width: 16%; text-align: right" title="Weighted Average. Exercise Price, Outstanding, beginning balance">2.08</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrPyFoX9mwK9" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zakui8Qwm8b3" style="text-align: right" title="Share-based Payment Award, Non-Option Equity Instruments, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6IT4LIzQJ9k" style="border-bottom: Black 1.5pt solid; text-align: right" title=" Share-based Payment Award, Non-Option Equity Instruments, Expirations"><span style="-sec-ix-hidden: xdx2ixbrl1452">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHFQiAJFEfSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding, Ending balance">373,847</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBIycJQy98z2" style="text-align: right" title="Weighted Average. Exercise Price, Outstanding, Ending balance">2.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z8S1ubqxtvD1" title="Weighted average remaining contractual life of the outstanding warrants in years">2.3</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ScheduleofWarrantsOutstandingTableTextBlock', window );">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleofWarrantsOutstandingTableTextBlock_z1jBO3cal1o3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding and exercisable as of March 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmlBmUS0EVja" style="display: none">SCHEDULE
OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Series</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left">Lender warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_900_ecustom--WarrantsIssuanceDate_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z6ZFhmiEdv9a" title="Issue Date">7/19/2017</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z8wZbmYFXGWf" style="width: 14%; text-align: right" title="Warrants Outstanding">373,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zlmFP81pJi6a" style="width: 14%; text-align: right" title="Exercise Price">2.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: center"><span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zw8drB9B6Ihc" title="Expiration Date">7/19/2024</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z4vPgSO6nvK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_ziDMPJsYYPw5" style="display: none">SCHEDULE
OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20220331_zSewNhZ8RMs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20210331_zeZ6gdo90dU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zzZCTPKEA8A5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,676,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">755,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkxhkmCyw9Qe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Employees &#8211; research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1480">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVUcNHC5VAfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Directors - selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z1PYRObGnws1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Consultants &#8211; research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1486">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zuRtxErxv2Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,016,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">855,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ScheduleofWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Warrants Outstanding [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ScheduleofWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505256808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc. common stockholders</a></td>
<td class="num">$ (2,438,000)<span></span>
</td>
<td class="nump">$ 217,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator - weighted average number of shares outstanding, basic</a></td>
<td class="nump">27,226,819<span></span>
</td>
<td class="nump">26,019,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198500368872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted', window );">Dilutive common equivalent shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,461,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted', window );">Dilutive common equivalent shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted', window );">Dilutive common equivalent shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of shares or units and dilutive common stock or unit equivalents outstanding in the calculation of proforma diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504005736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc.</a></td>
<td class="num">$ (2,438,000)<span></span>
</td>
<td class="nump">$ 217,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator &#8211; weighted average number of shares outstanding, basic</a></td>
<td class="nump">27,226,819<span></span>
</td>
<td class="nump">26,019,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted', window );">Dilutive common equivalent shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,461,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Number of shares used for diluted earnings per share computation</a></td>
<td class="nump">27,226,819<span></span>
</td>
<td class="nump">27,480,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of shares or units and dilutive common stock or unit equivalents outstanding in the calculation of proforma diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504114648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INVESTMENT (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost basis</a></td>
<td class="nump">$ 19,310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Share of Equity Method Losses</a></td>
<td class="num">(11,063,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentPaidInKindInterest', window );">Paid in Kind Interest</a></td>
<td class="nump">1,021,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">In Substance Capital Contributions</a></td>
<td class="num">(1,021,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Net carrying value</a></td>
<td class="nump">8,247,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost basis</a></td>
<td class="nump">5,810,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Share of Equity Method Losses</a></td>
<td class="num">(5,810,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentPaidInKindInterest', window );">Paid in Kind Interest</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Surface Ophthalmics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost basis</a></td>
<td class="nump">5,320,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Share of Equity Method Losses</a></td>
<td class="num">(5,320,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Net carrying value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=HROW_LoanMember', window );">Loan [Member] | Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost basis</a></td>
<td class="nump">13,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Share of Equity Method Losses</a></td>
<td class="num">(5,253,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentPaidInKindInterest', window );">Paid in Kind Interest</a></td>
<td class="nump">1,021,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">In Substance Capital Contributions</a></td>
<td class="num">(1,021,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Net carrying value</a></td>
<td class="nump">$ 8,247,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_InvestmentPaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment paid in kind interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_InvestmentPaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=25866437&amp;loc=d3e10491-115837<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=HROW_LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=HROW_LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198500847640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_EtonPharmaceuticalsIncMember', window );">Eton Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned</a></td>
<td class="nump">1,982,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares price</a></td>
<td class="nump">$ 4.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="nump">$ 2,835,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment owned, at fair value</a></td>
<td class="nump">$ 8,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_EtonPharmaceuticalsIncMember', window );">Eton Pharmaceuticals, Inc. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ReductionInCommonStockInvestment', window );">Reduction in common stock investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment Interest Rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member] | Management Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember', window );">Surface Ophthalmics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ReductionInCommonStockInvestment', window );">Reduction in common stock investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vestted, RSUs</a></td>
<td class="nump">277,405<span></span>
</td>
<td class="nump">223,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=HROW_StockOptionsUnvestedRSUsAndWarrantsMember', window );">Stock Options, Unvested RSUs and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">5,546,200<span></span>
</td>
<td class="nump">5,486,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ReductionInCommonStockInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in common stock investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ReductionInCommonStockInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5D<br> -Subparagraph (SX 210.12-13D(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=SL120429264-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_EtonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_EtonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_ManagementServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_ManagementServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=HROW_StockOptionsUnvestedRSUsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=HROW_StockOptionsUnvestedRSUsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198501136456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DISAGGREGATED REVENUE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 22,120,000<span></span>
</td>
<td class="nump">$ 15,443,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_ProductSalesNetMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">20,340,000<span></span>
</td>
<td class="nump">14,948,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_CommissionsMember', window );">Commissions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,320,000<span></span>
</td>
<td class="nump">485,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_TransferOfProfitMember', window );">Transfer Of Profit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">460,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_ProductSalesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_ProductSalesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_CommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_CommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_TransferOfProfitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_TransferOfProfitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503841736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue and customer deposits</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505577272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CONDENSED INCOME STATEMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">$ 22,120,000<span></span>
</td>
<td class="nump">$ 15,443,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">2,101,000<span></span>
</td>
<td class="nump">2,917,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,438,000)<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,337,000)<span></span>
</td>
<td class="num">(1,099,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,337,000)<span></span>
</td>
<td class="num">$ (1,099,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198500784856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF CONDENSED BALANCE SHEET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 62,315,000<span></span>
</td>
<td class="nump">$ 60,662,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">97,595,000<span></span>
</td>
<td class="nump">98,329,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">87,859,000<span></span>
</td>
<td class="nump">87,398,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total preferred stock and stockholders&#8217; deficit</a></td>
<td class="nump">10,091,000<span></span>
</td>
<td class="nump">11,286,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">97,595,000<span></span>
</td>
<td class="nump">98,329,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">9,025,000<span></span>
</td>
<td class="nump">11,278,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,385,000<span></span>
</td>
<td class="nump">11,278,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,313,000<span></span>
</td>
<td class="nump">15,732,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total preferred stock and stockholders&#8217; deficit</a></td>
<td class="num">(7,928,000)<span></span>
</td>
<td class="num">(4,454,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 9,385,000<span></span>
</td>
<td class="nump">$ 11,278,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198506582072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_ManagementServicesAgreementMember', window );">Management Services Agreement [Member] | Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdministrativeFeesExpense', window );">Administrative Fees Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AccountsReceivableTransferredToNoteReceivable', window );">Accounts receivable transferred to note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_MeltLoanAgreementMember', window );">Melt Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate stated percentage</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase in interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_AccountsReceivableTransferredToNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable transferred to note receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_AccountsReceivableTransferredToNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdministrativeFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdministrativeFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_ManagementServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_ManagementServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_MeltLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_MeltLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505707880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF CONDENSED INCOME STATEMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">$ 22,120,000<span></span>
</td>
<td class="nump">$ 15,443,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">2,101,000<span></span>
</td>
<td class="nump">2,917,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,438,000)<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember', window );">Surface Ophthalmics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,996,000)<span></span>
</td>
<td class="num">(2,831,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,996,000)<span></span>
</td>
<td class="num">$ (2,831,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504181736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF CONDENSED BALANCE SHEET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 62,315,000<span></span>
</td>
<td class="nump">$ 60,662,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">97,595,000<span></span>
</td>
<td class="nump">98,329,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">87,859,000<span></span>
</td>
<td class="nump">87,398,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total preferred stock and stockholders&#8217; deficit</a></td>
<td class="nump">10,091,000<span></span>
</td>
<td class="nump">11,286,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">97,595,000<span></span>
</td>
<td class="nump">98,329,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember', window );">Surface Ophthalmics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">19,920,000<span></span>
</td>
<td class="nump">21,731,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">411,000<span></span>
</td>
<td class="nump">412,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,331,000<span></span>
</td>
<td class="nump">22,143,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,937,000<span></span>
</td>
<td class="nump">1,514,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total preferred stock and stockholders&#8217; deficit</a></td>
<td class="nump">18,394,000<span></span>
</td>
<td class="nump">20,629,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 20,331,000<span></span>
</td>
<td class="nump">$ 22,143,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198503933320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative) - Surface Ophthalmics, Inc. [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned</a></td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505626328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVENTORIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,441,000<span></span>
</td>
<td class="nump">$ 2,441,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">44,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,911,000<span></span>
</td>
<td class="nump">1,776,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 4,396,000<span></span>
</td>
<td class="nump">$ 4,217,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198506589864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 455,000<span></span>
</td>
<td class="nump">$ 728,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Melt Pharmaceuticals</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">757,000<span></span>
</td>
<td class="nump">437,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Deposits and other current assets</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,334,000<span></span>
</td>
<td class="nump">$ 1,305,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198506578856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ComputerHardwareGross', window );">Computer hardware</a></td>
<td class="nump">$ 786,000<span></span>
</td>
<td class="nump">$ 772,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and equipment</a></td>
<td class="nump">521,000<span></span>
</td>
<td class="nump">443,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Lab and pharmacy equipment</a></td>
<td class="nump">4,142,000<span></span>
</td>
<td class="nump">4,056,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">5,728,000<span></span>
</td>
<td class="nump">5,703,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">&#160;Property, plant and equipment, gross</a></td>
<td class="nump">11,177,000<span></span>
</td>
<td class="nump">10,974,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(8,209,000)<span></span>
</td>
<td class="num">(7,833,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 2,968,000<span></span>
</td>
<td class="nump">$ 3,141,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ComputerHardwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Computer hardware gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ComputerHardwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198506627768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">$ 376,000<span></span>
</td>
<td class="nump">$ 436,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198500379768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Total gross capitalized software for internal-use</a></td>
<td class="nump">$ 1,101,000<span></span>
</td>
<td class="nump">$ 1,101,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(612,000)<span></span>
</td>
<td class="num">(569,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CapitalizedComputerSoftwareInternalUseInProcess', window );">Capitalized internal-use software in process</a></td>
<td class="nump">982,000<span></span>
</td>
<td class="nump">781,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Total finite lived intangible assets net</a></td>
<td class="nump">1,471,000<span></span>
</td>
<td class="nump">1,313,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_CapitalizedInternalUseSoftwareMember', window );">Capitalized Internal Use Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Total gross capitalized software for internal-use</a></td>
<td class="nump">942,000<span></span>
</td>
<td class="nump">942,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_ThirdPartySoftwareLicenseMember', window );">Third Party Software License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Total gross capitalized software for internal-use</a></td>
<td class="nump">$ 159,000<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CapitalizedComputerSoftwareInternalUseInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized computer software internal use in process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CapitalizedComputerSoftwareInternalUseInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_CapitalizedInternalUseSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_CapitalizedInternalUseSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_ThirdPartySoftwareLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_ThirdPartySoftwareLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504909048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_CapitalizedSoftwareDevelopmentCostsMember', window );">Capitalized Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_CapitalizedSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_CapitalizedSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198502035512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 16,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,134,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">15,415,000<span></span>
</td>
<td class="nump">$ 15,813,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(97,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">$ 875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember', window );">Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod', window );">Finite-Lived Intangible Assets, Amortization Method</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NewDrugApplicationsMember', window );">New Drug Applications [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 13,635,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(341,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">13,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">1,519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(619,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NonCompetitionClauseMember', window );">Non-Competition Clause [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_StatePharmacyLicensesMember', window );">State Pharmacy Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Non-Competition Clause [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">19 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Non-Competition Clause [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 35<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121554622&amp;loc=d3e15372-109273<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NewDrugApplicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NewDrugApplicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NonCompetitionClauseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NonCompetitionClauseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_StatePharmacyLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_StatePharmacyLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505339192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 404,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember', window );">Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NewDrugApplicationsMember', window );">New Drug Applications [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">341,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NewDrugApplicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NewDrugApplicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198506545048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 1,194,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,592,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">1,592,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">1,592,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">1,595,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour', window );">Thereafter</a></td>
<td class="nump">7,590,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">$ 15,155,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Amortization Expense After Year Four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505259000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">$ 5,595,000<span></span>
</td>
<td class="nump">$ 5,174,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">1,114,000<span></span>
</td>
<td class="nump">1,114,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 6,758,000<span></span>
</td>
<td class="nump">$ 6,337,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505624536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF FUTURE MINIMUM PAYMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 4,852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">6,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">6,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">6,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">77,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total minimum payments</a></td>
<td class="nump">101,417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Less: amount representing interest payments</a></td>
<td class="num">(26,417,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, gross</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Less: unamortized discount, net of premium</a></td>
<td class="num">(3,153,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of unamortized discount</a></td>
<td class="nump">$ 71,847,000<span></span>
</td>
<td class="nump">$ 71,654,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198501938088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2026</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,000<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=HROW_Sec8.625SeniorNotesDue2026Member', window );">8.625% Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Additional notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Premium on issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOtherLongTermDebt', window );">Interest Expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=HROW_Sec8.625SeniorNotesDue2026Member', window );">8.625% Senior Notes Due 2026 [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Debt instrument, redemption, description</a></td>
<td class="text">redemption
price equal to 100% of the principal amount of the Notes to be redeemed<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=HROW_Sec8.625SeniorNotesDue2026Member', window );">8.625% Senior Notes Due 2026 [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,909,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt issuance costs and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,091,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on long-term debt classified as other, including, but not limited to, interest on long-term notes and amortization of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=HROW_Sec8.625SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=HROW_Sec8.625SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504178024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">6,648,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">10,823,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest payments</a></td>
<td class="num">(3,555,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">7,268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion, operating lease liabilities</a></td>
<td class="num">(445,000)<span></span>
</td>
<td class="num">$ (272,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 6,823,000<span></span>
</td>
<td class="nump">$ 6,012,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due After Year Four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198506651704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest payments</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion, finance lease obligation</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">$ (8,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation, net of current portion</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198501101352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percentage</a></td>
<td class="nump">6.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">13 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments | $</a></td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="nump">$ 251,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense | $</a></td>
<td class="nump">$ 238,000<span></span>
</td>
<td class="nump">261,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate, percentage</a></td>
<td class="nump">6.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease, weighted average remaining lease term</a></td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization | $</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease, interest expense | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=HROW_CarlsbadMember', window );">Carlsbad [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land</a></td>
<td class="nump">5,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_LeaseExpirationDateDescription', window );">Lease expiration date description</a></td>
<td class="text">July 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=HROW_LedgewoodMember', window );">Ledgewood [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land</a></td>
<td class="nump">35,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_LeaseExpirationDateDescription', window );">Lease expiration date description</a></td>
<td class="text">July 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, option to extend</a></td>
<td class="text">an option to extend the term for two additional five-year periods.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AdditionalAreaOfLand', window );">Additional square footage</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=HROW_LedgewoodMember', window );">Ledgewood [Member] | Lease Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AdditionalAreaOfLand', window );">Additional square footage</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=HROW_NashvilleMember', window );">Nashville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_LeaseExpirationDateDescription', window );">Lease expiration date description</a></td>
<td class="text">December 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease term, option to extend</a></td>
<td class="text">an option to extend
    the term for two additional five-year periods.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office and Laboratory Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office and Laboratory Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_AdditionalAreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional area of land.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_AdditionalAreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_LeaseExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_LeaseExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=HROW_CarlsbadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=HROW_CarlsbadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=HROW_LedgewoodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=HROW_LedgewoodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_LeaseAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_LeaseAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=HROW_NashvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=HROW_NashvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=HROW_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=HROW_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505654440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details) - Stock Option Plan [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding, beginning balance | shares</a></td>
<td class="nump">3,039,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, beginning balance | $ / shares</a></td>
<td class="nump">$ 5.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, options granted | shares</a></td>
<td class="nump">170,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options granted | $ / shares</a></td>
<td class="nump">$ 7.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, options exercised | shares</a></td>
<td class="num">(126,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options exercised | $ / shares</a></td>
<td class="nump">$ 2.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, options cancelled/forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options cancelled/forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding, ending balance | shares</a></td>
<td class="nump">3,083,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, ending balance | $ / shares</a></td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average. remaining contractual life, options outstanding</a></td>
<td class="text">5 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding | $</a></td>
<td class="nump">$ 4,781,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, options exercisable | shares</a></td>
<td class="nump">2,408,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, options exercisable | $ / shares</a></td>
<td class="nump">$ 5.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average. remaining contractual life, options exercisable</a></td>
<td class="text">4 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, options exercisable | $</a></td>
<td class="nump">$ 4,639,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, options vested and expected to vest | shares</a></td>
<td class="nump">3,083,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options vested and expected to vest | $ / shares</a></td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average. remaining contractual life, options vested and expected to vest</a></td>
<td class="text">5 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, options vested and expected to vest | $</a></td>
<td class="nump">$ 4,781,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=HROW_StockOptionPlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=HROW_StockOptionPlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504989064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - Options Granted to Employees [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
<td class="nump">$ 4.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.54%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=HROW_OptionsEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=HROW_OptionsEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198501198536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 8.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">3,083,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">5 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">2,408,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 5.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 1.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">312,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">312,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">2.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 2.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">313,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">4 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">312,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 2.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">2.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 3.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">25,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">12,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeFourMember', window );">Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 3.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">370,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">370,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 3.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeFiveMember', window );">Range Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">4.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 6.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">578,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">5 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">525,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeSixMember', window );">Range Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">6.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 7.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">388,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">6 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">297,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 7.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeSevenMember', window );">Range Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">7.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 7.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">221,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">8 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">49,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 7.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeEightMember', window );">Range Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 7.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 7.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeNineMember', window );">Range Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">7.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 8.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">92,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">7 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">48,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 8.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTenMember', window );">Range Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 8.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">1 year 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 8.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198500746104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs unvested, Outstanding, Beginning balance | shares</a></td>
<td class="nump">2,233,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance | $ / shares</a></td>
<td class="nump">$ 6.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs vested | shares</a></td>
<td class="num">(144,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs vested | $ / shares</a></td>
<td class="nump">$ 6.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs cancelled/forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs unvested, Outstanding, Ending balance | shares</a></td>
<td class="nump">2,088,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance | $ / shares</a></td>
<td class="nump">$ 6.79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198502285656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares Warrants Outstanding, beginning balance</a></td>
<td class="nump">373,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1', window );">Weighted Average. Exercise Price, Outstanding, beginning balance | $ / shares</a></td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares Warrants Outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Share-based Payment Award, Non-Option Equity Instruments, Expirations</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares Warrants Outstanding, Ending balance</a></td>
<td class="nump">373,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1', window );">Weighted Average. Exercise Price, Outstanding, Ending balance | $ / shares</a></td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of the outstanding warrants in years</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198508028312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details) - Lender Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_WarrantsIssuanceDate', window );">Issue Date</a></td>
<td class="text">Jul. 19,  2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding | shares</a></td>
<td class="nump">373,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_WarrantsAndRightsOutstandingMaturityDates', window );">Expiration Date</a></td>
<td class="text">Jul. 19,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_WarrantsAndRightsOutstandingMaturityDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_WarrantsAndRightsOutstandingMaturityDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_WarrantsIssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issuance date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_WarrantsIssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_LenderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_LenderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198505610280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 2,016,000<span></span>
</td>
<td class="nump">$ 855,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_EmployeesMember', window );">Employees [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">1,676,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_EmployeesMember', window );">Employees [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">186,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_ConsultantMember', window );">Consultants [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198497785032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,016,000<span></span>
</td>
<td class="nump">$ 855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember', window );">2017 Incentive Stock and Awards Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares isssued</a></td>
<td class="nump">20,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsShares', window );">Common stock withheld for payroll tax withholdings, shares</a></td>
<td class="nump">14,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsValue', window );">Common stock withheld for payroll tax withholdings, value</a></td>
<td class="nump">$ 116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Common Stock [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares isssued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=HROW_StockOptionPlanMember', window );">Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ClosingPriceOfCommonStockPricePerShare', window );">Closing price of common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ForfeitureFactorPercentage', window );">Forfeiture factor, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to unvested stock options granted under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expense expected to recognize over the weighted-average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,000<span></span>
</td>
<td class="nump">452,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=HROW_StockOptionPlanMember', window );">Stock Option Plan [Member] | Employees and Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted avg. remaining contractual life, options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Share-based compensation arrangement by share-based payment award, plan modification, description and terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Vesting terms for options granted
to employees during the three months ended March 31, 2022 included the following vesting schedule: 25% of the shares subject to the option
vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest
and become exercisable quarterly in equal installments thereafter over three years. Certain option awards provide for accelerated vesting
if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=HROW_UnvestedRSUMember', window );">Unvested RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to unvested stock options granted under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,756,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expense expected to recognize over the weighted-average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,744,000<span></span>
</td>
<td class="nump">346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=HROW_SubsidiaryStockMember', window );">Subsidiary Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MarkLBaumMember', window );">Mark L. Baum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares isssued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CashlessExerciseOfOptionsShares', window );">Cashless exercise of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CashlessExerciseOfOptionsPricePerShares', window );">Cashless exercise of options, price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldOnCashlessExercise', window );">Common stock withheld on cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsShares', window );">Common stock withheld for payroll tax withholdings, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdings', window );">Common stock withheld for payroll tax withholdings, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_AndrewRBollMember', window );">Andrew R. Boll [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares isssued</a></td>
<td class="nump">29,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsShares', window );">Common stock withheld for payroll tax withholdings, shares</a></td>
<td class="nump">20,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsValue', window );">Common stock withheld for payroll tax withholdings, value</a></td>
<td class="nump">$ 162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_JohnPSaharekMember', window );">John P. Saharek [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares isssued</a></td>
<td class="nump">24,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsShares', window );">Common stock withheld for payroll tax withholdings, shares</a></td>
<td class="nump">25,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsValue', window );">Common stock withheld for payroll tax withholdings, value</a></td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CashlessExerciseOfOptionsPricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of options price per shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CashlessExerciseOfOptionsPricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CashlessExerciseOfOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of options shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CashlessExerciseOfOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ClosingPriceOfCommonStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ClosingPriceOfCommonStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommonStockWithheldForPayrollTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock withheld for payroll tax withholdings, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommonStockWithheldForPayrollTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock withheld for payroll tax withholdings, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommonStockWithheldForPayrollTaxWithholdingsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock withheld for payroll tax withholdings, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommonStockWithheldForPayrollTaxWithholdingsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommonStockWithheldOnCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock withheld on cashless exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommonStockWithheldOnCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ForfeitureFactorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forfeiture factor, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ForfeitureFactorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=HROW_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=HROW_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_EmployeesAndConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_EmployeesAndConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=HROW_UnvestedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=HROW_UnvestedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=HROW_SubsidiaryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=HROW_SubsidiaryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MarkLBaumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MarkLBaumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_AndrewRBollMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_AndrewRBollMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_JohnPSaharekMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_JohnPSaharekMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198498138568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_KlarityLicenseAgreementMember', window );">Klarity License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentInCash', window );">Milestone payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_KlarityLicenseAgreementMember', window );">Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RoyaltyPaymentDescription', window );">Royalty payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of
net sales, dependent upon the final formulation of the Klarity Product sold<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_InjectableAssetPurchaseAgreementMember', window );">Injectable Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentInCash', window );">Milestone payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_InjectableAssetPurchaseAgreementMember', window );">Injectable Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RoyaltyPaymentDescription', window );">Royalty payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales,
dependent upon the final formulation and patent protection of the Lindstrom Product sold<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InitialMilestonePayment', window );">Initial milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_DexycuAgreementMember', window );">Dexycu Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommissionExpirationDate', window );">Commission expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommissionRevenues', window );">Commission revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,320,000<span></span>
</td>
<td class="nump">485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember', window );">Sales and Marketing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DescriptionForCommissionPayments', window );">Description for commission payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under
the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to 10% - 14% of
net sales for products above and beyond the initial existing sales amounts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commission expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,047,000,000<span></span>
</td>
<td class="nump">804,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember', window );">Sales and Marketing Agreements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommissionPaymentsPercentage', window );">Commission payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember', window );">Sales and Marketing Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommissionPaymentsPercentage', window );">Commission payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_AssetPurchaseLicenseAndRelatedAgreementsMember', window );">Asset Purchase, License and Related Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="nump">232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SinteticaAgreementMember', window );">Sintetica Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payment for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SinteticaAgreementMember', window );">Sintetica Agreement [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payment for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,117,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SinteticaAgreementMember', window );">Sintetica Agreement [Member] | Due Within Thirty Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payment for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_WakamotoAgreementMember', window );">Wakamoto Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payment for royalties</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommercialPaymentsForRoyalties', window );">Commercial payments for royalties</a></td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_PresbyopiaAssetPurchaseAgreementMember', window );">Presbyopia Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentInCash', window );">Milestone payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentsOnPayables', window );">Milestone payments on payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_PresbyopiaAssetPurchaseAgreementMember', window );">Presbyopia Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RoyaltyPaymentDescription', window );">Royalty payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales,
dependent upon the final formulation and patent protection of the Presbyopia Product sold<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommercialPaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial payments for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommercialPaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommissionExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommissionExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommissionPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission payments, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommissionPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommissionRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommissionRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DescriptionForCommissionPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description for commission payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DescriptionForCommissionPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_InitialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_InitialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_MilestonePaymentInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_MilestonePaymentInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_MilestonePaymentsOnPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments on payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_MilestonePaymentsOnPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RoyaltyPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RoyaltyPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_KlarityLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_KlarityLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_RichardLLindstromMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_RichardLLindstromMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_InjectableAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_InjectableAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_DexycuAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_DexycuAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_AssetPurchaseLicenseAndRelatedAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_AssetPurchaseLicenseAndRelatedAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_SinteticaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_SinteticaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=HROW_DueWithinThirtyDaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=HROW_DueWithinThirtyDaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_WakamotoAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_WakamotoAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_PresbyopiaAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_PresbyopiaAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198502330488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember', window );">Cost of Goods and Service, Product and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Three Main Suppliers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_TwoProductConcentrationRiskMember', window );">Two Product Concentration Risk [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=HROW_ThreeMainSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=HROW_ThreeMainSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_TwoProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_TwoProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140198504004216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - Melt Pharmaceuticals, Inc. [Member] - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DescripitionOfLoanAmendment', window );">Descripition of loan amendment</a></td>
<td class="text">Melt
    is required to maintain a minimum cash balance of $7,000,000 for one (1) year following the effective date of the Amendment; and
    a minimum cash balance of $5,000,000 at all times after the one year anniversary of the effective date of the Amendment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MinimumAmountOfFinancing', window );">Minimum amount of financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DescripitionOfLoanAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Descripition of loan amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DescripitionOfLoanAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_MinimumAmountOfFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_MinimumAmountOfFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>form10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:HROW="http://harrowinc.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="hrow-20220331.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CommonStock0.001ParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">HROW:CommonStock0.001ParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2022-05-04</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_ProductSalesNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:ProductSalesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_ProductSalesNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:ProductSalesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_OtherRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_OtherRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:TotalHarrowHealthIncStockholdersEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsUnvestedRSUsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsUnvestedRSUsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_EtonPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_srt_MaximumMember_custom_EtonPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EtonPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_EtonPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">HROW:LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">HROW:LoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember_custom_SurfaceOphthalmicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CommissionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:CommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_CommissionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:CommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_TransferOfProfitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:TransferOfProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_TransferOfProfitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:TransferOfProfitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-02-012019-02-28_custom_ManagementServicesAgreementMember_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_MeltLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:MeltLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-09-012021-09-30_custom_MeltLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:MeltLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ManagementServicesAgreementMember_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SurfaceOphthalmicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfaceOphthalmicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_CapitalizedInternalUseSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CapitalizedInternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CapitalizedInternalUseSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CapitalizedInternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ThirdPartySoftwareLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:ThirdPartySoftwareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ThirdPartySoftwareLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:ThirdPartySoftwareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CapitalizedSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CapitalizedSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_CapitalizedSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CapitalizedSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MinimumMember_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MaximumMember_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_NewDrugApplicationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NewDrugApplicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_NewDrugApplicationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NewDrugApplicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MinimumMember_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MaximumMember_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MinimumMember_custom_NonCompetitionClauseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MaximumMember_custom_NonCompetitionClauseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_NonCompetitionClauseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_StatePharmacyLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_StatePharmacyLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_NewDrugApplicationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NewDrugApplicationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-30_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="From2021-05-012021-05-31_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="From2021-06-012021-06-30_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-06-012021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-04-30_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="From2026-01-312026-02-01_srt_ScenarioForecastMember_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-31</startDate>
            <endDate>2026-02-01</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member2184750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_srt_MinimumMember_custom_OfficeAndLaboratorySpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">HROW:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_srt_MaximumMember_custom_OfficeAndLaboratorySpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">HROW:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_CarlsbadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:CarlsbadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_CarlsbadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:CarlsbadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_LedgewoodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_LedgewoodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_LedgewoodMember_custom_LeaseAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LeaseAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_NashvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:NashvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_NashvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:NashvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_MarkLBaumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MarkLBaumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2019-02-012019-02-28_custom_AndrewRBollMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:AndrewRBollMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_AndrewRBollMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:AndrewRBollMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2019-02-012019-02-28_custom_JohnPSaharekMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:JohnPSaharekMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_JohnPSaharekMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:JohnPSaharekMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2019-02-012019-02-28_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_StockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_StockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_StockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_UnvestedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_UnvestedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_UnvestedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SubsidiaryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:SubsidiaryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SubsidiaryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:SubsidiaryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockOptionPlanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_StockOptionPlanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_StockOptionPlanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_OptionsEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_RangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_RangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmployeesMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_EmployeesMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmployeesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_EmployeesMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_DirectorMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_srt_DirectorMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_ConsultantMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_ConsultantMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2017-04-012017-04-30_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_KlarityLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_KlarityLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_KlarityLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_KlarityLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_InjectableAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_InjectableAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_InjectableAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_InjectableAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_DexycuAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:DexycuAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_DexycuAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:DexycuAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SalesAndMarketingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MinimumMember_custom_SalesAndMarketingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_srt_MaximumMember_custom_SalesAndMarketingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SalesAndMarketingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_AssetPurchaseLicenseAndRelatedAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:AssetPurchaseLicenseAndRelatedAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_AssetPurchaseLicenseAndRelatedAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:AssetPurchaseLicenseAndRelatedAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-07-31_custom_SinteticaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SinteticaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-07-31_custom_DueWithinThirtyDaysMember_custom_SinteticaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:DueWithinThirtyDaysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SinteticaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SinteticaAgreementMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SinteticaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-08-012021-08-31_custom_WakamotoAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:WakamotoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_TwoProductConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:TwoProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_TwoProductConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:TwoProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">HROW:ThreeMainSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">HROW:ThreeMainSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-03-31">0001360214</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0124"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:GainLossOnForgivenessOfDebt
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0247"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0305"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0317"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0375"
      unitRef="Shares"
      xsi:nil="true"/>
    <HROW:GainLossOnForgivenessOfDebt
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCash
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0550"
      unitRef="Shares"
      xsi:nil="true"/>
    <HROW:InvestmentPaidInKindInterest
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_MeltPharmaceuticalsIncMember"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Investments
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_SurfaceOphthalmicsIncMember"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_TransferOfProfitMember"
      id="xdx2ixbrl0644"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_us-gaap_LicenseMember"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember"
      id="xdx2ixbrl0666"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_MeltPharmaceuticalsIncMember"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_SurfaceOphthalmicsIncMember"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0748"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2022-03-31_us-gaap_PatentsMember"
      id="xdx2ixbrl0842"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2022-03-31_custom_LicensesMember"
      id="xdx2ixbrl0852"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0860"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2022-03-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0862"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2022-03-31_custom_NewDrugApplicationsMember"
      id="xdx2ixbrl0872"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember"
      id="xdx2ixbrl0884"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2022-03-31_us-gaap_TradeNamesMember"
      id="xdx2ixbrl0894"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-03-31_us-gaap_TradeNamesMember"
      id="xdx2ixbrl0896"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2022-03-31_custom_NonCompetitionClauseMember"
      id="xdx2ixbrl0906"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-03-31_custom_NonCompetitionClauseMember"
      id="xdx2ixbrl0908"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2022-03-31_custom_StatePharmacyLicensesMember"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0924"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-03-31_custom_NewDrugApplicationsMember"
      id="xdx2ixbrl0937"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2022-03-31_srt_MinimumMember_custom_OfficeAndLaboratorySpaceMember"
      id="xdx2ixbrl1033">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember"
      id="xdx2ixbrl1204"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember"
      id="xdx2ixbrl1206"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember"
      id="xdx2ixbrl1250"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1418"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1420"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1426"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1428"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1448"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1450"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1452"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-03-31_custom_EmployeesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      id="xdx2ixbrl1480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-03-31_custom_ConsultantMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      id="xdx2ixbrl1486"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-01-01to2022-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-03-31">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-03-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-03-31">001-35814</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-03-31">Harrow Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-03-31">45-0567010</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-03-31">102                                             Woodmont Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-03-31">Suite 610</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-03-31">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-03-31">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-03-31">37205</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-03-31">(615)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-03-31">733-4730</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-012022-03-31_custom_CommonStock0.001ParValuePerShareMember">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-012022-03-31_custom_CommonStock0.001ParValuePerShareMember">HROW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-012022-03-31_custom_CommonStock0.001ParValuePerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member">8.625%     Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member">HROWL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-05-04" decimals="INF" unitRef="Shares">27031127</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">41948000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">42167000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ShortTermInvestments contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">8642000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">8503000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">5995000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4470000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">4396000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4217000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1334000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1305000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">62315000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">60662000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2968000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3141000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1471000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1313000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6847000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5935000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">15415000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">15813000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <HROW:InvestmentsAndOtherNoncurrentAssetsOne contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">8247000</HROW:InvestmentsAndOtherNoncurrentAssetsOne>
    <HROW:InvestmentsAndOtherNoncurrentAssetsOne contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">11133000</HROW:InvestmentsAndOtherNoncurrentAssetsOne>
    <us-gaap:Goodwill contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">332000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">332000</us-gaap:Goodwill>
    <us-gaap:Assets contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">97595000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">98329000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6758000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6337000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1948000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3089000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">23000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">445000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">272000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">8000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">8000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9182000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">9722000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6823000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6012000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">7000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">10000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">71847000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">71654000</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">87859000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">87398000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">27031127</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">27031127</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">26902763</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">26902763</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">27000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">107909000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">106666000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-97845000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-95407000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">10091000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">11286000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-355000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-355000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9736000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">10931000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">97595000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">98329000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_ProductSalesNetMember"
      decimals="0"
      unitRef="USD">20340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_ProductSalesNetMember"
      decimals="0"
      unitRef="USD">14948000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_OtherRevenuesMember"
      decimals="0"
      unitRef="USD">1780000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_OtherRevenuesMember"
      decimals="0"
      unitRef="USD">495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">22120000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">15443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">5963000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">3770000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">16157000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">11673000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">13398000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">8164000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">658000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">592000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">14056000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">8756000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2101000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">2917000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">1792000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">513000</us-gaap:InterestExpense>
    <HROW:EquityInLossesOfUnconsolidatedEntities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2886000</HROW:EquityInLossesOfUnconsolidatedEntities>
    <HROW:EquityInLossesOfUnconsolidatedEntities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1319000</HROW:EquityInLossesOfUnconsolidatedEntities>
    <us-gaap:GainLossOnInvestments
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">139000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2835000</us-gaap:GainLossOnInvestments>
    <HROW:GainLossOnForgivenessOfDebt
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1967000</HROW:GainLossOnForgivenessOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-4539000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2438000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">217000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2438000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">217000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">27226819</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">26019255</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">27226819</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">27480622</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25749875</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">104557000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-77400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">27183000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-355000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">26828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">11301</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">27000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">27000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">27000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">230000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7500</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-57000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">-57000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-57000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">855000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">855000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">855000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">217000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25983676</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">105382000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-77183000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">28225000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-355000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">27870000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">26902763</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">27000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">106666000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-95407000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">11286000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-355000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">10931000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">89986</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">135000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">96622</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">-1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-776000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">-777000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-777000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2016000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">2016000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2016000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2438000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">-2438000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2438000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">27031127</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">27000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">107909000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-97845000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_custom_TotalHarrowHealthIncStockholdersEquityMember"
      decimals="0"
      unitRef="USD">10091000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-355000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9736000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2438000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">217000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">419000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">464000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">404000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">40000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">124000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">148000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">10000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">19000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">193000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">96000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <HROW:GainLossOnForgivenessOfDebt
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1967000</HROW:GainLossOnForgivenessOfDebt>
    <us-gaap:GainLossOnInvestments
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">139000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2835000</us-gaap:GainLossOnInvestments>
    <HROW:EquityInLossesOfUnconsolidatedEntities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2886000</HROW:EquityInLossesOfUnconsolidatedEntities>
    <HROW:EquityInLossesOfUnconsolidatedEntities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1319000</HROW:EquityInLossesOfUnconsolidatedEntities>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2016000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">855000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">1535000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">610000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">179000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">534000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">29000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">32000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">369000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1105000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-1141000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-684000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">7000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-63000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">967000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">3208000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">6000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">13000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">404000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">211000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-410000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-224000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">3000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">750000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">4000</us-gaap:ProceedsFromStockOptionsExercised>
    <HROW:PaymentOfTaxesForVestingOfRestrictedStockUnit
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-777000</HROW:PaymentOfTaxesForVestingOfRestrictedStockUnit>
    <HROW:PaymentOfTaxesForVestingOfRestrictedStockUnit
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-30000</HROW:PaymentOfTaxesForVestingOfRestrictedStockUnit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-776000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-781000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-219000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">2203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">42167000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">41948000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6504000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">41948000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6304000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">200000</us-gaap:RestrictedCash>
    <HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">41948000</HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod>
    <HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6504000</HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">1617000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">415000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">1036000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_801_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zscPxO6FEhjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_828_zFbnycVysiwh"&gt;DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Company
and Background&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Harrow
Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise
requires, the &#x201c;Company&#x201d; or &#x201c;Harrow&#x201d;) is an ophthalmic-focused healthcare company that specializes in the development,
production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through
its subsidiaries and deconsolidated companies. The Company owns one of the nation&#x2019;s leading ophthalmology-focused pharmaceutical
businesses, ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has non-controlling equity positions in Surface Ophthalmics,
Inc. (&#x201c;Surface&#x201d;) and Melt Pharmaceuticals, Inc. (&#x201c;Melt&#x201d;), both companies that began as subsidiaries of Harrow.
In 2020, Harrow created Visionology, Inc. (&#x201c;Visionology&#x201d;), which launched a digital eye health platform business during 2021.
Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles
generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the
rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes
required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring
adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31,
2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any other period.
For further information, refer to the Company&#x2019;s audited consolidated financial statements and footnotes thereto included in the
Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned
subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Harrow
consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity
(&#x201c;VIE&#x201d;) model to determine whether the Company is the primary beneficiary of that entity&#x2019;s operations. If an entity
is not deemed to be a VIE, the Company consolidates entities in which it holds and/or controls, directly or indirectly, more than
50% of the voting rights. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zZ5oQA7dB0k3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_827_zgt6Mo8oOVxa"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following represents an update for the three months ended March 31, 2022 to the significant accounting policies described in the Company&#x2019;s
Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zlikh7k4Jfld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z61yL2WHWdw"&gt;Risks,
Uncertainties and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company&#x2019;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result
of regulatory guidelines or inspections, this may have a material impact on the Company&#x2019;s financial condition, liquidity and results
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGEhHZSPonzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zkwHcxaMbNAi"&gt;Segments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to shifts in the Company&#x2019;s strategic plans to further focus on growing the Company&#x2019;s ImprimisRx business and suspension of
activities related to starting up development-stage pharmaceutical companies, along with changes to the Company&#x2019;s organizational
and internal reporting structure, beginning in January 2022 management no longer evaluates the Company&#x2019;s business in two segments
and instead focuses on the performance of the business as a single operating business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_z09jDRTdzUM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zK97u56dXbd8"&gt;Basic
and Diluted Net (Loss) Income per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net (loss) income per common share is computed by dividing net (loss) income attributable to common stockholders for the period by the
weighted average number of common shares outstanding during the period. Diluted net (loss) income per share is computed by dividing the
net (loss) income attributable to common stockholders for the period by the weighted average number of common and common equivalent shares,
such as stock options, restricted stock units (&#x201c;RSUs&#x201d;) and warrants, outstanding during the period. Common equivalent shares
(using the treasury stock method) from stock options, unvested RSUs and warrants were &lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zi4YTngRCKDb" title="Antidilutive securities"&gt;5,546,200&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zgKWeI7wFAOg" title="Antidilutive securities"&gt;5,486,678&lt;/span&gt; at March 31, 2022 and 2021,
respectively. For the three months ended March 31, 2022, the common equivalent shares are excluded in the calculation of diluted net
loss per share because the effect is anti-dilutive. Included in the basic and diluted net (loss) income per share calculation were RSUs
awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number
of shares underlying vested RSUs at March 31, 2022 and 2021 was &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNOovaasI2H1" title="Number of shares vestted, RSUs"&gt;277,405&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZzIAkghWppk" title="Number of shares vestted, RSUs"&gt;223,219&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNS0kGC3Spqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the computation of basic net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zIK2wVYRcfJb" style="display: none"&gt;SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20220331_zPZjySBbpEEb" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20210101__20210331_zK9PGkctLRE2" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zBSHDqd9SEe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Numerator &#x2013; net (loss) income attributable to Harrow Health, Inc. common stockholders&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(2,438,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;217,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zVkFlIgL0agf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Denominator - weighted average number of shares outstanding, basic&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,226,819&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,019,255&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_zedkPD5L7Keb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net (loss) income per share, basic&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zZdBqJnX6MLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--DilutedCommonEquivalentSharesTableTextBlock_ztS6hUdeceP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended March 31, 2021, the Company had net income. As a result, the Company computed diluted net income per share using
the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent
shares for the three months ended March 31, 2021, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zGv4Ux4CkOL9" style="display: none"&gt;SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20210101__20210331_zKlwQtQ6UHne" style="text-align: center; font-weight: bold"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;March 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Diluted shares related to: &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEluRcHYzuv1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%"&gt;Warrants &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 30%; text-align: right"&gt;576,275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLmA3bQlDFui" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Stock options &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;885,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_i_pdd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Dilutive common equivalent shares &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,461,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zEDTRvbryULd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--DilutedNetIncomePerShareTableTextBlock_zTLSbJwFaYn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the computation of diluted net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zbQUI7vKVAsf" style="display: none"&gt;SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20220331_zhckyztUZ068" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20210331_zME873UuxLr3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Numerator &#x2013; net (loss) income attributable to Harrow Health, Inc.&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(2,438,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;217,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zxoBmqdXKAv3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Denominator &#x2013; weighted average number of shares outstanding, basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,226,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,019,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_pid_z2WDYs3HKDoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dilutive common equivalent shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0550"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,461,367&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z5Rl0ws6trN2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Number of shares used for diluted earnings per share computation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,226,819&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,480,622&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zXD2dSROWCph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net (loss) income per share, diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z8eqhiriI7Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_zsDCERs0SWaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zpB9pPdiNes3"&gt;Investment in Eton Pharmaceuticals, Inc.&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2022, the Company owned &lt;span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zTJupoqpHCG3" title="Number of shares owned"&gt;1,982,000&lt;/span&gt; shares of Eton common stock, which represents less than &lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zd5SBrhuUHQd" title="Equity Method Investment, Ownership Percentage"&gt;10&lt;/span&gt;% of the equity interests of
Eton. At March 31, 2022, the fair market value of Eton&#x2019;s common stock was $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zirbFSENtIKi" title="Shares price"&gt;4.36&lt;/span&gt; per share. In accordance with the Accounting Standards
Update (&#x201c;ASU&#x201d;) 2016-01, &lt;i&gt;Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets
and Financial Liabilities&lt;/i&gt;, the Company recorded an unrealized investment gain (loss) from its Eton common stock position of $&lt;span id="xdx_907_eus-gaap--UnrealizedGainLossOnInvestments_c20220101__20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_z9IFkdPVayS6" title="Unrealized Gain (Loss) on Investments"&gt;139,000&lt;/span&gt;
and $(&lt;span id="xdx_90C_eus-gaap--UnrealizedGainLossOnInvestments_c20210101__20210331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zPiVkWlbQTT3" title="Unrealized Gain (Loss) on Investments"&gt;2,835,000&lt;/span&gt;) during the three months ended March 31, 2022 and 2021, respectively, related to the change in fair market value of its
investment in Eton during the measurement period. As of March 31, 2022, the fair market value of the Company&#x2019;s investment in Eton
was $&lt;span id="xdx_901_eus-gaap--InvestmentOwnedAtFairValue_iI_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zCD3tr1mWRee" title="Investment owned, at fair value"&gt;8,642,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--InvestmentOnePolicyTextBlock_z7ZR2aiQoUZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zUPoGjZBwjMd"&gt;Investment
in Melt Pharmaceuticals, Inc. &#x2013; Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company owns &lt;span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zX1EQ0YC1wZ9" title="Number of shares owned"&gt;3,500,000&lt;/span&gt; shares of common stock of Melt (representing approximately &lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z744nHYvrDi8" title="Ownership percentage"&gt;46&lt;/span&gt;% of the equity interests as of March 31, 2022). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests
in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant
influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this
method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying
amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31,
2021, the Company reduced the carrying value of its common stock investment in Melt to $&lt;span id="xdx_906_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkYZt5lFNR76" title="Reduction in common stock investment"&gt;0&lt;/span&gt; as a result of the Company recording its share
of equity losses in Melt since its deconsolidation in 2019. As of March 31, 2022 and at the time of entering into the Melt Loan Agreement
(see Note 4), the Company owned &lt;span id="xdx_905_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBYyKHO8OWw9" title="Investment Interest Rate"&gt;100&lt;/span&gt;% of Melt&#x2019;s indebtedness. Following the reduction of the carrying value of the Company&#x2019;s
common stock investment in Melt to $&lt;span id="xdx_904_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zEXoazSP5uqg" title="Reduction in common stock investment"&gt;0&lt;/span&gt;, the Company began recording &lt;span id="xdx_90D_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKy0RGpMjbR3" title="Investment Interest Rate"&gt;100&lt;/span&gt;% of the equity method losses of Melt, based on its ownership of
Melt&#x2019;s total indebtedness. In addition, the Company treats interest paid in kind on the Melt Loan Agreement as an in-substance
capital contribution and reduces its investment in Melt accordingly, rather than recording interest income. The Company has no other
requirements to advance funds to Melt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zHDKezjlAzC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s investments in Melt as of March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zOu6gAVnfeab" style="display: none"&gt;SCHEDULE OF INVESTMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Share of Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Paid-in-Kind&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;In-substance Capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Method Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt; Contributions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Carrying value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 15%; text-align: justify"&gt;Common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBkl2EaRCDC4" style="width: 14%; text-align: right" title="Cost Basis"&gt;5,810,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqfd0vzn9Si" style="width: 14%; text-align: right" title="Share of Equity Method Losses"&gt;(5,810,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJhT7QPahy73" style="width: 14%; text-align: right" title="Paid in Kind Interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Loan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z36QM1txxHVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost Basis"&gt;13,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_za6GSpCvubZ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses"&gt;(5,253,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXBKSmtqYxvk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Paid in Kind Interest"&gt;1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkJgzLHOo4wi" style="border-bottom: Black 1.5pt solid; text-align: right" title="In Substance Capital Contributions"&gt;(1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXiD29Wvcgr8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value"&gt;8,247,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6dIETxaG9Ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis"&gt;19,310,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSjrHuJ5eGWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses"&gt;(11,063,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zZE5JbYjMrNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest"&gt;1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zhg3MW8XrTdi" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions"&gt;(1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Investments_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zWU9pjd23XQi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value"&gt;8,247,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zS3V4anqotQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2022 and 2021, the Company recorded $&lt;span id="xdx_903_eus-gaap--DueFromRelatedParties_iI_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zSpqwczV4Jd1"&gt;30,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;due from Melt for reimbursable expenses and
amounts payable pursuant to a Management Services Agreement between the Company and Melt (the &#x201c;Melt MSA&#x201d;), which are included
in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 4 for more information and related party disclosure regarding Melt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--InvestmentTwoPolicyTextBlock_zsSi1v7tD1ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zXyiO94KHvEf"&gt;Investment
in Surface Ophthalmics, Inc. &#x2013; Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company owns &lt;span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zwq1TJ9qFRKf" title="Number of shares owned"&gt;3,500,000&lt;/span&gt; common shares of Surface (representing approximately &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zM7tBbks44u2"&gt;20&lt;/span&gt;% of Surface&#x2019;s equity interests following the closing
of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as
management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions
of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts
the carrying amount of its investment in Surface accordingly. The Company&#x2019;s share of earnings and losses are based on the Company&#x2019;s
ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company
reduced its common stock investment in Surface to $&lt;span id="xdx_90B_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zn44rm9BzRZ5" title="Reduction in common stock investment"&gt;0&lt;/span&gt; as a result of the Company recording its share of equity losses of Surface. The
Company has no other investments in Surface.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zgWdLIjhxxte" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s investment in Surface as of March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zyVpPQIkwx7b" style="display: none"&gt;SCHEDULE OF INVESTMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Share of Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Method Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Carrying value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 2.5pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zXw7lKRQkQXb" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Cost basis"&gt;5,320,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zilG9GbPwS9c" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Share of Equity Method Losses"&gt;(5,320,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z4ThatYSP1Mf" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Net carrying value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zLCrX4mbCnW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 5 for more information and related party disclosure regarding Surface.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zqjQq2ALREy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zwQT0bcs6oUa"&gt;Impairment
of Equity Method Investments and Note Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company&#x2019;s equity method
investments and note receivable may be other than temporarily impaired. Indicators include financial condition, operating performance,
and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate
both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is
determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity
method investments and note receivable. At March 31, 2022 and December 31, 2021, no indicators of impairment existed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <HROW:RisksUncertaintiesAndLiquidityPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_842_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zlikh7k4Jfld" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z61yL2WHWdw"&gt;Risks,
Uncertainties and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company&#x2019;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result
of regulatory guidelines or inspections, this may have a material impact on the Company&#x2019;s financial condition, liquidity and results
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HROW:RisksUncertaintiesAndLiquidityPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_849_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGEhHZSPonzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zkwHcxaMbNAi"&gt;Segments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to shifts in the Company&#x2019;s strategic plans to further focus on growing the Company&#x2019;s ImprimisRx business and suspension of
activities related to starting up development-stage pharmaceutical companies, along with changes to the Company&#x2019;s organizational
and internal reporting structure, beginning in January 2022 management no longer evaluates the Company&#x2019;s business in two segments
and instead focuses on the performance of the business as a single operating business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_z09jDRTdzUM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zK97u56dXbd8"&gt;Basic
and Diluted Net (Loss) Income per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net (loss) income per common share is computed by dividing net (loss) income attributable to common stockholders for the period by the
weighted average number of common shares outstanding during the period. Diluted net (loss) income per share is computed by dividing the
net (loss) income attributable to common stockholders for the period by the weighted average number of common and common equivalent shares,
such as stock options, restricted stock units (&#x201c;RSUs&#x201d;) and warrants, outstanding during the period. Common equivalent shares
(using the treasury stock method) from stock options, unvested RSUs and warrants were &lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zi4YTngRCKDb" title="Antidilutive securities"&gt;5,546,200&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zgKWeI7wFAOg" title="Antidilutive securities"&gt;5,486,678&lt;/span&gt; at March 31, 2022 and 2021,
respectively. For the three months ended March 31, 2022, the common equivalent shares are excluded in the calculation of diluted net
loss per share because the effect is anti-dilutive. Included in the basic and diluted net (loss) income per share calculation were RSUs
awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number
of shares underlying vested RSUs at March 31, 2022 and 2021 was &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNOovaasI2H1" title="Number of shares vestted, RSUs"&gt;277,405&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20210331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZzIAkghWppk" title="Number of shares vestted, RSUs"&gt;223,219&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNS0kGC3Spqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the computation of basic net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zIK2wVYRcfJb" style="display: none"&gt;SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20220331_zPZjySBbpEEb" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20210101__20210331_zK9PGkctLRE2" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zBSHDqd9SEe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Numerator &#x2013; net (loss) income attributable to Harrow Health, Inc. common stockholders&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(2,438,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;217,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zVkFlIgL0agf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Denominator - weighted average number of shares outstanding, basic&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,226,819&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,019,255&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_zedkPD5L7Keb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net (loss) income per share, basic&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zZdBqJnX6MLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--DilutedCommonEquivalentSharesTableTextBlock_ztS6hUdeceP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended March 31, 2021, the Company had net income. As a result, the Company computed diluted net income per share using
the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent
shares for the three months ended March 31, 2021, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zGv4Ux4CkOL9" style="display: none"&gt;SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20210101__20210331_zKlwQtQ6UHne" style="text-align: center; font-weight: bold"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;March 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Diluted shares related to: &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEluRcHYzuv1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%"&gt;Warrants &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 30%; text-align: right"&gt;576,275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLmA3bQlDFui" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Stock options &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;885,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_i_pdd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Dilutive common equivalent shares &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,461,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zEDTRvbryULd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--DilutedNetIncomePerShareTableTextBlock_zTLSbJwFaYn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the computation of diluted net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zbQUI7vKVAsf" style="display: none"&gt;SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20220331_zhckyztUZ068" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20210331_zME873UuxLr3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Numerator &#x2013; net (loss) income attributable to Harrow Health, Inc.&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(2,438,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;217,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zxoBmqdXKAv3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Denominator &#x2013; weighted average number of shares outstanding, basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,226,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,019,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_pid_z2WDYs3HKDoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dilutive common equivalent shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0550"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,461,367&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z5Rl0ws6trN2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Number of shares used for diluted earnings per share computation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,226,819&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,480,622&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zXD2dSROWCph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net (loss) income per share, diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z8eqhiriI7Z8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-03-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember"
      decimals="INF"
      unitRef="Shares">5546200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember"
      decimals="INF"
      unitRef="Shares">5486678</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">277405</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-01-012021-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">223219</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zNS0kGC3Spqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the computation of basic net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zIK2wVYRcfJb" style="display: none"&gt;SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20220331_zPZjySBbpEEb" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20210101__20210331_zK9PGkctLRE2" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zBSHDqd9SEe6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Numerator &#x2013; net (loss) income attributable to Harrow Health, Inc. common stockholders&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(2,438,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;217,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zVkFlIgL0agf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Denominator - weighted average number of shares outstanding, basic&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,226,819&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,019,255&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_zedkPD5L7Keb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net (loss) income per share, basic&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2438000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">217000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">27226819</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">26019255</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:EarningsPerShareBasic>
    <HROW:DilutedCommonEquivalentSharesTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89A_ecustom--DilutedCommonEquivalentSharesTableTextBlock_ztS6hUdeceP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended March 31, 2021, the Company had net income. As a result, the Company computed diluted net income per share using
the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent
shares for the three months ended March 31, 2021, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zGv4Ux4CkOL9" style="display: none"&gt;SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20210101__20210331_zKlwQtQ6UHne" style="text-align: center; font-weight: bold"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;March 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Diluted shares related to: &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zEluRcHYzuv1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%"&gt;Warrants &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 30%; text-align: right"&gt;576,275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLmA3bQlDFui" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Stock options &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;885,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_i_pdd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Dilutive common equivalent shares &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,461,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</HROW:DilutedCommonEquivalentSharesTableTextBlock>
    <us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted
      contextRef="From2021-01-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">576275</us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted>
    <us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted
      contextRef="From2021-01-012021-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">885092</us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted>
    <us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">1461367</us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted>
    <HROW:DilutedNetIncomePerShareTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_898_ecustom--DilutedNetIncomePerShareTableTextBlock_zTLSbJwFaYn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the computation of diluted net (loss) income per share of common stock for the three months ended March 31, 2022
and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zbQUI7vKVAsf" style="display: none"&gt;SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20220331_zhckyztUZ068" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20210331_zME873UuxLr3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Numerator &#x2013; net (loss) income attributable to Harrow Health, Inc.&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;(2,438,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;217,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zxoBmqdXKAv3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Denominator &#x2013; weighted average number of shares outstanding, basic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,226,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,019,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ProFormaWeightedAverageSharesOutstandingDiluted_pid_z2WDYs3HKDoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dilutive common equivalent shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0550"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,461,367&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_z5Rl0ws6trN2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Number of shares used for diluted earnings per share computation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,226,819&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,480,622&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zXD2dSROWCph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net (loss) income per share, diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.09&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</HROW:DilutedNetIncomePerShareTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2438000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">217000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">27226819</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">26019255</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">1461367</us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">27226819</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">27480622</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_zsDCERs0SWaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zpB9pPdiNes3"&gt;Investment in Eton Pharmaceuticals, Inc.&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2022, the Company owned &lt;span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zTJupoqpHCG3" title="Number of shares owned"&gt;1,982,000&lt;/span&gt; shares of Eton common stock, which represents less than &lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zd5SBrhuUHQd" title="Equity Method Investment, Ownership Percentage"&gt;10&lt;/span&gt;% of the equity interests of
Eton. At March 31, 2022, the fair market value of Eton&#x2019;s common stock was $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zirbFSENtIKi" title="Shares price"&gt;4.36&lt;/span&gt; per share. In accordance with the Accounting Standards
Update (&#x201c;ASU&#x201d;) 2016-01, &lt;i&gt;Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets
and Financial Liabilities&lt;/i&gt;, the Company recorded an unrealized investment gain (loss) from its Eton common stock position of $&lt;span id="xdx_907_eus-gaap--UnrealizedGainLossOnInvestments_c20220101__20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_z9IFkdPVayS6" title="Unrealized Gain (Loss) on Investments"&gt;139,000&lt;/span&gt;
and $(&lt;span id="xdx_90C_eus-gaap--UnrealizedGainLossOnInvestments_c20210101__20210331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zPiVkWlbQTT3" title="Unrealized Gain (Loss) on Investments"&gt;2,835,000&lt;/span&gt;) during the three months ended March 31, 2022 and 2021, respectively, related to the change in fair market value of its
investment in Eton during the measurement period. As of March 31, 2022, the fair market value of the Company&#x2019;s investment in Eton
was $&lt;span id="xdx_901_eus-gaap--InvestmentOwnedAtFairValue_iI_c20220331__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zCD3tr1mWRee" title="Investment owned, at fair value"&gt;8,642,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-03-31_custom_EtonPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Shares">1982000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-03-31_srt_MaximumMember_custom_EtonPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SharePrice
      contextRef="AsOf2022-03-31_custom_EtonPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="USDPShares">4.36</us-gaap:SharePrice>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2022-01-012022-03-31_custom_EtonPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">139000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2021-01-012021-03-31_custom_EtonPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">2835000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2022-03-31_custom_EtonPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">8642000</us-gaap:InvestmentOwnedAtFairValue>
    <HROW:InvestmentOnePolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_841_ecustom--InvestmentOnePolicyTextBlock_z7ZR2aiQoUZi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zUPoGjZBwjMd"&gt;Investment
in Melt Pharmaceuticals, Inc. &#x2013; Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company owns &lt;span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zX1EQ0YC1wZ9" title="Number of shares owned"&gt;3,500,000&lt;/span&gt; shares of common stock of Melt (representing approximately &lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z744nHYvrDi8" title="Ownership percentage"&gt;46&lt;/span&gt;% of the equity interests as of March 31, 2022). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests
in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant
influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this
method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying
amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31,
2021, the Company reduced the carrying value of its common stock investment in Melt to $&lt;span id="xdx_906_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkYZt5lFNR76" title="Reduction in common stock investment"&gt;0&lt;/span&gt; as a result of the Company recording its share
of equity losses in Melt since its deconsolidation in 2019. As of March 31, 2022 and at the time of entering into the Melt Loan Agreement
(see Note 4), the Company owned &lt;span id="xdx_905_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBYyKHO8OWw9" title="Investment Interest Rate"&gt;100&lt;/span&gt;% of Melt&#x2019;s indebtedness. Following the reduction of the carrying value of the Company&#x2019;s
common stock investment in Melt to $&lt;span id="xdx_904_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zEXoazSP5uqg" title="Reduction in common stock investment"&gt;0&lt;/span&gt;, the Company began recording &lt;span id="xdx_90D_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKy0RGpMjbR3" title="Investment Interest Rate"&gt;100&lt;/span&gt;% of the equity method losses of Melt, based on its ownership of
Melt&#x2019;s total indebtedness. In addition, the Company treats interest paid in kind on the Melt Loan Agreement as an in-substance
capital contribution and reduces its investment in Melt accordingly, rather than recording interest income. The Company has no other
requirements to advance funds to Melt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zHDKezjlAzC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s investments in Melt as of March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zOu6gAVnfeab" style="display: none"&gt;SCHEDULE OF INVESTMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Share of Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Paid-in-Kind&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;In-substance Capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Method Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt; Contributions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Carrying value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 15%; text-align: justify"&gt;Common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBkl2EaRCDC4" style="width: 14%; text-align: right" title="Cost Basis"&gt;5,810,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqfd0vzn9Si" style="width: 14%; text-align: right" title="Share of Equity Method Losses"&gt;(5,810,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJhT7QPahy73" style="width: 14%; text-align: right" title="Paid in Kind Interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Loan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z36QM1txxHVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost Basis"&gt;13,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_za6GSpCvubZ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses"&gt;(5,253,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXBKSmtqYxvk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Paid in Kind Interest"&gt;1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkJgzLHOo4wi" style="border-bottom: Black 1.5pt solid; text-align: right" title="In Substance Capital Contributions"&gt;(1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXiD29Wvcgr8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value"&gt;8,247,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6dIETxaG9Ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis"&gt;19,310,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSjrHuJ5eGWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses"&gt;(11,063,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zZE5JbYjMrNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest"&gt;1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zhg3MW8XrTdi" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions"&gt;(1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Investments_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zWU9pjd23XQi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value"&gt;8,247,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zS3V4anqotQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2022 and 2021, the Company recorded $&lt;span id="xdx_903_eus-gaap--DueFromRelatedParties_iI_c20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zSpqwczV4Jd1"&gt;30,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;due from Melt for reimbursable expenses and
amounts payable pursuant to a Management Services Agreement between the Company and Melt (the &#x201c;Melt MSA&#x201d;), which are included
in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 4 for more information and related party disclosure regarding Melt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HROW:InvestmentOnePolicyTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Shares">3500000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Pure">0.46</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <HROW:ReductionInCommonStockInvestment
      contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">0</HROW:ReductionInCommonStockInvestment>
    <us-gaap:InvestmentInterestRate
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:InvestmentInterestRate>
    <HROW:ReductionInCommonStockInvestment
      contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">0</HROW:ReductionInCommonStockInvestment>
    <us-gaap:InvestmentInterestRate
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentTableTextBlock contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember">&lt;p id="xdx_890_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zHDKezjlAzC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s investments in Melt as of March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zOu6gAVnfeab" style="display: none"&gt;SCHEDULE OF INVESTMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Share of Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Paid-in-Kind&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;In-substance Capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Method Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt; Contributions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Carrying value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 15%; text-align: justify"&gt;Common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zBkl2EaRCDC4" style="width: 14%; text-align: right" title="Cost Basis"&gt;5,810,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXqfd0vzn9Si" style="width: 14%; text-align: right" title="Share of Equity Method Losses"&gt;(5,810,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJhT7QPahy73" style="width: 14%; text-align: right" title="Paid in Kind Interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Loan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z36QM1txxHVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost Basis"&gt;13,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_za6GSpCvubZ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses"&gt;(5,253,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentPaidInKindInterest_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXBKSmtqYxvk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Paid in Kind Interest"&gt;1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zkJgzLHOo4wi" style="border-bottom: Black 1.5pt solid; text-align: right" title="In Substance Capital Contributions"&gt;(1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXiD29Wvcgr8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value"&gt;8,247,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z6dIETxaG9Ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis"&gt;19,310,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSjrHuJ5eGWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses"&gt;(11,063,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zZE5JbYjMrNf" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest"&gt;1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zhg3MW8XrTdi" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions"&gt;(1,021,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Investments_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zWU9pjd23XQi" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value"&gt;8,247,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentTableTextBlock>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">5810000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">5810000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">13500000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">5253000</us-gaap:EquityMethodInvestmentAggregateCost>
    <HROW:InvestmentPaidInKindInterest
      contextRef="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">1021000</HROW:InvestmentPaidInKindInterest>
    <us-gaap:InvestmentCompanyCommittedCapital
      contextRef="From2022-01-012022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">1021000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:Investments
      contextRef="AsOf2022-03-31_custom_LoanMember_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">8247000</us-gaap:Investments>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">19310000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">11063000</us-gaap:EquityMethodInvestmentAggregateCost>
    <HROW:InvestmentPaidInKindInterest
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">1021000</HROW:InvestmentPaidInKindInterest>
    <us-gaap:InvestmentCompanyCommittedCapital
      contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">1021000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:Investments
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">8247000</us-gaap:Investments>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2021-03-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember"
      decimals="0"
      unitRef="USD">30000</us-gaap:DueFromRelatedParties>
    <HROW:InvestmentTwoPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_845_ecustom--InvestmentTwoPolicyTextBlock_zsSi1v7tD1ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zXyiO94KHvEf"&gt;Investment
in Surface Ophthalmics, Inc. &#x2013; Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company owns &lt;span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zwq1TJ9qFRKf" title="Number of shares owned"&gt;3,500,000&lt;/span&gt; common shares of Surface (representing approximately &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zM7tBbks44u2"&gt;20&lt;/span&gt;% of Surface&#x2019;s equity interests following the closing
of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as
management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions
of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts
the carrying amount of its investment in Surface accordingly. The Company&#x2019;s share of earnings and losses are based on the Company&#x2019;s
ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company
reduced its common stock investment in Surface to $&lt;span id="xdx_90B_ecustom--ReductionInCommonStockInvestment_c20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zn44rm9BzRZ5" title="Reduction in common stock investment"&gt;0&lt;/span&gt; as a result of the Company recording its share of equity losses of Surface. The
Company has no other investments in Surface.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zgWdLIjhxxte" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s investment in Surface as of March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zyVpPQIkwx7b" style="display: none"&gt;SCHEDULE OF INVESTMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Share of Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Method Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Carrying value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 2.5pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zXw7lKRQkQXb" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Cost basis"&gt;5,320,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zilG9GbPwS9c" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Share of Equity Method Losses"&gt;(5,320,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z4ThatYSP1Mf" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Net carrying value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zLCrX4mbCnW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 5 for more information and related party disclosure regarding Surface.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</HROW:InvestmentTwoPolicyTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="INF"
      unitRef="Shares">3500000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="INF"
      unitRef="Pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <HROW:ReductionInCommonStockInvestment
      contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">0</HROW:ReductionInCommonStockInvestment>
    <us-gaap:InvestmentTableTextBlock contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember">&lt;p id="xdx_894_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zgWdLIjhxxte" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s investment in Surface as of March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zyVpPQIkwx7b" style="display: none"&gt;SCHEDULE OF INVESTMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Share of Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Method Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Carrying value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 40%; text-align: justify; padding-bottom: 2.5pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zXw7lKRQkQXb" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Cost basis"&gt;5,320,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zilG9GbPwS9c" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Share of Equity Method Losses"&gt;(5,320,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--Investments_iI_c20220331__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z4ThatYSP1Mf" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Net carrying value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0629"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentTableTextBlock>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">5320000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">5320000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zqjQq2ALREy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zwQT0bcs6oUa"&gt;Impairment
of Equity Method Investments and Note Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company&#x2019;s equity method
investments and note receivable may be other than temporarily impaired. Indicators include financial condition, operating performance,
and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate
both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is
determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity
method investments and note receivable. At March 31, 2022 and December 31, 2021, no indicators of impairment existed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_zqml2A6lcRm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3. &lt;span id="xdx_82C_zUB9vZOxnvQl"&gt;REVENUES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for contracts with customers in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;i&gt;Revenues
from Contracts with Customers.&lt;/i&gt; The Company has two primary streams of revenue: (1) revenue recognized from its sale of products within
pharmacy services and (2) revenue recognized from intellectual property license and asset purchase agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Product
Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company sells prescription drugs directly through its pharmacy and outsourcing facility. Revenue from the Company&#x2019;s pharmacy services
includes: (i) the portion of the price the client pays directly to the Company, net of any volume-related or other discounts paid back
to the client, (ii) the price paid to the Company by individuals, and (iii) customer copayments made directly to the pharmacy network.
Sales taxes are not included in revenue. Following the core principles of ASC 606, the Company has identified the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify
    the performance obligations in the contract: The order received contains the performance obligations to be met, in almost all cases
    the product the customer is wishing to receive. If we are unable to be meet the performance obligations the customer is notified.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determine
    the transaction price: the transaction price is based on the product being sold to the customer, and any related customer discounts.
    These amounts are pre-determined and built into the Company&#x2019;s order management software.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocate
    the transaction price to the performance obligations in the contract: The transaction price associated with the product(s) being
    ordered is allocated according to the pre-determined amounts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognize
    revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing facility
    the performance obligation has been met.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following revenue recognition policy has been established for the Company&#x2019;s pharmacy services:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
generated from prescription or office use drugs sold by the Company&#x2019;s pharmacies and outsourcing facility are recognized when the
prescription is shipped. At the time of shipment, the pharmacy services has performed substantially all of its obligations under its
client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4) is based
on management&#x2019;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of
those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and allowances
and other adjustments are provided for in the same period during which the related sales are recorded and are based on actual returns
history. The rate of returns is analyzed annually to determine historical returns experience. If the historical data we use to calculate
these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination
is made and revenues in that period could be materially affected. The Company will defer any revenues received for a product that has
not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been
delivered and no refund will be required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Commission
Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into an agreement whereby it is paid a fee calculated based on sales the Company generates from a pharmaceutical
product that is owned by a third party. The revenue earned from this arrangement is recognized at the time a customer has ordered the
pharmaceutical product and it has shipped from the third party (or one of its distributors or affiliates), at which point there is no
future performance obligation required by the Company and no consequential continuing involvement on the Company&#x2019;s part to recognize
the associated revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Transfer
of Acquired Product Profit Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into an agreement whereby it purchased the exclusive commercial rights to assets associated with certain ophthalmic
products from another pharmaceutical company (the &#x201c;Seller&#x201d;). During a temporary, six month transition period, the Seller
will continue to manufacture and market these products and transfer the net profit from the sale of the products to the Company. The
revenue recognized by the Company from the transfer of net profit is recognized at the time profit from the products sales has been calculated
by the Seller and confirmed by the Company, typically on a monthly basis, at which point there is no future performance obligation required
by the Company and no consequential continuing involvement on the Company&#x2019;s part to recognize the associated revenue. On
a quarterly basis, the Seller invoices the Company for all credits and reimbursements (&#x201c;Chargebacks&#x201d;) made to customers related
to the products. The Company uses historical actual experience to estimate Chargebacks associated with the net profit transferred. The
estimate is recorded as a reduction in revenues in the Company&#x2019;s condensed consolidated statements of operations and
accounts receivable in the condensed consolidated balance sheets, at the time the revenue is recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Intellectual
Property License Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company currently holds five intellectual property licenses and related agreements in which the Company has agreed to license or sell
to a customer with the right to access the Company&#x2019;s intellectual property. License arrangements may consist of non-refundable
upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds,
technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue
of which is recognized at the point in time that the performance obligation is met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-refundable
fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part
of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation
and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the
compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the
patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has
continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable
fee has no utility to the licensee and that are separate and independent of the Company&#x2019;s performance under the other elements
of the arrangement. In addition, if the Company&#x2019;s continued involvement is required, through research and development services
that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then
such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are
recognized on a straight-line basis over the applicable term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zQXOsddbBOpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
disaggregated by revenue source for the three months ended March 31, 2022 and 2021, consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zR6gEyzvRMdk" style="display: none"&gt;SCHEDULE
OF DISAGGREGATED REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20220101__20220331_zOW4uD1SJ9Wg" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20210101__20210331_zKieTB8t8vh" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;For the Three Months Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zs9nSw8zPHWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;20,340,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;14,948,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CommissionsMember_zkkGsAEXACH8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Commissions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,320,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;485,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfProfitMember_zMZB6cpbgOQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Transfer of profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;460,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zJcXuvzPmRbk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;License&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,120,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,443,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zSi1dO87BCGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
revenue and customer deposits at March 31, 2022 and December 31, 2021 were $&lt;span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20220331_zQGircum5OW8" title="Deferred revenue and customer deposits"&gt;23,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20211231_zy2KvS7fIh9k" title="Deferred revenue and customer deposits"&gt;16,000&lt;/span&gt;, respectively. All deferred revenue and
customer deposit amounts at December 31, 2021 were recognized as revenue during the three months ended March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zQXOsddbBOpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
disaggregated by revenue source for the three months ended March 31, 2022 and 2021, consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zR6gEyzvRMdk" style="display: none"&gt;SCHEDULE
OF DISAGGREGATED REVENUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20220101__20220331_zOW4uD1SJ9Wg" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20210101__20210331_zKieTB8t8vh" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;For the Three Months Ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zs9nSw8zPHWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;20,340,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;14,948,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CommissionsMember_zkkGsAEXACH8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Commissions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,320,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;485,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfProfitMember_zMZB6cpbgOQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Transfer of profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;460,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zJcXuvzPmRbk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;License&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,120,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,443,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_ProductSalesNetMember"
      decimals="0"
      unitRef="USD">20340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_ProductSalesNetMember"
      decimals="0"
      unitRef="USD">14948000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_CommissionsMember"
      decimals="0"
      unitRef="USD">1320000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_CommissionsMember"
      decimals="0"
      unitRef="USD">485000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_TransferOfProfitMember"
      decimals="0"
      unitRef="USD">460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">22120000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">15443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">23000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_802_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zHi0IBPSSDzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4. &lt;span id="xdx_822_zz2QFfqdg3f5"&gt;INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2018, the Company entered into an asset purchase agreement with Melt (the &#x201c;Melt Asset Purchase Agreement&#x201d;). Pursuant
to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company
to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively,
the &#x201c;Melt Products&#x201d;). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make mid-single digit royalty
payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2019, the Company and Melt entered into the Melt MSA, whereby the Company provides to Melt certain administrative services and
support, including bookkeeping, web services and human resources related activities, and Melt is required to pay the Company a monthly
amount of $&lt;span id="xdx_902_eus-gaap--AdministrativeFeesExpense_c20190201__20190228__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zYzzITmK6fg2" title="Administrative Fees Expense"&gt;10,000&lt;/span&gt;. As of March 31, 2022 and December 31, 2021, the Company was due $&lt;span id="xdx_909_eus-gaap--DueFromRelatedParties_iI_c20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zphIuyLIzUVf" title="Due from Related Parties"&gt;70,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DueFromRelatedParties_iI_c20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zPXKy8zvmjwc" title="Due from Related Parties"&gt;48,000&lt;/span&gt;, respectively, from Melt for reimbursable
expenses and amounts due under the Melt MSA. Melt did not make any payments to the Company during the three months ended March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer, Mark L. Baum, was previously a member of the Melt board of directors until his resignation during
the year ended December 31, 2021. Following Mr. Baum&#x2019;s departure, the Company no longer has any representation on Melt&#x2019;s
board of directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zSRRrC0Q5zwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed results of operations information of Melt is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z209h09UDAti" style="display: none"&gt;SCHEDULE OF CONDENSED INCOME STATEMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zTXh8GiQ2iEg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zlupJ2JUKVsj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;For the Three Months Ended &lt;br/&gt;
March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zO2i2yFigoSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revenues, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zq6rdl3psRmg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(3,337,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(1,099,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_zDluIhJtlKhk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,337,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,099,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zkzfTCylfvdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zcLzu4bOoxG" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed balance sheet information of Melt is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z9dE8G2IDlo1" style="display: none"&gt;SCHEDULE OF CONDENSED BALANCE SHEET&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zDUDBDUYrHH" style="font-weight: bold; text-align: center"&gt;At March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zdqnypoLIcSd" style="font-weight: bold; text-align: center"&gt;At December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsCurrent_iI_zy0cOf4VxwId" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Current assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;9,025,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;11,278,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AssetsNoncurrent_iI_zpSoeNsopG3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0681"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iI_zxGkTHwP6UY" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,385,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,278,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Liabilities_iI_zijkfMkukffk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,313,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;15,732,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zzgVUbOyOtfk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Total preferred stock and stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,928,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,454,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zV9uxU49tu1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,385,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,278,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zPnNZPkxSWj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Melt
Note Receivable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2021, the Company entered into a loan and security agreement in the principal amount of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_z76ZyWU7MJm5" title="Principal amount"&gt;13,500,000&lt;/span&gt; (the &#x201c;Melt Loan Agreement&#x201d;),
as lender, with Melt, as borrower. Amounts borrowed under the Melt Loan Agreement bear interest at twelve and one-half percent (&lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zL0Q8dYygfGb" title="Debt instrument interest rate stated percentage"&gt;12.50&lt;/span&gt;%)
per annum, which interest can be paid in-kind at the option of Melt until the maturity date. The Melt Loan Agreement permits Melt to
pay interest only on the principal amount loaned thereunder through the term and all amounts owed will be due and payable on September
1, 2022. Melt may elect to prepay all, but not less than all, of the amounts owed prior to the maturity date at any time without penalty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Melt
has granted the Company a security interest in substantially all of its personal property, rights and assets, including intellectual
property rights, to secure the payment of all amounts owed under the Melt Loan Agreement. The Melt Loan Agreement contains customary
representations, warranties and covenants, including covenants by Melt limiting additional indebtedness, liens, mergers and acquisitions,
dispositions, investments, distributions, subordinated debt, and transactions with affiliates. The Melt Loan Agreement includes customary
events of default, and upon the occurrence of an event of default (subject to cure periods for certain events of default), all amounts
owed by Melt thereunder may be declared immediately due and payable by the Company, and the interest rate on the loan may be increased
by three percent (&lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_c20210901__20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zeiY1tnPbW9g" title="Increase in interest rate"&gt;3&lt;/span&gt;%) per annum. See Note 17 regarding an Amendment to the Melt Loan Agreement entered into in April 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Melt Loan Agreement, the Company and Melt entered into a Right of First Refusal Agreement providing the Company with
the right, but not the obligation, to match any offer received by Melt associated with the commercial rights to any of Melt&#x2019;s drug
candidates for a period of five years following the effective date of the Melt Loan Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net funds received by Melt excluded $&lt;span id="xdx_900_ecustom--AccountsReceivableTransferredToNoteReceivable_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKbAYGZuugX5" title="Accounts receivable transferred to note receivable"&gt;908,000&lt;/span&gt; for amounts owed to the Company for reimbursable expenses and amounts due under the Melt
MSA prior to the effective date of the note receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AdministrativeFeesExpense
      contextRef="From2019-02-012019-02-28_custom_ManagementServicesAgreementMember_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">70000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">48000</us-gaap:DueFromRelatedParties>
    <HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_893_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zSRRrC0Q5zwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed results of operations information of Melt is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z209h09UDAti" style="display: none"&gt;SCHEDULE OF CONDENSED INCOME STATEMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zTXh8GiQ2iEg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20210331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zlupJ2JUKVsj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;For the Three Months Ended &lt;br/&gt;
March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zO2i2yFigoSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revenues, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zq6rdl3psRmg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(3,337,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(1,099,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_zDluIhJtlKhk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,337,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,099,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">-3337000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">-1099000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">-3337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">-1099000</us-gaap:NetIncomeLoss>
    <HROW:ScheduleOfCondensedBalanceSheetOneTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_896_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zcLzu4bOoxG" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed balance sheet information of Melt is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z9dE8G2IDlo1" style="display: none"&gt;SCHEDULE OF CONDENSED BALANCE SHEET&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zDUDBDUYrHH" style="font-weight: bold; text-align: center"&gt;At March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zdqnypoLIcSd" style="font-weight: bold; text-align: center"&gt;At December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AssetsCurrent_iI_zy0cOf4VxwId" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Current assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;9,025,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;11,278,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AssetsNoncurrent_iI_zpSoeNsopG3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0681"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iI_zxGkTHwP6UY" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,385,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,278,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Liabilities_iI_zijkfMkukffk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,313,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;15,732,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zzgVUbOyOtfk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Total preferred stock and stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,928,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,454,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zV9uxU49tu1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,385,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,278,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</HROW:ScheduleOfCondensedBalanceSheetOneTableTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">9025000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">11278000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">360000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">9385000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">11278000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">17313000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">15732000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">-7928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">-4454000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">9385000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">11278000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-09-30_custom_MeltLoanAgreementMember"
      decimals="0"
      unitRef="USD">13500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_custom_MeltLoanAgreementMember"
      decimals="INF"
      unitRef="Pure">0.1250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2021-09-012021-09-30_custom_MeltLoanAgreementMember"
      decimals="INF"
      unitRef="Pure">0.03</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <HROW:AccountsReceivableTransferredToNoteReceivable
      contextRef="AsOf2022-03-31_custom_ManagementServicesAgreementMember_custom_MeltPharmaceuticalsIncMember"
      decimals="0"
      unitRef="USD">908000</HROW:AccountsReceivableTransferredToNoteReceivable>
    <HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_805_ecustom--InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_zLbaooG7A5h1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5. &lt;span id="xdx_82B_zvcnQ6oDQcg8"&gt;INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the &#x201c;Surface License
Agreements&#x201d;). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual
property and related rights associated with Surface&#x2019;s drug candidates (collectively, the &#x201c;Surface Products&#x201d;). Surface
is required to make mid-single digit royalty payments to the Company on net sales of the Surface Products while any patent rights remain
outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2022, the Company owned &lt;span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z1OaSPehDWOg" title="Number of shares owned"&gt;3,500,000&lt;/span&gt; shares of Surface common stock (representing approximately &lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zNeDLCgLGzJg" title="Ownership percentage"&gt;20&lt;/span&gt;% of Surface&#x2019;s issued
and outstanding equity interests). A Company director, Richard L. Lindstrom, and the Company&#x2019;s Chief Executive Officer, Mark L.
Baum, are directors of Surface. Dr. Lindstrom is a principal of Flying L Partners, an affiliate of an investor who purchased Surface
Series A Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zaFV5yfixqbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed results of operations information of Surface is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_z2nUHKSrPoQ9" style="display: none"&gt;SUMMARY OF CONDENSED INCOME STATEMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zz5eImx0Xajl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210101__20210331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_ziQe1WCBizti" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zVIAmgsK7HXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Revenues, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0712"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingIncomeLoss_zprMrtaFqUF3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify; padding-bottom: 1.5pt"&gt;Loss from operations&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(1,996,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(2,831,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_zphBbIINa2Ri" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,996,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,831,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zMpvraidM3Gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zUaMI08gdbJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed balance sheet information of Surface is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_z9DYOciFWKzj" style="display: none"&gt;SUMMARY OF CONDENSED BALANCE SHEET&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z3UrTE5lRVuj" style="font-weight: bold; text-align: center"&gt;At March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zLOGRTHliMve" style="font-weight: bold; text-align: center"&gt;At December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zzNlI7Tuqx78" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Current assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;19,920,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21,731,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_ziWygcHThLl4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;411,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;412,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Assets_iI_zb1jhBCUKvOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,331,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,143,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Liabilities_iI_zW41pp0YzM9e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,937,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,514,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--StockholdersEquity_iI_zSTgmyTpzVXb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Total preferred stock and stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,394,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,629,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zjmufASaortk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total liabilities and stockholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,331,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,143,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zzdpIa8zujMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="INF"
      unitRef="Shares">3500000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="INF"
      unitRef="Pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_894_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zaFV5yfixqbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed results of operations information of Surface is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_z2nUHKSrPoQ9" style="display: none"&gt;SUMMARY OF CONDENSED INCOME STATEMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zz5eImx0Xajl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210101__20210331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_ziQe1WCBizti" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zVIAmgsK7HXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Revenues, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0712"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingIncomeLoss_zprMrtaFqUF3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify; padding-bottom: 1.5pt"&gt;Loss from operations&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(1,996,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(2,831,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_zphBbIINa2Ri" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,996,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,831,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">-1996000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">-2831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">-1996000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">-2831000</us-gaap:NetIncomeLoss>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_896_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zUaMI08gdbJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed balance sheet information of Surface is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_z9DYOciFWKzj" style="display: none"&gt;SUMMARY OF CONDENSED BALANCE SHEET&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20220331__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z3UrTE5lRVuj" style="font-weight: bold; text-align: center"&gt;At March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zLOGRTHliMve" style="font-weight: bold; text-align: center"&gt;At December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zzNlI7Tuqx78" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Current assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;19,920,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21,731,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_ziWygcHThLl4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Non-current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;411,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;412,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Assets_iI_zb1jhBCUKvOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,331,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,143,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Liabilities_iI_zW41pp0YzM9e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,937,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,514,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--StockholdersEquity_iI_zSTgmyTpzVXb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Total preferred stock and stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,394,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,629,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zjmufASaortk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total liabilities and stockholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,331,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,143,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">19920000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">21731000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">411000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">412000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">20331000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">22143000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">1937000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">1514000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">18394000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">20629000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">20331000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31_custom_SurfaceOphthalmicsIncMember"
      decimals="0"
      unitRef="USD">22143000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_zt88CVBUsn25" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_827_zx7MFXHDumO3"&gt;INVENTORIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zpTcmZWigGsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of March 31, 2022 and
December 31, 2021 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zmtyr5FMbDN" style="display: none"&gt;SCHEDULE OF INVENTORIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220331_zYFocsw1bgsd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231_zkHMuC7NR4Qd" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maINz1vg_zySRv7C76sIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,441,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,441,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz1vg_zWPXVndX7Xtf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in progress&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryFinishedGoods_iI_maINz1vg_zqeRsVxcnJNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,911,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,776,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryNet_iTI_mtINz1vg_z184sO7uAeNb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total inventories&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,396,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,217,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zbHGu2CAcbx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zpTcmZWigGsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of March 31, 2022 and
December 31, 2021 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zmtyr5FMbDN" style="display: none"&gt;SCHEDULE OF INVENTORIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220331_zYFocsw1bgsd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20211231_zkHMuC7NR4Qd" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maINz1vg_zySRv7C76sIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,441,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,441,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz1vg_zWPXVndX7Xtf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in progress&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryFinishedGoods_iI_maINz1vg_zqeRsVxcnJNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,911,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,776,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryNet_iTI_mtINz1vg_z184sO7uAeNb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total inventories&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,396,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,217,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2441000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2441000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">44000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1911000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1776000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">4396000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4217000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_805_eus-gaap--OtherAssetsDisclosureTextBlock_zaj16JKOlCph" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_827_z2xc96AyvzYb"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqPEeLwq7fn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets at March 31, 2022 and December 31, 2021, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zZSMDZgP1N8" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220331_zy4KO0UM0EP2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zgo4Qsrvmrha" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PrepaidInsurance_iI_maPEAOAz7FJ_zI4cUnolEfl6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;455,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;728,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DueFromRelatedParties_iI_maPEAOAz7FJ_zD5GgvX3f5Tj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due from Melt Pharmaceuticals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz7FJ_zl8dctplNAx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;757,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherAssetsCurrent_iI_maPEAOAz7FJ_zlNBpP9ltbJg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deposits and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;92,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz7FJ_z6aGjli0D5u2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,334,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,305,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zfvovfD58w4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherAssetsDisclosureTextBlock>
    <HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_899_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqPEeLwq7fn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets at March 31, 2022 and December 31, 2021, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zZSMDZgP1N8" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220331_zy4KO0UM0EP2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zgo4Qsrvmrha" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PrepaidInsurance_iI_maPEAOAz7FJ_zI4cUnolEfl6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;455,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;728,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DueFromRelatedParties_iI_maPEAOAz7FJ_zD5GgvX3f5Tj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due from Melt Pharmaceuticals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz7FJ_zl8dctplNAx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;757,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherAssetsCurrent_iI_maPEAOAz7FJ_zlNBpP9ltbJg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deposits and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;52,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;92,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz7FJ_z6aGjli0D5u2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,334,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,305,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">455000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">728000</us-gaap:PrepaidInsurance>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">70000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">48000</us-gaap:DueFromRelatedParties>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">757000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">437000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">52000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">92000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1334000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1305000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmcBUIuHVOZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8. &lt;span id="xdx_82B_zomMZUsLtIQb"&gt;PROPERTY, PLANT AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_ze1CgIm54nx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment at March 31, 2022 and December 31, 2021, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z6k2VxD3GSXj" style="display: none"&gt;SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220331_zQM2Nq6qjxH3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231_zXofIOFnnmD8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Property, plant and equipment, net:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ComputerHardwareGross_iI_maPPAEGzWKe_zPEZ9JFh67Tc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Computer hardware&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;786,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;772,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzWKe_zRnW5IVCP8Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;521,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;443,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzWKe_zVK4Z1UYQ24h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Lab and pharmacy equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,142,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,056,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzWKe_z7WADUw264m9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,728,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,703,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzWKe_maPPAENzhZF_z1eE7Kmoyhw4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,177,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,974,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzhZF_zIHsffSgMWq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,209,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,833,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzhZF_zXT8mQxmtbF4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,968,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,141,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zWIPmnj55Vy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended March 31, 2022 and 2021, depreciation related to the property, plant and equipment was $&lt;span id="xdx_90D_eus-gaap--Depreciation_c20220101__20220331_zDGQkceFrj79" title="Depreciation and amortization"&gt;376,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--Depreciation_c20210101__20210331_zaIXip8Nf6yk" title="Depreciation and amortization"&gt;436,000&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_ze1CgIm54nx2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment at March 31, 2022 and December 31, 2021, consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z6k2VxD3GSXj" style="display: none"&gt;SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220331_zQM2Nq6qjxH3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231_zXofIOFnnmD8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Property, plant and equipment, net:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ComputerHardwareGross_iI_maPPAEGzWKe_zPEZ9JFh67Tc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Computer hardware&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;786,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;772,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FurnitureAndFixturesGross_iI_maPPAEGzWKe_zRnW5IVCP8Tj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;521,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;443,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_maPPAEGzWKe_zVK4Z1UYQ24h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Lab and pharmacy equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,142,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,056,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LeaseholdImprovementsGross_iI_maPPAEGzWKe_z7WADUw264m9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,728,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,703,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGzWKe_maPPAENzhZF_z1eE7Kmoyhw4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,177,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,974,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzhZF_zIHsffSgMWq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,209,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,833,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzhZF_zXT8mQxmtbF4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,968,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,141,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <HROW:ComputerHardwareGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">786000</HROW:ComputerHardwareGross>
    <HROW:ComputerHardwareGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">772000</HROW:ComputerHardwareGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">521000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">443000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">4142000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4056000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">5728000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5703000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">11177000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">10974000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">8209000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7833000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2968000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3141000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">376000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">436000</us-gaap:Depreciation>
    <HROW:CapitalizedSoftwareDevelopmentCostsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_806_ecustom--CapitalizedSoftwareDevelopmentCostsTextBlock_zeW7yI8Yifh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_828_zp1UEkocrbZ1"&gt;CAPITALIZED SOFTWARE DEVELOPMENT COSTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--CapitalizedSoftwareDevelopmentCostsTableTextBlock_zf7Seo6HJNB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capitalized
software development costs at March 31, 2022 and December 31, 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zhjRVbjWx1Ua" style="display: none"&gt;SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220331_zzPoBne899Hc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zcGkC3TN8Z9g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedInternalUseSoftwareMember_zFvHdjm73Ydc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Capitalized internal-use software development costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;942,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;942,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_zTJ2NFmQbAQk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Acquired third-party software license for internal-use&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;159,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;159,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzJkV_zDJR8Ism6H71" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total gross capitalized software for internal-use&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,101,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,101,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzJkV_zXqLvHTMLooa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accumulated amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(612,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(569,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCCSNzJkV_zwoNzydOMbOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Capitalized internal-use software in process&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;982,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;781,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzJkV_zB3D3Db34jZ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total
    finite lived intangible assets net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,471,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,313,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zsCaBt9E1Rua" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded amortization expense of $&lt;span id="xdx_90C_eus-gaap--AdjustmentForAmortization_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zsM8waAgqnL6" title="Amortization"&gt;43,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AdjustmentForAmortization_c20210101__20210331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zNni26PVYxtj" title="Amortization"&gt;28,000&lt;/span&gt; related to capitalized software development costs during the three months
ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HROW:CapitalizedSoftwareDevelopmentCostsTextBlock>
    <HROW:CapitalizedSoftwareDevelopmentCostsTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_893_ecustom--CapitalizedSoftwareDevelopmentCostsTableTextBlock_zf7Seo6HJNB" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capitalized
software development costs at March 31, 2022 and December 31, 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zhjRVbjWx1Ua" style="display: none"&gt;SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220331_zzPoBne899Hc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231_zcGkC3TN8Z9g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedInternalUseSoftwareMember_zFvHdjm73Ydc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Capitalized internal-use software development costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;942,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;942,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_zTJ2NFmQbAQk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Acquired third-party software license for internal-use&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;159,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;159,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzJkV_zDJR8Ism6H71" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total gross capitalized software for internal-use&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,101,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,101,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzJkV_zXqLvHTMLooa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accumulated amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(612,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(569,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCCSNzJkV_zwoNzydOMbOi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Capitalized internal-use software in process&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;982,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;781,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzJkV_zB3D3Db34jZ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total
    finite lived intangible assets net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,471,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,313,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</HROW:CapitalizedSoftwareDevelopmentCostsTableTextBlock>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2022-03-31_custom_CapitalizedInternalUseSoftwareMember"
      decimals="0"
      unitRef="USD">942000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2021-12-31_custom_CapitalizedInternalUseSoftwareMember"
      decimals="0"
      unitRef="USD">942000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2022-03-31_custom_ThirdPartySoftwareLicenseMember"
      decimals="0"
      unitRef="USD">159000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2021-12-31_custom_ThirdPartySoftwareLicenseMember"
      decimals="0"
      unitRef="USD">159000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1101000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1101000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">612000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">569000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <HROW:CapitalizedComputerSoftwareInternalUseInProcess contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">982000</HROW:CapitalizedComputerSoftwareInternalUseInProcess>
    <HROW:CapitalizedComputerSoftwareInternalUseInProcess contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">781000</HROW:CapitalizedComputerSoftwareInternalUseInProcess>
    <us-gaap:CapitalizedComputerSoftwareNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1471000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1313000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2022-01-012022-03-31_custom_CapitalizedSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">43000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2021-01-012021-03-31_custom_CapitalizedSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">28000</us-gaap:AdjustmentForAmortization>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_807_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zmmgBScvSRZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10. &lt;span id="xdx_824_zipuKZp8kpFj"&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zJjWYWQsjHwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s intangible assets at March 31, 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zxgFjxmDBBYl" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Periods&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Impairment&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjf5wF2iXy15" title="Amortization periods (in years)"&gt;17&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zImd8lINgrh8" title="Amortization periods (in years)"&gt;19&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zehbq1WeiU88" style="width: 9%; text-align: right" title="Cost"&gt;972,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlfJmIfFhxQ1" style="width: 9%; text-align: right" title="Accumulated amortization"&gt;(97,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0Q4yhmF9Q7k" style="width: 9%; text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0842"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfzZMRiuoT1a" style="width: 9%; text-align: right" title="Net Carrying value"&gt;875,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeWgyYGFESy6" title="Amortization periods (in years)"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvVKD9f6aP9" style="text-align: right" title="Cost"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zNCzPEzPr34l" style="text-align: right" title="Accumulated amortization"&gt;(15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIbS2fmM6rCg" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_znlesKjCSMDh" style="text-align: right" title="Net Carrying value"&gt;85,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0koJpf1xUZ3" title="Finite-Lived Intangible Assets, Amortization Method"&gt;Indefinite&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zKpTejnk0qC8" style="text-align: right" title="Cost"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zll2HXJ0YgI" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV2aw1rKd6tj" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0862"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zMOochU6dJvk" style="text-align: right" title="Net Carrying value"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Acquired NDAs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zVYdkm2FSXd2" title="Amortization periods (in years)"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zHlU0qDpkfKg" style="text-align: right" title="Cost"&gt;13,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z820THJtV2P2" style="text-align: right" title="Accumulated amortization"&gt;(341,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zjQW5qUswlHe" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0872"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z36noIcOlKVe" style="text-align: right" title="Net Carrying value"&gt;13,294,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zirZ8X0bocTk" title="Amortization periods (in years)"&gt;3&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zfVV8Q3e0TGc" title="Amortization periods (in years)"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z3NDMTXnz9wj" style="text-align: right" title="Cost"&gt;1,519,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zOfTiUUyw7l4" style="text-align: right" title="Accumulated amortization"&gt;(619,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ztUO2SvFO869" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2r5IfCrgA5l" style="text-align: right" title="Net Carrying value"&gt;900,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Trade name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zdn33BHgRTy4" title="Amortization periods (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z48sa9Y7Jmk9" style="text-align: right" title="Cost"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEBqLhqiMHi3" style="text-align: right" title="Accumulated amortization"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQp1niDP54wb" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zDx1gHu34EDc" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-competition clause&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zgP1zPts6wP2" title="Amortization periods (in years)"&gt;3&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zNE9e9WAUqxe" title="Amortization periods (in years)"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zhfab4dWaoQc" style="text-align: right" title="Cost"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z9rGoZWRSmFj" style="text-align: right" title="Accumulated amortization"&gt;(50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zURC90oOrve3" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zdGWNGcngprj" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0908"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;State pharmacy licenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zh2wHWe5SxT" title="Amortization periods (in years)"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z0fWDQZkeYHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;8,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z84Dqt7Mr6H" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(7,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zQEqyTorbf13" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z68nKa56dLyh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331_zwGvikTRgpW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;16,549,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331_zDPdx6zi9o73" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(1,134,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331_zVlxrwN2Ltr" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331_zZgmAs7pThp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"&gt;15,415,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z5smofGy2AMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zK2eZFjQVHj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense for intangible assets for the three months ended March 31, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zCTvexaauAP5" style="display: none"&gt;SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 12pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20220331_z6zAM7UfccS5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20210331_zx49Vo3S5zyh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 12pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z3GoaCK4TD9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;22,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z45HYDtJNJWj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zMnd9cp9n6i7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Acquired NDAs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;341,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zTrMaLbIZt4l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Customer relationships&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AmortizationOfIntangibleAssets_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;404,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_zYEUDHOOap46" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zjlC3on5YG66" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimated
future amortization expense for the Company&#x2019;s intangible assets at March 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zIpkGufjwR6l" style="display: none"&gt;SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20220331_ze3p2LvbPte" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzqfW_zwUaRFyNHO4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Remainder of 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,194,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzqfW_zWx02eONrfp5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,592,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzqfW_zF3bJUCAECSb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,592,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzqfW_zzrN7DtMlStj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,592,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzqfW_zmRF1aGHsh6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,595,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzqfW_zjqyFLM7MD0c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,590,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzqfW_z01D7vJLeYRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,155,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zRwLv4zr47b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zJjWYWQsjHwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s intangible assets at March 31, 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zxgFjxmDBBYl" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Periods&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Impairment&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjf5wF2iXy15" title="Amortization periods (in years)"&gt;17&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zImd8lINgrh8" title="Amortization periods (in years)"&gt;19&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zehbq1WeiU88" style="width: 9%; text-align: right" title="Cost"&gt;972,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlfJmIfFhxQ1" style="width: 9%; text-align: right" title="Accumulated amortization"&gt;(97,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0Q4yhmF9Q7k" style="width: 9%; text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0842"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfzZMRiuoT1a" style="width: 9%; text-align: right" title="Net Carrying value"&gt;875,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeWgyYGFESy6" title="Amortization periods (in years)"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvVKD9f6aP9" style="text-align: right" title="Cost"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zNCzPEzPr34l" style="text-align: right" title="Accumulated amortization"&gt;(15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zIbS2fmM6rCg" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_znlesKjCSMDh" style="text-align: right" title="Net Carrying value"&gt;85,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0koJpf1xUZ3" title="Finite-Lived Intangible Assets, Amortization Method"&gt;Indefinite&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zKpTejnk0qC8" style="text-align: right" title="Cost"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zll2HXJ0YgI" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zV2aw1rKd6tj" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0862"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zMOochU6dJvk" style="text-align: right" title="Net Carrying value"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Acquired NDAs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zVYdkm2FSXd2" title="Amortization periods (in years)"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zHlU0qDpkfKg" style="text-align: right" title="Cost"&gt;13,635,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z820THJtV2P2" style="text-align: right" title="Accumulated amortization"&gt;(341,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zjQW5qUswlHe" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0872"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z36noIcOlKVe" style="text-align: right" title="Net Carrying value"&gt;13,294,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zirZ8X0bocTk" title="Amortization periods (in years)"&gt;3&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zfVV8Q3e0TGc" title="Amortization periods (in years)"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z3NDMTXnz9wj" style="text-align: right" title="Cost"&gt;1,519,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zOfTiUUyw7l4" style="text-align: right" title="Accumulated amortization"&gt;(619,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_ztUO2SvFO869" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2r5IfCrgA5l" style="text-align: right" title="Net Carrying value"&gt;900,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Trade name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zdn33BHgRTy4" title="Amortization periods (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z48sa9Y7Jmk9" style="text-align: right" title="Cost"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zEBqLhqiMHi3" style="text-align: right" title="Accumulated amortization"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQp1niDP54wb" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zDx1gHu34EDc" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-competition clause&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zgP1zPts6wP2" title="Amortization periods (in years)"&gt;3&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zNE9e9WAUqxe" title="Amortization periods (in years)"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zhfab4dWaoQc" style="text-align: right" title="Cost"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z9rGoZWRSmFj" style="text-align: right" title="Accumulated amortization"&gt;(50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zURC90oOrve3" style="text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zdGWNGcngprj" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0908"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;State pharmacy licenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zh2wHWe5SxT" title="Amortization periods (in years)"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z0fWDQZkeYHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;8,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z84Dqt7Mr6H" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(7,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zQEqyTorbf13" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z68nKa56dLyh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331_zwGvikTRgpW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;16,549,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331_zDPdx6zi9o73" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(1,134,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20220331_zVlxrwN2Ltr" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20220331_zZgmAs7pThp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"&gt;15,415,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_srt_MinimumMember_us-gaap_PatentsMember">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_srt_MaximumMember_us-gaap_PatentsMember">P19Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-03-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">972000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">-97000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-03-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">875000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_custom_LicensesMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-03-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">-15000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-03-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">85000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod contextRef="From2022-01-012022-03-31_us-gaap_TrademarksMember">Indefinite</us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-03-31_us-gaap_TrademarksMember"
      decimals="0"
      unitRef="USD">260000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-03-31_us-gaap_TrademarksMember"
      decimals="0"
      unitRef="USD">260000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_custom_NewDrugApplicationsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-03-31_custom_NewDrugApplicationsMember"
      decimals="0"
      unitRef="USD">13635000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_custom_NewDrugApplicationsMember"
      decimals="0"
      unitRef="USD">-341000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-03-31_custom_NewDrugApplicationsMember"
      decimals="0"
      unitRef="USD">13294000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_srt_MinimumMember_us-gaap_CustomerRelationshipsMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_srt_MaximumMember_us-gaap_CustomerRelationshipsMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      unitRef="USD">1519000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      unitRef="USD">-619000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      unitRef="USD">900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_us-gaap_TradeNamesMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-03-31_us-gaap_TradeNamesMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_us-gaap_TradeNamesMember"
      decimals="0"
      unitRef="USD">-5000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_srt_MinimumMember_custom_NonCompetitionClauseMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_srt_MaximumMember_custom_NonCompetitionClauseMember">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-03-31_custom_NonCompetitionClauseMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_custom_NonCompetitionClauseMember"
      decimals="0"
      unitRef="USD">-50000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-03-31_custom_StatePharmacyLicensesMember">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-03-31_custom_StatePharmacyLicensesMember"
      decimals="0"
      unitRef="USD">8000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_custom_StatePharmacyLicensesMember"
      decimals="0"
      unitRef="USD">-7000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-03-31_custom_StatePharmacyLicensesMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">16549000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-1134000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">15415000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zK2eZFjQVHj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense for intangible assets for the three months ended March 31, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zCTvexaauAP5" style="display: none"&gt;SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 12pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20220331_z6zAM7UfccS5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20210331_zx49Vo3S5zyh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the &lt;br/&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 12pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z3GoaCK4TD9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;22,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z45HYDtJNJWj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Licenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zMnd9cp9n6i7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Acquired NDAs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;341,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zTrMaLbIZt4l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Customer relationships&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AmortizationOfIntangibleAssets_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 12pt; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;404,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;40,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-03-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">22000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-03-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">6000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-03-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">8000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-03-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-03-31_custom_NewDrugApplicationsMember"
      decimals="0"
      unitRef="USD">341000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      unitRef="USD">33000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="0"
      unitRef="USD">33000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">404000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">40000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89D_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zjlC3on5YG66" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimated
future amortization expense for the Company&#x2019;s intangible assets at March 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zIpkGufjwR6l" style="display: none"&gt;SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20220331_ze3p2LvbPte" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzqfW_zwUaRFyNHO4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Remainder of 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,194,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzqfW_zWx02eONrfp5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,592,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzqfW_zF3bJUCAECSb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,592,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzqfW_zzrN7DtMlStj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,592,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzqfW_zmRF1aGHsh6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,595,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzqfW_zjqyFLM7MD0c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,590,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzqfW_z01D7vJLeYRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,155,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1194000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1592000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1592000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1592000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1595000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <HROW:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">7590000</HROW:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">15155000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_800_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z4w1lYBZiLwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11. &lt;span id="xdx_828_zsAXwb4jHwjg"&gt;ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zxQmhsPtaNV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable and accrued expenses at March 31, 2022 and December 31, 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zNMn0zIbKer5" style="display: none"&gt;SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220331_zm7ufVjUs2rj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20211231_zsCiPMOqwvxb" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALziP7_zvw8orfBEi35" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,595,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,174,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALziP7_zvs71AC3YS6f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAALziP7_z2487muc3H55" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,114,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,114,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALziP7_z19Vj5yde983" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total accounts payable and accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,758,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,337,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z6uu52gggDVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zxQmhsPtaNV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable and accrued expenses at March 31, 2022 and December 31, 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zNMn0zIbKer5" style="display: none"&gt;SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220331_zm7ufVjUs2rj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20211231_zsCiPMOqwvxb" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALziP7_zvw8orfBEi35" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,595,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,174,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALziP7_zvs71AC3YS6f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAALziP7_z2487muc3H55" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,114,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,114,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALziP7_z19Vj5yde983" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total accounts payable and accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,758,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,337,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">5595000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5174000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">49000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">49000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1114000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1114000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6758000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6337000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zEMSq80cdcle" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12. &lt;span id="xdx_82F_zPhxnX7D3ZO5"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;8.625%
Senior Notes Due 2026&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2021, the Company closed an offering of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z7AbIkzW0PF" title="Debt principal amount"&gt;50,000,000&lt;/span&gt; aggregate principal amount of 8.625% senior notes due April 2026, and in May
2021 issued an additional $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210501__20210531__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zct5JwrPOzEl" title="Additional notes issued"&gt;5,000,000&lt;/span&gt; of such notes pursuant to the full exercise of the underwriters&#x2019; option to purchase additional
notes (collectively, the &#x201c;April Notes&#x201d;). The April Notes were sold to investors at a par value of $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z24EbCdbOpee" title="Share price"&gt;25.00&lt;/span&gt; per April Note and
the offering resulted in net proceeds to the Company of approximately $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20210401__20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zTGtOHrCFAy8" title="Proceeds from issuance of debt"&gt;51,909,000&lt;/span&gt; after deducting underwriting discounts and commissions
and expenses of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zUQMBPVHvF7j" title="Debt issuance costs and discounts"&gt;3,091,000&lt;/span&gt;. In June 2021, in a further issuance of the April Notes, the Company sold an additional $&lt;span id="xdx_906_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210601__20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zxU5DUR2JMYf" title="Additional notes issued"&gt;20,000,000&lt;/span&gt; aggregate
principal amount of such notes (the &#x201c;June Notes,&#x201d; and together with the April Notes, the &#x201c;Notes&#x201d;), at a price
of $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z7WgrBDVN1Sk" title="Share price"&gt;25.75&lt;/span&gt; per June Note, with interest of $&lt;span id="xdx_906_eus-gaap--InterestExpenseDebt_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z7okaq6cV78b" title="Interest expense, debt"&gt;278,000&lt;/span&gt; on the June Notes being accrued from April 20, 2021 as of the date of issuance. The
June offering resulted in net proceeds to the Company of approximately $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zoJvGAuYq45l" title="Proceeds from issuance of debt"&gt;19,164,000&lt;/span&gt; after deducting underwriting discounts and commissions
and expenses of $&lt;span id="xdx_907_eus-gaap--DeferredFinanceCostsNet_iI_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zkpskDAkEgKb" title="Debt issuance costs"&gt;1,158,000&lt;/span&gt; and a premium on note issuance of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedPremium_iI_c20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zUCv1UfBrWXl" title="Premium on issuance of debt"&gt;322,000&lt;/span&gt;. The June Notes are treated as a single series with the April Notes
under the indenture governing the April Notes, dated as of April 20, 2021, and have the same terms as the April Notes (other than the
initial offering price and issue date). The Notes are senior unsecured obligations of the Company and rank equally in right of payment
with all of our other existing and future senior unsecured and unsubordinated indebtedness. The Notes are effectively subordinated in
right of payment to all of the Company&#x2019;s existing and future secured indebtedness and structurally subordinated to all existing
and future indebtedness of the Company&#x2019;s subsidiaries, including trade payables. The Notes bear interest at a rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zYy8qMEUq0qh" title="Debt instrument, interest rate"&gt;8.625&lt;/span&gt;% per
annum. Interest on the Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing
on July 31, 2021. The Notes will mature on April 30, 2026. The issuance costs were recorded as a debt discount and are being amortized
as interest expense, net of the amortization of the premium on note issuance, over the term of the Notes using the effective interest
rate method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to February 1, 2026, the Company may, at its option, redeem the Notes, in whole at any time or in part from time to time, at a &lt;span id="xdx_904_eus-gaap--DebtInstrumentRedemptionDescription_c20260131__20260201__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z9v9N2OofIHc" title="Debt instrument, redemption, description"&gt;redemption
price equal to 100% of the principal amount of the Notes to be redeemed&lt;/span&gt;, plus a make-whole amount, if any, plus accrued and unpaid interest
to, but excluding, the date of redemption. The Company may redeem the Notes for cash in whole or in part at any time at our option on
or after February 1, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest
to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
expense related to the Notes totaled $&lt;span id="xdx_908_eus-gaap--InterestExpenseOtherLongTermDebt_c20220101__20220331__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zWFNvBrw0ux6" title="Interest Expense, debt"&gt;1,810,000&lt;/span&gt; for the three months ended March 31, 2022, and included amortization of debt issuance
costs and discount of $&lt;span id="xdx_90D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20220331__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z4AIqJGy45hc" title="Amortization of debt issuance costs and discount"&gt;193,000&lt;/span&gt; for three months ended March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zeXit3iAI55j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2022, future minimum payments under the Company&#x2019;s debt were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zCaoB1YgDg5" style="display: none"&gt;SUMMARY OF FUTURE MINIMUM PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220331_zjCFRn231Vyf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maLTDz3L0_zRx4HQB7fzoe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Remainder of 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,852,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDz3L0_z3s7cGJj8Ukb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,469,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDz3L0_zgidYMhRg0u2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,469,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDz3L0_zaK6kVZsAHE3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,469,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDz3L0_zHWTd4zld0i2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,158,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz3L0_zPXXi5uAvz85" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total minimum payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,417,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_zNwMlipFUgD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: amount representing interest payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26,417,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DebtInstrumentCarryingAmount_iI_zAs5CTtwXl8i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Notes payable, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_z9wdwKyKH6N" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: unamortized discount, net of premium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,153,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermNotesPayable_iI_z7Ost3bAP696" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Notes payable, net of unamortized discount&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;71,847,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zq8GuC4BsL37" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-04-30_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="0"
      unitRef="USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="From2021-05-012021-05-31_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="0"
      unitRef="USD">5000000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="INF"
      unitRef="USDPShares">25.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2021-04-012021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="0"
      unitRef="USD">51909000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2021-04-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="0"
      unitRef="USD">3091000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="From2021-06-012021-06-30_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="0"
      unitRef="USD">20000000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="INF"
      unitRef="USDPShares">25.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:InterestExpenseDebt
      contextRef="From2021-06-012021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="0"
      unitRef="USD">278000</us-gaap:InterestExpenseDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2021-06-012021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="0"
      unitRef="USD">19164000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2021-06-30_us-gaap_InvestorMember_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="0"
      unitRef="USD">1158000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="AsOf2021-06-30_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="0"
      unitRef="USD">322000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2021-04-012021-04-30_custom_Sec8.625SeniorNotesDue2026Member"
      decimals="INF"
      unitRef="Pure">0.08625</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentRedemptionDescription contextRef="From2026-01-312026-02-01_srt_ScenarioForecastMember_custom_Sec8.625SeniorNotesDue2026Member">redemption
price equal to 100% of the principal amount of the Notes to be redeemed</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:InterestExpenseOtherLongTermDebt
      contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member2184750"
      decimals="0"
      unitRef="USD">1810000</us-gaap:InterestExpenseOtherLongTermDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2022-01-012022-03-31_custom_Sec8.625SeniorNotesDue2026Member2184750"
      decimals="0"
      unitRef="USD">193000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zeXit3iAI55j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2022, future minimum payments under the Company&#x2019;s debt were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zCaoB1YgDg5" style="display: none"&gt;SUMMARY OF FUTURE MINIMUM PAYMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220331_zjCFRn231Vyf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maLTDz3L0_zRx4HQB7fzoe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Remainder of 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,852,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDz3L0_z3s7cGJj8Ukb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,469,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDz3L0_zgidYMhRg0u2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,469,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDz3L0_zaK6kVZsAHE3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,469,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDz3L0_zHWTd4zld0i2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,158,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebt_iTI_mtLTDz3L0_zPXXi5uAvz85" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total minimum payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,417,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_zNwMlipFUgD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: amount representing interest payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26,417,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DebtInstrumentCarryingAmount_iI_zAs5CTtwXl8i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Notes payable, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_z9wdwKyKH6N" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: unamortized discount, net of premium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,153,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermNotesPayable_iI_z7Ost3bAP696" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Notes payable, net of unamortized discount&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;71,847,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">4852000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6469000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6469000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6469000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">77158000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">101417000</us-gaap:LongTermDebt>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">26417000</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">75000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-3153000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">71847000</us-gaap:LongTermNotesPayable>
    <HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80F_ecustom--LesseeOperatingLeaseAndFinanceLeaseTextBlock_zGDXUysbF93b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13. &lt;span id="xdx_821_zPB6DIhnzvca"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases office and laboratory space under non-cancelable operating leases listed below. These lease agreements have remaining
terms between &lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtYxL_c20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zXDguXswy201" title="Lease term::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;one&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zvc7MO7kr8mi" title="Lease term"&gt;five years&lt;/span&gt; and contain various clauses for renewal at the Company&#x2019;s option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
    operating lease for &lt;span id="xdx_905_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220331__srt--StatementGeographicalAxis__custom--CarlsbadMember_zVnNYGLr1TP9" title="Area of Land"&gt;5,789&lt;/span&gt; square feet of office space in Carlsbad, California, which commenced in January 2022 and will expire in
    &lt;span id="xdx_90E_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220331__srt--StatementGeographicalAxis__custom--CarlsbadMember_zVX6TPuvkiYf" title="Lease expiration date description"&gt;July 2027&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
    operating lease for &lt;span id="xdx_90A_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_zMHwbDQ9V0Z2" title="Area of Land"&gt;35,326&lt;/span&gt; square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in &lt;span id="xdx_905_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_zdaCGfEnL1Sj" title="Lease expiration date description"&gt;July 2026&lt;/span&gt;, with
    &lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_zHYsyAjH2RPe" title="Lease term, option to extend"&gt;an option to extend the term for two additional five-year periods.&lt;/span&gt; This includes an amendment that was made effective July 2020 that
    extended the term of the original lease and added &lt;span id="xdx_90D_ecustom--AdditionalAreaOfLand_uSquareFoot_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember_znyv5Utz8Hb8" title="Additional square footage"&gt;1,400&lt;/span&gt; of additional square footage to the lease and another amendment entered into
    in May 2021 that extended the term of the lease to July 2027 and added &lt;span id="xdx_905_ecustom--AdditionalAreaOfLand_uSquareFoot_c20220101__20220331__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zRmAUfKpx3uf"&gt;8,900&lt;/span&gt; square feet of space.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
    operating lease for &lt;span id="xdx_900_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220331__srt--StatementGeographicalAxis__custom--NashvilleMember_zqSieIigKnX4" title="Area of Land"&gt;5,500&lt;/span&gt; square feet of office space in Nashville, Tennessee that expires in &lt;span id="xdx_90B_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220331__srt--StatementGeographicalAxis__custom--NashvilleMember_zYPPIxvqIbYj" title="Lease expiration date description"&gt;December 2024&lt;/span&gt;, with &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20220101__20220331__srt--StatementGeographicalAxis__custom--NashvilleMember_zfF1QUHasLok" title="Lease term, option to extend"&gt;an option to extend
    the term for two additional five-year periods.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2022, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases
held by the Company were &lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_ztl0PM4oOc5c" title="Operating lease, weighted average discount rate, percentage"&gt;6.34&lt;/span&gt;% and &lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_zsIySPSGadud" title="Operating lease, weighted average remaining lease term"&gt;13.45&lt;/span&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2022 and 2021, cash paid for amounts included for the operating lease liabilities was $&lt;span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20220101__20220331_zahSIJ03sK82" title="Operating lease, payments"&gt;166,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OperatingLeasePayments_c20210101__20210331_zKzDWl8IAjZd" title="Operating lease, payments"&gt;251,000&lt;/span&gt;,
respectively, and the Company recorded operating lease expense of $&lt;span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20220101__20220331_zUSJ7GDzos6j" title="Operating lease, expense"&gt;238,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20210101__20210331_zUZ0ryx2mjE1" title="Operating lease, expense"&gt;261,000&lt;/span&gt;, included in selling, general and administrative
expenses, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIhB5Bo97Zf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
lease payments under operating leases as of March 31, 2022 were as follows&lt;b&gt;: &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B7_zPoLj2em0lGd" style="display: none"&gt;SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220331_z465aRPQBoD9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzIyO_zBtXXYhn7tc7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 78%"&gt;Remainder of 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;655,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzIyO_zQqVxQs35Pqg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;944,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzIyO_zqp51RqLT0d2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;970,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzIyO_zNzee68udGmg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;796,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzIyO_z6mRREQj8QPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;810,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzIyO_zywaK7VJ0MB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,648,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzIyO_zv9lk9ryrXX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,823,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zRrNnz7HqX56" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: amount representing interest payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zENYyAG2FZbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,268,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zByQzP6YkDx" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: current portion, operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(445,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zSX1Nsg0f066" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,823,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zNL0InFA7iFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also has a finance lease that is included in its lease accounting but is not considered significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zZQa6S4wHoec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
lease payments under the non-cancelable finance lease as of March 31, 2022 were as follows&lt;b&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B8_zsZDJjr1TXN8" style="display: none"&gt;SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220331_z6NLuqyySe12" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Finance Lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzZHK_zOncHOuLhKv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 78%"&gt;Remainder of 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzZHK_z54SOZeYTSOg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzZHK_z8a2vj9fIy9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzZHK_z5EFggVfzLRi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zddcqHmbwAb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: amount representing interest payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseLiability_iI_zICmpzDaD6Qd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_z6KSxa1ddWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: current portion, finance lease obligation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zbP0upLRnTj6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Finance lease obligation, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zaDiFaZZBxRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2022, the incremental borrowing rate and the remaining lease term for the finance lease held by the Company were &lt;span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220331_zbgmS1m3Zmq" title="Finance lease, weighted average discount rate, percentage"&gt;6.36&lt;/span&gt;% and
&lt;span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220331_z4aewc4aXczk" title="Finance lease, weighted average remaining lease term"&gt;1.83&lt;/span&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended March 31, 2022 and 2021, depreciation expense related to the equipment held under the finance lease obligation
was $&lt;span id="xdx_90D_eus-gaap--AdjustmentForAmortization_c20220101__20220331_zrIVlnGHbS6k" title="Amortization"&gt;2,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AdjustmentForAmortization_c20210101__20210331_zS52QDR5EAtb" title="Amortization"&gt;2,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended March 31, 2022 and 2021, cash paid and expense recognized for interest expense related to the finance lease obligation
was $&lt;span id="xdx_904_eus-gaap--FinanceLeaseInterestExpense_c20220101__20220331_zhPb1tjbZMjb" title="Finance lease, interest expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--FinanceLeaseInterestExpense_c20210101__20210331_ziaLFQcwq431" title="Finance lease, interest expense"&gt;1,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2022-03-31_srt_MaximumMember_custom_OfficeAndLaboratorySpaceMember">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:AreaOfLand
      contextRef="AsOf2022-03-31_custom_CarlsbadMember"
      decimals="INF"
      unitRef="SquareFoot">5789</us-gaap:AreaOfLand>
    <HROW:LeaseExpirationDateDescription contextRef="From2022-01-012022-03-31_custom_CarlsbadMember">July 2027</HROW:LeaseExpirationDateDescription>
    <us-gaap:AreaOfLand
      contextRef="AsOf2022-03-31_custom_LedgewoodMember"
      decimals="INF"
      unitRef="SquareFoot">35326</us-gaap:AreaOfLand>
    <HROW:LeaseExpirationDateDescription contextRef="From2022-01-012022-03-31_custom_LedgewoodMember">July 2026</HROW:LeaseExpirationDateDescription>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2022-01-012022-03-31_custom_LedgewoodMember">an option to extend the term for two additional five-year periods.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <HROW:AdditionalAreaOfLand
      contextRef="From2022-01-012022-03-31_custom_LedgewoodMember"
      decimals="INF"
      unitRef="SquareFoot">1400</HROW:AdditionalAreaOfLand>
    <HROW:AdditionalAreaOfLand
      contextRef="From2022-01-012022-03-31_custom_LedgewoodMember_custom_LeaseAmendmentMember"
      decimals="INF"
      unitRef="SquareFoot">8900</HROW:AdditionalAreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="AsOf2022-03-31_custom_NashvilleMember"
      decimals="INF"
      unitRef="SquareFoot">5500</us-gaap:AreaOfLand>
    <HROW:LeaseExpirationDateDescription contextRef="From2022-01-012022-03-31_custom_NashvilleMember">December 2024</HROW:LeaseExpirationDateDescription>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2022-01-012022-03-31_custom_NashvilleMember">an option to extend
    the term for two additional five-year periods.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-03-31" decimals="INF" unitRef="Pure">0.0634</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-03-31">P13Y5M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">166000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">251000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">238000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">261000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIhB5Bo97Zf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
lease payments under operating leases as of March 31, 2022 were as follows&lt;b&gt;: &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B7_zPoLj2em0lGd" style="display: none"&gt;SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220331_z465aRPQBoD9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating Leases&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzIyO_zBtXXYhn7tc7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 78%"&gt;Remainder of 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;655,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzIyO_zQqVxQs35Pqg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;944,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzIyO_zqp51RqLT0d2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;970,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzIyO_zNzee68udGmg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;796,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzIyO_z6mRREQj8QPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;810,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_maLOLLPzIyO_zywaK7VJ0MB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,648,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzIyO_zv9lk9ryrXX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,823,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zRrNnz7HqX56" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: amount representing interest payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zENYyAG2FZbi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,268,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zByQzP6YkDx" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: current portion, operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(445,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zSX1Nsg0f066" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities, net of current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,823,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">655000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">970000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">796000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">810000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <HROW:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6648000</HROW:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">10823000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">3555000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">7268000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">445000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6823000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zZQa6S4wHoec" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
lease payments under the non-cancelable finance lease as of March 31, 2022 were as follows&lt;b&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B8_zsZDJjr1TXN8" style="display: none"&gt;SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220331_z6NLuqyySe12" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Finance Lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzZHK_zOncHOuLhKv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 78%"&gt;Remainder of 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzZHK_z54SOZeYTSOg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzZHK_z8a2vj9fIy9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzZHK_z5EFggVfzLRi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zddcqHmbwAb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: amount representing interest payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseLiability_iI_zICmpzDaD6Qd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_z6KSxa1ddWd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: current portion, finance lease obligation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zbP0upLRnTj6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Finance lease obligation, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">6000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">16000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">15000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">8000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">7000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2022-03-31" decimals="INF" unitRef="Pure">0.0636</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-03-31">P1Y9M29D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">2000</us-gaap:AdjustmentForAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_801_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zOJ4Lp2zbyD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14. &lt;span id="xdx_82C_zShQsrSKYg8c"&gt;STOCKHOLDERS&#x2019; EQUITY AND STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Preferred
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2022 and December 31, 2021, the Company had &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_z4S8wiSqSe6j" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20220331_zP1z2UZ1JrWh" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt;&lt;/span&gt; shares of preferred stock, $&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zAOVPOwGKd6e" title="Preferred stock, par or stated value per share"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220331_z2CZYnreRvx1" title="Preferred stock, par or stated value per share"&gt;0.001&lt;/span&gt;&lt;/span&gt; par value, authorized and &lt;span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20211231_z4YKaKETbf03" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231_zoDCjAc9gh72" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20220331_zrSlVymUgmoj" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20220331_zErtlpKbPVWf" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares
of preferred stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2022, the Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z0KyBxngLjr2" title="Number of common stock issued"&gt;53,594&lt;/span&gt; shares of common stock to Mark L. Baum, the Company&#x2019;s Chief Executive
Officer, upon the cashless exercise of options to purchase &lt;span id="xdx_907_ecustom--CashlessExerciseOfOptionsShares_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zZo6M5cxeTT4" title="Cashless exercise of options, shares"&gt;125,000&lt;/span&gt; shares at an exercise price of $&lt;span id="xdx_907_ecustom--CashlessExerciseOfOptionsPricePerShares_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zAMxKz24FNLh" title="Cashless exercise of options, price per shares"&gt;2.40&lt;/span&gt; per share. The Company withheld
from Mr. Baum &lt;span id="xdx_90F_ecustom--CommonStockWithheldOnCashlessExercise_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zLQ7iW9Jiig7" title="Common stock withheld on cashless exercise"&gt;36,014&lt;/span&gt; shares as consideration for the cashless exercise and an additional &lt;span id="xdx_90C_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z7FsYO4vfI59" title="Common stock withheld for payroll tax withholdings, shares"&gt;35,392&lt;/span&gt; shares for payroll tax obligations totaling
$&lt;span id="xdx_908_ecustom--CommonStockWithheldForPayrollTaxWithholdings_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zkIaTLBgLD11" title="Common stock withheld for payroll tax withholdings, value"&gt;295,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20190201__20190228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zydEd7Xb509g" title="Number of restricted stock units granted"&gt;50,000&lt;/span&gt;
RSUs granted in February 2019 to Andrew R. Boll, the Company&#x2019;s Chief Financial Officer, vested, and in February 2022, the Company
issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zzbNiozXKIf4" title="Number of common stock issued"&gt;29,395&lt;/span&gt; shares of common stock to Mr. Boll, net of &lt;span id="xdx_90A_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zt70HWgvvUv5" title="Common stock withheld for payroll tax withholdings, shares"&gt;20,605&lt;/span&gt; shares of common stock withheld for payroll tax withholdings totaling
$&lt;span id="xdx_904_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_z4pGwaYZ3sk2" title="Common stock withheld for payroll tax withholdings, value"&gt;162,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20190201__20190228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_z2kalpzJQZpd" title="Number of restricted stock units granted"&gt;50,000&lt;/span&gt;
RSUs granted in February 2019 to John P. Saharek, the President of ImprimisRx, vested, and in February 2022, the Company issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zjppP1MaKh3e" title="Number of common stock issued"&gt;24,077&lt;/span&gt;
shares of common stock to Mr. Saharek, net of &lt;span id="xdx_90D_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zIJqqPnPKrQ1" title="Common stock withheld for payroll tax withholdings, shares"&gt;25,923&lt;/span&gt; shares of common stock withheld for payroll tax withholdings totaling $&lt;span id="xdx_907_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_z1vXs3m7Fqye" title="Common stock withheld for payroll tax withholdings, value"&gt;204,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20190201__20190228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkJo5qJn91nh" title="Number of restricted stock units granted"&gt;35,000&lt;/span&gt;
RSUs granted in February 2019 vested, and in February 2022, the Company issued &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgE73FhjhcC8" title="Number of common stock issued"&gt;20,298&lt;/span&gt; shares of common stock, net of &lt;span id="xdx_901_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyLpsIrtGqgd" title="Common stock withheld for payroll tax withholdings, shares"&gt;14,702&lt;/span&gt; shares of
common stock withheld for payroll tax withholdings totaling $&lt;span id="xdx_90E_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsKdV4ZRjD0j" title="Common stock withheld for payroll tax withholdings, value"&gt;116,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2022, the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDtQPIuVIAig" title="Number of shares isssued"&gt;1,000&lt;/span&gt; shares of common stock and received net proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0mPvATYj27i" title="Proceeds from purchase of common stock"&gt;4,000&lt;/span&gt; upon the exercise
of options to purchase &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTPUdlFcse5k" title="Number of options to purchase common stock"&gt;1,000&lt;/span&gt; shares of common stock with exercise price of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjoyUAjR1Psf" title="Exercise price"&gt;3.95&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2022, &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyB4Arl7Or48" title="Number of shares isssued"&gt;9,644&lt;/span&gt; shares of the Company&#x2019;s common stock underlying RSUs issued to directors vested, but
the issuance and delivery of these shares are deferred until the applicable director resigns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock
Option Plan&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
September 17, 2007, the Company&#x2019;s Board of Directors and stockholders adopted the Company&#x2019;s 2007 Incentive Stock and Awards
Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended,
the &#x201c;2007 Plan&#x201d;). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this
plan; however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or
are otherwise cancelled/forfeited. On June 13, 2017, the Company&#x2019;s Board of Directors and stockholders adopted the Company&#x2019;s
2017 Incentive Stock and Awards Plan which was subsequently amended on June 3, 2021 (as amended, the &#x201c;2017 Plan&#x201d; together
with the 2007 Plan, the &#x201c;Plans&#x201d;). As of March 31, 2022, the 2017 Plan provides for the issuance of a maximum of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_z9oEijQMSALc" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;6,000,000&lt;/span&gt;
shares of the Company&#x2019;s common stock. The purposes of the Plans are to attract and retain directors, officers, consultants, advisors
and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such
persons in the Company&#x2019;s development and financial success. Under the Plans, the Company is authorized to issue incentive stock
options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified stock options, restricted
stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company&#x2019;s Board of Directors.
The Company had &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_zBcD4jG6Tda3" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"&gt;2,229,399&lt;/span&gt; shares available for future issuances under the 2017 Plan at March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zJxL6dHkZQWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity under the Plans for the three months ended March 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zMfNdnqJrHK8" style="display: none"&gt;SCHEDULE
OF STOCK OPTION PLAN ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Options outstanding &#x2013; January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zs71DclQBMOi" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance"&gt;3,039,546&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLUzVHvgl5I2" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"&gt;5.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZATxOBiSMpi" style="text-align: right" title="Number of shares, options granted"&gt;170,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zlaZ40dISsag" style="text-align: right" title="Weighted average exercise price, options granted"&gt;7.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpIw669FcMr9" style="text-align: right" title="Number of shares, options exercised"&gt;(126,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWIYBRJqmDg4" style="text-align: right" title="Weighted average exercise price, options exercised"&gt;2.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options cancelled/forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zn1WOUkuwpdb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options cancelled/forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwd9Fh04h5wf" style="text-align: right" title="Weighted average exercise price, options cancelled/forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1206"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding &#x2013; March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zbwxm1CFj9hk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance"&gt;3,083,796&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJAW0Gkj0JT5" style="text-align: right" title="Weighted average exercise price, outstanding, ending balance"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWKDp5ZBcODh" title="Weighted average. remaining contractual life, options outstanding"&gt;5.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLu9Zj8MW3w7" style="text-align: right" title="Aggregate intrinsic value, options outstanding"&gt;4,781,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z6Cbdb4qDJS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable"&gt;2,408,629&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVAAOR1EgGog" style="text-align: right" title="Weighted average exercise price, options exercisable"&gt;5.29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVC7vOFHuPik" title="Weighted average. remaining contractual life, options exercisable"&gt;4.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOPPtIdiFQZ6" style="text-align: right" title="Aggregate intrinsic value, options exercisable"&gt;4,639,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options vested and expected to vest&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zDrp9jBJ4UJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest"&gt;3,083,796&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJ0KwgTMUvgg" style="text-align: right" title="Weighted average exercise price, options vested and expected to vest"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zMibHxxV6Hv7" title="Weighted average. remaining contractual life, options vested and expected to vest"&gt;5.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zshFV23Z9Zx6" style="text-align: right" title="Aggregate intrinsic value, options vested and expected to vest"&gt;4,781,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zXUWPVUGjh52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would
have been received by option holders if all option holders had exercised and immediately sold all shares underlying options with an exercise
price lower than the market price on March 31, 2022, based on the closing price of the Company&#x2019;s common stock of $&lt;span id="xdx_905_ecustom--ClosingPriceOfCommonStockPricePerShare_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zojVTmb68O4c" title="Closing price of common stock price per share"&gt;6.82&lt;/span&gt; on that
date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2022, the Company granted stock options to certain employees and a consultant. The stock options were
granted with an exercise price equal to the current market price of the Company&#x2019;s common stock, as reported by the securities exchange
on which the common stock was then listed, at the grant date and have contractual terms of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zR2pjA0e6qkl" title="Weighted avg. remaining contractual life, options exercisable"&gt;10&lt;/span&gt; years. &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_z1TB1lhRy9cb" title="Share-based compensation arrangement by share-based payment award, plan modification, description and terms"&gt;Vesting terms for options granted
to employees during the three months ended March 31, 2022 included the following vesting schedule: 25% of the shares subject to the option
vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest
and become exercisable quarterly in equal installments thereafter over three years. Certain option awards provide for accelerated vesting
if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term
of options granted to employees and directors was determined in accordance with the &#x201c;simplified approach,&#x201d; as the Company
has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free
interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time
of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual
effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of &lt;span id="xdx_900_ecustom--ForfeitureFactorPercentage_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zbxUNmZfSSr4" title="Forfeiture factor, percentage"&gt;10&lt;/span&gt;%. These
factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing
these assumptions, the fair value is determined at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z8zpcMEUVIpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions
used for valuing options granted to employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zg1IQqPsufYg" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Weighted-average fair value of options granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zmdp4Om773Kf" style="width: 18%; text-align: right" title="Weighted-average fair value of options granted"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected terms (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zzbfrGSUFxKa" title="Expected terms (in years)"&gt;6.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zGSII0nQ7aL7" title="Expected volatility"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zN27WN8Tdig6" title="Risk-free interest rate, minimum"&gt;1.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zomvtOcMH8d3" style="text-align: right" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zoQg66NxAmMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1gh4Ptrwfo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about stock options outstanding and exercisable at March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_8B2_zfz4KwQGn4je" style="display: none"&gt;SCHEDULE OF STOCK OPTION
OUTSTANDING AND EXERCISABLE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of Exercise Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life in Years&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY8PqxlEtXn7" title="Range of Exercise Prices, minimum"&gt;1.47&lt;/span&gt;
- $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMsCdx2YF4Y4" title="Range of Exercise Prices, maximum"&gt;1.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ztQo68yEhXz9" style="width: 13%; text-align: right" title="Number of Options Outstanding"&gt;312,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z24q1PU3O8E5" title="Weighted Average Remaining Contractual Life in Years"&gt;5.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zodfpNIeuAmf" style="width: 13%; text-align: right" title="Weighted Average Exercise Price"&gt;1.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zakIb0ukmuJk" style="width: 13%; text-align: right" title="Number Exercisable"&gt;312,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcB7TuUOL1of" style="width: 13%; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;1.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSGj6KDekUT3" title="Range of Exercise Prices, minimum"&gt;2.23&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z32dxiErRQc3" title="Range of Exercise Prices, maximum"&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2SSYXXsSL3c" style="text-align: right" title="Number of Options Outstanding"&gt;313,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zT25n5tfd1Di" title="Weighted Average Remaining Contractual Life in Years"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z7pxyjABYlCf" style="text-align: right" title="Weighted Average Exercise Price"&gt;2.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z75oIeqX9ei5" style="text-align: right" title="Number Exercisable"&gt;312,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1ux0QJvYD9e" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;2.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zlbZvTHqfLBj" title="Range of Exercise Prices, minimum"&gt;2.76&lt;/span&gt; - $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z3BhakphXJ9k" title="Range of Exercise Prices, maximum"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zX4NmiL2kUs1" style="text-align: right" title="Number of Options Outstanding"&gt;25,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXwXMGWvh39c" title="Weighted Average Remaining Contractual Life in Years"&gt;7.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDklN5SIoJB8" style="text-align: right" title="Weighted Average Exercise Price"&gt;3.49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIeS6xa7bWP6" style="text-align: right" title="Number Exercisable"&gt;12,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zARkKud69mYc" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;3.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zpVFjXx6hG55" title="Range of Exercise Prices"&gt;3.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zN5BPH4Uc7V2" style="text-align: right" title="Number of Options Outstanding"&gt;370,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRW91QoQ5nlh" title="Weighted Average Remaining Contractual Life in Years"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zMZRx6loRkk4" style="text-align: right" title="Weighted Average Exercise Price"&gt;3.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zAUALSjauKM5" style="text-align: right" title="Number Exercisable"&gt;370,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUYTQ9ezDwW8" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;3.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrJcySqDeen9" title="Range of Exercise Prices, minimum"&gt;4.08&lt;/span&gt; - $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zmvR4WUmEaR4" title="Range of Exercise Prices, maximum"&gt;6.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zYOWjPHdfYTf" style="text-align: right" title="Number of Options Outstanding"&gt;578,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zDzGhG9ubpS5" title="Weighted Average Remaining Contractual Life in Years"&gt;5.71&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zzScQ2irwIHf" style="text-align: right" title="Weighted Average Exercise Price"&gt;5.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zlKKSuX3bH7g" style="text-align: right" title="Number Exercisable"&gt;525,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zehLvUJ9aqHf" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;5.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zFssEYVhEJM" title="Range of Exercise Prices, minimum"&gt;6.81&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zH3KbASX2QE" title="Range of Exercise Prices, maximum"&gt;7.37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_ziQGewB6CGqe" style="text-align: right" title="Number of Options Outstanding"&gt;388,995&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF8rAJAetFX2" title="Weighted Average Remaining Contractual Life in Years"&gt;6.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zx6zFKvNQDGe" style="text-align: right" title="Weighted Average Exercise Price"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zhPb9Lacstl1" style="text-align: right" title="Number Exercisable"&gt;297,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zJoNEGvO2ZV1" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zn9AbrBJBnbl" title="Range of Exercise Prices, minimum"&gt;7.52&lt;/span&gt; - $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zEce5kFGZrvl" title="Range of Exercise Prices, maximum"&gt;7.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zxCWmPlRVlI2" style="text-align: right" title="Number of Options Outstanding"&gt;221,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zBLTyxICahH" title="Weighted Average Remaining Contractual Life in Years"&gt;8.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zdvSnIExzeek" style="text-align: right" title="Weighted Average Exercise Price"&gt;7.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zlhNBpCrBIJ9" style="text-align: right" title="Number Exercisable"&gt;49,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z8lHdRdM1aMc" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;7.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUXgtrH3q953" title="Range of Exercise Prices"&gt;7.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_znmaby7QTmIf" style="text-align: right" title="Number of Options Outstanding"&gt;600,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zXGSd2oC62af" title="Weighted Average Remaining Contractual Life in Years"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z6WLssJ6mn58" style="text-align: right" title="Weighted Average Exercise Price"&gt;7.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zxBXQ4JYDdJ2" style="text-align: right" title="Number Exercisable"&gt;300,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z3g2WSdXUIQk" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;7.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zj12WIIF2rRj" title="Range of Exercise Prices, minimum"&gt;7.89&lt;/span&gt; - $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJi9FRnGOXN7" title="Range of Exercise Prices, maximum"&gt;8.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zoairg7hWZmf" style="text-align: right" title="Number of Options Outstanding"&gt;92,673&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBCoLK9aiOO3" title="Weighted Average Remaining Contractual Life in Years"&gt;7.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z4hEfdWECo01" style="text-align: right" title="Weighted Average Exercise Price"&gt;8.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z8nMzmM2dE43" style="text-align: right" title="Number Exercisable"&gt;48,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zy8b5igvA4cb" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;8.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zHoL7MUV5Whf" title="Range of Exercise Prices"&gt;8.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zJ0ibE8PHbv2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding"&gt;180,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZVNxrAu0CM7" title="Weighted Average Remaining Contractual Life in Years"&gt;1.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zA4Ck5wftYM6" style="text-align: right" title="Weighted Average Exercise Price"&gt;8.99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zeg9x30DOTdi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable"&gt;180,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zog13riGQFGl" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;8.99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331_zAfyYlfe5RY8" title="Range of Exercise Prices, minimum"&gt;1.47&lt;/span&gt; - $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331_z1jNkg6szbWk" title="Range of Exercise Prices, maximum"&gt;8.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331_ztowcNr96WXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"&gt;3,083,796&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zFIPCqRg02Ll" title="Weighted Average Remaining Contractual Life in Years"&gt;5.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331_zVXgHCyBuZf9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331_zjnnezu8CiSk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"&gt;2,408,629&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331_z69dsw8Z2T91" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;5.29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zfyJxnHYScU9" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2022, there was approximately $&lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_z7uywyQlhDo2" title="Unrecognized compensation expense related to unvested stock options granted under the plan"&gt;1,806,000&lt;/span&gt; of total unrecognized compensation expense related to unvested stock options granted
under the Plans. That expense is expected to be recognized over the weighted-average remaining vesting period of &lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zKkdIitsaAJe" title="Expense expected to recognize over the weighted-average remaining vesting period"&gt;4.89&lt;/span&gt; years. The stock-based
compensation for all stock options was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_z0xAYBlVaSga" title="Stock-based compensation"&gt;272,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20210101__20210331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zP0ydY76AsDa" title="Stock-based compensation"&gt;452,000&lt;/span&gt; during the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
intrinsic value of options exercised during the three months ended March 31, 2022 was $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zMaTUvdj7FHa" title="Intrinsic value of options exercised"&gt;745,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units/Performance Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;RSU
awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria.
The grant date fair value of the RSUs, which has been determined based upon the market value of the Company&#x2019;s common stock on the
grant date, is expensed over the vesting period of the RSUs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zL3Fov38ZLo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s RSU activity (including performance stock units) and related information for the three months ended March
31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zKxp5nlKRWpa" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK UNITS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;RSUs unvested - January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeoqiQU4Cum4" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"&gt;2,233,202&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMeeYIVkYgVk" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;6.78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;RSUs granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjfsiSlInzFe" style="text-align: right" title="Number of RSUs granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1418"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAOkPaieR8jh" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1420"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;RSUs vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbN62HMPlyWc" style="text-align: right" title="Number of RSUs vested"&gt;(144,644&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znDhB7QraFv2" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;6.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;RSUs cancelled/forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFgbIgWQ0s8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1426"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTYSEKP7aTDl" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1428"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;RSUs unvested at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgbEvmKQ2qDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"&gt;2,088,558&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuXzSXRNnJ9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;6.79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zblHekinWO1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2022, the total unrecognized compensation expense related to unvested RSUs was approximately $&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zhC5lpryASM6" title="Unrecognized compensation expense related to unvested stock options granted under the plan"&gt;8,756,000&lt;/span&gt;, which is expected
to be recognized over a weighted-average period of &lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zHgIYywusSIl" title="Expense expected to recognize over the weighted-average remaining vesting period"&gt;1.33&lt;/span&gt; years, based on estimated and actual vesting schedules of the applicable RSUs.
The stock-based compensation for RSUs during the three months ended March 31, 2022 and 2021 was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zHxcx6c0WDwe" title="Stock-based compensation"&gt;1,744,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20210101__20210331__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zgPK0efEAbAk" title="Stock-based compensation"&gt;346,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company issues warrants to purchase shares of the Company&#x2019;s common stock to investors, lenders, underwriters
and other non-employees for services rendered or to be rendered in the future, or pursuant to settlement agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo5ixYfyrQ2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of warrant activity for the three months ended March 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_ztvBORS9irK" style="display: none"&gt;SCHEDULE
OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares Subject&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;to Warrants Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Warrants outstanding - January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPb4Gb1Jz4vc" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance"&gt;373,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyGJANhyi5j3" style="width: 16%; text-align: right" title="Weighted Average. Exercise Price, Outstanding, beginning balance"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrPyFoX9mwK9" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1448"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zakui8Qwm8b3" style="text-align: right" title="Share-based Payment Award, Non-Option Equity Instruments, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6IT4LIzQJ9k" style="border-bottom: Black 1.5pt solid; text-align: right" title=" Share-based Payment Award, Non-Option Equity Instruments, Expirations"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1452"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Warrants outstanding and exercisable - March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHFQiAJFEfSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding, Ending balance"&gt;373,847&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBIycJQy98z2" style="text-align: right" title="Weighted Average. Exercise Price, Outstanding, Ending balance"&gt;2.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average remaining contractual life of the outstanding warrants in years - March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z8S1ubqxtvD1" title="Weighted average remaining contractual life of the outstanding warrants in years"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zRbkYHtlAY7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleofWarrantsOutstandingTableTextBlock_z1jBO3cal1o3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding and exercisable as of March 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zmlBmUS0EVja" style="display: none"&gt;SCHEDULE
OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Warrant Series&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issue Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;Lender warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span id="xdx_900_ecustom--WarrantsIssuanceDate_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z6ZFhmiEdv9a" title="Issue Date"&gt;7/19/2017&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z8wZbmYFXGWf" style="width: 14%; text-align: right" title="Warrants Outstanding"&gt;373,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zlmFP81pJi6a" style="width: 14%; text-align: right" title="Exercise Price"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zw8drB9B6Ihc" title="Expiration Date"&gt;7/19/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zamDE5I7GWfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Subsidiary
Stock-Based Transactions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220101__20220331__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_zIxxPL6DdzFh" title="Stock-based compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20210101__20210331__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_z0IGk0lzu2Kl" title="Stock-based compensation"&gt;57,000&lt;/span&gt; in stock-based compensation expense related to subsidiary stock options during the three months ended
March 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-Based
Compensation Summary&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z4vPgSO6nvK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_ziDMPJsYYPw5" style="display: none"&gt;SCHEDULE
OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20220331_zSewNhZ8RMs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20210331_zeZ6gdo90dU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zzZCTPKEA8A5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Employees - selling, general and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,676,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;755,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkxhkmCyw9Qe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Employees &#x2013; research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1480"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVUcNHC5VAfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Directors - selling, general and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z1PYRObGnws1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Consultants &#x2013; research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1486"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zuRtxErxv2Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,016,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;855,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember"
      decimals="INF"
      unitRef="Shares">53594</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <HROW:CashlessExerciseOfOptionsShares
      contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember"
      decimals="INF"
      unitRef="Shares">125000</HROW:CashlessExerciseOfOptionsShares>
    <HROW:CashlessExerciseOfOptionsPricePerShares
      contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember"
      decimals="INF"
      unitRef="USDPShares">2.40</HROW:CashlessExerciseOfOptionsPricePerShares>
    <HROW:CommonStockWithheldOnCashlessExercise
      contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember"
      decimals="INF"
      unitRef="Shares">36014</HROW:CommonStockWithheldOnCashlessExercise>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsShares
      contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember"
      decimals="INF"
      unitRef="Shares">35392</HROW:CommonStockWithheldForPayrollTaxWithholdingsShares>
    <HROW:CommonStockWithheldForPayrollTaxWithholdings
      contextRef="From2022-01-012022-03-31_custom_MarkLBaumMember"
      decimals="0"
      unitRef="USD">295000</HROW:CommonStockWithheldForPayrollTaxWithholdings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2019-02-012019-02-28_custom_AndrewRBollMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-012022-02-28_custom_AndrewRBollMember"
      decimals="INF"
      unitRef="Shares">29395</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsShares
      contextRef="From2022-02-012022-02-28_custom_AndrewRBollMember"
      decimals="INF"
      unitRef="Shares">20605</HROW:CommonStockWithheldForPayrollTaxWithholdingsShares>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsValue
      contextRef="From2022-02-012022-02-28_custom_AndrewRBollMember"
      decimals="0"
      unitRef="USD">162000</HROW:CommonStockWithheldForPayrollTaxWithholdingsValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-02-012019-02-28_custom_JohnPSaharekMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-012022-02-28_custom_JohnPSaharekMember"
      decimals="INF"
      unitRef="Shares">24077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsShares
      contextRef="From2022-02-012022-02-28_custom_JohnPSaharekMember"
      decimals="INF"
      unitRef="Shares">25923</HROW:CommonStockWithheldForPayrollTaxWithholdingsShares>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsValue
      contextRef="From2022-02-012022-02-28_custom_JohnPSaharekMember"
      decimals="0"
      unitRef="USD">204000</HROW:CommonStockWithheldForPayrollTaxWithholdingsValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-02-012019-02-28_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-012022-02-28_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">20298</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsShares
      contextRef="From2022-02-012022-02-28_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14702</HROW:CommonStockWithheldForPayrollTaxWithholdingsShares>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsValue
      contextRef="From2022-02-012022-02-28_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">116000</HROW:CommonStockWithheldForPayrollTaxWithholdingsValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">3.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9644</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-03-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-03-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember"
      decimals="INF"
      unitRef="Shares">2229399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zJxL6dHkZQWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of stock option activity under the Plans for the three months ended March 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zMfNdnqJrHK8" style="display: none"&gt;SCHEDULE
OF STOCK OPTION PLAN ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Options outstanding &#x2013; January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zs71DclQBMOi" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance"&gt;3,039,546&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLUzVHvgl5I2" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"&gt;5.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZATxOBiSMpi" style="text-align: right" title="Number of shares, options granted"&gt;170,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zlaZ40dISsag" style="text-align: right" title="Weighted average exercise price, options granted"&gt;7.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpIw669FcMr9" style="text-align: right" title="Number of shares, options exercised"&gt;(126,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWIYBRJqmDg4" style="text-align: right" title="Weighted average exercise price, options exercised"&gt;2.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options cancelled/forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zn1WOUkuwpdb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options cancelled/forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwd9Fh04h5wf" style="text-align: right" title="Weighted average exercise price, options cancelled/forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1206"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding &#x2013; March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zbwxm1CFj9hk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance"&gt;3,083,796&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJAW0Gkj0JT5" style="text-align: right" title="Weighted average exercise price, outstanding, ending balance"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWKDp5ZBcODh" title="Weighted average. remaining contractual life, options outstanding"&gt;5.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLu9Zj8MW3w7" style="text-align: right" title="Aggregate intrinsic value, options outstanding"&gt;4,781,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z6Cbdb4qDJS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable"&gt;2,408,629&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVAAOR1EgGog" style="text-align: right" title="Weighted average exercise price, options exercisable"&gt;5.29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVC7vOFHuPik" title="Weighted average. remaining contractual life, options exercisable"&gt;4.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOPPtIdiFQZ6" style="text-align: right" title="Aggregate intrinsic value, options exercisable"&gt;4,639,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Options vested and expected to vest&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zDrp9jBJ4UJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest"&gt;3,083,796&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJ0KwgTMUvgg" style="text-align: right" title="Weighted average exercise price, options vested and expected to vest"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zMibHxxV6Hv7" title="Weighted average. remaining contractual life, options vested and expected to vest"&gt;5.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220331__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zshFV23Z9Zx6" style="text-align: right" title="Aggregate intrinsic value, options vested and expected to vest"&gt;4,781,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">3039546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">5.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">170250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">7.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">126000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">2.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">3083796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">5.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember">P5Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember"
      decimals="0"
      unitRef="USD">4781000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">2408629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember">P4Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember"
      decimals="0"
      unitRef="USD">4639000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">3083796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">5.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-03-31_custom_StockOptionPlanOneMember">P5Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2022-03-31_custom_StockOptionPlanOneMember"
      decimals="0"
      unitRef="USD">4781000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <HROW:ClosingPriceOfCommonStockPricePerShare
      contextRef="AsOf2022-03-31_custom_StockOptionPlanMember"
      decimals="INF"
      unitRef="USDPShares">6.82</HROW:ClosingPriceOfCommonStockPricePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember">Vesting terms for options granted
to employees during the three months ended March 31, 2022 included the following vesting schedule: 25% of the shares subject to the option
vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest
and become exercisable quarterly in equal installments thereafter over three years. Certain option awards provide for accelerated vesting
if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
    <HROW:ForfeitureFactorPercentage
      contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember"
      decimals="INF"
      unitRef="Pure">0.10</HROW:ForfeitureFactorPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z8zpcMEUVIpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions
used for valuing options granted to employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zg1IQqPsufYg" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Weighted-average fair value of options granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zmdp4Om773Kf" style="width: 18%; text-align: right" title="Weighted-average fair value of options granted"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected terms (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zzbfrGSUFxKa" title="Expected terms (in years)"&gt;6.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zGSII0nQ7aL7" title="Expected volatility"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zN27WN8Tdig6" title="Risk-free interest rate, minimum"&gt;1.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zomvtOcMH8d3" style="text-align: right" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-01-012022-03-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Pure">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z1gh4Ptrwfo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about stock options outstanding and exercisable at March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span id="xdx_8B2_zfz4KwQGn4je" style="display: none"&gt;SCHEDULE OF STOCK OPTION
OUTSTANDING AND EXERCISABLE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Range of Exercise Prices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life in Years&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY8PqxlEtXn7" title="Range of Exercise Prices, minimum"&gt;1.47&lt;/span&gt;
- $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zMsCdx2YF4Y4" title="Range of Exercise Prices, maximum"&gt;1.73&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ztQo68yEhXz9" style="width: 13%; text-align: right" title="Number of Options Outstanding"&gt;312,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z24q1PU3O8E5" title="Weighted Average Remaining Contractual Life in Years"&gt;5.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zodfpNIeuAmf" style="width: 13%; text-align: right" title="Weighted Average Exercise Price"&gt;1.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zakIb0ukmuJk" style="width: 13%; text-align: right" title="Number Exercisable"&gt;312,887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zcB7TuUOL1of" style="width: 13%; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;1.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSGj6KDekUT3" title="Range of Exercise Prices, minimum"&gt;2.23&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z32dxiErRQc3" title="Range of Exercise Prices, maximum"&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2SSYXXsSL3c" style="text-align: right" title="Number of Options Outstanding"&gt;313,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zT25n5tfd1Di" title="Weighted Average Remaining Contractual Life in Years"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z7pxyjABYlCf" style="text-align: right" title="Weighted Average Exercise Price"&gt;2.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z75oIeqX9ei5" style="text-align: right" title="Number Exercisable"&gt;312,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1ux0QJvYD9e" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;2.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zlbZvTHqfLBj" title="Range of Exercise Prices, minimum"&gt;2.76&lt;/span&gt; - $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z3BhakphXJ9k" title="Range of Exercise Prices, maximum"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zX4NmiL2kUs1" style="text-align: right" title="Number of Options Outstanding"&gt;25,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXwXMGWvh39c" title="Weighted Average Remaining Contractual Life in Years"&gt;7.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDklN5SIoJB8" style="text-align: right" title="Weighted Average Exercise Price"&gt;3.49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIeS6xa7bWP6" style="text-align: right" title="Number Exercisable"&gt;12,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zARkKud69mYc" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;3.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zpVFjXx6hG55" title="Range of Exercise Prices"&gt;3.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zN5BPH4Uc7V2" style="text-align: right" title="Number of Options Outstanding"&gt;370,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRW91QoQ5nlh" title="Weighted Average Remaining Contractual Life in Years"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zMZRx6loRkk4" style="text-align: right" title="Weighted Average Exercise Price"&gt;3.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zAUALSjauKM5" style="text-align: right" title="Number Exercisable"&gt;370,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUYTQ9ezDwW8" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;3.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrJcySqDeen9" title="Range of Exercise Prices, minimum"&gt;4.08&lt;/span&gt; - $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zmvR4WUmEaR4" title="Range of Exercise Prices, maximum"&gt;6.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zYOWjPHdfYTf" style="text-align: right" title="Number of Options Outstanding"&gt;578,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zDzGhG9ubpS5" title="Weighted Average Remaining Contractual Life in Years"&gt;5.71&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zzScQ2irwIHf" style="text-align: right" title="Weighted Average Exercise Price"&gt;5.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zlKKSuX3bH7g" style="text-align: right" title="Number Exercisable"&gt;525,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zehLvUJ9aqHf" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;5.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zFssEYVhEJM" title="Range of Exercise Prices, minimum"&gt;6.81&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zH3KbASX2QE" title="Range of Exercise Prices, maximum"&gt;7.37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_ziQGewB6CGqe" style="text-align: right" title="Number of Options Outstanding"&gt;388,995&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF8rAJAetFX2" title="Weighted Average Remaining Contractual Life in Years"&gt;6.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zx6zFKvNQDGe" style="text-align: right" title="Weighted Average Exercise Price"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zhPb9Lacstl1" style="text-align: right" title="Number Exercisable"&gt;297,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zJoNEGvO2ZV1" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zn9AbrBJBnbl" title="Range of Exercise Prices, minimum"&gt;7.52&lt;/span&gt; - $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zEce5kFGZrvl" title="Range of Exercise Prices, maximum"&gt;7.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zxCWmPlRVlI2" style="text-align: right" title="Number of Options Outstanding"&gt;221,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zBLTyxICahH" title="Weighted Average Remaining Contractual Life in Years"&gt;8.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zdvSnIExzeek" style="text-align: right" title="Weighted Average Exercise Price"&gt;7.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zlhNBpCrBIJ9" style="text-align: right" title="Number Exercisable"&gt;49,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z8lHdRdM1aMc" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;7.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zUXgtrH3q953" title="Range of Exercise Prices"&gt;7.87&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_znmaby7QTmIf" style="text-align: right" title="Number of Options Outstanding"&gt;600,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zXGSd2oC62af" title="Weighted Average Remaining Contractual Life in Years"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z6WLssJ6mn58" style="text-align: right" title="Weighted Average Exercise Price"&gt;7.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zxBXQ4JYDdJ2" style="text-align: right" title="Number Exercisable"&gt;300,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z3g2WSdXUIQk" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;7.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zj12WIIF2rRj" title="Range of Exercise Prices, minimum"&gt;7.89&lt;/span&gt; - $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zJi9FRnGOXN7" title="Range of Exercise Prices, maximum"&gt;8.98&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zoairg7hWZmf" style="text-align: right" title="Number of Options Outstanding"&gt;92,673&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zBCoLK9aiOO3" title="Weighted Average Remaining Contractual Life in Years"&gt;7.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z4hEfdWECo01" style="text-align: right" title="Weighted Average Exercise Price"&gt;8.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z8nMzmM2dE43" style="text-align: right" title="Number Exercisable"&gt;48,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zy8b5igvA4cb" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;8.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zHoL7MUV5Whf" title="Range of Exercise Prices"&gt;8.99&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zJ0ibE8PHbv2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding"&gt;180,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zZVNxrAu0CM7" title="Weighted Average Remaining Contractual Life in Years"&gt;1.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zA4Ck5wftYM6" style="text-align: right" title="Weighted Average Exercise Price"&gt;8.99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zeg9x30DOTdi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable"&gt;180,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zog13riGQFGl" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;8.99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220331_zAfyYlfe5RY8" title="Range of Exercise Prices, minimum"&gt;1.47&lt;/span&gt; - $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220331_z1jNkg6szbWk" title="Range of Exercise Prices, maximum"&gt;8.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331_ztowcNr96WXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"&gt;3,083,796&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zFIPCqRg02Ll" title="Weighted Average Remaining Contractual Life in Years"&gt;5.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220331_zVXgHCyBuZf9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220331_zjnnezu8CiSk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"&gt;2,408,629&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220331_z69dsw8Z2T91" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;5.29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">1.73</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="Shares">312887</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeOneMember">P5Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">1.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="Shares">312887</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">1.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">2.23</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">2.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="Shares">313068</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeTwoMember">P4Y10M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">2.26</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="Shares">312943</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">2.26</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">2.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">3.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="Shares">25500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeThreeMember">P7Y11M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">3.49</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="Shares">12906</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">3.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="USDPShares">3.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="Shares">370000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeFourMember">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="USDPShares">3.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="Shares">370000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="USDPShares">3.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeFiveMember"
      decimals="INF"
      unitRef="USDPShares">4.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeFiveMember"
      decimals="INF"
      unitRef="USDPShares">6.30</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeFiveMember"
      decimals="INF"
      unitRef="Shares">578850</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeFiveMember">P5Y8M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeFiveMember"
      decimals="INF"
      unitRef="USDPShares">5.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeFiveMember"
      decimals="INF"
      unitRef="Shares">525027</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeFiveMember"
      decimals="INF"
      unitRef="USDPShares">5.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeSixMember"
      decimals="INF"
      unitRef="USDPShares">6.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeSixMember"
      decimals="INF"
      unitRef="USDPShares">7.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeSixMember"
      decimals="INF"
      unitRef="Shares">388995</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeSixMember">P6Y3M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeSixMember"
      decimals="INF"
      unitRef="USDPShares">7.30</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeSixMember"
      decimals="INF"
      unitRef="Shares">297495</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeSixMember"
      decimals="INF"
      unitRef="USDPShares">7.30</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeSevenMember"
      decimals="INF"
      unitRef="USDPShares">7.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeSevenMember"
      decimals="INF"
      unitRef="USDPShares">7.79</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeSevenMember"
      decimals="INF"
      unitRef="Shares">221823</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeSevenMember">P8Y3M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeSevenMember"
      decimals="INF"
      unitRef="USDPShares">7.61</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeSevenMember"
      decimals="INF"
      unitRef="Shares">49323</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeSevenMember"
      decimals="INF"
      unitRef="USDPShares">7.66</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeEightMember"
      decimals="INF"
      unitRef="USDPShares">7.87</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeEightMember"
      decimals="INF"
      unitRef="Shares">600000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeEightMember">P3Y3M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeEightMember"
      decimals="INF"
      unitRef="USDPShares">7.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeEightMember"
      decimals="INF"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeEightMember"
      decimals="INF"
      unitRef="USDPShares">7.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeNineMember"
      decimals="INF"
      unitRef="USDPShares">7.89</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeNineMember"
      decimals="INF"
      unitRef="USDPShares">8.98</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeNineMember"
      decimals="INF"
      unitRef="Shares">92673</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeNineMember">P7Y5M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeNineMember"
      decimals="INF"
      unitRef="USDPShares">8.16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeNineMember"
      decimals="INF"
      unitRef="Shares">48048</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeNineMember"
      decimals="INF"
      unitRef="USDPShares">8.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-03-31_custom_RangeTenMember"
      decimals="INF"
      unitRef="USDPShares">8.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2022-03-31_custom_RangeTenMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_RangeTenMember">P1Y1M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31_custom_RangeTenMember"
      decimals="INF"
      unitRef="USDPShares">8.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2022-03-31_custom_RangeTenMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_custom_RangeTenMember"
      decimals="INF"
      unitRef="USDPShares">8.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">8.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">3083796</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-03-31">P5Y3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">5.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">2408629</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">5.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-03-31_custom_StockOptionPlanMember"
      decimals="0"
      unitRef="USD">1806000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember">P4Y10M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember"
      decimals="0"
      unitRef="USD">272000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31_custom_StockOptionPlanMember"
      decimals="0"
      unitRef="USD">452000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2022-01-012022-03-31_custom_StockOptionPlanMember"
      decimals="0"
      unitRef="USD">745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zL3Fov38ZLo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s RSU activity (including performance stock units) and related information for the three months ended March
31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zKxp5nlKRWpa" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK UNITS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;RSUs unvested - January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeoqiQU4Cum4" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"&gt;2,233,202&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMeeYIVkYgVk" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;6.78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;RSUs granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjfsiSlInzFe" style="text-align: right" title="Number of RSUs granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1418"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAOkPaieR8jh" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1420"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;RSUs vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbN62HMPlyWc" style="text-align: right" title="Number of RSUs vested"&gt;(144,644&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znDhB7QraFv2" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;6.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;RSUs cancelled/forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYFgbIgWQ0s8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1426"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTYSEKP7aTDl" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1428"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;RSUs unvested at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgbEvmKQ2qDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"&gt;2,088,558&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxuXzSXRNnJ9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;6.79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2233202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">144644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">2088558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">6.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-03-31_custom_UnvestedRSUMember"
      decimals="0"
      unitRef="USD">8756000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-01-012022-03-31_custom_UnvestedRSUMember">P1Y3M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_UnvestedRSUMember"
      decimals="0"
      unitRef="USD">1744000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31_custom_UnvestedRSUMember"
      decimals="0"
      unitRef="USD">346000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zo5ixYfyrQ2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of warrant activity for the three months ended March 31, 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_ztvBORS9irK" style="display: none"&gt;SCHEDULE
OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares Subject&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;to Warrants Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Warrants outstanding - January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPb4Gb1Jz4vc" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance"&gt;373,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyGJANhyi5j3" style="width: 16%; text-align: right" title="Weighted Average. Exercise Price, Outstanding, beginning balance"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrPyFoX9mwK9" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1448"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zakui8Qwm8b3" style="text-align: right" title="Share-based Payment Award, Non-Option Equity Instruments, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6IT4LIzQJ9k" style="border-bottom: Black 1.5pt solid; text-align: right" title=" Share-based Payment Award, Non-Option Equity Instruments, Expirations"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1452"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Warrants outstanding and exercisable - March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHFQiAJFEfSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding, Ending balance"&gt;373,847&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBIycJQy98z2" style="text-align: right" title="Weighted Average. Exercise Price, Outstanding, Ending balance"&gt;2.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average remaining contractual life of the outstanding warrants in years - March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z8S1ubqxtvD1" title="Weighted average remaining contractual life of the outstanding warrants in years"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">373847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.08</HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">373847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.08</HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1>
    <HROW:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember">P2Y3M18D</HROW:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1>
    <HROW:ScheduleofWarrantsOutstandingTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_897_ecustom--ScheduleofWarrantsOutstandingTableTextBlock_z1jBO3cal1o3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding and exercisable as of March 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zmlBmUS0EVja" style="display: none"&gt;SCHEDULE
OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Warrant Series&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issue Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;Lender warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span id="xdx_900_ecustom--WarrantsIssuanceDate_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z6ZFhmiEdv9a" title="Issue Date"&gt;7/19/2017&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_z8wZbmYFXGWf" style="width: 14%; text-align: right" title="Warrants Outstanding"&gt;373,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zlmFP81pJi6a" style="width: 14%; text-align: right" title="Exercise Price"&gt;2.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: center"&gt;&lt;span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zw8drB9B6Ihc" title="Expiration Date"&gt;7/19/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</HROW:ScheduleofWarrantsOutstandingTableTextBlock>
    <HROW:WarrantsIssuanceDate contextRef="From2022-01-012022-03-31_custom_LenderWarrantsMember">2017-07-19</HROW:WarrantsIssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-03-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Shares">373847</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">2.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <HROW:WarrantsAndRightsOutstandingMaturityDates contextRef="From2022-01-012022-03-31_custom_LenderWarrantsMember">2024-07-19</HROW:WarrantsAndRightsOutstandingMaturityDates>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-03-31_custom_SubsidiaryStockMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31_custom_SubsidiaryStockMember"
      decimals="0"
      unitRef="USD">57000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z4vPgSO6nvK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_ziDMPJsYYPw5" style="display: none"&gt;SCHEDULE
OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20220331_zSewNhZ8RMs8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210101__20210331_zeZ6gdo90dU8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;For the Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zzZCTPKEA8A5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Employees - selling, general and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,676,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;755,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zkxhkmCyw9Qe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Employees &#x2013; research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1480"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zVUcNHC5VAfj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Directors - selling, general and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z1PYRObGnws1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Consultants &#x2013; research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1486"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zuRtxErxv2Lh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,016,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;855,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31_custom_EmployeesMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">1676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-03-31_custom_EmployeesMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">755000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31_custom_EmployeesMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31_srt_DirectorMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-03-31_srt_DirectorMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-03-31_custom_ConsultantMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">54000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2016000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">855000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbmEPjPSzl7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15. &lt;span id="xdx_82C_z2mC8CTirizl"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Legal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
and Other&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make claims
or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial disputes.
Any of these claims could subject the Company to litigation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Product
and Professional Liability&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Product
and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize
traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any
given time reflects current market conditions, including cost and availability, when the policy is written.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Indemnities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the indemnification provisions contained in the Company&#x2019;s governing documents, the Company generally enters into separate
indemnification agreements with each of the Company&#x2019;s directors and officers. These agreements require the Company, among other
things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys&#x2019; fees, judgments, fines
and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual&#x2019;s status
or service as the Company&#x2019;s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly
fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the
individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors
in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for
any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred
any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed
consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Klarity
License Agreement &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into a license agreement in April 2017, as amended in April 2018 (the &#x201c;Klarity License Agreement&#x201d;), with
Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed
certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic
solution Klarity designed to protect and rehabilitate the ocular surface (the &#x201c;Klarity Product&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z6d1CLBuRVcj" title="Royalty payment description"&gt;Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of
net sales, dependent upon the final formulation of the Klarity Product sold&lt;/span&gt;. In addition, the Company was required to make certain milestone
payments to Dr. Lindstrom. All of the above referenced milestone payments were payable at the Company&#x2019;s election in cash or shares
of the Company&#x2019;s restricted common stock. Payments totaling $&lt;span id="xdx_90A_ecustom--MilestonePaymentInCash_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zSTYSntkUSXk" title="Milestone payment in cash"&gt;30,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--MilestonePaymentInCash_iI_c20210331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zYMWpbnK2gWj" title="Milestone payment in cash"&gt;35,000&lt;/span&gt; were made during the three months ended March 31,
2022 and 2021, respectively. $&lt;span id="xdx_90C_eus-gaap--RoyaltyExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_z7aVcoOiVGn4" title="Royalty expenses"&gt;71,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--RoyaltyExpense_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zNQyED0RiQ5k" title="Royalty expenses"&gt;35,000&lt;/span&gt; were incurred as royalty expenses during the three months ended March 31, 2022 and 2021,
respectively, and was included in accounts payable to Dr. Lindstrom.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Injectable
Asset Purchase Agreement &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, the Company entered into an asset purchase agreement (the &#x201c;Lindstrom APA&#x201d;) with Dr. Lindstrom, a member of
its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights
from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the &#x201c;Lindstrom Product&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms of the Lindstrom APA, &lt;span id="xdx_904_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z7yTs6ZVHQud" title="Royalty payment description"&gt;the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales,
dependent upon the final formulation and patent protection of the Lindstrom Product sold&lt;/span&gt;. In addition, the Company is required to make
certain milestone payments to Dr. Lindstrom including an initial payment of $&lt;span id="xdx_90C_ecustom--InitialMilestonePayment_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zEM577gDs0Wb" title="Initial milestone payment"&gt;33,000&lt;/span&gt; upon execution of the Lindstrom APA. Dr. Lindstrom
was paid $&lt;span id="xdx_908_ecustom--MilestonePaymentInCash_iI_c20220331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_ziRMRumqWQmd" title="Milestone payment in cash"&gt;8,000&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--MilestonePaymentInCash_iI_c20210331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zfHnAnS1qFT8"&gt;7,000&lt;/span&gt; in cash during the three months ended March 31, 2022 and 2021, respectively. The Company incurred $&lt;span id="xdx_90B_eus-gaap--RoyaltyExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zWuOSPbCmOCb" title="Royalty expenses"&gt;7,000&lt;/span&gt; and
$&lt;span id="xdx_901_eus-gaap--RoyaltyExpense_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zigytNiKJVQi" title="Royalty expenses"&gt;7,000&lt;/span&gt; for royalty expenses related to the Lindstrom APA during the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;Eyepoint
Commercial Alliance Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the &#x201c;Dexycu
Agreement&#x201d;) with Eyepoint Pharmaceuticals, Inc. (&#x201c;Eyepoint&#x201d;), pursuant to which Eyepoint granted the Company the non-exclusive
right to co-promote DEXYCU&lt;sup&gt;&#xae;&lt;/sup&gt; (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation
following ocular surgery in the United States.&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the &lt;span style="background-color: white"&gt;Dexycu Agreement&lt;/span&gt;, Eyepoint will pay the Company a fee calculated based on the quarterly
sales of DEXYCU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms of the &lt;span style="background-color: white"&gt;Dexycu
Agreement&lt;/span&gt;, the Company shall use commercially reasonable efforts to promote and market DEXYCU in the U.S.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
&lt;span style="background-color: white"&gt;Dexycu Agreement&lt;/span&gt; expires on &lt;span id="xdx_903_ecustom--CommissionExpirationDate_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zze7YtRgsA4i"&gt;August 1, 2025&lt;/span&gt;, subject to early termination in accordance with
the terms set forth therein. Either party may terminate the &lt;span style="background-color: white"&gt;Dexycu Agreement, subject to specified
notice periods and limitations,&lt;/span&gt; in the event of (i) uncured material breach by the other party or (ii) if DEXYCU ceases to have
&#x201c;pass-through&#x201d; payment status. In addition, subject to certain limitations, the Company may terminate the &lt;span style="background-color: white"&gt;Dexycu
Agreement&lt;/span&gt; (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a change
of control. Eyepoint may terminate the &lt;span style="background-color: white"&gt;Dexycu Agreement&lt;/span&gt;, subject to specified notice periods
and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods. During the three months
ended March 31, 2022 and 2021, the Company recorded $&lt;span id="xdx_90E_ecustom--CommissionRevenues_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zrC3cpRCRtn3" title="Commission revenues"&gt;1,320,000&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--CommissionRevenues_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zTIo62ADmUWh" title="Commission revenues"&gt;485,000&lt;/span&gt;, respectively, in commission revenues related to the Dexycu
Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Sales
and Marketing Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered various sales and marketing agreements with certain organizations to provide exclusive and non-exclusive sales and
marketing representation services to Harrow in select geographies in the U.S. in connection with the Company&#x2019;s ophthalmic pharmaceutical
compounded formulations or related products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--DescriptionForCommissionPayments_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zahTbaz2FEKb" title="Description for commission payments"&gt;Under
the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to &lt;span id="xdx_90A_ecustom--CommissionPaymentsPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zkVqI9bjFDbk" title="Commission payments percentage"&gt;10&lt;/span&gt;% - &lt;span id="xdx_90B_ecustom--CommissionPaymentsPercentage_pid_dp_uPure_c20220101__20220331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_z4LuF0bzkmY1" title="Commission payments percentage"&gt;14&lt;/span&gt;% of
net sales for products above and beyond the initial existing sales amounts&lt;/span&gt;. In addition, the Company is required to make periodic milestone
payments to certain organizations in shares of the Company&#x2019;s restricted common stock if net sales in the assigned territory reach
certain future levels by the end of their terms. Commission expenses of $&lt;span id="xdx_90F_eus-gaap--SalesCommissionsAndFees_pn3n3_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zGeVmRm8NCIb" title="Commission expenses"&gt;1,047,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--SalesCommissionsAndFees_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zolAxgvIbau" title="Commission expenses"&gt;804,000&lt;/span&gt; were incurred under these agreements during the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Asset
Purchase, License and Related Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related
parties (the &#x201c;Inventors&#x201d;) through multiple asset purchase agreements, license agreements, strategic agreements and commission
agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for
the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize
a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual
property and drug development opportunities presented by these Inventors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based
on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first
patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the
Company files the first investigational new drug application (&#x201c;IND&#x201d;) with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)
for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within
30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual
property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or
licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company&#x2019;s
development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the
Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where
data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property,
the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to
the Inventors. During the three months ended March 31, 2022 and 2021, $&lt;span id="xdx_905_eus-gaap--RoyaltyExpense_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zz2PtmNcJcX5" title="Royalty expense"&gt;213,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--RoyaltyExpense_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zYZDO92reQzi" title="Royalty expense"&gt;232,000&lt;/span&gt; were incurred under these agreements as royalty
expenses, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Sintetica
Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2021, the Company entered into a License and Supply Agreement (the &#x201c;Sintetica Agreement&#x201d;) with Sintetica S.A. (&#x201c;Sintetica&#x201d;),
pursuant to which Sintetica granted the Company the exclusive license and marketing rights to its patented ophthalmic drug candidate
(&#x201c;AMP-100&#x201d;) in the U.S. and Canada.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Sintetica Agreement, the Company will pay Sintetica a per unit transfer price to supply AMP-100, along with a per unit royalty
for units sold. The Company is required to pay Sintetica up to $&lt;span id="xdx_90D_eus-gaap--PaymentsForRoyalties_c20210701__20210731__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zLKCsCkfo5ph" title="Royalty payments"&gt;18,000,000&lt;/span&gt; in one-time milestone payments including a $&lt;span id="xdx_906_eus-gaap--PaymentsForRoyalties_c20210701__20210731__srt--StatementScenarioAxis__custom--DueWithinThirtyDaysMember__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zboQTHWuHZek" title="Royalty payments"&gt;5,000,000&lt;/span&gt; payment
(the &#x201c;Upfront Payment&#x201d;) due within 30 days of signing the Sintetica Agreement and the balance of payments due upon achievement
of certain regulatory and commercial milestones. Under the terms of the Sintetica Agreement, Sintetica will be responsible for regulatory
filings for AMP-100 in the U.S. The Upfront Payment along with an additional milestone payment of $&lt;span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z7626tFCAxkg"&gt;3,117,000&lt;/span&gt; was paid and recorded as
a R&amp;amp;D expenses during the year ended December 31, 2021. For the three months ended March 31, 2022, no amounts have been paid or accrued
under the Sintetica agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subject
to certain limitations, the term of the Sintetica Agreement is ten years, and allows for a ten-year extension if certain sales thresholds
are met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Wakamoto
Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
August 2021, the Company entered into a License Agreement and a Basic Sale and Purchase Agreement (together, the &#x201c;Wakamoto Agreements&#x201d;)
with Wakamoto Pharmaceutical Co., Ltd. (&#x201c;Wakamoto&#x201d;), pursuant to which Wakamoto granted the Company the exclusive license
and marketing rights to its ophthalmic drug candidate (&#x201c;MAQ-100&#x201d;) in the U.S. and Canada.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the &lt;span style="background-color: white"&gt;Wakamoto &lt;/span&gt;Agreements, Wakamoto will supply MAQ-100 to the Company, and the Company
will pay Wakamoto a per unit transfer price to supply MAQ-100. In addition, the Company is required to pay Wakamoto various one-time
milestone payments totaling up to $&lt;span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--WakamotoAgreementMember_zGLq77pOpHY1" title="Payment for royalties"&gt;2,000,000&lt;/span&gt; upon the achievement of certain regulatory milestones and up to $&lt;span id="xdx_909_ecustom--CommercialPaymentsForRoyalties_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--WakamotoAgreementMember_zfumzQTDWiJb" title="Commercial payments for royalties"&gt;6,200,000&lt;/span&gt; upon the achievement
of certain commercial milestones. Under the terms of the Agreements, the Company will be responsible for regulatory filings and fees
for MAQ-100 in the U.S. and Canada. Through March 31, 2022, no amounts have been paid or accrued under the Wakamoto agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subject
to certain limitations, the term of the Agreements is for five years from the date of the FDA&#x2019;s market approval of MAQ-100 and
allows for a five-year extension if certain unit sales thresholds are met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Presbyopia
Asset Purchase Agreement &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2019, the Company entered into an asset purchase agreement (the &#x201c;Presbyopia APA&#x201d;) with Richard L. Lindstrom, M.D.,
a member of its Board of Directors. Pursuant to the terms of the Presbyopia APA, the Company acquired certain intellectual property and
related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic topical product to treat presbyopia
(the &#x201c;Presbyopia Product&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms of the Presbyopia Product, &lt;span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z7Q763ZNmQ62"&gt;the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales,
dependent upon the final formulation and patent protection of the Presbyopia Product sold&lt;/span&gt;. Dr. Lindstrom was paid $&lt;span id="xdx_903_ecustom--MilestonePaymentInCash_iI_pn3n3_c20220331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zbRHq0ZChKOk" title="Milestone payment in cash"&gt;&lt;span id="xdx_906_ecustom--MilestonePaymentInCash_iI_pn3n3_c20210331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zzFarbzhcbg" title="Milestone payment in cash"&gt;0&lt;/span&gt;&lt;/span&gt; in cash during the
periods ended March 31, 2022 and 2021, and was due $&lt;span id="xdx_901_ecustom--MilestonePaymentsOnPayables_iI_pn3n3_c20220331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zgFoBNxDxh3h" title="Milestone payments on payables"&gt;&lt;span id="xdx_902_ecustom--MilestonePaymentsOnPayables_iI_pn3n3_c20210331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zJCOqJNO0Iy8" title="Milestone payments on payables"&gt;0&lt;/span&gt;&lt;/span&gt; at March 31, 2022 and 2021. The Company incurred $&lt;span id="xdx_905_eus-gaap--RoyaltyExpense_pn3n3_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zqAnyd65PQB7" title="Royalty expense"&gt;&lt;span id="xdx_901_eus-gaap--RoyaltyExpense_pn3n3_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zdwMCGfRnTxd" title="Royalty expense"&gt;0&lt;/span&gt;&lt;/span&gt; for royalty expenses related
to the Presbyopia APA during the periods ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <HROW:RoyaltyPaymentDescription contextRef="From2017-04-012017-04-30_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of
net sales, dependent upon the final formulation of the Klarity Product sold</HROW:RoyaltyPaymentDescription>
    <HROW:MilestonePaymentInCash
      contextRef="AsOf2022-03-31_custom_KlarityLicenseAgreementMember"
      decimals="0"
      unitRef="USD">30000</HROW:MilestonePaymentInCash>
    <HROW:MilestonePaymentInCash
      contextRef="AsOf2021-03-31_custom_KlarityLicenseAgreementMember"
      decimals="0"
      unitRef="USD">35000</HROW:MilestonePaymentInCash>
    <us-gaap:RoyaltyExpense
      contextRef="From2022-01-012022-03-31_custom_KlarityLicenseAgreementMember"
      decimals="0"
      unitRef="USD">71000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-01-012021-03-31_custom_KlarityLicenseAgreementMember"
      decimals="0"
      unitRef="USD">35000</us-gaap:RoyaltyExpense>
    <HROW:RoyaltyPaymentDescription contextRef="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales,
dependent upon the final formulation and patent protection of the Lindstrom Product sold</HROW:RoyaltyPaymentDescription>
    <HROW:InitialMilestonePayment
      contextRef="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="0"
      unitRef="USD">33000</HROW:InitialMilestonePayment>
    <HROW:MilestonePaymentInCash
      contextRef="AsOf2022-03-31_custom_InjectableAssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">8000</HROW:MilestonePaymentInCash>
    <HROW:MilestonePaymentInCash
      contextRef="AsOf2021-03-31_custom_InjectableAssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">7000</HROW:MilestonePaymentInCash>
    <us-gaap:RoyaltyExpense
      contextRef="From2022-01-012022-03-31_custom_InjectableAssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">7000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-01-012021-03-31_custom_InjectableAssetPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">7000</us-gaap:RoyaltyExpense>
    <HROW:CommissionExpirationDate contextRef="From2022-01-012022-03-31_custom_DexycuAgreementMember">2025-08-01</HROW:CommissionExpirationDate>
    <HROW:CommissionRevenues
      contextRef="From2022-01-012022-03-31_custom_DexycuAgreementMember"
      decimals="0"
      unitRef="USD">1320000</HROW:CommissionRevenues>
    <HROW:CommissionRevenues
      contextRef="From2021-01-012021-03-31_custom_DexycuAgreementMember"
      decimals="0"
      unitRef="USD">485000</HROW:CommissionRevenues>
    <HROW:DescriptionForCommissionPayments contextRef="From2022-01-012022-03-31_custom_SalesAndMarketingAgreementsMember">Under
the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to 10% - 14% of
net sales for products above and beyond the initial existing sales amounts</HROW:DescriptionForCommissionPayments>
    <HROW:CommissionPaymentsPercentage
      contextRef="From2022-01-012022-03-31_srt_MinimumMember_custom_SalesAndMarketingAgreementsMember"
      decimals="INF"
      unitRef="Pure">0.10</HROW:CommissionPaymentsPercentage>
    <HROW:CommissionPaymentsPercentage
      contextRef="From2022-01-012022-03-31_srt_MaximumMember_custom_SalesAndMarketingAgreementsMember"
      decimals="INF"
      unitRef="Pure">0.14</HROW:CommissionPaymentsPercentage>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2022-01-012022-03-31_custom_SalesAndMarketingAgreementsMember"
      decimals="-3"
      unitRef="USD">1047000000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2021-01-012021-03-31_custom_SalesAndMarketingAgreementsMember"
      decimals="-3"
      unitRef="USD">804000000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:RoyaltyExpense
      contextRef="From2022-01-012022-03-31_custom_AssetPurchaseLicenseAndRelatedAgreementsMember"
      decimals="0"
      unitRef="USD">213000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-01-012021-03-31_custom_AssetPurchaseLicenseAndRelatedAgreementsMember"
      decimals="0"
      unitRef="USD">232000</us-gaap:RoyaltyExpense>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2021-07-012021-07-31_custom_SinteticaAgreementMember"
      decimals="0"
      unitRef="USD">18000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2021-07-012021-07-31_custom_DueWithinThirtyDaysMember_custom_SinteticaAgreementMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2021-01-012021-12-31_custom_SinteticaAgreementMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">3117000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2021-08-012021-08-31_custom_WakamotoAgreementMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:PaymentsForRoyalties>
    <HROW:CommercialPaymentsForRoyalties
      contextRef="From2021-08-012021-08-31_custom_WakamotoAgreementMember"
      decimals="0"
      unitRef="USD">6200000</HROW:CommercialPaymentsForRoyalties>
    <HROW:RoyaltyPaymentDescription contextRef="From2019-12-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales,
dependent upon the final formulation and patent protection of the Presbyopia Product sold</HROW:RoyaltyPaymentDescription>
    <HROW:MilestonePaymentInCash
      contextRef="AsOf2022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember"
      decimals="-3"
      unitRef="USD">0</HROW:MilestonePaymentInCash>
    <HROW:MilestonePaymentInCash
      contextRef="AsOf2021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember"
      decimals="-3"
      unitRef="USD">0</HROW:MilestonePaymentInCash>
    <HROW:MilestonePaymentsOnPayables
      contextRef="AsOf2022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember"
      decimals="-3"
      unitRef="USD">0</HROW:MilestonePaymentsOnPayables>
    <HROW:MilestonePaymentsOnPayables
      contextRef="AsOf2021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember"
      decimals="-3"
      unitRef="USD">0</HROW:MilestonePaymentsOnPayables>
    <us-gaap:RoyaltyExpense
      contextRef="From2022-01-012022-03-31_custom_PresbyopiaAssetPurchaseAgreementMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-01-012021-03-31_custom_PresbyopiaAssetPurchaseAgreementMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--ConcentrationRiskDisclosureTextBlock_zaB4iy0Cwgk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
16. &lt;span id="xdx_827_zhZ9f4d7GrN1"&gt;CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two products that each comprised more than 10% of total revenues. These products collectively accounted for &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zqUQoz088484"&gt;32&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zNvYt9MOXRSj"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of revenues during the three months ended March
31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the
Company&#x2019;s total pharmacy sales during the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zOBkC85bSFj7" title="Concentration risk percentage"&gt;74&lt;/span&gt;% and
&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zluRvfoBDKd5" title="Concentration risk percentage"&gt;82&lt;/span&gt;% of active pharmaceutical ingredient purchases during the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-03-31_custom_TwoProductConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-03-31_custom_TwoProductConcentrationRiskMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember"
      decimals="INF"
      unitRef="Pure">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember"
      decimals="INF"
      unitRef="Pure">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zX6rswmRDxQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
17. &lt;span id="xdx_829_zOVUgaCJPov4"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has performed an evaluation of events occurring subsequent to March 31, 2022 through the filing date of this Quarterly Report.
Based on its evaluation, no events other than those described below need to be disclosed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Conditional
Melt Loan Amendment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;
In April 2022, the Company entered into a First Amendment (the &#x201c;Amendment&#x201d;) to its loan and security agreement previously
entered into on September 1, 2021 with Melt. The Amendment provides for:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--DescripitionOfLoanAmendment_c20220401__20220430__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4NsIwAzfXQ7" title="Descripition of loan amendment"&gt;Melt
    is required to maintain a minimum cash balance of $7,000,000 for one (1) year following the effective date of the Amendment; and
    a minimum cash balance of $5,000,000 at all times after the one year anniversary of the effective date of the Amendment&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    maturity date by which all amounts owed under the loan agreement are payable was extended to September 1, 2026, unless otherwise
    accelerated pursuant to the terms of the loan agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    definition of Material Adverse Effect was amended so that such an effect will be deemed to have occurred if the data from the phase
    2 study of MELT-300 fails to demonstrate the benefit of the combination MELT-300 study drug versus the individual components of the
    same MELT-300 study drug, as reasonably determined by the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    effectiveness of the Amendment is subject to, among other conditions, Melt consummating a qualifying financing of a minimum amount
    of $&lt;span id="xdx_904_ecustom--MinimumAmountOfFinancing_c20220831__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJpTmHOjbn45" title="Minimum amount of financing"&gt;15,000,000&lt;/span&gt; from third party investors by August 31, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:SubsequentEventsTextBlock>
    <HROW:DescripitionOfLoanAmendment contextRef="From2022-04-012022-04-30_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember">Melt
    is required to maintain a minimum cash balance of $7,000,000 for one (1) year following the effective date of the Amendment; and
    a minimum cash balance of $5,000,000 at all times after the one year anniversary of the effective date of the Amendment</HROW:DescripitionOfLoanAmendment>
    <HROW:MinimumAmountOfFinancing
      contextRef="AsOf2022-08-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">15000000</HROW:MinimumAmountOfFinancing>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M^((UN7J4ZQN^#:@5F,J\;O]'ZZVM-T!I4RNYV@[6"E:BV/QFW[>)V!N ?<L
MLAU WCJ ;@?0-M"-LC:L*Z;8^*R2:U09:^W-7+2Y:4?K:$1A7N-45?I3H<>I
M\:4L,OU2>(;T52USD3&E;RY8SHJ4HZEQ7*,3]'EZA7Y[]_O92.F'FJ&C=/N
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MQD!_OI!2O=Z8[T!VWWF-_P=02P,$%     @ UX.E5&L"_[MT @  G 8  !@
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MC=2<_+"BSP<8%T#[&ZWQ.'$=JO\@Y7\!4$L#!!0    ( ->#I53,EK&\@ 4
M ,45   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULI5A-;^,V$/TKA-%#
M F1CD?H.' ,;)VT#;%HC:;J'H@?:HFTADN@E*2?[[SN49,F.*,9%+K&DS S?
M&W+FD9R\<O$B-XPI])9GA;P>;93:7HW'<KEA.967?,L*^,^*BYPJ>!7KL=P*
M1I/**<_&Q'&"<4[38C2=5-_F8CKAI<K2@LT%DF6>4_'SAF7\]7J$1_L/C^EZ
MH_2'\72RI6OVQ-3S=B[@;=Q&2=*<%3+E!1)L=3WZBJ]FKJ,=*HN_4_8J#YZ1
MIK+@_$6_W"?7(T<C8AE;*AV"PL^.S5B6Z4B XT<3=-2.J1T/G_?1?ZW( YD%
ME6S&L^]IHC;7HVB$$K:B9:8>^>OOK"'DZWA+GLGJ+WJM;4,8<5E*Q?/&&=[S
MM*A_Z5N3B ,'B&-V((T#>>_@#3BXC8-;$:V15;1NJ:+3B>"O2&AKB*8?JMQ4
MWL F+?0T/BD!_TW!3TUGO$A@4EB"X$GR+$VH@I<G!3\P6THBOD)_;IF@.NL2
MG3T7M$Q2L#E'7]#STRTZ^^5\,E8 10<<+YMA;^IAR<"P+GK@A=I(= ?#)\?^
M8Z#0\B!['C?$&O"!BDODX@M$'$(,>&:GNV,+'+=-JUO%\P?B/;(=*THFKRRQ
MO#:65\5R!V+]Q17-H&3JB*9<U_Y!Y:_K=C<E!$,A.\YDO#M,0M\0^Y[G'AH>
M0?1;B+X5XHQ+I1>*I)D98>WN'0S\Q8\#MX_08.B&H3.(,&@1!E:$OPDN)=H*
MODJ5"6#0&Q<'V _[  V&. B'4QBV $/KBFEJK%@C]K;5%6E=.U$;-;+2?H+^
M"#$OT)H5$#]#M$@03:"1I%+I\7;,E(VH3])UXZB?C;YAA -O,!EQ"SNVPGYD
MDE&QW%1P$UCY&=_J;F3"&O<@!+X!:=_,C\D@4.QT_=,YH3IY;_:,/='IY]5S
M_*"/UF 9A<>&QW@/^CVVXKTOECQG:"5XOD<-?=V(%O<P$.Q@ UB#88S#8;"D
M TOL1:$V3*"S)J?G**W VPH#=QT:NQ\D0C'!H&\UT2]0P8P+K(ESU)-P>+QX
MFD08+'T\W!MP)P'8K@%W/\I4_03^*(,^QBI5+B$9!Y(-Y9&J=&#A>7U@)(I,
M"\]@B5T<#W/H- +;1>*^V$&Z=1FC->POT9FF<EZOQ#L%6[KYAL+&;,E*E2YI
M9B;2UP?LQ@8:!ATAD>L/T^B$!'^@)!H[H(4M]!K:9\%D-1OS^1SFAA9&U-:(
M>J=^);= _'H$6W')Q(Z-ILBTB<$&]8D#2Z5UZH/#4]I856\?%D383Z[G&Z?!
M8$DJ-1\"W D;MBO;V;=J]=0= 2T83 ?;ORGZ-E '?;WZ0CS7(!<&2V)K:9VR
M8;NTW7\$T>K^?];*YP,=[\0[221V2?P#3I]-<3<30I42Z:)4=)$!=8[@8PXE
M!*>;Y<N&9PD3QEPTXP0?3Y?!TC9=I)-+8I?+&RK3I2Z$=XQ .9&$?L5T[1_2
M,?*HQX@.>3B73OR>1-\,K/  A4Y$";%2N$VS4@O$9TF0TTCTS2PD.K4F=K7^
M7IW'@07=P9YES5!1Y@N KP\=FH%\3P'Q4DD%^\=J^[O0TVADU9=L$A(21+A'
MS& 9.#@FOC] KE-W8E?W3Y)+Z@DVTNO+^1 ]DZ47.8$^3AOI=<)/[,(_%SPI
MEPH]Z=/A!=+MX9\'IAG^:^LWG2*3X-.';=(I(3E%"6W'[2; 4;-Q7,]PWC98
M8B_VHN'&U.D?L>M?O37>4S\IH9U&D?C3"74[.7!/.2'9$NKVNS<.(T,^#89>
M;-C4C0\NQ'(FUM4]H802*@M5WRFU7]N[R*_5#=R[[S?X:E;?*'9AZ@O.!PK;
MOT*BC*T@I',90C)%?6=8ORB^K:[=%EPIGE>/&T9!ZK0!_'_%N=J_Z ':F]OI
M?U!+ P04    " #7@Z54QZ%J7TH&  #I)@  &    'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;+5:VV[;.!#]%<)88%N@KD7*NA6)@?JJ/K0(DDWW8;$/C,7$
M0B71E>@X^?NE9,6VS!$M=]D\Q)(]<V:&<T3Q4+K:\OQ'L6),H)<TR8KKWDJ(
M]:?!H%BN6$J+CWS-,OG+(\]3*N1I_C0HUCFC4>64)@-B6>X@I7'6&UU5W]WD
MHRN^$4F<L9L<%9LTI?GKF"5\>]W#O;<O;N.GE2B_&(RNUO2)W3%QO[[)Y=E@
MCQ+%*<N*F&<H9X_7O<_X4TB<TJ&R^!ZS;7%TC,I2'CC_49Y\B:Y[5ID12]A2
ME!!4?CRS"4N2$DGF\;,&[>UCEH['QV_H\ZIX6<P#+=B$)W_'D5A=]_P>BM@C
MW23BEF]#5A=4);CD25']1]O:UNJAY:80/*V=909IG.T^Z4L]$$<.LE#8@=0.
MY-2!M#C8M8-]XF"[+0[#VF%X&L%K<7!J!^?$P6F+X-8.[FE*=HN#5SMX)PZX
MS<&O'?RJN[MV5+V<4D%'5SG?HKRTEFCE046(RENV,,Y*[MZ)7/X:2S\QFO L
MDDQD$9)'!4_BB IY<B?DAZ2H*!!_E&=\^6/%DXCEQ9]H]G,3BU?T[CZCFRB6
MUN]1']W?3=&[/]Y?#81,JH0>+.L$QKL$2$L"-Y*K+,^KF#(*^N<K2Q]8_B^
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M&^NNHYZ@U-+ K:4V?.WYA#G0WK]X,:J*OCOZMPY6_X6)7A,N-39P:^Q;PEK
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MO^"^X_.E-+]$UZ2+(+867"O3(_8$E H3X#L#0?_""H;_#%S\"U!+ P04
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M>/C)W9@ZF<=&9MK(N#.C3^_[],Q4O+ !C) T;.:&J8V[>%-'Z!_ON"'7Y+:
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M=O;5P)-#GNGZZ6)_HNK:OF<W6 '3:;3\0>8/9#2?W8]G*TQYK(#Y=$Q6,1:
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MJM?V/,_:?K]K[-8"M<C7:76OK&>UM*+C=<XU8#DU\=N^;_'/5NM.:,H,T\O
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M]: /JGI8*L'(P@WSK33T-+CEB=YB5-: ]@^2 JL%>T#SNH__!5!+ P04
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MXKI6LI;)X@"G(]U)*$)VT,,XX3(I>$V&<"J4R2P'E$)#10/4P?<)P*);WQ
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M_;.7W7+]XR'H_QYN@\2QQ%:G'PR/1*%_D*,?RGS#/X*YR\LR7_/7E8P00+0
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M%>HV$[91)FJSD;GK10\>#'6%\F758L;)M^)(?/<M#DY*5"A6YI3&,E61J\'
M365\?""=4>@'W?;PX8YL @K,Q,ED-)E,Q,D9?SR<]K]=E%2$RD6NDCEJ8T?>
M!'?\C/A!J7.N4N^=\/V_#+4QC*B2"V\ 7"3>15;?,IU:YE?S:!</P0.M#>(B
M^:JX&!PU9%VFP8I?&@O)'Q,+T%87 C@\&J@MCW>K['/=>8_D?X +S[ZE!2?D
MPZ+SX>2S?)C+?DF)+<9VS[.W! V^?<)N_,B[]M;?5QM5&=B/D#XV9_,<J8DR
M1^?A\.5YLT([0U."R4 I](4[4L;?V[6A8MO<$@;!:%9GFIK=BP(Y $77NT\C
M\?KUR]'=C++_^+Y!S]6G3=HD6\G"AT&41UP-.C.@Q$69CL5A(!*7=9FFZ@6#
M+ZE:4BL8D$N#?B.*Z]*41^H3&B.+9BIA%Z?=J3F"=0K81YR_^N>_7GX Y].'
MIT_:>$M"O'E)>F+>%8U3\-:J8 @_L3G;HC+J&F?3-0D)"A:JIQ&:VF2Q58C5
M$]2S=?;6N=/1R<P#Y>DCCXW7Y+O<-%QRRTA./N_ZGGX!0353-'F<9[#K,R=%
MN_UN Q8AQM0K6>I?93NHB*5@:P F-#!)=T#2'=!V^#ZD0I_!)'^4-4V=--TE
M-$/S:&#[:MTKO#Z,K\>[:O==34H/I(9S@H2*-].4H<R+\6VIQ8B(&;#,W@M3
M^[6WA5M=([R%8#27T3Q)Z$ ,:VA"8<1T(J:GL/WDU /&H\DI?W(R3&(R'+7)
MGQB*>7"/+[0YA,'=@(S'@AUY)-1143$48<$I:$FME2. T65I;H(:&6B[Y'0#
M#F*;'J@D<6;61Y:+N+*%E(ALL)#35:[NS=+0]U9-3/VWHUYQ!0?H^36QT:D\
MZ9[0I"3::11J_]Z^Z/'<I!+;+;_<U8(F*8SJN[L>20YK%J0-<I+M#$+ME.\J
M@E'N3^CMX9$T'TU]7#?=8Q^3UI2<E-42Y'U:I,"34-THIOQ6%WXC#<ADF\7I
M50!*EMCP[&.--1?G2MO-6N=LWIDHA):Z!HBB'6LLE=3==N[-NS.2@?A9W:PB
M\PR*IJH@71.ZLP M;<-O>T8B'KE!@PUK&?7>"6=U/YOO"X6MV-[J7@?%R-!5
M6*M)T"KA4*[BN3%B"@UD<33:&/5@@UFW##-F^5@<3A] G>$<^F1CD^>!PLE$
M9'(#Q2^=\B+"V1M.ZK'=)_4GP14CMD*+D.&:>I0=PX+?\,Y#O:0)RH,GXG#V
M):RUL+0DL3OF&#ALG SCI%+=>OO+JLKC%"46%!=OSH>%2)LLOC?&H]PY[9UG
M!:*0<:&__?OSMIQ/HE=X+MJ1[]>KX^3!8!@3+-"ZQ.A>927;=KQ/63N5TRH"
MXHG?(U:R0RQ2Z>'I@U:LK3I\@!]4:J/Q4;KB5(*+FVXLUX/)77F=,BU2<^(1
MW@= '-9]*5*U HR"4E$#@ 01/>R-A(4?"3_855<D??RA<;REM&0 H!0]S#7/
M?0-WP)TEM59YSC--Z!^5T08XW#<K38RB8P0++O:DN]$@<)1FE@_E;_E9')R1
M\U!,"$0-%#MJ?:-614A2.W9I EF642*Q-MF&7CK4*@'ODE 0L$I&'5$5=;AX
MP/N64H?QIP<RM[M?&T(D<?.5YATE0U(TAZ6J#:U<F+M\AG9#H?)+HZS;3KBU
M.L)&O;K##G+YNC2Y6=%+LB$78W'>U*14KB'7.$44_AVRG]!=4DYN7P'SZ;C
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M_#*CKPIJYT#G&Z5L8[@ [7=J\AM02P,$%     @ UX.E5!)<'5I%!   ( D
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M<:%DI P-P.^S#/:7+Z2@OLC_^%]02P,$%     @ UX.E5.>D;TMY!0  V!
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M",V8_Y_@G3C>"C107R59W5A$C#'!8H72T$>(C2HIJ5& *87:I)S2ZW7J%%]
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M9\V4/BDH#8#V%T+HC6,2-!^IT6]02P,$%     @ UX.E5*=N_ 49 P  S@8
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MR@;0^TI*L[]8@7KS#_\ 4$L#!!0    ( ->#I53]%3YZZ (  "P&   9
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M"JBL 7U?26F.$QN@_O48_@=02P,$%     @ UX.E5/K[*:O' P  5P\  !D
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M(VC181433N:J29D2+EH>-9R)KA2H-!#?(T+X>B(=5'VN]Q]02P,$%     @
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M2V+DQ;[!S"[2=<*&70S?+R>XS^UTV&%4I@CW6#X&I'GYV!NMD.Y#5=\Q)[D
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M)=E/R)(H3J-IMES'*7R<H2*428B)$,2T^9,&I =1D!QAW92J)*RBN=1D=3Z
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M]YQ[SC6^)!47KW(+H-!;09D<.UNERDO7E=D6"BP'O 2F=]9<%%CIJ=BXLA2
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MLB""%+,+DD,FWJP)33$74[I164X!AZ53FJB&IMEJBN-,\4;E,Y]Z(U+P),[
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MRLI%TZBL"ALL-B@SYR0SB<:7W')E_AR@;("Y7TB)NXU-4/Z+.K\ 4$L#!!0
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M02@4!):/#70@BA22Y/%[!VKD,95C<?V$?J.3E\G,,(<.C;Z1N5@UC;J!YK#
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M!W<J*O0&6-]PKMXFNFN7M[3!/U!+ P04    " #7@Z54S2]CC]D"  ! "
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6R55EEOXC 0_BM6M ^MU#87
M9Q60*(=:B;((RJ[VT80)6$WLK.U ^^_73D*6-L=V7X@G]G?,Q![CG1A_%0<
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M==6IX]EUE062Q6G'WS*I[H]T>%!7/'"]0,T'C,ESH"^1XD_#\ ]02P,$%
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M*[/&;K?^;PUW8^X;'KHZ4SDT=OOF;>EB%TA82D@+8*Q90Z?<<#0[0$%ZE0^
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M^Y,YO/0?G\?07RR>I[-?DZ>?"[@9H2:4J5NHP%-J]U+!#TD2C3%H 6.>,G%
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MA39-U@VWYE9#:0W,][40^C2Q/RCNR>@/4$L#!!0    ( ->#I50_H)I!#0@
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MT.M?#V^'U[_A^RDJ0A/Y _;@C@A!F(+["TRG*![:KM+XQHH;KK%."BS_#:P
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M4G7>!HYR6Y2YEN:4&C_=FP\OQZ/[JS'<7L!#?S;KW]S-X?;^;G[7OQE-;GZ
M&=X/QK_'L^%DWA\8AR\CU(0R]16^P17R!"4\$"D)UPH>KS%;H'SJ^-HPVDA^
MO.49%#SA$9X(K@77J8*Q44P^^OLFMS+!<)?@(*P4O":R!E']%,(@##^##RHE
M$E7QK="/R@N,G'[SB/X(EV8G@0%R,],P983#B*J8"95+A,<K<PP3C9EZJ@C7
M*,,U7+CH2+B)4CF"*34>NMMJWY\YJT']^^FGDY,PJ+<J:)HE3;-2L2SX;:Z5
M)CRA? 5_X=#E%H"%7,/)V7[QVHM:4;MA6%X/8)R5&&>5&.,WE#%5"%-)8S0
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MBK-%$^*@ILI=9=M&;"$=;) .O@MI+$3>;!>#O2!M([9 #C<@AU:0TV^4A[&
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M&")A2!/@?7VE7FCP33PO9H5D#!$$=2Z8DUI=^P5+T%LB5.,2CCQ2C]5&%'^
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M;/JJS8R)WW3-YXY:[C5\PZ+^Z[=<VIH9$[]>^^&1Q?(,&_OVVN\RBSA]1'?
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MVV6J)RX*XZ#/MYRKP\8$<#-\_ =02P,$%     @ UX.E5&D^CO?C @  J08
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MNWW)QV$_>1\&CBZ3.1V']Z=O?S127[X)W/WDW<E)[_[L<M]^:H&S,/*27AQ
M>M[KX<0 8N3)8>3/<5OJJ$W09%1(L9LG,)C8I*3! ^'C,".<314#KX*4C*^<
M>0"&F>12!=H4R(CI@Z5^='#?S:!V+4_)A%0VMHO@?J?M\CU@/0.!C/-.X"!T
MALFH(EI3):[,Q"ZVQB=0T([O5I51.%=DU1]<A!L'>S-!IE+E5'5A^N':-!EQ
M6H <Q>8+N&M910!J+4LSR!F92T&LAK5'.S"T,\KY+33V]V*'>UEL5;4'-17=
MT AJAX[&38!_F\UQ;]/V7L4;5.Q!ZL^-V8ZP<V@6>J-HP99VOBPZ 1A['V<G
M5<57GSB;BY*ZS1\<<#(B:[]@(15[--&@56;&0%48/%"EV6S;\E.1ZHXN];J=
ME@6N>?!?\PN:YU101?BV:-/[!RB./_PMR?89W1?\4E;_;/>^.JOM:77<:6U/
MOV,7F1R_R#@]2HU1>^IL'6T[!UMG#> %8AQ^@Y<5O@D:3!O&-1/M;,'RG(HG
MYYNAUV1J7@=W^,WZG!:DX?JN \?A9GQ-<]:4:;?J!A+1KMJ,O\+V^DGW]F)B
M,9'3)<VS=JKF4SL,S,!$;2]PV$>N[.5',!^'^1' L#B8 LS'>6%Q_J7]#-']
M. S3-O0B0]1GB/HX+Q^2V0\6Q^^3FLN_TS2-XR3!,IIE7@49EK<D@:^?#=,&
M'E@<B/1[N<:KC7?(\WV U?2Y#L%VBG<BME,\UX#X\P8>:>JO-A8'/+ J8+T#
M\?UQH*?\/G$,5<6T84\PCJ0IAD O^GLT29#L)/#QUP=[2N(X3?T(8'X%<8PA
M\#3B"*8 -&!('-MS<.\\BM;G5+3YCV3R"U!+ P04    " #7@Z54EXJ[',
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M;%C@CF=I Q.'H;LO"0-7$,94%E@C*K0/T>R.)%LE(J_2NK)H24=@F"T,S;9
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M"1LAZH=QRC^HE?*GX0XQ,0O9$S9"8I[GOBHTUUF:B>13'V)B%K(G;(0N+&[
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M<F]P<R]A<' N>&UL4$L! A0#%     @ UX.E5%S4*,_M    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ UX.E
M5)E<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #7@Z54F'RBNJ8%  "%&   &
M@($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ UX.E
M5(>I@R"Q!@  _QH  !@              ("!Z T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( ->#I51K O^[= (  )P&   8
M      " @<\4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #7@Z54S):QO( %  #%%0  &               @(%Y%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ UX.E5,>A:E]*!@  Z28  !@
M             ("!+QT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( ->#I53T['Y:/0@  -PA   8              " @:\C  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #7@Z54!N33Q?0&   E
M$   &               @($B+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ UX.E5*\IH:.4"@  @!P  !@              ("!3#,
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ->#I52I;"A9
M)0T  .PB   8              " @18^  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #7@Z5411M'! $(  #0$@  &0
M@(%Q2P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ->#
MI50 P,%/LP0  )0*   9              " @:E3  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ UX.E5.C;LES_ @  808  !D
M         ("!DU@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #7@Z542 ]\]ND"  "=!@  &0              @(')6P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ->#I50%].S\+0,  $4'
M   9              " @>E>  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ UX.E5-,MC*TZ P  +0<  !D              ("!36(
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #7@Z54=M !
MQE,$  "Z"0  &0              @(&^90  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( ->#I50&7%@BJ (  !\&   9
M  " @4AJ  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MUX.E5$./_/_. P  Z0<  !D              ("!)VT  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #7@Z54/)+2? P%  !J#0  &0
M            @($L<0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( ->#I53S]3D<'PX  "$E   9              " @6]V  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ UX.E5("5+/P##@
M_BD  !D              ("!Q80  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #7@Z54'L"&ROP"  "S!@  &0              @('_
MD@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ->#I502
M7!U:100  " )   9              " @3*6  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ UX.E5)X%[6[%"@  U!\  !D
M     ("!KIH  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ->#I51_F4*P  ,  &(&   9              "
M@1FV  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ UX.E
M5 UKMGCM @  @ 8  !D              ("!4+D  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #7@Z54S";?BP,#  "P!@  &0
M        @(%TO   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( ->#I52G;OP%&0,  ,X&   9              " @:Z_  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ UX.E5!(]D0UY!   %@L
M !D              ("!_L(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #7@Z54][?!@*H"   %!@  &0              @(&NQP
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ->#I53]%3YZ
MZ (  "P&   9              " @8_*  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ UX.E5$UXT2]7 P  !0D  !D
M ("!KLT  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #7
M@Z54%77$Q!\(  #C%@  &0              @($\T0  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ->#I526@B6U^P(  /(&   9
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M970T,BYX;6Q02P$"% ,4    " #7@Z54V-4*91\#  #S"@  &0
M    @(&1[   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M ->#I52X3'TX#P(  'D$   9              " @>?O  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ UX.E5.'D.47< @  >P@  !D
M             ("!+?(  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #7@Z54NX9JM$$#  "0"P  &0              @(% ]0  >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ->#I53SE=3 !00
M /D-   9              " @;CX  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ UX.E5**]I[O: @  >0@  !D              ("!
M]/P  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #7@Z54
M_PR1$S<#  !L"P  &0              @($%  $ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ->#I50CL3)), (  % $   9
M      " @7,# 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ UX.E5!))!'-X @  8 8  !D              ("!V@4! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #7@Z54'#R"3\\"  !L!P
M&0              @(&)" $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( ->#I502QHHO# ,  *L(   9              " @8\+ 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ UX.E5"!H*%12
M @  )04  !D              ("!T@X! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " #7@Z54F+6&+A@#  #^"0  &0
M@(%;$0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ->#
MI53'[Y8[EP(  )<&   9              " @:H4 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ UX.E5!PQXS!B!@  ["D  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( ->#I530/*<L&@0  /4/   9
M  " @1TJ 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
MUX.E5'O0" <= P  L0D  !D              ("!;BX! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " #7@Z54S2]CC]D"  ! "   &0
M            @('",0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( ->#I52P,3C7DP0  !X3   9              " @=(T 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ UX.E5!Q#:)1P!
M#A(  !D              ("!G#D! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " #7@Z54S_(!%O("   S!P  &0              @(%#
M/@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ->#I50_
MH)I!#0@  %@X   9              " @6Q! 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ UX.E5+684_5O P  -@L  !D
M     ("!L$D! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ->#I53'I S3-@<  *8D   9              "
M@5!A 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ UX.E
M5#1Q6S*D @  SP<  !D              ("!O6@! 'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    " #7@Z54:3Z.]^,"  "I!@  &0
M        @(&8:P$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( ->#I53L)L"5% ,  # 1   -              "  ;)N 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ UX.E5)>*NQS     $P(   L
M ( !\7$! %]R96QS+RYR96QS4$L! A0#%     @ UX.E5' =6^ D!@  ,C(
M  \              ( !VG(! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M ->#I51S?'@L40(  /LL   :              "  2MY 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ->#I53.%<Q?#P(  .HK   3
M              "  ;1[ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !4
- %0  Q<  /1] 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>223</ContextCount>
  <ElementCount>357</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>89</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Revenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions</Role>
      <ShortName>INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions</Role>
      <ShortName>INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts</Role>
      <ShortName>CAPITALIZED SOFTWARE DEVELOPMENT COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Concentrations</Role>
      <ShortName>CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/RevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/Revenues</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables</Role>
      <ShortName>INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables</Role>
      <ShortName>INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/Inventories</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables</Role>
      <ShortName>CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/Debt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails</Role>
      <ShortName>SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails</Role>
      <ShortName>SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails</Role>
      <ShortName>SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SCHEDULE OF INVESTMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfInvestmentDetails</Role>
      <ShortName>SCHEDULE OF INVESTMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails</Role>
      <ShortName>SCHEDULE OF DISAGGREGATED REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - REVENUES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/RevenuesDetailsNarrative</Role>
      <ShortName>REVENUES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/RevenuesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails</Role>
      <ShortName>SCHEDULE OF CONDENSED INCOME STATEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails</Role>
      <ShortName>SCHEDULE OF CONDENSED BALANCE SHEET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails</Role>
      <ShortName>SUMMARY OF CONDENSED INCOME STATEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails</Role>
      <ShortName>SUMMARY OF CONDENSED BALANCE SHEET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - SCHEDULE OF INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfInventoriesDetails</Role>
      <ShortName>SCHEDULE OF INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative</Role>
      <ShortName>CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails</Role>
      <ShortName>SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/DebtTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails</Role>
      <ShortName>SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/LeasesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails</Role>
      <ShortName>SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>00000075 - Disclosure - CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ConcentrationsDetailsNarrative</Role>
      <ShortName>CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/Concentrations</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>00000076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/SubsequentEvents</ParentRole>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10q.htm">form10q.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>hrow-20220331.xsd</File>
    <File>hrow-20220331_cal.xml</File>
    <File>hrow-20220331_def.xml</File>
    <File>hrow-20220331_lab.xml</File>
    <File>hrow-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="762">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10q.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 223,
   "dts": {
    "calculationLink": {
     "local": [
      "hrow-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "hrow-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hrow-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hrow-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hrow-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 588,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 83,
    "http://harrowinc.com/20220331": 12,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 99
   },
   "keyCustom": 51,
   "keyStandard": 306,
   "memberCustom": 61,
   "memberStandard": 25,
   "nsprefix": "HROW",
   "nsuri": "http://harrowinc.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://harrowinc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS",
     "role": "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions",
     "shortName": "INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS",
     "role": "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions",
     "shortName": "INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - INVENTORIES",
     "role": "http://harrowinc.com/role/Inventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "role": "http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - PROPERTY, PLANT AND EQUIPMENT",
     "role": "http://harrowinc.com/role/PropertyPlantAndEquipment",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:CapitalizedSoftwareDevelopmentCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS",
     "role": "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts",
     "shortName": "CAPITALIZED SOFTWARE DEVELOPMENT COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:CapitalizedSoftwareDevelopmentCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://harrowinc.com/role/IntangibleAssetsAndGoodwill",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "role": "http://harrowinc.com/role/AccountsPayableAndAccruedExpenses",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - DEBT",
     "role": "http://harrowinc.com/role/Debt",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - LEASES",
     "role": "http://harrowinc.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://harrowinc.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION",
     "role": "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://harrowinc.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - CONCENTRATIONS",
     "role": "http://harrowinc.com/role/Concentrations",
     "shortName": "CONCENTRATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://harrowinc.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:RisksUncertaintiesAndLiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:RisksUncertaintiesAndLiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - REVENUES (Tables)",
     "role": "http://harrowinc.com/role/RevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)",
     "role": "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables",
     "shortName": "INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)",
     "role": "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables",
     "shortName": "INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - INVENTORIES (Tables)",
     "role": "http://harrowinc.com/role/InventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://harrowinc.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "role": "http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "role": "http://harrowinc.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "HROW:CapitalizedSoftwareDevelopmentCostsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:CapitalizedSoftwareDevelopmentCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)",
     "role": "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables",
     "shortName": "CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "HROW:CapitalizedSoftwareDevelopmentCostsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:CapitalizedSoftwareDevelopmentCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "role": "http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - DEBT (Tables)",
     "role": "http://harrowinc.com/role/DebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - LEASES (Tables)",
     "role": "http://harrowinc.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION (Tables)",
     "role": "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails",
     "shortName": "SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:DilutedCommonEquivalentSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2021-01-012021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
     "shortName": "SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:DilutedCommonEquivalentSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2021-01-012021-03-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ProFormaWeightedAverageSharesOutstandingDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://harrowinc.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails",
     "shortName": "SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "HROW:InvestmentOnePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentOwnedAtCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - SCHEDULE OF INVESTMENT (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfInvestmentDetails",
     "shortName": "SCHEDULE OF INVESTMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "HROW:InvestmentOnePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentOwnedAtCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31_custom_EtonPharmaceuticalsIncMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
     "shortName": "SCHEDULE OF DISAGGREGATED REVENUE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_CommissionsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - REVENUES (Details Narrative)",
     "role": "http://harrowinc.com/role/RevenuesDetailsNarrative",
     "shortName": "REVENUES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
     "shortName": "SCHEDULE OF CONDENSED INCOME STATEMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_MeltPharmaceuticalsIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
     "shortName": "SCHEDULE OF CONDENSED BALANCE SHEET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfCondensedBalanceSheetOneTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31_custom_MeltPharmaceuticalsIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative",
     "shortName": "INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2019-02-012019-02-28_custom_ManagementServicesAgreementMember_custom_MeltPharmaceuticalsIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AdministrativeFeesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)",
     "role": "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
     "shortName": "SUMMARY OF CONDENSED INCOME STATEMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_SurfaceOphthalmicsIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)",
     "role": "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
     "shortName": "SUMMARY OF CONDENSED BALANCE SHEET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "role": "http://harrowinc.com/role/StatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HROW:InvestmentTwoPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31_custom_SurfaceOphthalmicsIncMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative",
     "shortName": "INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - SCHEDULE OF INVENTORIES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfInventoriesDetails",
     "shortName": "SCHEDULE OF INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "HROW:ComputerHardwareGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
     "shortName": "SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "HROW:ComputerHardwareGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)",
     "role": "http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:CapitalizedSoftwareDevelopmentCostsTableTextBlock",
       "HROW:CapitalizedSoftwareDevelopmentCostsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "HROW:CapitalizedSoftwareDevelopmentCostsTableTextBlock",
       "HROW:CapitalizedSoftwareDevelopmentCostsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative)",
     "role": "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative",
     "shortName": "CAPITALIZED SOFTWARE DEVELOPMENT COSTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HROW:CapitalizedSoftwareDevelopmentCostsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_CapitalizedSoftwareDevelopmentCostsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_PatentsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails",
     "shortName": "SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://harrowinc.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails",
     "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)",
     "role": "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails",
     "shortName": "SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - DEBT (Details Narrative)",
     "role": "http://harrowinc.com/role/DebtDetailsNarrative",
     "shortName": "DEBT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2021-04-30_custom_Sec8.625SeniorNotesDue2026Member",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails",
     "shortName": "SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails",
     "shortName": "SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - LEASES (Details Narrative)",
     "role": "http://harrowinc.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HROW:LesseeOperatingLeaseAndFinanceLeaseTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2021-12-31_custom_StockOptionPlanOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
     "shortName": "SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2021-12-31_custom_StockOptionPlanOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_OptionsEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
     "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_OptionsEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails",
     "shortName": "SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000069 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
     "shortName": "SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
     "role": "http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation",
     "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000070 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails",
     "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "HROW:ScheduleofWarrantsOutstandingTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_LenderWarrantsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:WarrantsIssuanceDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000071 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails",
     "shortName": "SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "HROW:ScheduleofWarrantsOutstandingTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_custom_LenderWarrantsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:WarrantsIssuanceDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000072 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
     "shortName": "SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000073 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)",
     "role": "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31_custom_KlarityLicenseAgreementMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "HROW:MilestonePaymentInCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000074 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "AsOf2022-03-31_custom_KlarityLicenseAgreementMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "HROW:MilestonePaymentInCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000075 - Disclosure - CONCENTRATIONS (Details Narrative)",
     "role": "http://harrowinc.com/role/ConcentrationsDetailsNarrative",
     "shortName": "CONCENTRATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_CostOfGoodsProductLineMember_us-gaap_SupplierConcentrationRiskMember_custom_ThreeMainSuppliersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-04-012022-04-30_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:DescripitionOfLoanAmendment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000076 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://harrowinc.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-04-012022-04-30_custom_MeltPharmaceuticalsIncMember_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:DescripitionOfLoanAmendment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - REVENUES",
     "role": "http://harrowinc.com/role/Revenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10q.htm",
      "contextRef": "From2022-01-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 89,
   "tag": {
    "HROW_AccountsReceivableTransferredToNoteReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable transferred to note receivable.",
        "label": "Accounts receivable transferred to note receivable"
       }
      }
     },
     "localname": "AccountsReceivableTransferredToNoteReceivable",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_AdditionalAreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area of land.",
        "label": "Additional square footage"
       }
      }
     },
     "localname": "AdditionalAreaOfLand",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "HROW_AndrewRBollMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Andrew R. Boll [Member]",
        "label": "Andrew R. Boll [Member]"
       }
      }
     },
     "localname": "AndrewRBollMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_AssetPurchaseLicenseAndRelatedAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase, License and Related Agreements [Member]",
        "label": "Asset Purchase, License and Related Agreements [Member]"
       }
      }
     },
     "localname": "AssetPurchaseLicenseAndRelatedAgreementsMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CapitalizedComputerSoftwareInternalUseInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CapitalizedComputerSoftwareNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized computer software internal use in process.",
        "label": "Capitalized internal-use software in process"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareInternalUseInProcess",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_CapitalizedInternalUseSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Internal Use Software [Member]",
        "label": "Capitalized Internal Use Software [Member]"
       }
      }
     },
     "localname": "CapitalizedInternalUseSoftwareMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CapitalizedSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Software Development Costs [Member]",
        "label": "Capitalized Software Development Costs [Member]"
       }
      }
     },
     "localname": "CapitalizedSoftwareDevelopmentCostsMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CapitalizedSoftwareDevelopmentCostsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Software Development Costs [Table Text Block]",
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "CapitalizedSoftwareDevelopmentCostsTableTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_CapitalizedSoftwareDevelopmentCostsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Software Development Costs [Text Block]",
        "label": "CAPITALIZED SOFTWARE DEVELOPMENT COSTS"
       }
      }
     },
     "localname": "CapitalizedSoftwareDevelopmentCostsTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCosts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_CarlsbadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carlsbad [Member]",
        "label": "Carlsbad [Member]"
       }
      }
     },
     "localname": "CarlsbadMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Cash Equivalents And Restricted Cash At End Of Period.",
        "label": "CashCashEquivalentsAndRestrictedCashAtEndOfPeriod",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsAndRestrictedCashAtEndOfPeriod",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_CashlessExerciseOfOptionsPricePerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of options price per shares.",
        "label": "Cashless exercise of options, price per shares"
       }
      }
     },
     "localname": "CashlessExerciseOfOptionsPricePerShares",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "HROW_CashlessExerciseOfOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of options shares.",
        "label": "Cashless exercise of options, shares"
       }
      }
     },
     "localname": "CashlessExerciseOfOptionsShares",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_ClosingPriceOfCommonStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing price of common stock price per share.",
        "label": "Closing price of common stock price per share"
       }
      }
     },
     "localname": "ClosingPriceOfCommonStockPricePerShare",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "HROW_CommercialPaymentsForRoyalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial payments for royalties.",
        "label": "Commercial payments for royalties"
       }
      }
     },
     "localname": "CommercialPaymentsForRoyalties",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_CommissionExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission expiration date.",
        "label": "Commission expiration date"
       }
      }
     },
     "localname": "CommissionExpirationDate",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "HROW_CommissionPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission payments, percentage.",
        "label": "Commission payments percentage"
       }
      }
     },
     "localname": "CommissionPaymentsPercentage",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "HROW_CommissionRevenues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission revenues",
        "label": "Commission revenues"
       }
      }
     },
     "localname": "CommissionRevenues",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_CommissionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commissions [Member]",
        "label": "Commissions [Member]"
       }
      }
     },
     "localname": "CommissionsMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CommonStock0.001ParValuePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, $0.001 par value per share [Member]",
        "label": "Common Stock, $0.001 Par Value Per Share [Member]"
       }
      }
     },
     "localname": "CommonStock0.001ParValuePerShareMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CommonStockWithheldForPayrollTaxWithholdings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock withheld for payroll tax withholdings, value.",
        "label": "Common stock withheld for payroll tax withholdings, value"
       }
      }
     },
     "localname": "CommonStockWithheldForPayrollTaxWithholdings",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_CommonStockWithheldForPayrollTaxWithholdingsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock withheld for payroll tax withholdings, shares.",
        "label": "Common stock withheld for payroll tax withholdings, shares"
       }
      }
     },
     "localname": "CommonStockWithheldForPayrollTaxWithholdingsShares",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_CommonStockWithheldForPayrollTaxWithholdingsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock withheld for payroll tax withholdings, value.",
        "label": "CommonStockWithheldForPayrollTaxWithholdingsValue",
        "verboseLabel": "Common stock withheld for payroll tax withholdings, value"
       }
      }
     },
     "localname": "CommonStockWithheldForPayrollTaxWithholdingsValue",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_CommonStockWithheldOnCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock withheld on cashless exercise.",
        "label": "Common stock withheld on cashless exercise"
       }
      }
     },
     "localname": "CommonStockWithheldOnCashlessExercise",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_ComputerHardwareGross": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer hardware gross.",
        "label": "Computer hardware"
       }
      }
     },
     "localname": "ComputerHardwareGross",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants [Member]",
        "label": "Consultants [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_DescripitionOfLoanAmendment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Descripition of loan amendment.",
        "label": "Descripition of loan amendment"
       }
      }
     },
     "localname": "DescripitionOfLoanAmendment",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_DescriptionForCommissionPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description for commission payments.",
        "label": "Description for commission payments"
       }
      }
     },
     "localname": "DescriptionForCommissionPayments",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_DexycuAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dexycu Agreement [Member]",
        "label": "Dexycu Agreement [Member]"
       }
      }
     },
     "localname": "DexycuAgreementMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_DilutedCommonEquivalentSharesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diluted Common Equivalent Shares [Table Text Block]",
        "label": "SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES"
       }
      }
     },
     "localname": "DilutedCommonEquivalentSharesTableTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_DilutedNetIncomePerShareTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diluted Net Income Per Share [Table Text Block]",
        "label": "SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES"
       }
      }
     },
     "localname": "DilutedNetIncomePerShareTableTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_DisclosureCapitalizedSoftwareDevelopmentCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Software Development Costs"
       }
      }
     },
     "localname": "DisclosureCapitalizedSoftwareDevelopmentCostsAbstract",
     "nsuri": "http://harrowinc.com/20220331",
     "xbrltype": "stringItemType"
    },
    "HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Surface Ophthalmics Inc. - Related Party Transactions"
       }
      }
     },
     "localname": "DisclosureInvestmentInSurfaceOphthalmicsInc.RelatedPartyTransactionsAbstract",
     "nsuri": "http://harrowinc.com/20220331",
     "xbrltype": "stringItemType"
    },
    "HROW_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "terseLabel": "Schedule Of Future Lease Payment Under Finance Lease",
        "verboseLabel": "Schedule Of Future Lease Payment Under Operating Leases"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://harrowinc.com/20220331",
     "xbrltype": "stringItemType"
    },
    "HROW_DueWithinThirtyDaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due Within Thirty Days [Member]",
        "label": "Due Within Thirty Days [Member]"
       }
      }
     },
     "localname": "DueWithinThirtyDaysMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_EmployeesAndConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Consultant [Member]",
        "label": "Employees and Consultant [Member]"
       }
      }
     },
     "localname": "EmployeesAndConsultantMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees [Member]",
        "label": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_EquityInLossesOfUnconsolidatedEntities": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity in losses of unconsolidated entities.",
        "label": "Equity in losses of unconsolidated entities",
        "negatedLabel": "Equity in losses of unconsolidated entities"
       }
      }
     },
     "localname": "EquityInLossesOfUnconsolidatedEntities",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_EtonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eton Pharmaceuticals, Inc. [Member]",
        "label": "Eton Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "localname": "EtonPharmaceuticalsIncMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets Amortization Expense After Year Four.",
        "label": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_FiniteLivedIntangibleAssetsImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived intangible assets impairment.",
        "label": "Impairment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsImpairment",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_ForfeitureFactorPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forfeiture factor, percentage.",
        "label": "Forfeiture factor, percentage"
       }
      }
     },
     "localname": "ForfeitureFactorPercentage",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "HROW_GainLossOnForgivenessOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Loss On Forgiveness Of Debt.",
        "label": "Gain on forgiveness of PPP loan",
        "negatedLabel": "Gain on forgiveness of PPP loan"
       }
      }
     },
     "localname": "GainLossOnForgivenessOfDebt",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_InitialMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial milestone payment.",
        "label": "Initial milestone payment"
       }
      }
     },
     "localname": "InitialMilestonePayment",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_InjectableAssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Injectable Asset Purchase Agreement [Member]",
        "label": "Injectable Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "InjectableAssetPurchaseAgreementMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_InvestmentOnePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment One [Policy Text Block]",
        "label": "Investment in Melt Pharmaceuticals, Inc. \u2013 Related Party"
       }
      }
     },
     "localname": "InvestmentOnePolicyTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_InvestmentPaidInKindInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment paid in kind interest.",
        "label": "Paid in Kind Interest"
       }
      }
     },
     "localname": "InvestmentPaidInKindInterest",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_InvestmentTwoPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Two [Policy Text Block]",
        "label": "Investment in Surface Ophthalmics, Inc. \u2013 Related Party"
       }
      }
     },
     "localname": "InvestmentTwoPolicyTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Agreements Related Party Transactions [Text Block]",
        "label": "INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_InvestmentsAndOtherNoncurrentAssetsOne": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments and other noncurrent assets one.",
        "label": "Investment in Melt Pharmaceuticals"
       }
      }
     },
     "localname": "InvestmentsAndOtherNoncurrentAssetsOne",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_JohnPSaharekMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "John P. Saharek [Member]",
        "label": "John P. Saharek [Member]"
       }
      }
     },
     "localname": "JohnPSaharekMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_KlarityLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Klarity License Agreement [Member]",
        "label": "Klarity License Agreement [Member]"
       }
      }
     },
     "localname": "KlarityLicenseAgreementMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LeaseAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Amendment [Member]",
        "label": "Lease Amendment [Member]"
       }
      }
     },
     "localname": "LeaseAmendmentMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LeaseExpirationDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration date description.",
        "label": "Lease expiration date description"
       }
      }
     },
     "localname": "LeaseExpirationDateDescription",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_LedgewoodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ledgewood [Member]",
        "label": "Ledgewood [Member]"
       }
      }
     },
     "localname": "LedgewoodMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LenderWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lender Warrants [Member]",
        "label": "Lender Warrants [Member]"
       }
      }
     },
     "localname": "LenderWarrantsMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LesseeOperatingLeaseAndFinanceLeaseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease And Finance Lease [Text Block]",
        "label": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAndFinanceLeaseTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Payments Due After Year Four.",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_LicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses [Member]",
        "label": "Licenses [Member]"
       }
      }
     },
     "localname": "LicensesMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan [Member]",
        "label": "Loan [Member]"
       }
      }
     },
     "localname": "LoanMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ManagementServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Services Agreement [Member]",
        "label": "Management Services Agreement [Member]"
       }
      }
     },
     "localname": "ManagementServicesAgreementMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MarkLBaumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mark L. Baum [Member]",
        "label": "Mark L. Baum [Member]"
       }
      }
     },
     "localname": "MarkLBaumMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MeltLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melt Loan Agreement [Member]",
        "label": "Melt Loan Agreement [Member]"
       }
      }
     },
     "localname": "MeltLoanAgreementMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MeltPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melt Pharmaceuticals Inc [Member]",
        "label": "Melt Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "localname": "MeltPharmaceuticalsIncMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MilestonePaymentInCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment in cash.",
        "label": "Milestone payment in cash"
       }
      }
     },
     "localname": "MilestonePaymentInCash",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_MilestonePaymentsOnPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments on payables.",
        "label": "Milestone payments on payables"
       }
      }
     },
     "localname": "MilestonePaymentsOnPayables",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_MinimumAmountOfFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of financing.",
        "label": "Minimum amount of financing"
       }
      }
     },
     "localname": "MinimumAmountOfFinancing",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_NashvilleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nashville [Member]",
        "label": "Nashville [Member]"
       }
      }
     },
     "localname": "NashvilleMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_NewDrugApplicationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Drug Applications [Member]",
        "label": "New Drug Applications [Member]"
       }
      }
     },
     "localname": "NewDrugApplicationsMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_NonCompetitionClauseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Competition Clause [Member]",
        "label": "Non-Competition Clause [Member]"
       }
      }
     },
     "localname": "NonCompetitionClauseMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory Space [Member]",
        "label": "Office and Laboratory Space [Member]"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_OptionsEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Granted to Employees [Member]",
        "label": "Options Granted to Employees [Member]"
       }
      }
     },
     "localname": "OptionsEmployeesMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_PaymentOfTaxesForVestingOfRestrictedStockUnit": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of taxes for vesting of restricted stock unit.",
        "label": "Payment of taxes upon vesting of RSUs and exercise of stock options"
       }
      }
     },
     "localname": "PaymentOfTaxesForVestingOfRestrictedStockUnit",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_PresbyopiaAssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presbyopia Asset Purchase Agreement [Member]",
        "label": "Presbyopia Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PresbyopiaAssetPurchaseAgreementMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ProductSalesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Sales Net [Member]",
        "label": "Product Sales, Net [Member]"
       }
      }
     },
     "localname": "ProductSalesNetMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Eight [Member]",
        "label": "Range Eight [Member]"
       }
      }
     },
     "localname": "RangeEightMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Five [Member]",
        "label": "Range Five [Member]"
       }
      }
     },
     "localname": "RangeFiveMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Four [Member]",
        "label": "Range Four [Member]"
       }
      }
     },
     "localname": "RangeFourMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Nine [Member]",
        "label": "Range Nine [Member]"
       }
      }
     },
     "localname": "RangeNineMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range One [Member]",
        "label": "Range One [Member]"
       }
      }
     },
     "localname": "RangeOneMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Seven [Member]",
        "label": "Range Seven [Member]"
       }
      }
     },
     "localname": "RangeSevenMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Six [Member]",
        "label": "Range Six [Member]"
       }
      }
     },
     "localname": "RangeSixMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Ten [Member]",
        "label": "Range Ten [Member]"
       }
      }
     },
     "localname": "RangeTenMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Three [Member]",
        "label": "Range Three [Member]"
       }
      }
     },
     "localname": "RangeThreeMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Two [Member]",
        "label": "Range Two [Member]"
       }
      }
     },
     "localname": "RangeTwoMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Cash Cash Equivalents And Restriced Cash At End Of Period Abstract.",
        "label": "RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_ReductionInCommonStockInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in common stock investment.",
        "label": "Reduction in common stock investment"
       }
      }
     },
     "localname": "ReductionInCommonStockInvestment",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_RichardLLindstromMDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Richard L. Lindstrom, M.D [Member]",
        "label": "Richard L. Lindstrom, M.D [Member]"
       }
      }
     },
     "localname": "RichardLLindstromMDMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks Uncertainties And Liquidity [Policy Text Block]",
        "label": "Risks, Uncertainties and Liquidity"
       }
      }
     },
     "localname": "RisksUncertaintiesAndLiquidityPolicyTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_RoyaltyPaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment description.",
        "label": "Royalty payment description"
       }
      }
     },
     "localname": "RoyaltyPaymentDescription",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_SalesAndMarketingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and Marketing Agreements [Member]",
        "label": "Sales and Marketing Agreements [Member]"
       }
      }
     },
     "localname": "SalesAndMarketingAgreementsMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of condensed Balance Sheet One [Table Text Block]",
        "label": "SCHEDULE OF CONDENSED BALANCE SHEET"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetOneTableTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of condensed Income Statement One [Table Text Block]",
        "label": "SCHEDULE OF CONDENSED INCOME STATEMENT"
       }
      }
     },
     "localname": "ScheduleOfCondensedIncomeStatementOneTableTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_ScheduleofWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Warrants Outstanding [Table Text Block]",
        "label": "SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE"
       }
      }
     },
     "localname": "ScheduleofWarrantsOutstandingTableTextBlock",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_Sec8.625SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.625% Senior Notes due 2026 [Member]",
        "label": "8.625% Senior Notes Due 2026 [Member]"
       }
      }
     },
     "localname": "Sec8.625SeniorNotesDue2026Member",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/Cover",
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.",
        "label": "Weighted Avg. Exercise Price, Outstanding, beginning balance",
        "periodEndLabel": "Weighted Average. Exercise Price, Outstanding, Ending balance",
        "periodStartLabel": "Weighted Average. Exercise Price, Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term.",
        "label": "Weighted average remaining contractual life of the outstanding warrants in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "HROW_SinteticaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sintetica Agreement [Member]",
        "label": "Sintetica Agreement [Member]"
       }
      }
     },
     "localname": "SinteticaAgreementMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_StatePharmacyLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Pharmacy Licenses [Member]",
        "label": "State Pharmacy Licenses [Member]"
       }
      }
     },
     "localname": "StatePharmacyLicensesMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_StockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Plan [Member]",
        "label": "Stock Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlanMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_StockOptionPlanOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Plan [Member]",
        "label": "Stock Option Plan [Member] [Default Label]",
        "verboseLabel": "Stock Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlanOneMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_StockOptionsUnvestedRSUsAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, Unvested RSUs and Warrants [Member].",
        "label": "Stock Options, Unvested RSUs and Warrants [Member]"
       }
      }
     },
     "localname": "StockOptionsUnvestedRSUsAndWarrantsMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SubsidiaryStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Stock [Member]",
        "label": "Subsidiary Stock [Member]"
       }
      }
     },
     "localname": "SubsidiaryStockMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SurfaceOphthalmicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surface Ophthalmics, Inc. [Member]",
        "label": "Surface Ophthalmics, Inc. [Member]"
       }
      }
     },
     "localname": "SurfaceOphthalmicsIncMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ThirdPartySoftwareLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Party Software License [Member]",
        "label": "Third Party Software License [Member]"
       }
      }
     },
     "localname": "ThirdPartySoftwareLicenseMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ThreeMainSuppliersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Main Suppliers [Member]",
        "label": "Three Main Suppliers [Member]"
       }
      }
     },
     "localname": "ThreeMainSuppliersMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_TotalHarrowHealthIncStockholdersEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total harrow health inc stockholders equity [Member]",
        "label": "Total Harrow Health, Inc. Stockholders' Equity [Member]"
       }
      }
     },
     "localname": "TotalHarrowHealthIncStockholdersEquityMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_TransferOfProfitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer Of Profit [Member]",
        "label": "Transfer Of Profit [Member]"
       }
      }
     },
     "localname": "TransferOfProfitMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_TwoProductConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Product Concentration Risk [Member]",
        "label": "Two Product Concentration Risk [Member]"
       }
      }
     },
     "localname": "TwoProductConcentrationRiskMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Incentive Stock and Awards Plan [Member]",
        "label": "2017 Incentive Stock and Awards Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_UnvestedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested RSUs [Member]",
        "label": "Unvested RSUs [Member]"
       }
      }
     },
     "localname": "UnvestedRSUMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_WakamotoAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wakamoto Agreement [Member]",
        "label": "Wakamoto Agreement [Member]"
       }
      }
     },
     "localname": "WakamotoAgreementMember",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_WarrantsAndRightsOutstandingMaturityDates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Expiration Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDates",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "HROW_WarrantsIssuanceDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issuance date.",
        "label": "Issue Date"
       }
      }
     },
     "localname": "WarrantsIssuanceDate",
     "nsuri": "http://harrowinc.com/20220331",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r563",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of directors.",
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r209",
      "r231",
      "r267",
      "r309",
      "r311",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r501",
      "r504",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r209",
      "r231",
      "r267",
      "r309",
      "r311",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r501",
      "r504",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r151",
      "r207",
      "r208",
      "r289",
      "r292",
      "r441",
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r151",
      "r207",
      "r208",
      "r289",
      "r292",
      "r441",
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r197",
      "r205",
      "r207",
      "r208",
      "r209",
      "r231",
      "r267",
      "r302",
      "r309",
      "r311",
      "r348",
      "r349",
      "r350",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r501",
      "r504",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r197",
      "r205",
      "r207",
      "r208",
      "r209",
      "r231",
      "r267",
      "r302",
      "r309",
      "r311",
      "r348",
      "r349",
      "r350",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r501",
      "r504",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r98",
      "r310",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r98",
      "r103",
      "r203",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r88",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "SUMMARY OF CONDENSED BALANCE SHEET"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "auth_ref": [
      "r88",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.",
        "label": "SUMMARY OF CONDENSED INCOME STATEMENT"
       }
      }
     },
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r289",
      "r293",
      "r503",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r572",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area."
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r289",
      "r293",
      "r503",
      "r533",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r98",
      "r103",
      "r203",
      "r310",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r155",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r467",
      "r492"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/AccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r468",
      "r491"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r12",
      "r193"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r49",
      "r50",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r427"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r359",
      "r360",
      "r361",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r76",
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r313",
      "r362",
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdministrativeFeesExpense": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.",
        "label": "Administrative Fees Expense"
       }
      }
     },
     "localname": "AdministrativeFeesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r76",
      "r251",
      "r262",
      "r263",
      "r400"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of debt issuance costs and discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r76",
      "r181",
      "r187"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r15",
      "r85",
      "r134",
      "r143",
      "r149",
      "r166",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r377",
      "r379",
      "r388",
      "r425",
      "r427",
      "r460",
      "r482"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r35",
      "r85",
      "r166",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r377",
      "r379",
      "r388",
      "r425",
      "r427"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r85",
      "r166",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r377",
      "r379",
      "r388",
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r343",
      "r344",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r89",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DescriptionOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalizedComputerSoftwareNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.",
        "label": "Capitalized Computer Software, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalizedComputerSoftwareNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Total gross capitalized software for internal-use"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized software costs, net",
        "totalLabel": "Total finite lived intangible assets net"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r10",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r78",
      "r80"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r71",
      "r78",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period",
        "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r389"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r83",
      "r85",
      "r107",
      "r108",
      "r109",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r166",
      "r215",
      "r220",
      "r221",
      "r222",
      "r226",
      "r227",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r388",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r276",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r276",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r469",
      "r489"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r210",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, sharess authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r427"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value, 50,000,000 shares authorized, 27,031,127 and 26,902,763 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r126",
      "r127",
      "r154",
      "r385",
      "r386",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r126",
      "r127",
      "r154",
      "r385",
      "r386",
      "r510",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r126",
      "r127",
      "r154",
      "r385",
      "r386",
      "r510",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/Concentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r126",
      "r127",
      "r154",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r123",
      "r126",
      "r127",
      "r128",
      "r385",
      "r387",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r126",
      "r127",
      "r154",
      "r385",
      "r386",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r278",
      "r279",
      "r290"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenue and customer deposits"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/RevenuesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r58",
      "r441"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsProductLineMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Cost of Goods and Service, Product and Service Benchmark [Member]"
       }
      }
     },
     "localname": "CostOfGoodsProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r245",
      "r252",
      "r253",
      "r255",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r256",
      "r461",
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Notes payable, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r228",
      "r260",
      "r261",
      "r399",
      "r402",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Principal amount",
        "verboseLabel": "Debt principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Additional notes issued"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r42",
      "r248",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt instrument, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Increase in interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt instrument interest rate stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of debt redemption features under terms of the debt agreement.",
        "label": "Debt instrument, redemption, description"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r84",
      "r88",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r260",
      "r261",
      "r262",
      "r263",
      "r271",
      "r272",
      "r273",
      "r274",
      "r398",
      "r399",
      "r402",
      "r403",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r241",
      "r257",
      "r260",
      "r261",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt issuance costs and discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r241",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Less: unamortized discount, net of premium"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r241",
      "r398",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Premium on issuance of debt"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r241",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r76",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r76",
      "r191"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r289",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "SCHEDULE OF DISAGGREGATED REVENUE"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r20",
      "r87",
      "r218",
      "r220",
      "r221",
      "r225",
      "r226",
      "r227",
      "r421",
      "r466",
      "r493"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "verboseLabel": "Due from Melt Pharmaceuticals"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r55",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r104",
      "r107",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r383",
      "r384",
      "r472",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic net (loss) income per share of common stock",
        "verboseLabel": "Net (loss) income per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r55",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r107",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r383",
      "r384",
      "r472",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted net (loss) income per share of common stock",
        "verboseLabel": "Net (loss) income per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Net (Loss) Income per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll and related liabilities"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation expense related to unvested stock options granted under the plan"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expense expected to recognize over the weighted-average remaining vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r49",
      "r50",
      "r51",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r102",
      "r119",
      "r169",
      "r270",
      "r275",
      "r359",
      "r360",
      "r361",
      "r367",
      "r368",
      "r382",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r419",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "negatedLabel": "Share of Equity Method Losses"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r70",
      "r165",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Impairment of Equity Method Investments and Note Receivable"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r406",
      "r412",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance lease, interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r405",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Current portion of finance lease obligations",
        "negatedLabel": "Less: current portion, finance lease obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance lease obligations, net of current portion",
        "verboseLabel": "Finance lease obligation, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r408",
      "r413"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance lease, weighted average discount rate, percentage"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r415",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Amortization periods (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r14",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Remainder of 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.",
        "label": "Finite-Lived Intangible Assets, Amortization Method"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r186",
      "r189",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r186",
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r182",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r186",
      "r442"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r62",
      "r76",
      "r159"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Investment gain (loss) from Eton Pharmaceuticals",
        "negatedLabel": "Investment (gain) loss from investment in Eton"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r13",
      "r174",
      "r175",
      "r176",
      "r178",
      "r427",
      "r459"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r57",
      "r85",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150",
      "r166",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r388"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150",
      "r456",
      "r470",
      "r475",
      "r497"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r195",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r101",
      "r102",
      "r133",
      "r366",
      "r369",
      "r370",
      "r498"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r75",
      "r439"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue and customer deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "verboseLabel": "Accrued payroll and related liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r180",
      "r184"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net",
        "verboseLabel": "Net Carrying value"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r52",
      "r132",
      "r397",
      "r400",
      "r474"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r64",
      "r249",
      "r259",
      "r262",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOtherLongTermDebt": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on long-term debt classified as other, including, but not limited to, interest on long-term notes and amortization of issuance costs.",
        "label": "Interest Expense, debt"
       }
      }
     },
     "localname": "InterestExpenseOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r69",
      "r72",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "negatedLabel": "Less: amount representing interest payments"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r468",
      "r491"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r32",
      "r427"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyCommittedCapital": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funds committed to investment company from investors.",
        "label": "Investment Company, Committed Capital",
        "negatedLabel": "In Substance Capital Contributions"
       }
      }
     },
     "localname": "InvestmentCompanyCommittedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Investment Interest Rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Cost basis"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r512",
      "r521",
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.",
        "label": "Investment owned, at fair value"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r513",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Number of shares owned"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r165",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment in Eton Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r162",
      "r163",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "SCHEDULE OF INVESTMENT"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Net carrying value"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r457",
      "r476",
      "r532",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lease term, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r85",
      "r144",
      "r166",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r378",
      "r379",
      "r380",
      "r388",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Total liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r85",
      "r166",
      "r388",
      "r427",
      "r463",
      "r487"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Total liabilities and stockholders\u2019 deficit",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "verboseLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r41",
      "r85",
      "r166",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r378",
      "r379",
      "r380",
      "r388",
      "r425",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r242",
      "r258",
      "r260",
      "r261",
      "r461",
      "r483"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r88",
      "r213",
      "r247"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r88",
      "r213",
      "r247"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r88",
      "r213",
      "r247"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r88",
      "r213",
      "r247"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "verboseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Loans payable, net of current portion and unamortized debt discount",
        "verboseLabel": "Notes payable, net of unamortized discount"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Lab and pharmacy equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r46",
      "r85",
      "r166",
      "r215",
      "r220",
      "r221",
      "r222",
      "r226",
      "r227",
      "r388",
      "r462",
      "r486"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r74",
      "r77"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r47",
      "r48",
      "r51",
      "r54",
      "r77",
      "r85",
      "r93",
      "r95",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r110",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150",
      "r166",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r384",
      "r388",
      "r471",
      "r494"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net (loss) income attributable to common stockholders",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/StatementsOfCashFlows",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r104",
      "r105",
      "r111",
      "r114",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Numerator \u2013 net (loss) income attributable to Harrow Health, Inc. common stockholders",
        "verboseLabel": "Numerator \u2013 net (loss) income attributable to Harrow Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails",
      "http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r275",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Loss from operations",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current portion of operating lease obligations",
        "negatedLabel": "Less: current portion, operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease obligations, net of current portion",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r409",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating lease, weighted average discount rate, percentage"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r415",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r468",
      "r491"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r34",
      "r427"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Deposits and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r33",
      "r173"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payment for royalties"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Investment in patent and trademark assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment and capitalized software development costs"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r343",
      "r344",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r343",
      "r344",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par or stated value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r172",
      "r173"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average number of shares or units and dilutive common stock or unit equivalents outstanding in the calculation of proforma diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.",
        "label": "Dilutive common equivalent shares"
       }
      }
     },
     "localname": "ProFormaWeightedAverageSharesOutstandingDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
      "http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from purchase of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r66",
      "r358"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r196",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r11",
      "r192"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r194",
      "r427",
      "r477",
      "r488"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r56",
      "r170"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r303",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r303",
      "r420",
      "r424",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Principal payment on SWK loan"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r365",
      "r440",
      "r551"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r10",
      "r80",
      "r458",
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "periodEndLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r275",
      "r427",
      "r485",
      "r508",
      "r509"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r102",
      "r169",
      "r359",
      "r360",
      "r361",
      "r367",
      "r368",
      "r382",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r130",
      "r131",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r154",
      "r288",
      "r289",
      "r441"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenues",
        "verboseLabel": "Revenues, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r291",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r414",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use assets obtained in exchange for new operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesCommissionsAndFees": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).",
        "label": "Commission expenses"
       }
      }
     },
     "localname": "SalesCommissionsAndFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r126",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r182",
      "r185",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CapitalizedSoftwareDevelopmentCostsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "SCHEDULE OF INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "SCHEDULE OF INVENTORIES"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Net Investment Income [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "auth_ref": [
      "r61",
      "r64",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.",
        "label": "Investment Income [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "SUMMARY OF FUTURE MINIMUM PAYMENTS"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r312",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r343",
      "r344",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r319",
      "r339",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF STOCK OPTION PLAN ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r276",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "SCHEDULE OF WARRANTS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Number of RSUs cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of RSUs granted",
        "verboseLabel": "Number of restricted stock units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted-average fair value of options granted",
        "verboseLabel": "Weighted Average Grant Date Fair Value, RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of RSUs unvested, Outstanding, Ending balance",
        "periodStartLabel": "Number of RSUs unvested, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted Average Grant Date Fair Value, RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Payment Award, Non-Option Equity Instruments, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Share-based Payment Award, Non-Option Equity Instruments, Expirations"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Shares Warrants Outstanding, Granted",
        "verboseLabel": "Number of restricted stock units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of Shares Warrants Outstanding, Ending balance",
        "periodStartLabel": "Number of Shares Warrants Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based compensation arrangement by share-based payment award, number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based compensation arrangement by share-based payment award, number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of shares, options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted average exercise price, options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Number of shares, options cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of shares, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, outstanding, ending balance",
        "periodStartLabel": "Number of shares, outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, outstanding, ending balance",
        "periodStartLabel": "Weighted average exercise price, outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Aggregate intrinsic value, options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number of shares, options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average exercise price, options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.",
        "label": "Share-based compensation arrangement by share-based payment award, plan modification, description and terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r343",
      "r344",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, options cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of Exercise Prices, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Number Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Number of Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of Exercise Prices, maximum",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Shares price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected terms (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average. remaining contractual life, options exercisable",
        "verboseLabel": "Weighted avg. remaining contractual life, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average. remaining contractual life, options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average. remaining contractual life, options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Number of shares vestted, RSUs"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Weighted Average Exercisable Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r277",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Share price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares",
        "periodStartLabel": "Beginning Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r34",
      "r464",
      "r465",
      "r481"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Investment in Eton Pharmaceuticals"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r83",
      "r85",
      "r107",
      "r108",
      "r109",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r166",
      "r215",
      "r220",
      "r221",
      "r222",
      "r226",
      "r227",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r388",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r45",
      "r49",
      "r50",
      "r51",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r102",
      "r119",
      "r169",
      "r270",
      "r275",
      "r359",
      "r360",
      "r361",
      "r367",
      "r368",
      "r382",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r419",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r119",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/Cover",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Exercise of employee options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r270",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares isssued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "negatedLabel": "Shares withheld related to net share settlement of equity awards, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r270",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Vesting of RSUs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r270",
      "r275",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares, options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Exercise of employee options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares withheld related to net share settlement of equity awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r18",
      "r19",
      "r270",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Vesting of RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r85",
      "r158",
      "r166",
      "r388",
      "r427"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Total preferred stock and stockholders\u2019 deficit",
        "totalLabel": "TOTAL HARROW HEALTH STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r50",
      "r85",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r166",
      "r169",
      "r275",
      "r359",
      "r360",
      "r361",
      "r367",
      "r368",
      "r375",
      "r376",
      "r381",
      "r382",
      "r388",
      "r390",
      "r391",
      "r395",
      "r419",
      "r506",
      "r507"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r396",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r396",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r396",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r396",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r428",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInAndNoteReceivableFromMeltPharmaceuticalsInc.-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r106",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average number of shares of common stock outstanding, diluted",
        "verboseLabel": "Number of shares used for diluted earnings per share computation"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r104",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average number of shares of common stock outstanding, basic",
        "terseLabel": "Denominator \u2013 weighted average number of shares outstanding, basic",
        "verboseLabel": "Denominator - weighted average number of shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails",
      "http://harrowinc.com/role/ScheduleOfDilutedNetIncomeLossPerSharesDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121554622&loc=d3e15372-109273"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.8)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=25866437&loc=d3e10491-115837"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r552": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r553": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r554": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r555": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r556": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r557": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r558": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r561": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r563": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r564": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r565": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r566": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r567": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r570": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r571": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03"
  },
  "r572": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r573": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r574": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r575": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r576": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r577": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r578": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r579": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r580": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r581": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r582": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r583": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r584": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r585": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001493152-22-012261-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-012261-xbrl.zip
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MU7,(*(EEH<+*B8S[M\7JWI(V&^3Z"I^&T;2,HEPA-5:BULU2G9Q4:@,7\4U
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MO@]&*($9:KWDW YQ;B<Q1[>$<FUFH.E<FKF4[&D2!9@RAC0%2;=I%4P:APR
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MZ<S?)B%[CW T!A"">+I7.O,K!#*Y#6C<FY;IPKA];]J8FD6RC[++,9-%V:H
MZ#8W )EJG!/![QC\<;O1]RH%CV%^X\%JE)S<,4[NZ';,R9:0\O_;CG'OQ44Y
M;(-"(Z%N6\9<(9<05&MQD>61ZU+H!XN1"Q-I&G&KM%DDK.X$M)LDW%K&_D::
M#A6DQ'@]XF"D:V1/95: $C0H-^$OKHWF0&??4@Z..&ZG,G3[UOOEKLLNX6PG
M:;8MNRXMD;V#@DMF'%B%NZ.XV1IR!E#)DLW%QL>,T3M,'/U"E4L=W6*;>W,O
M?S'E45ZMU8)^>X+J!537R"H:06W#%JKJ4;9E2W10!0 %01+X%-; ")@T 3R
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M^AG 1Z+0]9-&&2-Q? QA&J-5BG9BZ^X--U&FJ]AURA5;8CZUG<W%MW%R1-X
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MA[ 2#@!AS?X+GO\M;O\]_PM02P,$%     @ UX.E5+(SC)1.> $ =Y80  L
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M-YMM7:'G.-]Q9C,4B7]"(D UO0/5GH7EI;;I&XD;8!:<#5NZN<-6=G*.Z8V
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M1D[\"T,]"XD<!(@7<!S+A07$ISVUJ)#(IM(!\,E#R,1Q$.;(:G  VH6^"!I
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M_ !$+1K;R;?MYM.E-R:&L[O,Q-)'[<NV??6+3M#I\/2K8'-5+N[H.5/1V-]
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M04Z+W*O5UD8TY"NF.O[%\@^;\;A=<,'HL0II^O<BZ3!9H>"Q;]YS-?TC$5I
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MY,D#(]B(( TBC3@R0<%(\E.TF1H]B@*SUO-RFKWNGEK;ZTB%A@@842\5T:A
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M9)VB_,_+9!VP:948L(@9L!PQ8*<H_S,P8)J\,&&G:(Z<J\@>"A>8F6V@:HK
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MD-158-T")9L+0R.L@+DT[+DD\$K)U@(-.ES/^9ZDP=P# >%[P%1ZM_[M$_>
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M1W>ND$" A(O3.KO.<BHDW:-'C_OXC0Q9 ;ENF -%T;BW1%K"O_'2>N:_W>_
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MSE^)60]]Y47J9F"/ \N*"RL4<XQ;.=)#N.8419Y@98PX41MB92SUSIF?FCQ
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M&H ?P&\-1#;RBVJK8,*RF4B.X)<)$L'7Y4G/^EA!I-/'N4;:0,/T=$6A'3Z
MM08F->D^[_7HBT')^#1H=RFB!*,.$?[FEVZQ.<Z]M! Z/:&]O81=1S+A"WK=
M[&8MBI,P!@0:AA?4GB@#^A4 )7"T&VLW'51?"!RI/9&7@R-Y^M"+W^K,U);
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MP=I^"*<#'@8'<S\):? O1//?V,:BQ)?MX@1&H&MUOUE0O8@WQ12# HNQ#-L
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M #^J0R+M9?/%)'0RH;$P72*"SWP)TI:O9>[96,D0??!'\&CR2'BT9(:];-[
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M6-CB*WC*![UD.P8]0!(D2LV@[H+7U>^#^M"Q04)C5\2V<7M>\^<HF$ \'@*
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M?ZK0;2$75:")F6+E\*C/Z:+Q GULV!ARCU8_84$(YR,QY N.SS,_\1I?#3N
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M4V]<MZ\+=]5*\= &QQRAUHP*JGGE2!@LM<R1*'/C85JZTL>2%WR"1!R[%E3
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M:?S6OQT<@@VW%HNL$S),QC+),/S0\+@A6()@)U'#)?R12\3;US?:8Z*1.+X
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MCXY)@&+'QR:)K=CD4M87C9]1\Y+EKJ[588;;H53)'!O# .VBXI<PP)Q]E5"
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M %/$;-!V:.=%:H0;JP\(GJ*>8P@U-IQL2V^ ]M=:B6L?FUAP!*%W+OJ=("K
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M<Y@%& =EK/S'&286=U@UG&N:63NI?MPPZ"9+RME9%\Y;<U 3&.Z38U2:)^_
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MRO;8UOUY!SV*1(&,C!)J!JX6.> 0_.%$AO2C028N&M<@AHW>NJS2M@?$S6
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MT[8D#X%J[4F)]!: 1]?O9')X#1G\8)5$JO="+N^*%:W'IL[TI$*[X[!P6L-
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M5^[$;'Y6&3W-W1J?NT12'<F97JIN=\?!F\Q^T( ". \&ZFPB&<OGW21L% _
M.B:+J1$N5J9";KB+SMT+L*783L]4,OV1:-VGFOF*2\<^W18V5D-9ED/97.6M
M$C*7L/7ZB9@[WU*,3>N%&1&1X^26W[^_TV%[Y()%+BS0]8+T?$Q$1M^(S&#2
MJ+%J<>S2$MK=3PQ0XT1D-W:DEA;,-#=TND@<I/T99I:83-0,,_J]UHNK[V/U
MVM'JV#+K"%MC3MH>K;%5ZB,7EOIP;L8R@14===&_R'75^V8](:Y6%SA7)_*J
M8\V=.'A5L:,B $<D=J?1U^)/BKYVIZ)^/#N7;]F;,OM^WTU]V^BKL=RM#U;R
M/.D9*J-<@J^AQ?07@Z\1XZI4DOGB*E+[KN^+JPXR !LD5V67E&IM4$(07+E'
M:&(QJH%5"Q,G.YWGIR>Y4T_UUPRL1L-\WR*8NAUOF^9[*A;/YE=:(N$R\Q;U
M?_N/HD4B,&HY$]UD1L@H R91YO8<&'5GT8,(C*;/\^E RMG7/AIN'FOI&/!<
MSO.YR=?LK7CQS)?6#WC^C"!GH ;VZGYVNS)^?ESPTLKT&;'&?CP56"[C)W@9
M#8MGBX!E4!9/,E9(N[F(.Q?KJUN__X1 I(6C$^I7_.[Z\[E<8+<*1'[/X&.D
M1/CN01/V&WQT]#C]UL%' )#7#R7?>_GL7GT,ZA=OWS?\:"XX@,/EVN_7,P"Y
M&OOI.P4@K9R5NAC1[Y/1TW7A_?N&( /DK-1Y)JI!R-"8.+)!2"LC/Z4;8ZZ>
M?+^7$S\N#+DE?QM2,Q/+^.AN&Y4X9&BF^Z''(6W'8OIT>_GX.4H5^ON.1'IP
MZ4'$(G/GA4QT8I&.B$M$(F$14@?E=[Z1Z=3$ZXO\,1JY ZLH78A,/'(U]/AW
MBT=:&;_&=K)?=*[WV,K^C(AD0,8/A"3C.P^JNTGWZC$DN<C4Q?;[C<ID"^/G
M)5;,SPU*!BO)M\U$B%PBY ]--*N*JJ0?H,E#]>WI*SNZS&16AGD.++IC+C,
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MF14^;_*1=KP<IK/$Z#"5;N:#Q6Q@22$#9R9-&GB6\*T.$!2C& Z]%["%L(F
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M\DGDE8"JTA"2U8*-\-T982HH8,7I:9PI<$D*)K"3/$+F'; G-%E@CWN_@[C
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M_$S_^M.YO^A4[NXKC2Y5>4#__V##H(?;5\(1#44"&007 >UD/VE>I?6$/-Q
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MY+"BM8O]]W/JD:54*'R:B2I$ ?OH& Y48&U(<4)$()W'!)G3[VUTB'_&@ L
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M^NJIZ9MQCZZ>-M'T<,&[8TDX<"$SF#_YWU$>_*,,,_(+XRDI*A :</ZCA[3
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MF/0Y,U#1>F![*DEL%=;#X#E$4K O96[DR"C="NNB2:K<+TS<2XY5;L\!V%<
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MM(:,K%OZ,P>&&X4;_),,5JHBN+,Q'5(I*Y#JC>JS4@5%QX#GD\%SI_$$J-K
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MYP?93P$W:!3&PZ W%1YH9J&53W2DMW@)MB]^8E@6HY0Y\!\KS=>3<YGN*^)
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MNK79LE+;)"W(AFF_@;M&'M,G:X%Q1),!+!:)!_(21H^9-;P92=_%/K#(?M'
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M'-JM/5Q60M;V:P_*=]DS#G1MKQT0-O/3.T&7MA #5PENNP"7/.% 8<O6B_+
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M%%H/#P%ZP*%GFG^TL*!&(AWG4[Q:;^K7N5Y'OK?!WGB3C*G#DAJW;AD)]2=
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M)=[!0Y6Z_R,OQ\]/0&*(%/'3RL8V_W;CR;"A]A"](8-KK##(+E/D=?3M647
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MR$\[8,@/=^3P8D>+<.S/D/_D+!#P#@9I6MQ2*#CBGK\ Z06A4"!T^MQ:2EP
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MOC&<_9G& KR.XQV&<;["Q)C.?^_-I\9H9O3G@_%(HP?"^M@ENH\3&O+%2A;
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M:^1CVCK9!&D0ST8N!"_MK^\U5X)ZCI<C/Z;&>]>D=@C3PS*$]'<!MD<1=78
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M$-<E!D1>W+@E\F81#Q[LE*U5B7*D\Y&Q+.VU:P$2#+J%NQ:@T%,B"\L]5 =
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MU9?1]'9R966<.$;@1U]G>=L[!8-YBE3#=OBE@=Z-H"3BSOEICE'VNLX;VJM
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M*4]5JA1L=F ]\-;A9ZDTF$ZMA<AEM6"[C-NRD^-"!0BCA.>B107N"%IGD/8
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M*N;1Z_1A$F3H-V08>L->FOT6,!G5QXJT:C!(J#ADI-$Y _(I=_*ODLS]:*G
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M;2\VJ-23=67%M[_/_JPO<+=34XUW:Z*RSX==/"90/A+^??7PRH5=A\]A@./
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MW_R,BRLG-O>=?2D5_V7$\E%.=0;]W I@]+2%SN-KD(OO;8A8-.3L]G>$OK;
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M2PFG;>8-HE/]R(?[O/<]^BI-EXNDI%\2)KPA2C#@^O_J&N'N0-%KK'F% DP
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MJY!.%)Y/?9N%U,_MI7P_*;>%<AWWSBJF%(7M"^MUN*+3CA/]&;?DW.=V@8*
M>V$%T8V"!<M*]G=>SFK=8QDR_K[GK83;OJ0C%!?<FZP"#U#0Z:Y6/JO;G?R'
M4?)6A$EE<[ 7RP D!/0:PO]W:OQ_!^<_[@U72J\A_/].C?_?P?F/>\N5THO)
M_Q[]<>(OO,\<]SFW,93WN+=<":V8G(_G/_&GOO=B)T_)R-A?Z@'%P(3+KYAJ
MU"60: 00^<]:0AEOPD6XFDI,AD^](+2<_[%W,D6TNCV4^29<B444G]N\F0@
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M[IL0YRND&0>%UV,J?Y)5*(2@HC6X9(0)_.=2BU4=Y?#$X)P5<K9\#OM%[:$
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M_A][Y9?^YO\#4$L! A0#%     @ UX.E5(K^=G@."   XT8   H
M     ( !     &5X,S$M,2YH=&U02P$"% ,4    " #7@Z546$C>PB@(   C
M1P  "@              @ $V"   97@S,2TR+FAT;5!+ 0(4 Q0    ( ->#
MI536I(0A+P4  $0?   *              "  880  !E>#,R+3$N:'1M4$L!
M A0#%     @ UX.E5+(SC)1.> $ =Y80  L              ( !W14  &9O
M<FTQ,'$N:'1M4$L! A0#%     @ UX.E5+JNWAL\%@  "^P  !$
M     ( !5(X! &AR;W<M,C R,C S,S$N>'-D4$L! A0#%     @ UX.E5+L[
M#4GN&0  .$<! !4              ( !OZ0! &AR;W<M,C R,C S,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( ->#I52;/X:.$T4  .R:!  5              "
M >"^ 0!H<F]W+3(P,C(P,S,Q7V1E9BYX;6Q02P$"% ,4    " #7@Z54/IJ
M_,:   ".6 < %0              @ $F! ( :')O=RTR,#(R,#,S,5]L86(N
M>&UL4$L! A0#%     @ UX.E5!92%,@A60  ^14& !4              ( !
M'X4" &AR;W<M,C R,C S,S%?<')E+GAM;%!+!08     "0 ) "P"  !SW@(
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
